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Abstract 
 
Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis that presents with 
painful nodules, abscesses and sinus tracts in apocrine gland-bearing regions. Disease 
pathogenesis is poorly understood and there is a consequent paucity of effective 
treatment options. HS has been associated with smoking and obesity and can be 
inherited in an autosomal dominant (AD) manner. Heterozygous mutations in the 
gamma-secretase genes NCSTN, PSEN1 and PSENEN have recently been reported in 
some Chinese multiplex kindreds with HS. The overall aim of this programme of 
research was to understand the genetic architecture of HS, the ultimate goal being to 
clarify the molecular mechanisms involved in disease pathogenesis. The principle 
objectives were four-fold: 1/ Explore the involvement of mutations in NCSTN, PSEN1 
and PSENEN in British familial cases of HS. 2/ Functionally characterise any identified 
mutations. 3/ Determine the contribution of mutations in NCSTN, PSEN1 and PSENEN 
in the general disease population. 4/ Analyse the clinical phenotype of individuals 
harbouring gamma-secretase gene mutations.  
Heterozygous gamma-secretase gene mutations were detected in affected individuals 
from two of seven British multiplex kindreds demonstrating AD inheritance. Mutations 
were detected in NCSTN (c.1125+1 G>A) and PSENEN (c.66_67insG) which resulted 
in aberrant splicing (p.Glu333_Gln367del) and a frameshift (p.Phe23ValfsX98) 
respectively.  Both mutant transcripts appeared unstable and subject to decay in primary 
human fibroblasts. A corresponding reduction in respective protein expression in mutant 
versus wild type fibroblasts implied that haploinsufficiency of the gamma-secretase 
components may underlie the development of HS in those cases. This apparent 
haploinsufficiency did not however affect gamma-secretase endopeptidase or 
carboxypeptidase activity in vitro. 
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Forty eight individuals were sequentially recruited from a tertiary referral HS clinic and 
screened for variation in NCSTN, PSENEN and PSEN1. Three individuals harboured 
novel variants in NCSTN but no novel or rare (<1% population frequency) variation 
was detected in PSEN1 or PSENEN. All three NCSTN variants were of uncertain 
pathogenicity. Mutations in the gamma-secretase genes NCSTN, PSENEN and PSEN1 
would therefore appear to underlie up to 7% of British cases of HS.  
Phenotypic analysis of individuals with likely pathogenic gamma-secretase mutations 
revealed early onset, severe, widespread and treatment resistant disease often associated 
with atypical flexural pigmentation and prominent cystic changes in atypical areas. 
Given that gamma-secretase gene mutations only appear to underlie a small proportion 
of HS cases it was hypothesised that there is further genetic heterogeneity underlying 
HS. Unexplained familial cases and unrelated but carefully phenotyped and sub-
grouped individuals were therefore assessed using a combination of traditional and next 
generation gene mapping techniques. No pathogenic mutations in additional genes were 
identified.  
The identification of gamma-secretase gene mutations in HS informs disease 
pathogenesis, potentially implicates the gamma-secretase-Notch signalling axis in 
disease development, provides a platform for ongoing functional studies and will 
hopefully facilitate the identification of new therapeutic targets in this debilitating 
disease. Ongoing genetic and functional investigation is now required to confirm the 
presence of further genetic heterogeneity and to establish the relevance of gamma-
secretase-Notch signalling in the wider patient cohort.   
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Chapter 1: Introduction 
1.1 Hidradenitis suppurativa 
Hidradenitis suppurativa (HS, acne inversa, OMIM 142690) was first described by 
Alfred Velpeau, a distinguished French surgeon, in 1839
1
. He described the formation 
of superficial abscesses in the axillae, sub-mammary folds and the perianal region. A 
surgical colleague, Aristide Verneuil, documented further cases in 1854 and, believing 
that it was a disease of sweat glands, proposed the name “hidrosadenite 
phlegmoneuse”2. Despite this, and as was tradition at the time, the condition was 
frequently referred to as Velpeau’s or Verneuil’s disease in the literature. As knowledge 
of sweat gland physiology evolved it was hypothesised that HS was primarily a disease 
of the apocrine gland
3
. This was supported by the presence of a peri-glandular 
inflammatory infiltrate in affected skin and the anatomical distribution of the disease 
(mainly but not exclusively affecting apocrine-gland bearing areas)
4; 5
. Further work 
demonstrating that physical occlusion of axillary skin induces apocrine duct plugging 
and nodule formation further supported this theory
5
. More recent histo-pathological 
evidence would however implicate the hair follicle rather than the apocrine gland in HS 
pathogenesis, suggesting that follicular plugging is the primary histopathological 
mechanism underlying HS
6; 7
. This has led some to question the accuracy of the term 
hidradenitis (inflammation of sweat glands) in describing this disease and an alternative 
name, “acne inversa”, has recently been proposed but is rarely used8. 
1.1.1 Disease definition 
A consensus definition for hidradenitis suppurativa was devised at the Second 
International HS Research Symposium, San Francisco, 2009: 
“HS is a chronic, inflammatory, recurrent, debilitating, skin follicular disease that 
usually presents after puberty with painful deep seated, inflamed lesions in the apocrine 
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gland-bearing areas of the body, most commonly, the axillary, inguinal and anogenital 
regions.” 
1.1.2 Epidemiology 
HS develops at an average age of 22.1 years (usually post-pubertal but can occur at any 
age) and persists for an average of 18.8 years
9; 10
. There is a female predominance, with 
reported female to male ratios as high as 5:1
10
. The 1 year prevalence is estimated to be 
1-4% 
11; 12
 in European populations and 0.03- 0.053% in the United States (US)
13; 14
. 
The apparent variation may in part be a consequence of the variable methodologies 
employed in the respective studies. Important factors may include the diagnostic 
criteria, diagnostic accuracy (some studies relied on patient self-reporting), methods of 
data collection (eg. survey, patient health insurance claims, all of which have their own 
biases) and the particular populations studied. Low presentation and diagnosis rates due 
to factors such as embarrassment and a lack of clinical knowledge about the condition 
are further confounding factors. Consistent with the latter two studies, the incidence is 
6/ 10 000 in the US and has significantly increased over the last 40 years, particularly in 
females (4.3/ 100 000 - 9.6/ 100 000). This increase should be interpreted with caution 
however as numerous factors, including higher presentation rates and more accurate 
diagnosis, may have influenced this statistic
15
. The incidence was highest in females 




1.1.2.1 HS has been associated with obesity and smoking 
Body Mass Index (BMI) appears to confer an impact on disease development and 
progression
11
. 43 - 77% of HS patients are overweight (BMI 25-30) or clinically obese 
(BMI > 30) 
11; 16-18
 and the average disease severity progressively increases in groups of 
individuals with a BMI of less than 25 (Hidradenitis severity score (HSS) 32), between 
25 and 30 (HSS 44) and over 30 (HSS 50), suggesting that weight loss may be of 
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benefit
16
. Up to 93.7% of patients with HS are current or ex-cigarette smokers compared 
with 46% of controls
19
 (the percentage of HS patients with a smoking history varies 
from 69% -  93.7% across studies
11; 19
). The average disease severity is highest in 
current smokers and reduces through ex-smokers and non-smokers suggesting that 
smoking cessation may be of potential benefit in HS
16; 20
.  
1.1.3 Clinical presentation 
HS is a chronic inflammatory skin condition that presents with comedones 
(characteristically paired), papules, pustules, nodules, cysts, abscesses, sinus tracts and 
fistulae in flexural areas
21
. The condition is associated with significant pain, tenderness, 
burning, stinging, pruritis, chronic discharge (serous, purulent or blood-stained) and a 
persistent malodour
4
. Longstanding disease can result in fibrosis, dermal contractures, 
scarring and a consequent reduction in mobility (see Figure 1.1). The disease targets 
flexural areas, notably the post-auricular region, axillae, submammary region, 
abdominal fold, groin, perineum, buttocks and medial thighs. Rarer sites include the 
scalp, face, neck, back and legs. Of 48 patients in one study, 98% were affected in the 
groin, 94% in the axilla, 79% buttocks and 34% sub-mammary region
22
. Of 66 female 
patients in a further study, 56% were affected in the groin, 68% in the axilla, 32% 
buttocks and 36% sub-mammary region
23
. There appears to be a differential distribution 
in men and women. Women are more likely to present with axillary, sub-mammary and 
groin involvement whereas men are more commonly affected in the perineal and 
perianal region and at rarer sites such as ears, face, chest and back
15; 24
. There is 
significant inter-individual variation in disease course and severity. Of over 300 cases in 
one study, 68.2% had “mild” disease (as defined by a method of staging called the 
Hurley score, discussed in a later section), 27.6% “intermediate” disease and 3.9% 
“severe disease”9. On average, men are more severely affected than women15.  
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Complications associated with HS include fistula formation (affecting the urethra, 
bladder or rectum), lymphoedema and the development of squamous cell carcinoma 
(SCC). SCC development is rare in HS (5 of 2119 cases retrospectively analysed in one 
study) and predominantly arises in the context of longstanding perianal disease
25
. 
Metabolic syndrome is commonly associated with HS and that association appears 
independent of patient age, disease severity or disease duration
26
. Features of the 
metabolic syndrome include central obesity, hypo-HDL-cholesterolaemia, 
hypertriglyceridaemia, hypertension and hyperglycaemia. Consequently, HS patients 




Figure 1.1. The clinical appearance of HS. A) An abscess in the sub-mammary region. B) 
Inflammatory nodules, sinus tracts and scarring in the axilla. C) Paired comedones, 
inflammatory nodules, sinus tracts and scarring in the axilla. D) Widespread fistula formation 
and scarring over the buttocks as a result of longstanding, persistent and severe disease. Photos 
courtesy of Guy’s and St. Thomas’ National Health Service (NHS) Foundation Trust, all 
individuals consented to publication. 
 
1.1.4 Histopathology 
Common histopathological features include follicular hyperkeratosis,  follicular 
hyperplasia and follicular occlusion with an associated spongiform 
infundibulofolliculitis
7
. These changes may be associated with follicular dilatation, 
follicular rupture and the formation of keratin containing cysts (lined by stratified 
squamous epithelium), abscesses, sinus tracts, granulomas, fibrosis and scarring. Other 
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features include an interfollicular psoriasiform epidermal hyperplasia, sebaceous gland 
involution and apocrine gland hyperplasia which is often associated with a peri-
glandular inflammatory infiltrate
6; 27; 28
. Subepidermal, dermal and subcutaneous 
inflammation is observed in 82%, 76% and 31% of cases respectively and the 
inflammatory infiltrate comprises predominantly lymphocytes in the early stages 




1.1.5 Phenotypic classification 
The significant inter-individual variability regarding the site of disease, the type of 
lesions present and the associated systemic symptoms (such as fever, general malaise 
and arthralgia) during disease flares indicates that there may be multiple, as yet poorly 
defined, phenotypes within HS. No phenotypic classification existed upon 
commencement of this project. A recent French study performed a latent class analysis 
of clinical variables in 618 HS patients which identified three broad phenotypic 
groups
30
. The first group (axillary-mammary) exhibited mainly breast and axillary 
involvement associated with hypertrophic scars and was mainly comprised of female 
patients. The second group (follicular) exhibited ear, axillary, breast, chest, back and leg 
involvement with a greater tendency to develop comedones, epidermal cysts and 
pilonidal sinuses. Patients in this group were more commonly obese, male, smokers, 
had more severe disease and reported a past medical history of acne. The third group 
(Gluteal) had gluteal disease with superimposed follicular papules and folliculitis. This 
group exhibited less severe disease, a higher smoking rate but a lower average BMI than 
the other two groups. 
Some rarer but more specific phenotypic sub-groups have been described. Pyogenic 
arthritis, pyoderma gangrenosum and acne (PAPA) syndrome has been associated with 
HS and is due to heterozygous mutations in the PSTPIP1 gene
31
. The combination of 
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PAPA and HS has recently been referred to as PAPASH syndrome
32
. A related 
phenotypic group comprises individuals with pyoderma gangrenosum, acne and 
suppurative hidradenitis (PASH syndrome)
33
. SAPHO syndrome can also comprise HS, 
encompassing a variety of clinical presentations including sterile osteomyelitis, osteitis 
or arthritis and pustular psoriasis, acne or HS
34
. Two further phenotypic groups have 
been reported, one with HS and keratitis, the other with HS, spondyloarthropathy and 
acne conglobate
35; 36
. Keratitis was observed in 4 of 62 HS patients in one case series 
(HS preceded the development of keratitis by an average of 7 years) and has been 
reported in several case reports since
37; 38
. The group with HS, acne conglobate and 
arthropathy develop an axial and/ or large joint arthropathy which is commonly 
associated with disease flares.  
1.1.6 Clinical diagnosis and staging 
The diagnosis is usually based on a clinical history of chronic, painful, inflammatory 
lesions in characteristic apocrine-gland bearing areas. The first reported diagnostic 
criterion for HS were proposed in 2000 for the purposes of research
39
. The key 
principles of those criterion were that individuals required typical and recurrent lesions 
in characteristic sites. Typical lesions were defined as painful and/ or erythematous 
papules, nodules, abscesses, dermal contractures or paired comedones. Characteristic 
sites were defined as the axillae and groin. For diagnosis, individuals required either a) 
one active lesion and a history of three or more painful or discharging lumps (not 
specified) in characteristic sites or b) a history of five or more painful or discharging 
lumps in characteristic sites.  
Formal clinical diagnostic criterion were recently proposed at The Second Congress Of 
The Hidradenitis Suppurativa Foundation mirroring many of those original statements 
but with minor alterations in the definition of typical lesions and typical sites. They state 
that individuals require 1) typical lesions (painful nodules, abscesses, sinus tracts, 
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bridged scars or open comedones) in 2) typical sites (axillae, groin, perineal region, 
perianal region, infra and inter mammary folds or buttocks) and that 3) the disease must 
be chronic and recurrent
29
.  
Disease severity is most commonly documented using Hurley staging or the Sartorius 
score. Hurley staging is a comparatively simple system based upon the presence of 
sinus tracts and scarring. The disease is broadly categorised into three groups, stage 1 
(abscesses with no sinus tracts or scarring), stage 2 (multiple abscesses and evidence of 
sinus tract formation) or stage 3 (multiple abscesses, sinus tracts and scarring affecting a 
wide area)
40
. The Sartorius score incorporates the number and type of lesions present, 
distance between lesions, presence of normal skin and the anatomical locations 
affected
41




1.1.7 The impact of the disease on quality of life 
The associated pain, chronic purulent discharge, persistent malodour and the 
involvement of intimate sites in HS can result in significant patient morbidity. This is 
often confounded by an initial embarrassment to seek medical advice, delayed or 
misdiagnosis and a lack of effective treatment options (the average time from first 
symptoms to formal diagnosis is 12 years)
43
. Hospitalised patients have reported worse 
quality of life scores than those documented in psoriasis, chronic urticaria and atopic 
eczema
44
. A survey of 114 patients referred to secondary care revealed an average 
Dermatology Life Quality Index (DLQI) score of 8.9.
45
 Factors such as disease severity, 
duration and location all impact upon quality of life.  Up to 40% of HS patients are 
diagnosed with depression
15
. The disease can have far reaching social and economic 
consequences, affecting both relationships and employment. The average patient takes 
2.7 days off work a year due to the condition
46
. 
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1.1.8 Treatment of hidradenitis suppurativa 
There is currently a paucity of effective treatment options for HS and very few 
treatments have been rigorously validated in blinded, randomized and placebo-
controlled trials. Mild disease can be managed with topical clindamycin
47
. Intra-lesional 
steroid injections are of unproven efficacy. More severe disease is more often treated 
with systemic therapy including antibiotics (tetracyclines, clindamycin, rifampicin), 
retinoids, dapsone, ciclosporin and oral steroids. That said, oral tetracycline (500mg 
twice daily) has not been shown to confer any benefit over twice daily topical 
clindamycin over a three month period, but clinical observations would suggest that it 
can take up to four months for the oral antibiotics to reach their maximal effect
48
. 
Clindamycin and rifampicin in combination (both 300mg bd) can significantly improve 
both disease severity and quality of life
49; 50
. It remains unclear as to whether the clinical 
benefits of oral antibiotics occur as a result of their anti-bacterial or anti-inflammatory 
properties. Retinoids appear to be of mixed benefit. Acitretin confers a long-lasting 
improvement in disease severity in up to 75% of cases whereas isotretinoin is only 
minimally effective but may alleviate mild forms of the disease
51; 52
. A variety of 
hormonal therapies (mainly anti-androgen agents) have been used to treat HS in females 
however their efficacy appears inconsistent and has not been rigorously assessed in 
clinical trials. Cyproterone acetate, norgestrel (in combination with ethinyloestradiol) 
and finasteride may confer a benefit in over 50% cases
53-55
.  Immunosuppressants 
including prednisolone, dapsone and ciclosporin can be effective
56; 57
. Colchicine 
confers a minimal effect and Methotrexate is ineffective
58; 59
.  
Anti-TNF agents have recently been trialled in HS. A recent systematic review reported 
that 50% of individuals on infliximab show a good response, 39% a moderate response 
and 11% no response
60
. 44%, 35% and 21% showed a good, moderate and no response 
to adalimumab and 39%, 17% and 44% respectively to etanercept. Four patients have 
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recently received ustekinumab on which two improved significantly, one moderately 
and one failed to respond
60
.  
Other treatment options include radiotherapy, psoralen and UVA (PUVA) phototherapy, 
photodynamic therapy, laser therapy (Neodymium:yttrium-aluminium-garnet and 
carbon-dioxide lasers) and surgery
61-65
. Surgical options include incision and drainage, 
local excision and extensive excision but recurrence is common. Regrettably, many 
patients fail to respond to the medical and surgical approaches documented here and 
more targeted, disease-specific therapies are required to treat this debilitating condition. 
1.1.9 Conditions associated with hidradenitis suppurativa 
HS can arise as part of a follicular occlusion tetrad comprising HS, acne conglobate, 
dissecting cellulitis of the scalp and pilonidal cysts/ abscesses
66-68
. 23 - 70% of HS 
patients report a history of acne vulgaris however there appears to be no correlation 
between the severity of the two conditions
15; 22; 69
. It has also been associated with 
conditions including Dowling-Degos disease, Jackson-Lawler pachyonychia congenita, 
Keratitis-ichthyosis-deafness syndrome, PAPA syndrome, Crohn’s disease and Fox-
Fordyce Disease. Dowling Degos disease is characterised by macular hyper-
pigmentation in the flexures (axilla, sub-mammary region, groin) and is caused by 
heterozygous mutations in Keratin 5 (KRT5)
70; 71
. Jackson-Lawler pachyonychia 
congenita is characterised by pachyonychia, palmar, plantar and follicular 
hyperkeratosis, steatocystoma multiplex and multiple epidermal cysts over trunk, neck 
and scalp and is caused by heterozygous mutations in the Keratin 6B and Keratin 17 
genes (KRT6B, KRT17)
72-74
. KID syndrome presents with keratitis, ichthyosis and 
deafness and is due to heterozygous mutations in Connexin 26 (GJB2)
75
. As previously 
mentioned, PAPA syndrome has been associated with HS and is associated with 
heterozygous mutations in the PSTPIP1 gene
31
. A PSTPIP1 gene mutation has recently 
been reported in a patient with PAPA and HS, named PAPASH by the authors
33
. Fox-
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Fordyce disease comprises itchy papules on the chest, axillae and pubic region
76
. The 
genetic basis of Fox-Fordyce disease is unknown. Crohn’s disease is an inflammatory 
bowel disease that has been associated with variants in multiple genes including pattern-
recognition receptors (NOD2, TLR4 and NLRP3), genes involved in autophagy 
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1.2 Pathogenesis of Hidradenitis Suppurativa 
HS was once considered a disease of the apocrine gland but recent histopathological 
evidence firmly implicates follicular involvement in disease pathogenesis. 
Histopathological features observed in over 95% of early lesions (less than three days 
old) include hyperkeratosis, occlusion of the follicular unit and an associated 
perifolliculitis. These are often accompanied by dilatation of the hair follicle and 
subsequent stasis in both the apocrine and eccrine glands
7
. Whilst apocrine stasis, 
hyperplasia and a peri-glandular inflammatory infiltrate is observed in and around the 
apocrine glands in 33-90% of HS cases it is universally accompanied by extensive 
inflammation of the hair follicle, eccrine gland and cystic structures
6; 7; 27
. This implies 
that changes observed in and around the apocrine glands are likely to arise secondary to 
primary follicular occlusion
7
. It has recently been observed that there is a thinning of the 
basement membrane zone (BMZ) around the sebo-follicular junction (neck of the 
ductus seboglandularis) in HS skin. This area of weakness may predispose to spillage of 
follicular contents into the dermis and a subsequent inflammatory response
80
. The 
identification of free keratin filaments in the dermis supports that mechanism and is 
consistent with follicular rupture playing a key role in disease pathogenesis
81
.  
Taken together, these studies suggest that follicular plugging, dilatation and rupture 
underlies the development of HS (Figure 1.2). The driving forces behind these 
characteristic histological changes remain unclear however a number of endogenous and 
exogenous factors have been implicated in the development and propagation of the 
condition. This section aims to summarise the involvement of the immune system, 
hormones, bacteria and, of particular relevance to this thesis, genetic predisposition. 
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Figure 1.2. The current histolopathological model of HS.  A resting pilo-sebaceous unit is 
represented on the left comprising a thinned BMZ at the sebo-follicular junction. In HS, 
epidermal and follicular hyperplasia is associated with the development of a keratinous plug in 
the follicular outlet. This results in the build up of substances including keratin and bacteria 
within the follicle and consequent dilatation of the pilosebaceous unit (represented in centre). 
The follicle then ruptures, potentially at the region of weakness at the sebo-follicular junction, 
extruding its contents in to the dermis. This initiates a significant inflammatory response. 
 
1.2.1 Aberrant immune responses in HS 
The intense inflammation observed in HS has led many to speculate that aberrant 
immune responses may play a role in disease pathogenesis
82
. This is supported by the 
efficacy of immunomodulatory agents such as oral steroids, ciclosporin and more 
recently anti-TNFα therapy in treating HS83. The latter (Infliximab and Adalimumab) 
specifically imply the involvement of the cytokine TNFα in disease pathogenesis and 
indeed, TNF-α levels are elevated in the skin and circulation of HS patients84; 85and 
TNF-α receptor 1 and TNF-α receptor 2 expression is increased in affected skin82. TNF-
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α is capable of recruiting and activating lymphocytes and neutrophils, both of which are 
prominent in early HS infiltrates, and stimulating the production of a wide array of other 
pro-inflammatory cytokines
86
. One such cytokine, IL-1β is over-expressed in the skin 
and circulation of HS patients and levels appear to correlate with disease severity
82
. IL-
1β is produced by monocytes and macrophages and is activated by the inflammasome. 
Inflammasomes are innate immune sensors situated within the cytosol which are 
triggered by a variety of danger signals including pathogen associated molecular 
patterns (PAMPS) and damage associated molecular pattern molecules (DAMPS). In 
the context of HS, these signals may originate from of bacterial sequences, free keratin 
or DAMPS produced as a result of tissue destruction and scarring. Macrophages and 
dendritic cells initially recognise these danger signals through pattern recognition 
receptors situated within the cell membrane such as Toll like receptor 2 (TLR2). 
Macrophages and dendritic cells harvested from affected HS skin have correspondingly 
been shown to over-express TLR2
87
. IL-10 expression is also elevated in HS skin, 
however in contrast to IL-1β, IL-10 is an anti-inflammatory cytokine capable of limiting 
the response to bacteria and thus reducing overall tissue damage
82
. It can be produced 
by both cells of the innate and adaptive immune system including macrophages which 
are prominent in HS infiltrates
82
.  
The above evidence suggests that innate mechanisms may initiate the inflammatory 
response observed in HS. However, cytokine profiles are not consistent across studies 
and that may in part be due to the exact skin compartments studied and the methods by 
which expression levels were analysed. A study that focussed explicitly on the 
expression of cytokines in the epidermis corroborated the finding that IL-10 expression 
is raised. It also found that the expression of TNFα, TLR-2,3,7,9, β-defensin 2,4, 
ICAM-1, IL-6, IGF-1, α-MSH and TGF-β was reduced in affected and unaffected 
epidermis versus control epidermis and epidermis from subjects with other 
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inflammatory dermatoses including psoriasis and acne vulgaris. The apparent down 
regulation of these innate markers led the authors to postulate that HS may be a disease 
of deficient innate immunity
88
. In support of this, monocyte responses to bacteria are 
reduced in HS and the number of circulating Natural Killer (NK) cells diminishes over 
time
89; 90
. Furthermore, IL-20 and IL-22 receptor expression is reduced in HS skin and 
expression of the natural antagonist to those receptors, IL-22 binding protein, is 
increased
91
.   
The involvement of the innate immune system in disease pathogenesis is further 
supported by the association of HS with Crohn’s disease (17% of Crohn’s patients have 
HS)
92
. Like HS, Crohn’s disease was once thought of as a direct consequence of 
bacterial infection. Recent genetic advances however suggest that Crohns disease arises 
as a result of subtle defects in mucosal immunity. NOD2 was the first susceptibility 
gene to be identified which encodes an innate intracellular pattern recognition 
receptor
79
. The NOD2 receptor recognises bacterial peptides and in turn, enhances 
intestinal epithelial cell barrier function and mediates chemokine production
93
. In 
animal models the loss of function variants observed in Crohn’s disease disable that 
receptor function resulting in a defective barrier, bacterial invasion and a chronic 
inflammatory response (colitis)
94
. Further variants have now been identified in more 
pattern-recognition receptors (TLR4 and NLRP3), genes involved in autophagy 




Antimicrobial peptides represent another mechanism of innate immunity in the skin. 
They confer anti-microbial, immunomodulatory and pro-inflammatory properties and 
can promote keratinocyte proliferation and differentiation. Examples include the β-
defensins, cathelicidin, psoriasin, ribonuclease 7 and dermcidin
95-98
. The role of 
antimicrobial peptides in HS is a subject of ongoing investigation. Human β-defensin 2 
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and 3, cathelicidin (LL-37) and psoriasin have been reported to be over-expressed in HS 
skin (LL-37 appears particularly upregulated in apocrine epithelium), ribonuclease 7 is 
reduced and there is no discernible difference in the level of dermcidin
99-102
.  
These data provide an insight in to the immune response underlying HS. Epidermal 
studies and the association with Crohn’s disease potentially implicate aberrant innate 
immunity as a causative factor but the consequential effects on the adaptive response 
and the exact mechanisms by which any such immune deficiency could result in the 
severe inflammatory responses observed are yet to be elicited. It remains unclear as to 
whether immune dysregulation is a primary event, somehow resulting in the 
characteristic follicular occlusion noted on histology, or in some way a consequence of 
the cascade of events that follow initial follicular plugging. 
Many subtle mechanisms by which the hair follicle contributes to cutaneous immunity 
and inflammation have been characterised and may be of direct relevance in the 
pathogenesis of HS. The hair follicle is considered “immune priviledged” as, at certain 
times in the hair cycle, it can protect itself from immune recognition and inflammatory 
responses via a loss of Major Histocompatibility Complex (MHC) class I and II 
expression and by expressing CD200, alpha-melanocyte stimulating hormone, 
transforming growth factor-beta2, macrophage migration inhibitory factor and 
indoleamine-2,3,-dioxygenase
103; 104
. Multiple immune cells, including Langerhans 
cells, T cells (CD4 +ve and CD8 +ve), macrophages and mast cells are commonly 
located in and around the hair follicle
103
. Langerhans cells have been a particular focus 
of recent study. They form an important bridge between the innate and adaptive immune 
response and are integral in stimulating cells such as TH17 and TH2 lymphocytes to 
react against fungal and bacterial infections
105; 106
. Keratinocyte subsets within the hair 
follicle have been reported to play an integral role in facilitating the migration of 
Langerhan cell precursors in to the epidermis. Specific expression of the chemokine 
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ligands CCL2 and CCL20 appears pro-migratory and CCL8 inhibitory
107
. This recent 
advance has lead some to speculate that the hair follicle acts as the “gate-keeper” to the 
epidermis
108
. The emerging immune function of the hair follicle, or indeed any 
malfunction thereof, may be of direct relevance in HS and this requires investigation.  
1.2.2 Hormonal influence 
The female predominance, post-pubertal onset, pre-menstrual flares (57% of affected 
women)
17
 and clinical improvement often observed during pregnancy and post-
menopause imply a role for hormones in HS pathogenesis
109
. Given the role of 
androgens in acne vulgaris it has been proposed that they may also play a role in HS. In 
concordance with this, female patients often suffer with pre-menstrual flares (when 
progesterone levels are high) and are more likely to present with other androgen related 
sequelae such as acne, hirsutism and irregular menses (data was never replicated in 
larger cohorts)
110; 111
. Case reports lend further evidence to the involvement of 
androgens in HS, documenting that progestogens (androgens) within oral contraceptive 
agents may induce disease flares. Furthermore, In vivo mouse models indicate that 
androgens may induce a pro-inflammatory state by increasing TLR mediated monocyte 
expression of TNFα112; 113. Therapeutically however, anti-androgens (cyproterone 
acetate) combined with oestrogens were no more beneficial than oestrogens alone
110
 and 
plasma testosterone, dehydroepiandrosterone and apocrine gland androgen converting 
enzyme levels are no different in HS patients
23; 114
. Furthermore, the female 
predominance and the fact that the disease often starts many years after puberty are not 
consistent with androgen involvement in HS. Overall, the impact of androgens remains 
uncertain and the mechanism of hormonal involvement in HS requires further 
clarification. 
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1.2.3 Bacterial infection 
The role of bacteria in HS is controversial. Studies using superficial sampling 
techniques have shown that a wide variety of bacteria overly HS lesions, including 
aerobes (Staphlococcus aureus, Streptococcus viridans), corynebacteria and 
anaerobes
115
. The reliability of these results is however questionable given that many 
bacteria on the skin surface are likely to be colonisers rather than directly involved in 
the disease process. Furthermore, there was very little consistency in the bacterial 
strains identified across the different studies. One study involving deep needle 
aspiration of lesions, thus excluding superficial colonising bacteria, revealed no growth 
in 51% of cases. In the remaining 49% of cases, Staphlococcus aureus, coagulase 
negative staphylococci and occasional anaerobes were detected
116
 . Two further studies 
employed CO2 laser to dissect through deeper tissue planes. One study focussed on 
patients with an acute exacerbation
117
, whereas the other looked at patients with chronic 
disease
118
. Coagulase negative staphylococci were found to be the most abundant 
organism in superficial and deep planes in both acute and chronic lesions. 
Corynebacterium and anaerobes were the next most abundant organisms in acute lesions 
(staphylococcus aureus not present at any level in the 10 individuals studied) whereas 
Staphlococcus aureus and anaerobes were the next most abundant organisms in chronic 
disease. Polymicrobial growth was noted in at least one tissue plane in all patients 




Taken together it would appear that bacteria are found within the majority of, but not 
all, HS lesions. There was considerable inter-individual variation in the number and 
type of organisms present, although coagulase-negative staphylococci were most 
common. The lack of consistent organism, the failure of patients to develop infectious 
complications such as cellulitis, the normal appearance of regional lymph nodes and the 
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efficacy of oral steroids in HS support a secondary rather than primary role for bacteria 
in disease pathogenesis
119
. One mechanism by which they may confer such a role is by, 
upon follicular rupture, being recognised by pattern recognition receptors and triggering 
an immune response. Eradication of these bacteria may therefore be one mechanism by 
which antibiotics alleviate symptoms in HS.  That said, it remains a matter of debate as 
to whether antibiotics act via their anti-bacterial actions or through independent anti-
inflammatory mechanisms in this context.  
1.2.4 Obesity and smoking 
Obesity may have an impact on HS by mechanically increasing friction at flexural sites 
(thus potentially damaging follicular outlets), increasing sweat retention or increasing 
the circulating level of pro-inflammatory cytokines (eg. IL-1β and TNF-α are both 
secreted by macrophages within visceral fat)
10
. Circulating mononuclear cells reportedly 
exhibit a pro-inflammatory state in obese individuals (IL-6 and TNF-α gene expression 
is upregulated)
120
. Furthermore, elevated circulatory levels of palmitate in obese 
individuals may also predispose to inflammation by interacting with TLR’s and 
activating innate immune mechanisms
121
. Alterations to the microbiome in regions of 
opposed skin  may also predispose to disease development
122
. 
The exact mechanisms by which smoking contributes to disease pathogenesis are 
unclear however nicotine has been shown to induce epidermal hyperplasia and follicular 
plugging
123
. Further mechanisms by which smoking may confer an impact on the 
disease are that it appears to cause an initial overstimulation and eventual reduction of 
glandular secretion
124
, results in the secretion of noxious metabolites in sweat, 
stimulates neutrophil chemotaxis
115
 and increases the expression of pro-inflammatory 
cytokines such as IL-β and TNF-α125. Furthermore smoking has been shown to reduce 
cutaneous blood flow, reduce tissue oxygenation and impair wound healing, all of 
which may be detrimental to the healing of HS lesions
126; 127
. Reactive oxygen species 
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within tobacco smoke confer immunomodulatory effects by detrimentally affecting 
phagocytosis, potentially facilitating any infective involvement in disease 
pathogenesis
128
. Affects on fibroblast migration and activation
129; 130
 and an 
upregulation of MMP1 and MMP3 activity may have a significant impact on the 
supporting structure in the skin, such as collagen, elastin and proteoglycan
131
, and 
consequently impact upon the histopathological evolution of the disease. 
1.2.5 The genetics of hidradenitis suppurativa 
Genetic factors appear to play an important role in disease pathogenesis given that up to 
42% of patients report a family history of the condition
22
. Familial studies performed in 
the 1980’s indicated that the condition may be inherited in an autosomal dominant 
manner
132
 and that was confirmed by a follow up study (analysing the same kindreds) 
15 years later
39
. The transmission rate in those pedigrees was less than the 50% that you 
would expect with strict autosomal dominant inheritance and the authors proposed that 
this may have been as a consequence of the diagnostic criteria used or incomplete 
penetrance
39
. Variability in disease penetrance may also partly reflect the many intrinsic 
and environmental factors that can impact upon disease development or progression 




1.2.6 Mutations in the gamma-secretase genes  
Until recently, only one putative genetic locus had been reported in HS (80cM locus on 
chromosome 1, 1p21.1-1q25.3)
134
.  In 2010, heterozygous mutations were reported in 
the gamma-secretase genes PSENEN, PSEN1 and NCSTN in six Chinese multiplex 
kindreds, all showing full co-segregation
135
. One of these genes, NCSTN, lies within the 
previously reported region of linkage on chromosome 1
134
. Mutations have since been 
reported in two British, six Chinese, one Japanese and three French multiplex kindreds 
as well as four apparently sporadic cases 
135-142
. To date, eighteen mutations have been 
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reported in NCSTN, three in PSENEN and one in PSEN1
135-141
 of which four are 
nonsense mutations, seven result in frameshifts, seven in altered splicing and four are 
missense mutations. The data presented in this thesis contributed to this genetic 
summary and, to our knowledge, represents the most comprehensive functional 
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1.3 Gamma-secretase 
Gamma-secretase is an aspartyl intra-membrane protease complex capable of 
hydrolysing and cleaving in excess of 50 type-1 transmembrane proteins including 
amyloid-precursor protein (APP), Notch receptors, N-cadherin, E-cadherin, neuregulin, 
Erb4 and Nectin-1α143-145 (full table of substrates shown in Appendix 1). These 
membrane proteins have large ectodomains which are cleaved by a variety of sheddases. 
The remaining intramembranous portions are then cleaved by gamma-secretase 
(endopeptidase activity,   ε-cleavage), releasing the intracellular component of each 
protein. Some of these intracellular fragments, such as Notch intracellular domain 
(NICD), play important biological roles within the cell
146
. Following the initial ε-
cleavage, some substrates undergo further processing by gamma-secretase whereby the 
remaining intramembranous stub is sequentially cleaved to form by-products of varying 
sizes (carboxypeptidase-like activity). This is evident in both APP and Notch 
processing.  
Despite the intricate and complex mechanisms by which this enzyme interacts with and 
cleaves its respective substrates it appears to demonstrate a remarkable lack of substrate 
specificity. Correspondingly, no common recognition sequence is shared between all 
substrates. Four factors appear to determine whether a membrane protein will be 
targeted by gamma-secretase, orientation (type I), physical conformation (must contain 
a hydrophobic α-helix), prior ectodomain shedding (gamma-secretase will not interact 
until this cleavage has occurred) and the residual length of the ectodomain following 
initial cleavage by another sheddase (proteins with ectodomains of less than 50 amino 
acids are effectively cleaved)
147
. Furthermore, substrates are required to have 
“permissive” transmembrane and cytoplasmic domains that may, for instance, enable 
any conformational changes that are required for proteolysis
148
.  
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Gamma-secretase has traditionally been viewed as playing two key roles. The first is to 
catalyse cleavage of the potentially biologically relevant intracellular portions of 
substrates (eg. NICD in the context of Notch signalling), a process known as regulated 
intra-membrane proteolysis (RIP) 
149
. The second is to remove intramembranous 
proteins from the cell membrane and thus maintain healthy cell cycling and 
homeostasis
150
. The biological role of short peptides produced as part of that process 
(via carboxypeptidase-like processing of the remaining intramembranous stubs) remains 
unclear (eg. β-amyloid (Aβ) in the case of APP processing).  
The components of gamma-secretase are conserved through metazoans, higher plants 
and even slime mould. Work in plants and mould indicates that the enzyme may have 
functions outside of membrane clearance and RIP that are integral to normal cell 
function. No enzyme substrates have been identified in plants, moulds or mosses yet 
null mutations in presenilin (a component of gamma-secretase) affect growth patterns, 
chloroplast movement, membrane internalisation and endosome trafficking in moss 
(Physcomitrella patens)
151
 and affect phagocytosis in slime mould
152
. Similar 
phenotypes were observed in nicastrin (another component of gamma-secretase) null 
mutants. In addition to RIP and removing and recycling cell membrane proteins, 
gamma-secretase would therefore appear to be involved in a diverse range of cellular 
mechanisms including endocytosis (including receptor mediated endocytosis), protein 
trafficking (eg. APP) and phagocytosis (further confirmed by looking at macrophage 
function in mice)
153-156
. The functions of RIP and re-cycling cell membrane proteins 
may only have developed as more complex membrane proteins evolved
152; 157
. The 
cellular functions of gamma-secretase are shown in Figure 1.3. 
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Figure 1.3. The key roles of gamma-secretase in cellular functioning.  Gamma-secretase is 
involved in regulated intramembranous proteolysis, the clearance of protein membrane stubs 
from the cell membrane, endocytosis, protein trafficking and phagocytosis. 
 
1.3.1 The composition of the gamma-secretase complex 
Gamma-secretase is a protein complex composed of at least four fundamental sub-units 
comprising presenilin, nicastrin, PEN-2 and APH-1. The combination of these four 
proteins in a 1:1:1:1 ratio forms an active enzyme complex
158; 159
 (Figure 1.4). These 
proteins are encoded by the genes PSEN1 or PSEN2, NCSTN, PSENEN and APH1A or 
APH1B respectively. Because presenilin can be encoded by PSEN1 or PSEN2 and 
APH-1 can be encoded by APH1A or APH1B there are at least four different protein 
combinations that can potentially form an active enzyme complex and this is further 
compounded by alternative splicing of APH1A (APH-1aS, APH-1aL). 
Immunoprecipitation experiments have indeed confirmed the existence of these 
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alternative complexes (weight varies from 380 – 550kDa) and furthermore, that they 
can co-exist in the same cell type.
160
 The biological rationale for the existence of 
multiple subtly different complexes is as yet unknown, however it maybe that each 
confers a degree of substrate specificity
161
. Interestingly PSEN1, PSEN2 and APH-1B 
demonstrate a degree of tissue specificity (eg. PSEN1 expression higher in testis, 
PSEN2 expression higher in liver, APH-1B expression higher in brain) whereas APH-




Figure 1.4. The gamma-secretase complex.  The gamma-secretase complex is an 
intramembranous multi-protein complex composed of 4 subunits, presenilin, PEN-2, nicastrin 
and APH-1, encoded by PSEN1/ PSEN2, PSENEN, NCSTN and APH1A/ APH1B respectively.  
 
The production, maturation, migration, stability and eventual activity of these individual 
proteins appears to be closely intertwined such that any imbalance or dysfunction of any 
one unit will impact on the others and ultimately affect enzyme activity
161
. Most studies 
demonstrate that if one subunit is missing (through knockdown or knock-out) then the 
other proteins are proteasomally degraded, thus abolishing enzyme activity
162
. Down 
regulation of any one component inhibits enzyme activity
163-166
 and over-expression of 
all four increases enzyme activity
145; 164; 165
.  
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Immunoprecipitation of active enzyme complexes confirms that one of each protein 
forms an active complex
145
. That said, all four subunits are not essential for enzyme 
activity under certain experimental conditions. Mutagenesis of specific residues within 
PSEN1 (S438P + one of 15 other mutations) enables minimal gamma-secretase activity 
in the absence of nicastrin in vitro (in yeast and mouse fibroblasts)
167
. The S438P 
mutation in PSEN1 trans-membrane (TM) segment 9 was proposed to induce a 
conformational change in the complex that was sufficient to allow substrates to access 
to the catalytic site in the absence of NCSTN. It was noteworthy however that the 
mutant presenilin fragments were unstable in the absence of nicastrin and that enzyme 
activity was notably reduced compared to wild-type complexes containing nicastrin. A 
further study demonstrated that mutant PSEN1 (again lacking part of the TM9 
sequence) alone and wild-type presenilin and PEN-2 in combination can exhibit some 
enzyme activity when re-constituted in proteoliposomes
168
.  In summary, mutant forms 
of presenilin, alone or in combination with PEN-2/ APH-1, but not NCSTN, are still 
catalytically active and wild-type presenilin/ PEN-2 complexes can confer some enzyme 
activity. It should be noted however these experiments were performed under very 
specific experimental conditions that do not necessarily reflect the true in vivo 
environment of gamma-secretase and mainly studied mutant proteins. Even the work 
with wild type presenilin does not reflect the complicated assembly, maturation, 
trafficking and general stability of gamma-secretase in the body. Whilst it is therefore 
possible that not all wild type complex components are necessary to confer strict 
catalytic activity under experimental conditions they appear essential in producing and 
maintaining stable, mature and active complexes in vivo. Correspondingly, mRNA 
expression of each complex component very tightly mirrors that of the other three 
across different tissues. The mechanisms underlying this coordinated transcriptional 
regulation are poorly understood
160
. 
- 55 - 
Presenilin was the first component to be characterised following the identification of 
PSEN1 and PSEN2 mutations in familial Alzheimer’s disease (discussed further in 
section 1.3.7)
169
. Despite exhibiting the features and sequence of an aspartyl protease, 
presenilin alone exhibited no catalytic activity
170
. Consequently it was hypothesised that 
further proteins may be required to facilitate enzyme activity. Co-immunoprecipitation 
of presenilin lead to the subsequent identification and purification of nicastrin and a 
screen for proteins that are integral to Notch-pathway signalling in C.elegans identified 
the final two components, PEN-2 and APH-1
163; 171; 172
. The exact function of each of 
the individual components within the gamma-secretase complex is still poorly 
understood but is discussed in the following sections. 
1.3.1.1 Presenilin 
Presenilin (encoded by PSEN1 or PSEN2) is a multi-pass membrane protein comprising 
nine trans-membrane (TM) domains which forms the catalytic core of the gamma-
secretase complex. The immature protein is produced in the endoplasmic reticulum 
(ER) which is subsequently cleaved (endoproteolytic cleavage between PSEN1 Thr291 
and Ala299) to form a C-terminal fragment and an N-terminal fragment, referred to as 
mature presenilin
173; 174
. This cleavage is associated with a conformational change of the 
complex which facilitates enzyme activity. Each fragment harbours one of two key and 
highly conserved aspartate residues (TM 6 and 7, aa’s 256 and 385) which together 
form the active catalytic unit
175
.  
One of these aspartate residues lies within a highly conserved Glycine-X-Glycine-
Aspartic acid motif (aa 382-385, where amino acid X varies between species) and whilst 
the aspartic acid residue within this motif is critical for catalytic activity the two glycine 
residues and the variable X residue also confer important and diverse roles in enzyme 
activity. Mutational analysis of these residues suggests that the first (PSEN Gly382) is 
required for effective endopeptidase activity and the second (PSEN Gly384) for 
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effective carboxypeptidase-like activity
143
. They may also play a role in substrate 
specificity
176
. The polarity, charge and size of the variable “X” residue effects 
carboxypeptidase-like activity, possibly by altering the conformation of the protein
177
. 
Met139 is a further specific amino acid which seems to be selectively important in 
carboxypeptidase-like but not endopeptidase activity inferring that it may be in close 




A Pro-Ala-Leu sequence in TM9 (the PAL motif) is another highly conserved and 
functionally important region of presenilin. Mutagenesis of this region prevents 
nicastrin binding and renders the enzyme inactive
179; 180
. Cross-linking experiments and 
more recently x-ray crystallography have shown that this motif lies very close to the 
catalytically critical aspartate residue in TM6 (Asp256)
181; 182
. TM9 may therefore be 
important in facilitating substrate migration to the active catalytic site within 
presenilin
183
. The fact that presenilin can be co-precipitated with substrates infers that 
the two are in prolonged contact
184
. This potentially supports the hypothesis that a 
conformational change of the complex is required to move the substrate to the cleavage 
site and may imply that there is a significant distance between any potential substrate 
binding site and the catalytic cleavage site
185; 186
.  
Presenilin appears to form the main cohesive link in the gamma-secretase complex as it 
is the only subunit that can interact with all of the other constituents. PSEN1 can 
interact with NCSTN and PEN-2 in the absence of APH-1A, NCSTN and APH-1A in 
the absence of PEN-2 and with APH-1A and PEN-2 in the absence of nicastrin. NCSTN 
and APH-1A can interact with one another in the absence of PSEN1 but not with PEN-
2
162
 Presenilin is therefore required to mediate any reaction between APH-1A/NCSTN 
and PEN-2. The PSEN1-NCSTN interaction is particularly interesting as PSEN1 needs 
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NCSTN for stability and NCSTN requires PSEN1 to exit the ER and mature (mature 
nicastrin is not produced in PSEN1 deficient mouse embryonic fibroblasts (MEF))
 99; 112
. 
The function of presenilin within the complex is further complicated by the existence of 
two isoforms, PSEN1 and PSEN2. All mature gamma-secretase complexes contain 
either PSEN1 or PSEN2 but not both
160
. These isoforms share 67% of their sequence 





. In vivo, PSEN1 knockout is lethal whereas PSEN2 knockout mice demonstrate a 
mild phenotype with apparent lung fibrosis
188; 189
. In vitro, PSEN1 and 2 deficient cells 
display no enzyme activity (APP as substrate), PSEN1 deficient cells display very little 
enzyme activity and PSEN2 deficient cells display almost normal activity
190
. This may 
in part be due to the fact that PSEN1 is required for the effective trafficking of NCSTN 
out of the ER, thus its absence would impact upon PSEN2 complex formation. That 
effect does not appear to be reciprocated in PSEN2 deficient cells where normal PSEN1 
complexes are assembled
160
. Once formed, there is conflicting data regarding the 
relative efficacy of each complex in cleaving APP. Purified PSEN1 and PSEN2 gamma-
secretase complexes appear to show no significant difference in APP processing but 
PSEN2 complexes do however seem less likely to form than their PSEN1 
counterparts
166; 167
. There is some evidence to suggest that the nature of the assembled 
isoform differentially facilitates binding with varying complex interactors (eg. proteins 
that regulate gamma-secretase activity, discussed further in section 1.3.4) and may 
ultimately direct complex activity towards very separate signalling cascades, for 
example PSEN2 appears particularly important in PDGF signalling.  
Presenilin is clearly integral to gamma-secretase enzyme activity but there is emerging 
data suggesting that it may also be involved in biological processes unrelated to the 
complex. Independent functions may include protein trafficking (including proteins 
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Nicastrin (encoded by NCSTN) is a single pass trans-membrane protein composed of a 
large hydrophilic ectodomain (669aa), a short hydrophobic trans-membrane domain 
(20aa) and a short hydrophilic C-terminus (20aa)
171
. It is thought to be involved in 
complex assembly, migration, maturation and substrate recognition and accounts for 
just under half of the molecular weight of the gamma-secretase complex
144; 192
. An 
endoglycosidase-H-sensitive glycosylated precursor protein (immature form, 110kDa) 
is synthesised in the ER which undergoes glycosylation in the Golgi apparatus and 
sialylation in the trans-Golgi network (mature form, 130kDa, stable for up to 24 
hours)
186
. The ratio of immature to mature nicastrin varies in different cell types, for 
example it is high in fibroblasts and low in neurons
186
. Mature nicastrin is preferentially 
found in gamma-secretase complexes (PSEN1 has a higher affinity for mature nicastrin 
than immature nicastrin
162
) however immature forms do not detrimentally affect enzyme 
activity
186





. APH-1 binding is essential in forming the initial nicastrin-APH-1 
subcomplex in the ER which precedes full assembly of the complex (section 1.3.2) and 
PSEN1 binding is required for immature nicastrin to exit the ER
186
.  
The importance of nicastrin in overall complex assembly and activity has been 
demonstrated in animal studies. Fibroblasts harvested from nicastrin knock-out mouse 
embryos exhibit unstable and largely inactive gamma-secretase complexes (studying 
APP as a substrate)
195; 196
. Conversely, over-expression of nicastrin is sufficient to 
enhance gamma-secretase activity in vitro and in vivo (enhances APP processing)
197
. 
Over-expression was also shown to induce behavioural changes (suggestive of a lack of 
memory) and increase the expression of the other complex components in mice in 
- 59 - 
vivo
198
. The apparent memory deficit was postulated to occur as a consequence of 
altered APP processing and subsequent production of the amyloidogenic β-amyloid 42 
(Aβ42) peptide198. 
The exact functions of nicastrin within the gamma-secretase complex remain poorly 
defined. A conformational change in the ectodomain upon integration in to the gamma-
secretase complex is required for normal enzyme activity
199
. Three domains within the 
Nicastrin protein are highly conserved between animal species (amino acids 306 – 360, 
419 – 458, 625 – 662). The first of these has been a focus of investigation because it 
contains a very highly conserved and seemingly important DYIGS motif (aa 336-340) 
171
. Because this region of the ectodomain resembles aminopeptidase structures it is 
referred to as the DYIGS and peptidase homologous (DAP) region
171
. Mutagenesis of 
the DYIGS motif to AAIGS increases gamma-secretase carboxypeptidase-like 
processing of APP (increasing Aβ peptide secretion)171. Conversely, homozygous 
deletion of residues 312-369 and 312-340 (containing DYIGS) reduces APP processing 
(significant reduction in Aβ40 and Aβ42 levels, the effect was more pronounced with the 
deletion of residues 312-369). These larger deletions appeared to affect the nicastrin-
PSEN1 interaction.  
Mutation of the nearby E333 residue completely inactivates the gamma-secretase 
complex
192
. It was proposed that this residue binds to the amino terminus of membrane 
proteins (following initial shedding of their ectodomains) and may act as a substrate 
recognition site for gamma-secretase
192
. A later study disputed this claim, 
demonstrating that whilst mutations affecting this residue reduce nicastrin 
glycosylation, incorporation in to the complex and the amount of complex present they 
did not in fact alter the enzyme activity per complex
200
. Furthermore, deletion of 
residues 312-340 and 312-369, both containing E333, did not appear to affect substrate 
binding
171; 199; 201
 and mutagenesis of other residues within the aminopeptidase-like 
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domain of nicastrin that are integral to the catalytic function of related aminopeptidases 
conferred no significant effect on substrate binding
200
. Despite these data not supporting 
a substrate-recognition role for this part of the ectodomain it was later shown that 
NCSTN and APH-1A can both directly interact with APP in the absence of PSEN1 
(NCSTN with a higher affinity).
162
 Furthermore, PSEN1 seems unable to bind APP in 
the absence of APH-1 or NCSTN inferring that the NCSTN-APH-1A subcomplex plays 
a key role in substrate recruitment to the gamma-secretase complex
162
.  Furthermore, 
monoclonal antibodies have recently been developed which target the ectodomain of 
NCSTN and neutralise gamma-secretase activity in vivo and in vitro
202; 203
 with 
immunoprecipitation experiments indicating that one of the antibodies inhibits nicastrin-
substrate binding
202
. Specific mutagenesis of the L571 residue within the antibody 
binding region was found to inhibit substrate binding and consequently inhibit enzyme 
activity without affecting complex assembly
203
.  In summary, the NCSTN-APH1 sub-
complex and more specifically the L571 residue within the ectodomain of NCSTN 
appear to play a key role in gamma-secretase substrate recognition. Interestingly, 
combined C213S and C230S mutations affecting the NCSTN ectodomain affected APP 
but not Notch cleavage suggesting that different regions of the ectodomain may exhibit 
substrate specificity
198
. G365 and S425 represent two further functionally important 
amino acids within the ectodomain, with mutagenesis experiments demonstrating that 
they are important in complex formation but do not affect enzyme activity upon 
complexes forming.  
Nicastrin appears integral to optimal gamma-secretase activity however, as with 
presenilin, it may be able to function independently of the complex. In support of this, 
levels of nicastrin and presenilin are not co-ordinately regulated
204
 and some nicastrin 
and presenilin is not co-localised in cells. There is early evidence to suggest that 
nicastrin  may be involved in p53 mediated cell death
205
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1.3.1.3 PEN-2 
PEN-2 (encoded by PSENEN) is a 101 amino acid membrane protein comprising two 
extra-cellular termini, two trans-membrane domains, and one cytoplasmic loop. It is the 
smallest component of the gamma-secretase complex and the last to be assembled. It 
stabilises the complex (the other components are rapidly degraded  in the absence of 
PEN-2) and may induce a conformational change in the active site of presenilin to 
facilitate enzyme activity. PEN-2 binds to an “NF” motif in PSEN1 TM4206. The length 
and sequence of the C-terminal domain and the sequence of the proximal two-thirds of 




Alterations in PEN-2 expression affect the maturation of presenilin. Inhibition of PEN-2 
increases the ratio of full length PSEN1 to PSEN1-CTF/ PSEN1-NTF and PEN-2 
knockout results in no expression of PSEN1-CTF/ PSEN1-NTF
164
. On this basis it was 
proposed that PEN-2 is required for the endoproteolysis and thus maturation, 
stabilisation and activation of presenilin
207; 208
. However, recent work has shown that 
PSEN1-CTF and PSEN1-NTF are still produced in the absence of PEN-2 but are 
rapidly degraded by the proteosome (reversed in a time-dependent manner with 
proteosome inhibitors). This also appeared to be the case in NCSTN or APH1 knockout 
cells. Thus it was proposed that PEN-2 (and NCSTN and APH-1) is required to 
facilitate effective endoproteolysis of presenilin by stabilising the PSEN1-CTF and 
PSEN1-NTF products, rather than by having any direct involvement in the actual 
cleavage
162
. As mentioned previously, PEN-2 and presenilin alone are sufficient to 
support some catalytic activity in proteoliposomes
168
. This suggests that NCSTN and 
APH-1 are not essential for the stabilisation of PSEN1-CTF and PSEN1-NTF in that 
experimental setting and that PEN-2 may be the more dominant of the three in fulfilling 
that role
168
. This is supported by the increased ratio of full length presenilin to PSEN1-
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CTF/ PSEN1-NTF observed in PEN-2 knockdown cells. Increased levels of full length 
PSEN1 suggests that the Nicastrin-APH1A complex alone can stabilise and protect the 
full length PSEN1 protein but that it is not sufficient to stabilise the products of 
endoproteolysis without PEN-2
162
.   
1.3.1.4 APH-1 
APH-1 (encoded by APH1A or APH1B) is a multi-pass membrane protein with seven 
trans-membrane domains. Along with nicastrin, it appears to act as a scaffold upon 
which the complex can be assembled and may play a role in substrate recognition
209
. 
NCSTN and APH-1A have a very high affinity for one another and if the expression of 
one is reduced it has a profound effect on the expression of the other
162
. PSEN1 and 
PEN-2 appear to confer further stability to these components
162
. Aside from forming an 
important scaffold, the NCSTN/ APH-1 interaction appears to facilitate effective 
transfer of nicastrin to the outer cell membrane
172
 and, as mentioned previously, may 
play a role in substrate binding
162
. Two highly conserved histidine residues (H171, 
H197) in TM5 and TM6 respectively are integral to complex assembly, stability and 
ultimately activity
210




The differential roles of APH-1A (and associated splice forms APH-1aS and APH-1aL) 
and APH-1B remain unclear however APH-1A would appear to be the more dominant 
isoform given that APH1A knockout results in lethality which is not seen with APH1B 
knockout mice
212; 213
. APH-1A deficiency reduces the expression of the other enzyme 
components, increases the expression of APH-1B and inhibits enzyme activity. 
Conversely, APH-1B deficiency confers no effect on the expression of APH-1A, 
presenilin, nicastrin or PEN-2 and does not affect enzyme activity. Despite this, there is 
some evidence to suggest that APH-1B may play a dominant role in APP processing 
(Aβ production)212. It has been postulated that the APH-1 subtype, and therefore 
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potentially the splice variants of APH-1A, in each complex may affect which regulatory 
proteins are able to bind to and thus regulate complex activity
214
. . 
1.3.2 The assembly of the gamma-secretase complex 
All of the gamma-secretase components are synthesised in the ER. The formation of a 
sub-complex comprising immature nicastrin and APH-1 appears to initiate complex 
assembly
215
 however it should be noted that presenilin can form a sub-complex with 
APH-1 in the absence of nicastrin
162
. Presenilin and PEN-2 are then sequentially added 
to complete the complex and presenilin is cleaved (auto-proteolysis) to form PSEN1-
CTF and PSEN1-NTF. Any components that are not incorporated in to forming 
complexes are subject to rapid proteosomal degradation. Only a minority of the gamma-
secretase complexes (up to 5%) migrate to the Golgi apparatus and mature (nicastrin is 
subject to further N-glycosylation and matures in the Golgi). These mature complexes 
are then trafficked to the cell membrane and endosomes where they are catalytically 
active
189
. Whilst complex constituents are found throughout the ER and Golgi apparatus 
it is intriguing that enzyme activity is only detectable at or very close to the cell 
membrane
216; 217
. These active complexes constitute a minority of the total number of 
complexes within the cell. Up to 95% are seemingly inactive and remain within or cycle 
between the ER and Golgi
218; 219
. Stringent quality control mechanisms appear to be in 
place to ensure that only correctly folded and mature complexes can exit the ER. Each 
component of the complex appears to contain at least one ER retention sequence and it 
has been proposed that the correct assembly of the complex results in the masking of 
these specific motifs, thus allowing exit from the ER
179; 220-222
. Further mechanisms are 
in place to restrict complex formation in the ER. Rer1 protein for example regulates 
complex formation by competing for binding with NCSTN and PEN-2
221; 222
.  
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1.3.3 The structure of the gamma-secretase complex  
Regulated intra-membrane proteolysis describes the process of protein cleavage within 
the lipid by-layer by a membrane-bound protease. These membrane-bound proteases 
can be divided in to three broad groups, aspartyl proteases (presenilin and signal peptide 
proteases), metalloprotease site 2 protease and serine protease rhomboid. Whilst it is 
known to contain 19 trans-membrane domains the three dimensional structure of the 
gamma-secretase complex has been hard to elicit
144
. Studies using negative stain 
electron microscopy and electron cryo-microscopy have produced slightly conflicting 
results regarding the exact shape and volume of the complex. Overall, they indicated 
that the complex adopts a cylindrical structure harbouring a fully or partially patent 
aqueous cavity
223; 224
 and that the complex weighs around 230kDa, (consistent with the 
theory that each complex is made up of each of the four component parts in a 1:1:1:1 
ratio)
224
. This cylindrical globular structure has recently been corroborated via x-ray 
crystallography of the archeal presenilin homologue (PSH). Whilst this is not presenilin, 
the highly conserved amino acids account for just under half of the total aligned 
sequences and the catalytic motifs are completely conserved. The nine TM domains are 
arranged at varying angles in the membrane and the NTF arches like a horse-shoe over 
the CTF fragment. There is a fully patent pore created by TM 2, 3, 5 and 7 (Figure 1.5). 
The catalytically active residues (Asp162 and Asp220 in TM 6 and 7) lie at the bottom 
of a separate cytoplasm facing cavity (8Å from lipid membrane surface). They face one 
another and are situated 6.7Å apart. Water would be available through this cavity which 
is essential for peptide cleavage. The distance between aspartyl residues in related 
aspartyl proteases is less than that of a hydrogen-bond (just over 3.1Å) which is 
required for successful proteolytic activity. The larger distance in the archael presenilin 
homologue supports the notion that a conformational change is required, perhaps on 
substrates binding to the gamma-secretase complex, for the presenilin to become active. 
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The resting conformation may in fact act to prevent non-specific cleavage of membrane 
proteins. Substrate entry is proposed to be between TM6 and TM9. Via structural 
modelling these authors predicted that PEN-2 would bind to the opposite side of PSEN-
CTF to nicastrin and APH-1 which is in accordance with the aforementioned process of 
complex formation (Figure 1.6)
182
. Overall, these imaging studies suggest that an 
aqueous cavity within the protease facilitates intramembranous cleavage of membrane 
proteins. 
 
Figure 1.5. The 3D structure of the archael presenilin homologue (PSH).  This figure was 
taken directly from a paper by Li et al., 2013
182
. The nine trans-membrane domains of PSH are 
orientated at varying angles. The protein contains a fully patent pore surrounded by TM 
domains 2,3,5,7. The catalytically active aspartyl residues D220 and D162 face one another 
across a cytoplasm-facing cavity. Substrates are proposed to enter between TM6 and TM9. 
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Figure 1.6. The predicted structure of the gamma-secretase complex.  Mature presenilin is 
comprised of PSEN-CTF and PSEN-NTF. The C-terminal end of PSEN-CTF is predicted to be 
in contact with APH-1A and NCSTN and the N-terminal end in contact with PEN-2. 
  
1.3.4 Proteins that associate with the gamma-secretase complex 
The molecular weight of the complex varies significantly between studies, often far 
surpassing the cumulative predicted molecular weight of the four constituents. This may 
in part be due to the array of molecular techniques adopted however it may also be due 
to a variety of different proteins associating with the complex at the time of 
measurement. Multiple proteins have now been identified which can affect complex 
assembly, trafficking, activity and degradation but overall understanding of regulatory 
mechanisms governing enzyme activity remains in its infancy. 
A number of proteins have been shown to support complex activity. These comprise 
parkin, G-protein-coupled receptor 3, β-arrestin 1, β-arrestin 2, ATP-binding cassette 
transporter 2 (ABCA2), gamma-secretase activating protein (GSAP) and NADH 
dehydrogenase iron-sulfur protein 7 (NDUFH7)
225-231
. Parkin interacts with the 
presenilin promoter to upregulate PSEN1 transcription
225
. ABCA2 facilitates the 
glycosylation and trafficking of Nicastrin. Β-arrestin 1 is required for the assembly of 
the nicastrin-APH-1 subcomplex. G-protein-coupled receptor 3 and β-arrestin 2 confer 
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an effect on the cellular location of active gamma-secretase complexes (G-protein-
coupled receptor 3 also appears able to increase overall complex formation)
226; 228
. 
GSAP and NDUFH7 appear to be required for effective Aβ processing230; 231.  
Opposed to these apparent enzyme activity enhancers a number of proteins have 
recently been reported to surpress complex activity. These comprise retention in 
endoplasmic reticulum 1 (Rer1), serum and glucocorticoid-induced protein kinase 1 
(SGK1), retinoic acid, calreticulin, tubulin polymerisation promoting protein, 
tetraspanins, TMP21 and CD147
222; 231-237
. Retention in endoplasmic reticulum 1 (Rer1) 
is a negative regulator of gamma-secretase complex assembly. Rer1 competes with 
APH-1 for binding to the trans-membrane domain of nicastrin, thus preventing 
subcomplex formation and nicastrin release from the ER
222
. It can also prevent PEN-2 
from leaving the ER
221
. Synoviolin appears to regulate the proteosomal and lysosomal 
degradation of Rer1 via ubiquitination. Over-expression of synoviolin increases 
complex formation, enzyme activity and Aβ formation238. SGK1 phosphorylates 
nicastrin to induce its proteosomal or lysosomal degradation, thus reducing complex 
formation
232
. Over-expression of retinoic acid or calreticulin reduces Aβ levels233; 234. 
Knockdown or silencing of tubulin polymerisation promoting protein, tetraspanins 
(CD9, CD81, EWI-F or CD98hc), TMP21 and CD147 increases Aβ production231; 235-
237
. 
Given the link with Alzheimer’s disease the vast majority of research in this field has 
focussed on the interaction of gamma-secretase with APP. Many of the above 
interactors only appear to affect Aβ processing (carboxypeptidase-like activity) rather 
than ε-cleavage (endopeptidase activity) and as such may confer specificity towards 
APP as a substrate. Regardless, this work provides a unique insight in to the variable 
machinery that can associate with the complex to influence enzyme activity and 
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demonstrates that some of these proteins may differentially regulate the endopeptidise 
and carboxypeptidase-like activity of gamma-secretase.    
Two large studies have recently been performed to define the gamma-secretase 
interactome. The first of these used PSEN1 and PSEN2 knock-out mouse embryonic 
fibroblasts
235
. By transfecting flag-tagged PSEN1 and PSEN2 they were able to pull 
down active complexes and identify associated proteins via SDS-PAGE and mass 
spectrometry. The second analysed TAP-tagged presenilin from mouse brains and 
HEK293 cells in a similar manner
239
. Both studies identified the three other integral 
complex components NCSTN, PEN-2 and APH-1 along with 134 other proteins. These 
comprised families of proteins involved in protein trafficking, cell adhesion, cell 
signalling, transporter proteins, proteins involved in glycosylation, proteins integral to 
effective protein folding and proteins integral to the tetraspanin web. Ten proteins were 










- 69 - 
Table 1.1. Proteins that have been shown to interact with PSEN1 in two independent 
studies 
Function Protein Gene 








Transporters Na(+)/ K(+) ATPase1 
Proteolipid protein 2 
V-ATPase subunit D1 





Tetraspanin PGRL IGSF8 
Protein folding HSC70 HSPA8 
 
Whilst there was some disparity between the proteins identified in these studies they do 
provide an insight in to further complex interactors. Furthermore, the complex 
specificity of some of these proteins lends support to the growing evidence that subtle 
variation in complex composition (ie. PSEN1/ PSEN2, APH-1A/APH-1B) alters 
enzyme interactions and behaviour. For example, signal peptide peptidase (SPP) only 
appears to interact with PSEN2 containing complexes whereas catenins, cadherins and 
plakaphilins are more associated with PSEN1
239
.  
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1.3.5 Gamma-secretase processing of APP 
Gamma-secretase cleaves in excess of 30 type 1 membrane proteins however the 
mechanisms by which it processes APP and Notch have been studied in the most detail 
and provide an insight in to enzymatic function.  
The biological role of APP is unclear however it appears to affect fibroblast growth 
patterns, synapse density and memory retention in animals and play a role in neurite 
outgrowth
221; 222; 223; 224; 240
. APP is produced in the ER, modified in the Golgi 
(glycosylated, phophorylated and undergoes tyrosine sulphation) and a small proportion 
(10%) is transported to the cell membrane. The 695aa protein comprises a large 
ectodomain, a transmembrane region and an intracellular domain. The large ectodomain 
is initially cleaved by a β-secretase (BACE1)241 or an α-secretase (ADAM17, ADAM9, 
ADAM10, MDC-9, BACE-2)
242
 which directs further processing down one of two 
routes, amyloidogenic or non-amyloidogenic pathways respectively (Figure 1.7, Figure 
1.8). β-secretase cleavage leaves the transmembrane and intracellular domain of APP 
intact (100 peptide termed C100 protein). Gamma-secretase cleaves this protein 
(endopeptidase activity) resulting in the release of the APP intracellular domain 
(AICD). This initial cleavage leaves a portion of the protein within the cell membrane 
(β-amyloid) which is processed via a series of sequential cleavages (each removing 3 - 
4aa’s, carboxypeptidase-like activity).  This results in the release of β-amyloid peptides 
of different lengths. Depending upon the length of the membrane stub left following 
AICD cleavage (can differ by 1aa, Aβ48 or Aβ49), two different paths of Aβ processing 
can be followed generating peptides of different lengths (see Figure 1.7)
178
. Most 
secreted Aβ is of the Aβ40 length (90%), smaller amounts of Aβ42 and Aβ38 are 
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α-secretase cleavage of APP leaves a shorter transmembrane and intracellular domain 
(α-CTF) which is cleaved by gamma-secretase to form AICD and an N-terminally 
truncated Aβ (p3)240. The N-terminally truncated Aβ does not undergo any further 
processing by gamma-secretase. The biological role of AICD is unclear, however like 
NICD it may re-locate to the nucleus and affect gene transcription
244
. The biological 
role of Aβ is unknown. 
 
Figure 1.7. β-secretase/ γ-secretase processing of amyloid precursor protein (APP).  The 
APP ectodomain is initially cleaved by β-secretase, releasing the APP extra-cellular domain 
(APPsβ) and leaving a portion within the cell membrane (β-CTF/ C100). C100 is then cleaved 
by γ-secretase to release the APP intracellular domain. This leaves an intramembranous stub 
which is sequentially cleaved (“processed”) to form shorter and shorter Aβ fragments. The 
shorter fragments are eventually released from the membrane. These comprise Aβ38, aβ40, 
aβ42 and Aβ43. The longer peptides, particularly Aβ42, are more prone to aggregation and can 
from the amyloid plaques that are found in Alzheimer’s disease.  
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Figure 1.8. α-secretase/ γ-secretase processing of amyloid precursor protein (APP).  The 
APP ectodomain is initially cleaved by α-secretase, releasing the APP extra-cellular domain 
(APPsα) and leaving a portion within the cell membrane (α-CTF). α-CTF is then cleaved by γ-
secretase to release the APP intracellular domain (AICD) and the N-terminally truncated Aβ 
protein. This mechanism of APP processing does not result in the formation and deposition of 
short Aβ peptides, hence it is also referred to as the non-amyloidogenic pathway. 
 
1.3.6 Gamma-secretase processing of Notch 
Notch signalling controls cell fate decisions, differentiation, proliferation, apoptosis and 
cell and tissue patterning across the diverse array of tissue types required for normal 
human development
245
. Notch is synthesised in the ER as a 300kDa precursor protein 
and then transported to the Golgi where it is cleaved by furin-like convertase. The two 
cleavage products are non-covalently linked to form the notch heterodimer receptor 
which then undergoes sequential glycosylation prior to incorporation in to the cell 
membrane. EGF-repeats within the Notch ectodomain bind to the N-terminal ligand 
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domain of CSL ligands (Delta, Serrate and Jagged) expressed on the surface of other 
cells. The associated conformational change enables cleavage of the Notch ectodomain 
by ADAM10, ADAM 17, Kuz or SUP-17 leaving the Notch extracellular truncation 
(NEXT) in the membrane. The intracellular portion (Notch intracellular domain, NICD) 
is subsequently cleaved by gamma-secretase (endopeptidase activity), re-locates to the 
nucleus and affects gene transcription by binding with CSL, Mastermind (Mam) and co-
activators
245; 246
 (Figure 1.9). The remaining membrane stub is sequentially cleaved (as 
with Aβ in the case of APP processing) to form Nβ peptides of varying lengths247. The 
functional consequences of these peptides are unclear.    
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Figure 1.9. Gamma-secretase processing of Notch receptors.  The Notch receptor sits in the 
cell membrane and binds to ligands on opposing cell membranes. Binding induces a 
conformational change in the receptor that allows ADAM10 or ADAM17 to cleave the extra-
cellular portion of the receptor. This leaves the Notch extracellular truncation (NEXT) in the 
membrane which is in turn cleaved by gamma-secretase (endopeptidase activity) to release the 
notch intracellular domain (NICD). This re-locates to the nucleus and can affect gene 
transcription. The remaining intramembranous stub is sequentially cleaved (“processed”, 
carboxypeptidase-like activity) by gamma-secretase resulting in the release of Nβ peptides. 
 
1.3.7 PSEN1 and PSEN2 mutations reported in familial Alzheimer’s disease 
(FAD) 
The gamma-secretase complex became a focus of intense investigation following the 
discovery of heterozygous mutations in PSEN1 and PSEN2 in familial Alzheimer’s 
Disease (FAD)
169; 248
. Over 100 mutations have now been reported in presenilin and 
these are almost exclusively heterozygous missense variants 
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(http://www.molgen.ua.ac.be/ADMutations). Whilst some of these mutations affect the 
initial endopeptidase cleavage of APP they unanimously appear to affect the carboxy-
peptidase-like activity of gamma-secretase
178
. All mutations appear to increase the 
Aβ42: Aβ40 ratio178; 249 by increasing Aβ42 production, reducing Aβ40 production or 
via a combination of the two mechanisms. This appears to be due to an impairment of 
the fourth and final cleavage step in each of the two Aβ processing pathways (Aβ43 > 
Aβ40 and Aβ42 > Aβ38, see Figure 1.7) increasing the number of longer peptides 
produced. This may occur as a result of the peptides being prematurely released before 
the final cleavage can occur
178
. These longer peptides (Aβ42 and Aβ43) are more prone 
to aggregate (more amyloidogenic) and may be neurotoxic
250-252
. The functional 
consequences of these mutations therefore support the theory that the cerebral 
deposition of amyloid in the form of amyloid plaques drives the development of 
Alzheimer’s disease (the amyloid hypothesis)243; 253. Another interesting observation is 
that mutations have been reported in APP in Alzheimer’s disease which appear to 
preferentially direct processing down the Aβ42/ Aβ38 pathway rather than the Aβ43/ 
Aβ40 route. This effect was also observed with some PSEN1 variants178. Subtle changes 
in the ratios of these Aβ peptides significantly alter their biological behaviours, both in 
terms of aggregation and toxicity
254
. The ability of Aβ40 to stabilise the more 
amyloidogenic peptides and thus negate their aggregatory and toxic potential explains 
why a shift towards the Aβ42/Aβ38 pathway may be detrimental (Aβ38 does not confer 
the same level of stability as Aβ40)178. Rather than considering the total amount of Aβ 
peptides present as being the most important factor in disease pathogenesis, the recent 
data suggests that it is the ratio of the individual peptides that plays a more crucial 
role
255
. Gamma-secretase inhibitors (eg. Semagacestat) have recently been trialled in 
Alzheimer’s but conferred a negative impact on cognition and were associated with an 
array of what were thought to be Notch-related side effects including skin rashes. 
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Gamma-secretase modulators have more recently been developed (one being a non-
steroidal anti-inflammatory drug (NSAID) derivative) which appear to selectively 
modulate the carboxypeptidase activity of gamma-secretase, increasing the fourth 
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1.4 Aims and objectives 
The overall aim of this programme of research was to understand the genetic 
architecture of HS, the ultimate goal being to clarify the molecular mechanisms 
involved in disease pathogenesis. The principle objectives were three-fold: 
1/ Identify genetic variants that underlie susceptibility to familial HS. 
2/ Functionally characterise the identified mutations to elicit the molecular mechanisms 
by which they cause HS.   
3/ Determine the contribution of any identified disease gene(s) to other familial and 
sporadic cases of HS 
Shortly after this project started mutations were reported in the gamma-secretase genes 
in a small number of Chinese HS kindreds. Objective one therefore changed 
accordingly and became; assess the involvement of mutations in NCSTN, PSENEN and 
PSEN1 in familial cases of HS.  
The first part of this thesis (Chapter 3) explores the involvement of NCSTN, PSEN1 and 
PSENEN mutations in seven British multiplex kindreds with HS. The second part 
(Chapter 4) describes the functional characterisation of the identified mutations. This 
section investigates the effect of each mutation on the relevant gene transcript, protein 
and on gamma-secretase enzyme activity. The histological distribution of these proteins 
in both healthy and diseased skin was assessed via immunohistochemistry. The third 
part (Chapter 5) explores the involvement of NCSTN, PSENEN and PSEN1 mutations in 
a large cohort of affected individuals recruited from a tertiary referral hidradenitis 
clinic. The aim of that study was to determine the prevalence of mutations in these 
genes in the general disease population. Mutations in NCSTN, PSENEN and PSEN1 
only appeared to account for a minority of HS cases thus the fourth part of the thesis 
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(Chapter 6) describes the pursuit of further disease genes in unresolved familial cases 
and in well-defined phenotypic subgroups using a combination of gene mapping 
techniques including linkage analysis and next generation sequencing. The final part 
(Chapter 7) examines the clinical phenotype of all of the individuals found to harbour 
mutations in the gamma-secretase genes.   
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Chapter 2: Materials and Methods 
2.1 Patient and control cohorts 
2.1.1 Regulatory and ethical approval 
Prior to proceeding with patient recruitment the following steps were completed: 
1/ Mandatory training (Good Clinical Practice (GCP) course) 
2/ Designing a study protocol 
3/ Drafting study documentation 
3/ Application for ethical approval 
4/ Application for local Research and Development approval 
I was actively involved in designing the study protocol, writing the study documentation 
and preparing the ethics application for this project. I attended all relevant research 
ethics committee meetings and made any necessary amendments to the study protocol 
and documents prior to commencement. This study was approved by East London 
Research Ethics Committee 2 (09/H0704/50) and London Stanmore Research Ethics 
Committee (11/LO/0966) and conducted in accordance with Declaration of Helsinki 
principles. All approved study documentation (protocol, letters of invitation, patient 
information leaflets, consent documents, clinical research forms and advertisements to 
recruit control subjects) can be seen in Appendix 2. 
2.1.2 Clinical definition of Hidradenitis Suppurativa 
Based on diagnostic criterion previously devised for the purposes of research and 
formal clinical diagnostic criterion agreed at a recent international HS conference, the 
diagnostic criteria applied in this study were as follows: 
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A history of five or more painful or discharging nodules, abscesses or sinus tracts in the 
axillae, infra-mammary folds, groin, perineal region, perianal region or buttocks.   
2.1.3 Patient recruitment 
All probands were recruited from tertiary referral hidradenitis suppurativa clinics at 
either St. John’s Institute of Dermatology, Guy’s and St. Thomas’ Hospitals, London or 
St. George’s Hospital, London. All patients were presented with a letter of invitation 
and an information leaflet about the study. If they were happy to take part they were 
consented and a clinical history and examination was performed as detailed in the 
patient clinical research form, Appendix 2. If they were deemed to fulfil the diagnostic 
criteria detailed above they were asked to donate a blood (18ml in EDTA) or saliva 
sample (Oragene sample collection kit, DNA Genotek Inc., Kanata, Ontario, Canada) 
for DNA and RNA analysis. Selected individuals were also asked to donate two 6x6 
mm skin biopsies to provide tissue for histological analysis and fibroblasts for culture. 
The two skin biopsies were harvested from an affected and unaffected area of the axilla.  
2.1.4 Recruitment of family members 
Those individuals who presented with a family history of HS were asked to discuss the 
project with their respective family members. Any relatives who were interested in the 
study were sent a letter of invitation and an information leaflet. If, having read those 
documents, they were happy to be involved in the study then they were asked to return a 
reply slip and a formal appointment was arranged at St. John’s Institute of Dermatology. 
Individuals were consented, questioned, examined, had their affection status determined 
and asked to provide samples as documented above. For the minority of individuals 
who could not attend the outpatient department arrangements were made for a telephone 
interview and postal collection of a saliva sample, or a patient visit (Dermatologist 
accompanied by a Dermatology Specialist Nurse).  
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A total of 300 individuals were consented and recruited to the study. These comprised 
237 probands and 63 family members from 10 families (40 with, 23 without HS).  
2.1.5 Recruitment of healthy volunteer subjects (controls) 
Healthy volunteers were recruited following the release of a University-wide 
advertisement (Appendix 2). All volunteers were seen in the St. John’s Institute of 
Dermatology outpatient department where they were given a study invitation and 
information leaflet. If they were happy to take part they were subsequently consented to 
the study and provided a clinical history and underwent an examination as documented 
in the volunteer CRF (Appendix 2). Inclusion criteria were as follows: 
No history of comedones, papules, pustules, nodules, abscesses, sinus tracts or 
hypertrophic scars in the post-auricular region, axillae, infra or intra-mammary folds, 
abdominal fold, supra-pubic region, groin, perineal region, perianal region, buttocks or 
medial thighs. No history of an associated disorder of follicular occlusion or acne 
vulgaris and no family history of HS.   
All healthy volunteers who fulfilled the above criteria were asked to provide a blood 
sample for DNA or RNA analysis and 2 skin biopsies (performed exactly as 
documented above for the patients). Volunteers were age and sex-matched as closely as 
possible to the patients against whom they were being compared and were paid for their 
time. A total of 6 healthy volunteers were recruited to the study. 
2.1.6 Recruitment of patients with nodulocystic acne  
Patients with acne vulgaris have recently been recruited from general dermatology 
clinics at St. John’s Institute of Dermatology for a genome wide association study of 
acne vulgaris (study conducted in accordance with Declaration of Helsinki principles 
and approved by the St. Thomas’ Hospital Research Ethics Committee 
(05/Q0702/114)). Study criteria stated that all individuals had to have moderate-severe 
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acne, as evidenced by a Leeds Grading Score of >5 or a clinical report of moderate 
disease and previous treatment with isotretinoin (examined by a Dermatologist). In each 
case, the clinical sub-type of acne (eg. nodulocystic acne) was documented on the 
clinical research form. All patients were asked to donate a blood or saliva sample for 
DNA analysis. Forty eight patients with nodulocystic acne vulgaris were identified from 
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2.2 Antibodies used 
The following table (Table 2.1) lists the antibodies used in this study: 
Table 2.1. Antibodies used 
Primary Antibody Supplier Dilution Order 
number 
Rabbit polyclonal nicastrin  Abcam (Cambridge, UK) 1:400 WB 
1:200 IHC 
Ab24741 
Rabbit polyclonal nicastrin Abcam  1:750  Ab122969 














DAKO UK Ltd (Ely, 
UK) 
1:5000 A0398 
Rabbit polyclonal anti-CD3 DAKO UK Ltd 1:500 A0452 
Mouse monoclonal anti-L26 DAKO UK Ltd 1:100 M0755 
Mouse monoclonal anti-
CD68 
Abcam 1:1 Ab844 
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Secondary Antibody Supplier Dilution Order number 
Donkey anti-rabbit IgG 
horseradish peroxidise 
linked-antibody 
GE Healthcare UK Ltd. 
(Amersham, UK) 
1:10000 NA934V 
Goat polyclonal anti-mouse 
IgG horseradish 
peroxidase-linked antibody 
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2.3 Buffers used 
The following table (Table 2.2) lists the common buffers used in this study.  




573.18g guanidium hydrochloride (Sigma) in 1l dH2O 
7.5M ammonium acetate 115.62g ammonium acetate (Sigma) in 200ml dH2O 
20% sodium sarkyl 100g N lauryl sarcosine (Sigma) in 500ml dH2O 
96% ethanol 48ml pure ethanol (VWR International Limited, 
Lutterworth), 2ml dH20 
95% ethanol 47.5ml pure ethanol (VWR International Limited), 2.5ml 
dH20 
70% ethanol 35ml pure ethanol (VWR International Limited), 15ml 
dH20 
Tris-EDTA (TE) buffer 10ml 100x TE buffer (Sigma) diluted in 1l dH20  
3M sodium acetate (pH 
5.5) 
81.64g sodium acetate (Sigma) in 200ml dH20 
10xTBE 890 mM Tris-base, 890 mM Boric acid and 20mM EDTA 
(pH 8.0) 
1xTBE 100ml 10 x TBE, 900ml dH20 
10xTBS 30g Tris, 44g NaCl, 350ml dH2O, pH adjusted to 7.6 and 
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volume topped up to 500ml with dH20 
1xTBS 50ml 10x TBS, 450ml dH2O 
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2.4 Molecular biology techniques 
2.4.1 DNA extraction from blood (leucocytes) 
Blood samples were placed in 50ml centrifuge tubes and mixed with 30ml ice cold 
dH20 to induce erythrocyte cell lysis. Samples were spun at 1250g for 20 minutes at 4ºC 
and the supernatant was discarded. The leukocyte-rich cell pellet was solubilised in 
30ml ice cold 1% IGEPAL (SIGMA) and the sample was vortexed and spun at 1250g 
for 20 minutes at 4ºC (Rotanta 460R, Hettich, Salford, UK). The supernatant was 
discarded and DNAase inhibition and denaturation of the leukocyte lysates was 
achieved by adding 7ml of filtered 6M guanidium hydrochloride (SIGMA), 0.5ml 7.5M 
ammonium acetate (SIGMA), 0.5ml 20% sodium sarkosyl (SIGMA) and 150 µl 
proteinase K (SIGMA) (10mg/ml). Samples were vortexed and incubated at 60ºC for 90 
minutes. DNA was precipitated by adding 17ml 96% ethanol (EtOH) and gently mixing 
the sample. DNA was spooled out on to the tip of a Pasteur pipette. Pipette tips were 
placed in 1 ml of tris-EDTA (TE) buffer (SIGMA) in 10 ml centrifuge tubes. The DNA 
was detached from the pipette tips and re-dissolved overnight at 5ºC. DNA was re-
precipitated with 100µl 3M sodium acetate (pH 5.5, SIGMA) and 2.5ml ice cold 96% 
EtOH. DNA was spooled out as before, allowed to dry and re-dissolved in 500µl of TE 
buffer at 5ºC. The DNA concentration was measured on the Nanodrop 
Spectrophotometer (ND-1000, Thermo Scientific, Loughborough, UK) and samples 
were stored at -80 ºC. 
2.4.2 DNA extraction from saliva 
Saliva was collected as per manufacturer protocol in Oragene saliva vials (Oragene 
sample collection kit, DNA Genotek Inc., Ontario, Canada). Vials were incubated at 
50ºC for 60 minutes and each sample was divided in to 4 1ml aliquots. 40µl PrepIT L2P 
(commercial proprietary reagent, contents not disclosed by company, DNA Genotek 
Inc.) was added to each tube and the tubes were inverted and incubated on ice for 10 
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minutes. Samples were spun at 15000g (Centrifuge model 5415R, Eppendorf UK 
Limited, Stevenage, UK) for 3 minutes at room temperature and the supernatant from 
all four tubes was combined in one 15ml centrifuge tube. An equal volume of 95% 
EtOH was added to precipitate DNA and samples were inverted and allowed to stand 
for 10 minutes at room temperature. Each sample was spun at 1100g for 10 minutes at 
room temperature and the supernatant was discarded. A further spin at 1100g for 2 
minutes was performed and all excess supernatant was removed. The pellet was allowed 
to dry and was re-dissolved in 500µl TE buffer overnight at 5ºC. The DNA 
concentration was measured on the Nanodrop (Thermo Scientific) and samples was 
stored at -80 ºC 
2.4.3 Polymerase chain reaction (PCR) 
Primers were designed to amplify all coding exons and associated splice sites of NCSTN 
(17 exons), PSEN1 (10 exons), PSENEN (3 exons) (primer sequences listed in 
Appendix 3). All primers were ordered from Eurofins MWG Operon, Ebersberg, 
Germany. The PCR reaction mix totalled 10µl (components shown in Table 2.3): 




10 µM forward primer 
 
0.3 µl 
10 µM reverse primer 
 
0.3 µl 
2 µM dNTPs (ABgene Limited., Epsom, UK) 
 
1 µl 
10x polymerase buffer (ABgene) 
 
1 µl 







Every PCR comprised a denaturation step (96ºC for 5 minutes), 35 replication cycles 
(96ºC for 30 seconds, 56 - 62ºC (depending on primer requirements) for 30 seconds 
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(annealing) and 72ºC for 30 seconds (elongation)) and a final clean-up step (72ºC for 10 
minutes). All PCR cycles were performed on the G-Storm GS4 Thermal cycler (Labtech 
International Ltd., Ringmer, UK). 
2.4.4 Analysis of PCR products by agarose gel electrophoresis 
1g of agarose (Sigma) was added to 100ml of 1 x TBE buffer and heated in the 
microwave for 2 minutes until fully dissolved. 5 µl ethidium bromide (Sigma) was then 
added to the cooled agarose solution and it was poured out and allowed to set. DNA 
samples were mixed with 5 x loading buffer (Bioline, London, UK) and run on the gel 
at 100mA for 20-30 minutes. The amplified products were analysed on a UV 
transilluminator (GelDoc-It Imaging System, UVP, Cambridge, UK). 
2.4.5 Direct nucleotide sequencing 
All PCR products were purified using ExoSAP (Affymetrix, High Wycombe, UK). 2 µl 
DNA was added to 0.26 µl of ExoSAP and 5.74 µl dH20 and incubated at 37ºC for 30 
minutes and 80ºC for 15 minutes. The product was sequenced using a Big-dye 
terminator kit (Life Technologies Limited, Paisley, UK). 3.5 µl of product was added to 
1.25 µl Big-dye sequence buffer (Life Technologies), 0.25 µl Big-dye 3.1 (Life 
Technologies) and 0.25 µl forward primer. A further 3.5 µl of product was added to 
1.25 µl Big-dye sequence buffer, 0.25 µl Big-dye 3.1 and 0.25 µl reverse primer. Both 
mixes were thermo-cycled at 96ºC for 30 seconds, 50ºC for 15 seconds and 60ºC for 60 
seconds for a total of 30 cycles. Samples were further purified via ethanol precipitation. 
26 µl of precipitation solution (50ml EtOH, 2ml 3M NaOAc pH4.6 (SIGMA)) was 
added to each sample. Sampled were allowed to stand for 10 minutes then spun at 
3000rpm for 30 minutes at room temperature. 100 µl 70% EtOH was added to each 
sample and samples were spun at 3000rpm for 10 minutes at room temperature and then 
left to dry for 10 minutes. 10 µl HiDi Formamide (Life Technologies) was added to 
each reaction and the products were heat denatured (incubated at 90ºC for 2 minutes). 
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All sequencing reactions were run in 96 well plates on the ABI 3730XL Automated 
Sequencer (reagents supplied by Applied Biosystems, Life Technologies). Results were 
analysed using Sequencher software (Gene Codes Corporation, Michigan, USA). All 
sequence variants were detected via visual inspection. 
2.4.6 Genotyping using Exome chip 
Genotyping was performed using the Illumina Infinium HD Assay Ultra kit and 
Infinium HumanExome 12v1.1 chip following the published protocol (Illumina, Little 
Chesterford, UK). All samples were prepared using automation (Freedom Evo, Tecan 
Group Ltd., Reading, UK). 200ng DNA was denatured and neutralised. The denatured 
DNA was isothermally amplified overnight (increasing total amount of DNA by several 
thousand-fold) and fragmented via a controlled enzymatic process using end-point 
fragmentation. DNA was precipitated by adding isopropanol and pelleted with 
centrifugation. The precipitated DNA was re-suspended in hybridisation buffer and 
loaded on to a BeadChip, divided by an IntelliHyb seal. The chip was incubated 
overnight in a hybridisation oven resulting in the hybridisation of DNA fragments to 
locus specific 50-mers (all covalently linked to one of up to 300000 bead types). The 
Beadchip was washed to remove any unhybridised or non-specifically hybridised DNA. 
The bound DNA was used as a template to add a single labelled base to the oligos on 
the BeadChip (single-base extension). The oligos are designed in such a way that the 
base following the sequence of bases forming the oligo is the one of interest (single base 
polymorphism). Thus the identity of the single base extension (A, T, C or G) represents 
the genotype call for that particular SNP in that sample. These single bases are labelled 
so when the Beadchip is placed in a BeadArray Reader the identity of these bases can be 
identified (a laser excites the fluorophore of the single-base extension product and the 
scanner records high resolution images of the light emitted from the fluorophores).   
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2.4.7 Exome chip data analysis to define regions of linkage within pedigrees 
Data for around 5000 single nucleotide polymorphisms (SNPs), representing a linkage 
panel (www.illumina.com/exome), was collated for individuals within any one 
multiplex kindred and analysed using MERLIN (Multipoint Engine for Rapid 
Likelihood Inference) software
256
. An affected only analysis was performed given the 
variable age of onset observed in HS and an autosomal dominant model was adopted as 
the disease segregated as an autosomal dominant trait in the pedigrees studied.      
2.4.8 Whole exome sequencing method 
Whole exome capture was performed via in-solution hybridisation followed by 
massively parallel sequencing. In-solution hybridisation was performed using the 
SureSelect All Exon 50Mb Target Enrichment System (Agilent, Wokingham, UK). The 
first 16 samples were manually prepared and the remaining 52 samples were prepared 
using automation (Agilent Bravo, Agilent BenchCel 4R, Agilent PlateLoc, Agilent). 
3µg of genomic DNA was sheared to.create DNA fragments with a maximum length of 
150 – 200bp. These fragments were subjected to end-repair, blunting the ends of each 
fragment, and 5’-phosphorylation. Adenine bases were added to the 3’ end to create an 
overhang. Adaptors were ligated to both ends of each fragment and unligated adaptors 
were removed. The adaptor-ligated library was then amplified (4 PCR cycles) to form 
the prepped library. Biotinylated RNA library “baits” (Agilent Whole Exome XT Baits, 
Agilent), designed to bind to coding regions, were hybridized to the prepped genomic 
sample (24 hour hybridization) and bound DNA fragments were harvested using 
Streptavidin coated magnetic beads which selectively bind to the biotinylated RNA 
“baits” (bead capture or hybrid capture selection). Unbound DNA fragments were 
discarded. DNA fragments were eluted from the Streptavidin coated beads and the 
biotinylated RNA “baits” bound to the DNA fragments were digested. The DNA was 
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amplified via PCR (12 cycles) and index tags were added. Samples were pooled and 
sequenced on the HiSeq 2000 (Illumina) with 100bp paired end reads.  
2.4.9 Whole exome sequencing data preparation 
Sequence reads were aligned to the reference genome (hg19) with Novoalign 
(Novocraft Technologies, Kuala Lumpur, Malaysia). Reads mapping to multiple 
locations and duplicate reads (resulting from PCR clonality or optical duplicates) were 
excluded from downstream analysis. The depth and breadth of sequence coverage was 
calculated with custom scripts and the BedTools package
257
. More than 4.1Gb of 
sequence was generated for each individual and an average of 89.3% of the coding 
bases of the RefSeq-defined exome were represented by at least 20 reads. Single 
nucleotide substitutions and small insertion/ deletion variants were identified and 
quality filtered using the SamTools software package
258
 and in-house software tools. 
Annovar
259
 was used to annotate variants according to genes and transcripts. All 
variants were filtered against dbSNP137, NHLBI Exome Sequencing Project Exome 
Variant Server (EVS, http://evs.gs.washington.edu/EVS/), the 1000 Genomes Project 
database
260
 and over 600 high quality in-house control exomes (sequenced and analysed 
by the method described above) to determine their novelty. Copy number variation was 
identified and quality filtered using the Exome Depth package
261
 and annotated using 
BedTools
257
. All variants were filtered against the database of genomic variants 
(http://dgvbeta.tcag.ca/dgv/app/home) to determine novelty.  
2.4.10 RNA isolation from whole blood 
500µl of anti-coagulated (EDTA) whole blood was added to 1.3ml RNA later (Life 
Technologies) and mixed. RNA was extracted using a Ribopure Extraction Kit (Life 
Technologies, all reagents, spin columns and tubes were provided as part of this kit 
unless otherwise stated). The sample was centrifuged at 16000g for 1 minute at room 
temperature and the supernatant was removed. 800 µl lysis solution and 50µl sodium 
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acetate solution were added to the cell pellet to induce lysis and the sample was 
vortexed. 500µl of acid-phenol: chloroform was added and the sample was vortexed and 
left at room temperature for 5 minutes. The sample was the centrifuged at 16000g for 1 
minute at room temperature and the aqueous (upper) phase was transferred to a new 2ml 
tube. The sample was loaded to a gDNA eliminator mini spin column to remove DNA 
and spun at 8000g for 30s at room temperature. The column was discarded and 600µl of 
100% EtOH was added to the remaining sample to precipitate RNA. 700µl of the 
sample was added to a filter cartridge assembly and spun at 16000g for 10 seconds. This 
was repeated with a further 700µl of sample and the flow-through was discarded. 700µl 
wash solution 1 was applied to the cartridge and spun at 16000g for 10 seconds, the 
through-flow was discarded. 700µl wash solution 2/3 was applied to the cartridge and 
spun at 16000g for 10 seconds and the through-flow was discarded. This step was 
repeated to thoroughly wash the RNA. The cartridge assembly was centrifuged at 
16000g for 1 minute and transferred to a collection tube. 25 µl of elution buffer (pre-
heated to 75 ºC) was added and left for 20 seconds. The tube was spun at 16000g for 30 
seconds to recover the RNA. RNA concentration was measured on the Nanodrop 
(Thermo Scientific) and the sample was stored at -80 ºC. 
2.4.11 RNA isolation from cells 
Cell media was aspirated and the cells were washed with phosphate buffered saline 
(PBS, Gibco, Life Technologies). Cell detachment was induced with TrypLE Express 
1x (Gibco, Life Technologies). Once the cells had detached they were mixed with an 
equal volume of medium containing serum (DMEM (1x) + GlutaMAX + 10% fetal 
bovine serum (FBS)) to inactivate the trypsin. The cells were transferred to a 15ml 
centrifuge tube and centrifuged at 1000rpm for 5 minutes at room temperature. The 
supernatant was aspirated and the cell pellet was suspended in 100-150ul RNA later 
solution (Life Technologies), transferred to a 1.5ml micro-centrifuge tube and frozen at 
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-80 ºC. RNA was extracted from this sample using the Qiagen RNA Easy Plus Mini Kit 
(Qiagen, Crawley, UK) (all reagents, spin columns and tubes stated in the below 
method are provided with this kit unless otherwise stated). The sample was thawed on 
ice and the eppendorf was flicked twice. 600 µl of Buffer RLT Plus was mixed with 6 
µl of β-Mercaptoethanol. 600µl of this mixture was added to the cell sample and the 
sample was vortexed for 3s to mix (to induce cell lysis). The lysate was homogenised 
by pipetting it in to a QIAshredder spin column placed in a 2ml collection tube and 
centrifuging at 15000rpm for 2 minutes. The spin column was discarded and the 
homogenised lysate was transferred to a gDNA Eliminator spin column and centrifuged 
at 8000rpm for 30s at room temperature to eliminate DNA from the sample. The spin 
column was discarded and 600 µl of 70% EtOH was added to the flow through to 
precipitate RNA and the sample was mixed well by pipetting. 700 µl of the sample was 
placed in an RNeasy spin column placed in a 2ml collection tube and centrifuged at 
10000rpm for 15s at room temperature. The flow through was discarded. This step was 
repeated until of the sample had been run through the RNeasy spin column. 700 µl of 
Buffer RW1 was then added to the RNeasy spin column and centrifuged at 10000rpm 
for 15s at room temperature to wash the spin column membrane. The flow through was 
discarded. 500 µl of Buffer RPE was added to the RNeasy spin column and centrifuged 
at 10000rpm for 15s at room temperature to further wash the spin column membrane. 
The flow through was discarded. One final wash was performed by adding another 500 
µl Buffer RPE to the RNeasy spin column and the column was centrifuged at 10000rpm 
for 2 minutes. The RNeasy spin column was placed in a new 2ml collection tube and 
centrifuged at 15000rpm for 1 minute to eliminate any remaining RPE buffer. The 
RNeasy spin column was then placed in a new 1.5ml collection tube. 30 µl RNase-free 
water was added to the spin column membrane and centrifuged at 10000rpm for 1 
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minute to elute the RNA. The RNA concentration was measured on the Nanodrop 
(Thermo Scientific) and the sample was stored at -80 ºC. 
2.4.12 RNA interference 
35000 primary human fibroblasts were seeded in a 24-well tissue culture plate (Costar, 
Corning, New York, USA) well and grown until 30-50% confluent (roughly 24 hours, 
see maintenance of primary human fibroblasts, section 2.6.3). Cell media was removed 
and cells were washed with 1ml PBS (Gibco, Life Technologies) and the PBS was 
aspirated. A 20µM stock solution of NCSTN SiRNA (ON-TARGETplus SMARTpool 
siRNA J-008043-08, J-008043-07, J-008043-06, J-008043-05, Thermo Fisher 
Scientific, Loughborough, UK) was made up and diluted to 25nM in OptiMEM I 
Reduced Serum Medium (Gibco, Life Technologies). 1µl of Lipofectamine 2000 
Transfection reagent (Invitrogen) was diluted in 50µl OptiMEM I Reduced Serum 
Medium and incubated at room temperature for 5 minutes. 50 µl of this solution was 
combined with 50µl of the 25nM SiRNA solution, mixed and incubated at room 
temperature for 20 minutes. This mixture was added to the well and the well was topped 
up with an additional 400µl OptiMEM I Reduced Serum Medium. After 3 hours a 
further 500µl Cascade 106 media (Gibco, Life Technologies) + LSGS supplement kit 
(S-003-K, Gibco, Life Technologies) was added to the well and the cells were left 
incubating at 37ºC for 48 hours. All SiRNA experiments were performed in triplicate. 
RNA was extracted from one well and protein was extracted from the remaining two 
wells. A further three wells of cells were seeded for each patient and not exposed to 
SiRNA but cultured in identical media without SiRNA so as to act as controls. RNA 
and protein were extracted from one well and two wells respectively as with the 
SiRNA-treated cells. RNA facilitated real time PCR (section 2.4.16) to determine if the 
knockdown had been successful and protein was used for immunoblotting as detailed in 
section 2.7.4.  
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2.4.13 Verification of the specificity of an NCSTN antibody by RNA interference 
RNA interference was performed to confirm the identity of the NCSTN protein band on 
immunoblotting. When RT-PCR had been performed and clarified that effective 
knockdown had occurred, protein from cells exposed to SiRNA and not exposed to 
SiRNA was subjected to electrophoresis and immunoblotted (see section 2.7.4). If the 
protein band observed does indeed represent NCSTN, then the band observed using 
protein harvested from knocked-down cells should be smaller and less dense than that 
observed from untreated cells.  
2.4.14 Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR was performed using the high capacity cDNA reverse transcription kit (Life 
Technologies). The PCR reaction components used are shown in  
Table 2.4, each reaction totalled 20µl. 




10 x RT buffer 
 
2 µl 
25 x dNTP Mix (100mM) 
 
0.8 µl 
10 x RT random primers 
 
2 µl 







The mix was incubated at 25ºC for 10 minutes, 37ºC for 120 minutes and 85ºC for 5 
minutes on the G-Storm GS4 Thermal cycler (Labtech International Ltd.). cDNA was 
stored at -20ºC. 
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2.4.15 cDNA PCR and direct sequencing 
Exonic primers were designed to amplify a segment of PSENEN cDNA and the full 
length NCSTN cDNA (Table 2.5, ordered from Eurofins MWG Operon). PCR was 
performed as described in section 2.4.3 for PSENEN cDNA (but cDNA was used 
instead of DNA). Due to the size of the full length NCSTN transcript (2944kb) the PCR 
reaction mix was altered (see Table 2.6) and the reagents from the KOD Hot Start DNA 
Polymerase Kit (Novagen) were used. The PCR cycle was also different comprising a 
denaturation step (95ºC for 5 minutes), 40 replication cycles (95ºC for 30 seconds, 58ºC 
for 30 seconds (annealing) and 70ºC for 150 seconds (elongation)) and a final clean-up 
step (72ºC for 10 minutes). 
Table 2.5. cDNA primers used for sequencing NCSTN and PSENEN cDNA 
Gene 
transcript 
Forward primer Reverse primer 
NCSTN  
(spanning 
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10 µM forward primer 
 
1.5 µl 






2 mM dNTPs  
 
5 µl 
10 x Buffer KOD Hot Start DNA Polymerase 
 
5 µl 
KOD Hot Start DNA polymerase (1U/ µl) 
 
1 µl 




Direct sequencing was performed as described in section 2.4.5. Due to the length of the 
full length NCSTN transcript five pairs of overlapping primers (not including those 
used for the PCR step) were designed for sequencing (shown in Table 2.7) (Eurofins).  
Table 2.7. Primers used to sequence the full length NCSTN transcript 
Gene 
transcript 
Forward primer Reverse primer 
NCSTN  TCCTTCGCCTTCTGTCTTTC CTAAAGTCTTCATAAGCCAA 
NCSTN TATGGGCCAGAGTTTGCTCA CGAGCTGCCAATGTAGTCAA 
NCSTN GGGACATTAAAGCCTGACGA TGGTTCCGTACAGACTCATTTTT 
NCSTN GCAGCTCGAGGATGGTCTAC TTAGGTCCTGCCTGAGGATA 
NCSTN GAACCAACTTCAGCGACACA AGAAGATGAGGATGCCGAAG 
 
2.4.16 Gene expression assays 
Total NCSTN and PSENEN mRNA levels were assessed by multiplex real-time PCR 
using validated Taqman Gene Expression Assays (Life Technologies) as per the 
manufacturer’s instructions. The PCR reaction mix comprised the components shown in  
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Table 2.8, totalling 20µl. 




20 x TaqMan Gene expression Assay (probe) 
 
1 µl 
2 x TaqMan Gene Expression Master Mix 
 
10 µl 







All PCR reactions were carried out in 96-well optical plates (ABgene) with optical 
adhesive lids. Samples were amplified in an Applied Biosystems 7900HT Sequence 
Detection System and all reactions were performed in triplicate. NCSTN and PSENEN 
amplification (Taqman probe details shown in Table 2.9) was performed under the 
following cycling conditions: 95°C for 10 minutes followed by 40 cycles of 95°C for 15 
sec and 60°C for 1 min. Target gene expression was normalized to that of GAPDH and/ 
or 18sRNA endogenous genes (Assay ID 4326317E, 4310893E respectively, Life 
Technologies). Results were analysed using SDS 2.4 (Life Technologies). Real-time 







Ct value was calculated using the formula: 
ΔΔ
Ct= (CT,Target - 
C,Endogenous)Treated - (CT,Target - C,Endogenous)Untreated.  
Table 2.9. Taqman probes used to study NCSTN and PSENEN transcript expression 
Assay ID* Gene Target exon Target sequence 
Hs00299716_m1 NCSTN Exon 2 TGGCTGCCAGTCTTCAATTAGTGGA 
 
Hs01033959_g1 PSENEN Exon 1 AGTGAGCTCTCCTGGGGCGTGGTTG 
* All assays were purchased from Applied Biosystems 
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2.4.17 Multiplex Ligation-dependent Probe Amplification (MLPA) 
Assays were performed as per manufacturer protocol with SALSA MLPA kit P254 
PSEN1 and SALSA MLPA kit P200-A1 (MRC-Holland, Amsterdam, Netherlands) 
which contains eleven reference probes and additional space for the insertion of user-
designed custom probes. Custom probes were designed for all exons of PSENEN (added 
to P254 PSEN1) and NCSTN (added to P200-A1) as per MRC-Holland instructions 
(http://mlpa.com) and manufactured by Eurofins MWG Operon (probe sequences 
shown in Appendix 4). They were prepared and diluted according to the synthetic 
MLPA protocol (http://mlpa.com), as described in Hills et al. 2010
263
.  
At least three control samples (unaffected individuals) and a no DNA control sample 
were run with every reaction. For analysis, 3ul of PCR product was added to 0.3ul 
Genescan 500 LIZ size standard (Applied Biosystems) and 15ul HiDi formamide prior 
to size separation on a 3730XL genetic analyser (Life Technologies) as per 
manufacturers instructions.  
Data was analysed using GeneMarker v1.8 software (SoftGenetics, State College, 
USA). The maximum raw data peak height was set at 15000 relative fluorescent units 
(rfu) with a lower limit of 250 rfu (samples outside of these limits were failed). Peak 
height data from MRC-Holland P200 kits with added custom probes were analysed 
according to recommendations on data normalisation provided on the MRC-Holland 
website (http://mlpa.com), as described in Hills et al. 2010
263
. Peak height data from 
MRC-Holland P200 kits with added custom probes were analysed according to 
recommendations on data normalisation provided on the MRC-Holland website, as 
described in Hills et al. 2010
263
. Panels were designed to detect one or more custom 
probes per kit.  
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Copy number changes were displayed via application of the MLPA Ratio function 
(peak height ratios defined deletion as <0.71, duplication > 1.23). Patient data was then 
compared to a synthetic control which was generated from at least two good quality 
control samples. If reference probe peaks ratios were outside of the normal range then 
the sample was failed, as was the case if there were high QC fragment peaks.
263
 
Figure 2.1a shows an electropherogram with custom probes for NCSTN exons (on the 
left hand side of the trace) against the reference probes in the MRC-Holland P200 kit 
(on the right). Figure 2.1b shows the analysed data of this sample. The green dots 
represent the exons of the genes of interest (in this case PSEN1 and PSENEN) and the 
blue dots represent the reference probes. As can be seen, there is always some slight 
variability in the peak height ratio of each exon but in this example they all fall within 
normal limits (represented by the horizontal green lines, MLPA peak height ratios 
defined as deletion <0.71, duplication > 1.23)
263
. 
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Figure 2.1. Example of MLPA results.  A) A graph showing the raw peak heights (relative 
fluorescent units) relating to 5 exons of NCSTN (green) and reference probes (blue) in one 
individual. B) Graph showing the normalised peak ratios of each exon (control probes shown in 
blue). The normal limits are delineated by horizontal green lines. Duplications would be 
expected to be above the top line and deletions below the lower line. 
 
2.4.18 Preparation of Luria Bertani (LB) medium and 2 x LB media 
Luria Bertani medium was prepared by adding 10g bacto-tryptone (Becton, Dickinson 
and Company, Sparks, USA), 5g yeast extract (Becton, Dickinson and Company) and 
10g sodium chloride (VWR, Lutterworth, UK) to 800ml distilled water. pH was 
adjusted to 7.5 using sodium hydroxide (BDH Laboratory Supplies, Poole, UK) and the 
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final volume of media was made up to 1l with distilled water. The media was sterilised 
in an autoclave (200/35L, Boxer Laboratory Equipment Ltd., London, UK). 2 x LB 
medium was prepared by adding 20g bacto-tryptone, 10g yeast extract and 20g sodium 
chloride to 800ml distilled water. The pH was adjusted to 7.5, the volume made up to 1l 
and the media was sterilised as per 1x media.  
2.4.19 Preparation of C100-Flag pET-21b (-) plasmid 
A C100-Flag pET-21b (-) plasmid was provided by Dr Oliver Holmes, Centre for 
Neurological Diseases, Harvard Medical School, Boston, USA
264
. This plasmid was 
formed by generating a DNA fragment encoding amino acids 596-695 of the 695 amino 
acid isoform of amyloid precursor protein (APP), adding a Flag sequence 
(DYKDDDDK) at the C-terminus and inserting the whole fragment between Hind III 
and Nde I in to the prokaryotic expression vector pET-21b (Novagen, Merck Serono 
Ltd., Feltham, UK)
265
. The Methionine at the N-terminus (amino acid 596) serves as the 
translation start site. This plasmid was shipped on filter paper and extracted by placing 
the filter paper in 100ul TE buffer for 24 hours (4ºC). 
2.4.20 Transformation of NEB 5-alpha competent E Coli with C100-Flag pET-21b 
(-) plasmid  
Bacterial transformation was performed by taking 50ul competent cells (NEB 5-alpha 
competent E Coli, New England Biolabs, C2988), adding 5ul C100F plasmid DNA and 
incubating on ice for 30s. The cells were heat-shocked at 42ºC for exactly 45 seconds 
(to permeabilise the cell membranes and allow plasmid uptake) and incubated on ice. 
Cells were placed in 250ul SOC media and shaken at 37ºC for 1 hour. 100µl was spread 
over a pre-warmed LB plate (25ml 1xLB + 25µl 100mg/µl Ampicillin (Sigma) spread 
over the surface). This plasmid confers resistence to ampicillin thus the use of an 
ampicillin containing plate encourages growth of the plasmid-expressing bacteria. When 
the plate was dry it was incubated at 37ºC overnight (inverted) to allow the bacteria to 
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multiply. One colony was isolated on a pipette tip and added to 5ml LB. This was 
shaken (300rpm) at 37ºC for 8 hours. A larger 150ml LB culture was inoculated with 
the whole 5 ml starter culture and shaken (300rpm) at 37ºC for 16 hours. Bacterial cells 
were harvested by spinning at 6000 x g for 15 minutes at 4ºC. The supernatant was 
discarded and plasmid was purified from the cell pellet as detailed below. 
2.4.21 Plasmid purification 
Plasmid purification was performed using the Qiagen HiSpeed Plasmid Midi Kit 
(Qiagen) (all reagents, spin columns and tubes stated in the below method are provided 
with this kit unless otherwise stated). The bacterial cell pellet was suspended in 6ml 
Buffer P1 and 6ml Buffer P2 was added. The tube was inverted and incubated at room 
temperature for 5 minutes to induce bacterial cell lysis. 6ml chilled Buffer P3 was added 
to the lysate and the sample was inverted 4 times to mix and then placed in a QIAfilter 
cartridge. The cartridge was incubated for 10 minutes at room temperature and filtered 
in to a HiSpeed Midi tip (removing precipitated protein, genomic DNA and detergent). 
The sample was allowed to enter the HiSpeed Midi tip resin by gravity flow (plasmid 
DNA is held within this resin). Plasmid DNA was washed by adding 20ml Buffer QC to 
the tip and then eluted with 5ml Buffer QF. DNA was precipitated by adding 3.5ml 
isopropanol (room temperature), mixing and incubating the sample for 5 minutes. This 
sample was added to a 20ml syringe and filtered through a QIAprecipitator Midi 
Module. The DNA was washed with 70% ethanol, dried (by pushing air through the 
QIAprecipitator) and eluted with 400µl TE Buffer. The purified plasmid was stored at -
80ºC.    
2.4.22 Transformation of E-Coli BL21 DE3 cells with C100Flag – pET-21b 
plasmid 
BL21 (DE3) competent E. coli (New England Biolabs, C2527I) were defrosted on ice 
and 100ng plasmid was added to 50μl of cells. The sample was incubated on ice for 30 
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minutes and then heat-shocked at 42 ºC for exactly 10 seconds to permeabilise the cell 
membranes. The sample was placed in 950μl SOC media and shaken for 1 hour at 37ºC. 
100μl sample was spread over a pre-warmed LB plate (25µl 100mg/µl Ampicillin 
spread over the surface) and the plate was left inverted at 37ºC overnight. A 5ml LB 
culture (+ 100µg/ml ampicillin) was inoculated with one island of bacterial cells and 
shaken at 180rpm for 8 hours at 37ºC. 25µl of 100mg/ml ampicillin was added to this 
culture and it was stored at 4ºC overnight. 4ml of this starter culture was warmed and 
added to 200ml warm 2 x LB media (+100µg/ml ampicillin). The culture was shaken at 
180rpm at 37 ºC until the OD600 was 0.8 (3-4 hours, light absorbance measured on 
FLUOstar Omega plate reader, BMG Labtech, Almendgruen, Germany). Protein 
expression was induced by adding 1.0mM IPTG (SIGMA) to the culture and leaving it 
shaking at 180rpm at 37ºC for 4 hours. The sample was spun at 3000 x g for 10 minutes 
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2.5 Immunohistochemistry  
2.5.1 Embedding of skin biopsies in paraffin 
Skin biopsies were placed in formalin for 48 hrs and transferred to 70% EtOH. The 
sample was then processed in the Leica TP2020 Processor (standard machine protocol) 
and embedded in paraffin using the Leica EG1150C embedding machine. 
2.5.2 Sectioning and staining paraffin embedded skin 
Paraffin sections were mounted on Superfrost Plus slides and left at 60ºC overnight. The 
sections were de-waxed with xylene (2 x 5 minutes, VWR International) and 100% 
industrial methylated spirit (4 x 2 minutes, VWR International) and incubated in 3% 
hydrogen peroxide (VWR International) for 10 minutes (to remove any endogenous 
peroxidases). The slides were rinsed thoroughly with tap water. Slides were placed in 
boiling antigen retrieval working solution (2.1g citric acid in 1000ml dH20) for 5 
minutes and dried. Sections were covered with blocking solution for 5 minutes and then 
incubated in primary antibody overnight at 21ºC. This was rinsed off with TBS and the 
slides were washed with TBS for 10 minutes. The sections were incubated in 
biotinylated goat anti-rabbit IgG secondary antibody (1:200, Vector Laboratories) 
diluted in blocking buffer (2g bovine serum albumin (Sigma), 20ml 0.5M TBS (pH7.6), 
180 dH2O, 2ml 10% sodium azide) for 1 hour at room temperature. Slides were rinsed 
and washed in TBS for a further 10 minutes, then incubated in StreptABComplex-HRP 
(10µl Reagent A (Streptavidin), 10µl Reagent B (Biotinylated HRP), 1ml TBS) 
(Vectorlabs) for 30 minutes at room temperature. The slides were rinsed and washed 
with TBS for 5 minutes and then developed by being immersed in DAB solution (1ml 
5% DAB (VWR International), 200ml Tris buffer (0.1M, pH6), 200µl 100vol H2O2) for 
10 minutes (with gentle agitation). After a 5 minute wash with water, sections were 
counterstained with haematoxylin for 2 minutes and washed until clear. Sections were 
dehydrated by rinsing with 100% IMS (4 x 2 minutes), rinsed in xylene (2 x 5 minutes) 
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and mounted with distyrene plasticizer and xylene (DPX, SIGMA). Antigen staining 
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2.6 Cell Culture 
2.6.1 Isolation of primary fibroblasts from skin biopsies 
Skin samples were harvested and placed in PBS. They were transferred to an uncoated 
10cm petri dish and washed with PBS (Life Technologies). Subcutaneous fat and any 
loose connective tissue was detached with a scalpel and tweezers leaving epidermis and 
dermis. The skin was placed in 10ml Dispase 2 (Stemcell Technologies, Grenoble, 
France) overnight at 4ºC. The epidermis was peeled from the dermis with tweezers. The 
dermis was cut in to small fragments, dried and distributed over the coated surface of a 
scored 25cm
2 
tissue culture flask (Corning). After 30 seconds, Cascade Biologics media 
106 (Gibco) + LSGS supplement kit (Life Technologies, this media always has this 
supplement kit added unless otherwise stated) was slowly added to the flask (so as not 
to disturb the skin fragments) and the flask was placed in a 37°C (5% CO2) incubator. 
After 24 hours the lid on the flask was slightly unscrewed to allow the cells to breathe. 
Media was replaced after seven days and every three days thereafter. When sufficient 
cell numbers had grown out from the skin fragments, cells were detached and passaged 
(section 2.6.2).  
2.6.2 Passage of primary human fibroblasts 
Cell media was aspirated and the cells were washed with 5-10ml sterile PBS (Gibco, 
Life Technologies). The cells were then incubated in 5-7ml TrypLE Express 1x (Gibco, 
Life Technologies) for 5 minutes to induce cell detachment. Once the cells had detached 
they were mixed with an equal volume of DMEM (1x) + GlutaMAX supplemented with 
10% FBS (Biosera, Uckfield, UK), penicillin (250 units/ml) and streptomycin 
(250µg/ml) (this media always contains these supplements unless otherwise stated) to 
inactivate the TrypLE Express. The cells were transferred to a 15ml centrifuge tube and 
centrifuged at 1000rpm for 5 minutes at room temperature. The supernatant was 
aspirated and the cell pellet was suspended in 5 ml Cascade Biologics medium 106 
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(Gibco, Life Technologies) and re-seeded (Corning tissue culture flasks) or frozen in 
liquid nitrogen for storage as detailed in section 2.6.5. 
2.6.3 Maintenance of primary human fibroblasts 
Cells were maintained in Cascade Biologics medium 106 (Gibco, Life Technologies) 
supplemented with EGF, hydrocortisone, insulin, FCS, gentamycin and amphotericin B 
(LSGS kit S-003-K, Gibco, Life Technology) (when this media is mentioned in the 
remainder of the methods section it always contains these supplements unless otherwise 
stated). Cell media was aspirated and changed every 3 days. Tissue culture flasks were 
kept at 37°C (5% CO2). Cells were passaged when they became >80% confluent. Flasks 
were discarded if any sign of infection was observed. 
2.6.4 Maintenance of S20 cell line 
S-20 is a Chinese hamster ovary (CHO) cell line that stably expresses Nicastrin-V5/His, 
human PSEN1, N-terminally FLAG-tagged Pen-2 and C-terminally HA-tagged Aph-
1α2266. As it over-expresses the gamma-secretase components it can be used as a 
positive control in gamma-secretase activity assays. Cells were maintained in DMEM 
(1x) + GlutaMAX. Cell media was aspirated and changed every 2 days. S1 and S20 
cells were otherwise maintained and passaged as stated for primary human fibroblasts.  
2.6.5 Storing cells in liquid nitrogen 
Cells were detached, pelleted and suspended in FBS (Biosera)/ DMSO (Sigma) 
(90%FBS/ 10%DMSO). 1ml aliquots (1ml cryo-vials, Corning) were frozen at -80°C in 
Mr Frosty Freezing containers (Thermo Scientific) containing 100% isopropyl alcohol 
(Sigma). Cells were transferred to liquid nitrogen for long term storage. Cells were 
recovered by briefly warming at 37°C, suspending in 15ml DMEM (to wash DMSO 
off) and spinning at 1000rpm for 5 minutes at room temperature. The supernatant was 
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aspirated and the cell pellet suspended in 15ml growing media and seeded in a tissue 
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2.7 Protein analysis 
2.7.1 Isolation of total protein from primary human fibroblasts in culture 
Cell media was aspirated and the cells were washed with PBS (Life Technologies). Cell 
detachment was induced with TrypLE Express 1x (Gibco). Once the cells had detached 
they were mixed with an equal volume of medium containing serum (DMEM (1x) + 
GlutaMAX) to inactivate the TrypLE Express. The cells were transferred to a 15ml 
centrifuge tube and centrifuged at 1000rpm for 5 minutes at room temperature. The 
supernatant was aspirated and the cell pellet was suspended in 100-150μl RIPA buffer 
(Sigma) for 20 minutes on ice. The sample was transferred to a 1.5ml micro-centrifuge 
tube, spun at 15000rpm for 30 minutes at 4°C and frozen at -80°C. 
2.7.2 Isolation and solubilisation of cell membrane proteins (including gamma-
secretase microsomes) from cells in culture  
Primary human fibroblasts were cultured and passaged until the predicted cell count 
reached around 5x10
7 
cells for each individual (roughly 18 x 175cm
2
 tissue culture 
flasks, Corning). Based on previous publications, this cell number was predicted to 
harvest a quantity of gamma-secretase sufficient for enzyme activity assays
264
. Cell 
media was aspirated from each flask and cells were washed with PBS (Life 
Technologies). Cell detachment was induced with TrypLE Express 1x (Gibco). Upon 
cell detachment an equal volume of medium containing serum (DMEM (1x) + 
GlutaMAX) was added to inactivate the TrypLE Express. The cells from each flask 
were transferred and combined in 50ml centrifuge tubes and centrifuged at 250g for 10 
minutes at room temperature. The supernatant was aspirated and cells were re-
suspended in 2.5ml ice cold MES buffer (50mM MES pH 6 (Sigma), 150mM NaCl 
(VWR), 5mM MgCl2 (Sigma), 5mM CaCl2 (Sigma) with complete protease inhibitor 
cocktail with EDTA (Roche)).  Cell suspensions were combined in one 50ml tube and 
kept on ice. Cells were lysed using a 15ml glass homogeniser (>30 plunges). The nuclei 
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and unbroken cells were harvested by centrifuging the sample at 3000g for 10 minutes 
at 4°C. The postnuclear supernatant was centrifuged at 100000g for 1 hour (4°C) to 
pellet the total cell membranes (L8-60M Ultracentrifuge, Beckman Coulter Ltd, High 
Wycombe, UK). The supernatant was discarded and the pellet was fully re-suspended in 
5ml ice cold sodium bicarbonate buffer (0.1M NaHCO3 pH 11.3, Sigma) and incubated 
at 4°C for 20 minutes. The washed membranes were pelleted by spinning at 100000g 
for 1 hour (4°C) and fully re-suspended in 140µl solubilisation buffer (1% CHAPSO 
(Sigma), 50mM HEPES pH7 (Sigma), 150mM NaCl (VWR), 5Mm MgCl2 (Sigma), 
5mM CaCl2 (Sigma)). The sample was incubated for 1 hour at 4°C. Insoluble material 
was pelleted by spinning the sample at 100000g for 1 hour (4°C) and the supernatant 
(soluble fraction) was aliquoted, snap frozen on dry ice and stored at -80°C. For the 
purpose of performing gamma-secretase enzyme assays this supernatant is defined as 
soluble gamma-secretase preparation (used as crude gamma-secretase fractions in 
enzyme activity assays). 
2.7.3 Protein quantification  
Protein samples were quantified using the Pierce Microplate Bicinchoninic Acid (BCA) 
Protein Assay Kit (Thermo Scientific, Loughborough, UK). BCA working reagent was 
made up by mixing 50 parts reagent A with 1 part reagent B. 200 µl BCA working 
reagent was mixed with 10µl of each protein sample in a 96 well plate (samples mixed 
well by pipetting up and down). The protein samples in every run comprised 7 pre-made 
albumin standards (Thermo Scientific), the protein samples to be quantified and a 
control sample (10ul BCA working reagent). All runs were performed in duplicate. The 
plate was incubated at 37°C for 30 minutes and cooled at room temperature for 5 
minutes.  
The absorbance of the standards, protein samples to be quantified and the control 
sample was measured at 562nm on a plate reader. The two readings generated for the 
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duplicate runs performed for each sample were then averaged. If the two readings 
differed significantly for any one sample the experiment was repeated for that sample. 
Table 2.10  shows an example of the light absorbance readings achieved with the 
protein standards. The standard control was used as a blank. The average 562nm 
absorbance value of the control sample was subtracted from the average 562nm 
absorbance value of each of the standards and the protein samples to be quantified. A 
standard curve was drawn by plotting the average blank-corrected 562nm value for each 
albumin standard versus its concentration (µg/ml) (Figure 2.2). The standard curve was 
used to determine the protein concentration of each unknown sample.  
Table 2.10. Table demonstrating variation in light absorbance with protein standards 
Sample  Protein Concentration 
(µg/ml)  
Average absorbance at 562nm  
Blank  0  0.093  
Standard 1  125  0.189  
Standard 2  250  0.267  
Standard 3  500  0.43  
Standard 4  750  0.573  
Standard 5  1000  0.685 
Standard 6  1500  0.932  
Standard 7  2000  1.213  
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Figure 2.2. Example of a standard curve plotted for albumin protein standards.  The curve 
was drawn by plotting the average blank-corrected 562nm value for each protein standard 
versus its concentration (µg/ml). 
 
2.7.4 Immunoblotting Nicastrin and PEN-2  
Protein samples were thawed on ice and the desired concentration/ quantity of protein 
(20µg for NCSTN, 25µg for PEN-2) was mixed with 6x Laemmli buffer (Sigma) (5 
parts protein to 1 part 6x Laemmli buffer) and heated to 95 degrees for 5 minutes. This 
denatured the protein in the sample, removing secondary and tertiary protein structure, 
thus allowing proteins to be separated according to their molecular weight. Negatively 
charged Sodium docedyl sulphate within the Laemmli buffer attached to the sample 
protein thus enabling separation of the proteins by electrophoresis.  Samples were 
quickly spun down and loaded in to the wells of a 10% Tris-HCL Ready Gel (Biorad, 
Hemel Hempstead, UK) for NCSTN and a 4-20% gradient Ready Gel (Biorad) for 
PEN-2. The first and last well of each gel were loaded with 7 µl of pre-stained protein 
ladder (Protein Plus Protein Standards Dual Colour, Biorad) which enabled the 
detection of proteins between 10 and 250 kDa. Gels were placed in a running tank 
y = 1820.2x - 231.41 





























Average blank-corrected 562nm  light absorbance    
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(Biorad) with 1x Tris/ Glycine/ SDS buffer (Biorad) and an electronic current was 
passed through the gel (100V for 5 minutes, increased to 200V for the remaining time) 
to separate the proteins by molecular weight. Protein was transferred onto an ECL 
membrane using a Trans-blot TURBO Transfer System Transfer Pack (Biorad). The 
membrane was washed in distilled water for 10 minutes and then blocked in 5% non-fat 
dry milk (Marvel original, Marvel, Spalding, UK) in TBS-T for 30 minutes at room 
temperature. The membrane was washed in TBS-T for 30 minutes (3 x 10 minute 
washes) at room temperature and incubated in primary antibody in 5% non-fat dry milk 
in TBS-T overnight at 4°C (NCSTN Ab24741 (Abcam), PSENEN Ab18189 (Abcam). 
The membrane was washed in TBS-T for a further 30 minutes (3 x 10 minutes) and 
incubated in a horseradish peroxidise-linked anti-rabbit secondary antibody (NA934V, 
GE Healthcare UK Ltd) for 1 hour at room temperature. The membrane was washed in 
TBS-T for 30 minutes (3 x 10 minutes) and protein bands were visualised using ECL 
Prime Western Blotting Reagent (GE Healthcare).  
2.7.5 Immunoblotting β-actin 
Following the immunoblotting of NCSTN and PEN-2, the same membranes were 
blotted for β-actin.  β-actin is endogenously expressed and therefore acts as a loading 
control, reflecting the total amount of protein originally loaded for each sample. This 
information is required to calculate any inter-individual variation in NCSTN and PEN-2 
expression. Following the visualisation of NCSTN and PEN-2 bands, membranes were 
washed in TBS-T for 10 minutes. They were then placed in stripping buffer (30ml Tris-
HCL (Sigma) pH 6.8, 3.5ml β-mercaptoethanol (Sigma), 50ml 20% SDS (Sigma), 
416.5ml dH2O) at 50 ºC for 30 minutes. The membrane was washed for a further 10 
minutes in TBS-T and then incubated in primary antibody (1:1000, 4967S, Cell 
signalling Technology) in 5% non-fat dry milk in TBS-T for 1 hour at room 
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temperature. The remaining process was as described for day two of immunoblotting 
NCSTN and PEN-2 (section 2.7.4). 
2.7.6 Immunoblotting Flag-tagged proteins 
As described for the immunoblotting of NCSTN and PEN-2 with the following 
variations. Protein samples were run on a 4-20% gradient Tris-HCL Ready Gel 
(Biorad). The ECL membrane was incubated in primary antibody (F3165, Sigma) in 5% 
non-fat dry milk in TBS-T for 1 hour at room temperature. 
2.7.7 Analysis of western blots 
Band density was measured using Image J software (National Institute of Health, USA). 
All analyses were performed in triplicate and an average value was calculated for each 
band. The density of the protein band in question (ie. NCSTN or PEN-2) divided by the 
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2.8 Cell based assays 
2.8.1 Addition of cycloheximide to assess for nonsense mediated decay 
1 000 000 primary human dermal fibroblasts (suspended in Cascade Biologics media 
106, Gibco, Life Sciences) were plated in 10cm diameter circular tissue culture dishes 
and left overnight to facilitate attachment. Plates were labelled as time = 0, 6 and 24 
hours. Cell media was aspirated from all three dishes. 10ml of Cascade Biologics media 
106 was replaced in the T=0 plate. 10ml Cascade Biologics media 106 plus 20µg/ml 
cycloheximide (Sigma) was added to each of the remaining two plates. RNA was 
isolated from the t = 6 hours cells after 6 hours and the t = 0 and 24 hours cells at 24 
hours as previously described in section 2.4.11. Total NCSTN and PSENEN mRNA 
levels were assessed by multiplex real-time PCR as previously described (section 
2.4.16). Cycloheximide is an inhibitor of protein biosynthesis that acts by inhibiting the 
translocation stage of protein synthesis. As a consequence it is known to inhibit 
nonsense-mediated decay
267
. If nonsense mediated decay is present then the expression 
of the relevant gene transcript should incrementally increase the longer the cells are 
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2.9 Gamma-secretase enzyme activity assays 
2.9.1 Purification of C100-Flag substrate 
The cell pellet described in section 2.4.22 was re-suspended in 10ml lysis buffer (250µl 
1M Tris pH 7.0 (Sigma), 750µl 5M NaCl (VWR), 250µl Triton X-100 (Sigma), 250µl 
bacterial protease inhibitors (P8465 5ml protease inhibitors, SIGMA), 23.5ml dH2O) 
and homogenised with a 15ml glass homogeniser. The sample was spun at 3000 x g for 
10 minutes. The cell lysate supernatant (containing protein) was removed and stored at 
4ºC and the pellet (insoluble fraction) was discarded. 4ml M2 agarose slurry (A2220, 
SIGMA) was washed with 10ml lysis buffer (4ºC) and spun at 1000 x g for 5 minutes. 
The supernatant was removed leaving 2ml equilibrated M2 agarose beads. The cell 
lysate supernatant was added to the 2ml equilibrated M2 agarose beads and mixed at 
room temperature for 1-2 hours (allowing the C100-Flag to bind to the beads). The 
sample was transferred to a drip column (BioRad 731-1550, Biorad) and the unbound 
fraction was allowed to drip through (discarded). The drip column membrane was 
washed 5 times with 5ml lysis buffer and the C100-Flag protein was eluted five times 
with five separate 2ml volumes of elution buffer (110µl Igepal (Sigma), 1.1ml 1M 
glycine pH 2.7 (Sigma), 9.8ml dH2O). Samples were stored at -80ºC. The agarose beads 
were washed with 10ml PBS, suspended in storage buffer (5ml Glycerol (Sigma), 1ml 
10 x PBS (Life Technologies), 4ml dH2O, 20µl Sodium Azide (Sigma)) and kept at -20 
ºC (could be re-used once).  Immunoblotting of the elutes was performed to assess for 
the presence of purified C100-Flag (as per anti-Flag western protocol section 2.7.6). 
C100-Flag would be used as a substrate in gamma-secretase activity assays.  
2.9.2 Gamma-secretase activity assay  
6µl of L-α-phosphatidylethanolamine chloroform (PC, 10mg/ml) and 1.5µl L-α-
phosphatidylethanolamine chloroform (PE, 10mg/ml) (Avanti Polar Lipids, Alabaster, 
USA) were dried under Nitrogen for 10 minutes. Each lipid was dissolved in 6µl and 
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3µl of HEPES buffer (50mM HEPES pH 7.4, 150mM NaCl) respectively, incubated at 
room temperature for 10 minutes and sonicated (XB3 Ultrasonic Bath, Grant, Shepreth, 
UK) at room temperature for 10 minutes. Cholesterol (C4951, SIGMA) was dissolved 
to a concentration of 31.75mg/ml in water. The protein concentration of the soluble 
gamma-secretase preparation (described in section 2.7.2) obtained from each individual 
was calculated using a BSA assay. 8µg soluble gamma-secretase preparation was added 
to 5µl PC, 2.5µl PE and 2µl cholesterol and the mix was made up to 50ul with HEPES 
buffer. 
Final reaction concentrations: 
PC 1mg/ml 
PE 0.25mg/ml 
Cholesterol 0.065mg/ml  
CHAPSO 0.25%  
 
This mixture was allowed to incubate at 32ºC for 30 minutes and on ice for a further 10 
minutes. 1ul C100-Flag peptide (see section 2.9.1) was added to the mix to act as the 
enzyme substrate and the reaction was left to incubate at 37 ºC for 4 hours. A 12µl 
aliquot of reaction was mixed with 12µl 2 x Laemmli buffer and frozen at -80ºC. All 
samples for analysis were run in the same assay, using the same reagents. Experiments 
were performed four times on separate occasions to ensure consistency. Soluble 
gamma-secretase preparation obtained from S20 cells (a cell line known to over-express 
the gamma-secretase components) was run with every assay as a positive control. A 
gamma-secretase inhibitor (L458) was added to some reactions as a negative control.  
Immunoblotting of the reaction mixtures (mixture + Laemmli buffer totalling 24µl) was 
performed using an anti-FLAG antibody (F3165, Sigma) as detailed in section 2.7.6. 
Enzyme activity assays were ultimately performed by collaborators in the Centre for 
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Neurological Diseases, Harvard Medical School, USA, as I was unable to successfully 
generate enzyme activity data in-house. They developed immunoblots using a Li-Cor 
Odyssey system (Li-Cor, Lincoln, USA), a representative blot is shown in Figure 2.3. 
The large band detectable at 15kDa is the C100-Flag substrate. The smaller band viable 
at 8kDa is an enzyme product, amyloid precursor protein intracellular domain (AICD). 
When gamma-secretase cleaves APP (Ɛ-cleavage) it produces AICD and Amyloid-β 
peptides. The amount of AICD produced in the assay is regarded as a measure of total 
gamma-secretase activity.  
 
Figure 2.3. An example western blot generated from a gamma-secretase activity assay.  
The C100-Flag substrate can be seen at 15kDa and the AICD product at 5 kDa. 
 
Amyloid-β peptides are sequentially shortened (processed) by gamma-secretase 
(carboxy-peptidase activity). Enzyme-linked immunosorbent assays (ELISA) were 
performed by our collaborators at Harvard Medical School, USA, to quantify the levels 
of two such peptides, Aβ40 and Aβ42, in the reaction mixtures (Human Abeta40 and 
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2.10 Statistical analysis 
Bar graphs were drawn and error calculations were performed using Microsoft Excel. 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software Inc, La 
Jolla, USA). All real-time PCR experiments were performed in triplicate and repeated 
three times. The average fold change and standard deviation across all three repeat 
experiments was calculated. Unpaired t-tests were performed to assess the statistical 
significance of the results generated. In-house immunoblots were analysed using Image 
J software (NIH, USA). Band densities were recorded three times from which average 
band densities and standard deviation were calculated. Statistical significance was 
assessed using unpaired t-tests. Immunoblots generated for the purpose of assessing 
gamma-secretase enzyme activity were analysed by collaborators in the Centre for 
Neurological Diseases, Harvard Medical School, using the Li-Cor Odyssey system 
analysis software (Li-Cor). All data analysis was performed in house. Average values 
and standard errors were calculated using data from all seven repeat enzyme activity 
assays. Statistical analyses were performed using one-way ANOVA tests (Kruskal-
Wallis with Dunn's correction). 
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Chapter 3: Results: Mutations in the gamma-secretase 
genes PSENEN and NCSTN underlie some familial forms 
of hidradenitis suppurativa 
 
3.1 Introduction  
HS is inherited in an autosomal dominant manner in some families
132
. Molecular 
genetic analysis of such families always therefore had the potential to further our 
understanding of disease pathogenesis. The benefits of this approach were realised in 
2010 when heterozygous mutations were reported in the gamma-secretase genes 
NCSTN, PSENEN and PSEN1 in six Chinese multiplex kindreds with HS
135
. All six 
kindreds demonstrated full co-segregation. In parallel with the publication of that data 
we had recruited seven extended British Caucasian pedigrees and were planning 
experiments to identify novel disease-causing genes.  
3.1.1 Hypothesis and objectives 
In light of the Chinese data, it was hypothesised that mutations in NCSTN, PSENEN and 
PSEN1 underlie British familial cases of HS. The aim of this work was therefore to 
investigate the role of mutations in NCSTN, PSEN1 and PSENEN in seven British 
kindreds with HS. As discussed in the introduction, gamma-secretase is a four sub-unit 
enzyme encoded by six different genes. It could therefore have been hypothesised that 
the remaining genes, APH1A, APH1B and PSEN2, also underlie some forms of HS. 
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3.2 Patient cohort and samples 
Fifty three individuals were recruited from seven multigenerational pedigrees in which 
HS was inherited as an autosomal dominant trait (see Figure 3.1, Figure 3.2, Figure 
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II:1 II:2 II:3 II:4 II:5 II:6
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Figure 3.1. Family pedigrees recruited for genetic analysis. Red stars mark the individuals in 
whom NCSTN, PSENEN and PSEN1 were sequenced. Green stars mark individuals assessed for 
large scale deletions and duplications in those genes via multiplex ligation-dependent probe 
amplification (MLPA). 
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Figure 3.2. Family pedigrees recruited for genetic analysis.  Red stars mark the individuals 
in whom NCSTN, PSENEN and PSEN1 were sequenced. Green stars mark individuals assessed 
for large scale deletions and duplications in those genes via MLPA. 
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II:1 II:2















Figure 3.3. Family pedigrees recruited for genetic analysis. Red stars mark the individuals in 
whom NCSTN, PSENEN and PSEN1 were sequenced. Green stars mark individuals assessed for 
large scale deletions and duplications in those genes via MLPA. 
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Study participants provided blood or saliva samples for DNA. All coding regions of 
NCSTN (17 exons), PSEN1 (10 exons) and PSENEN (3 exons) were amplified by PCR 
(polymerase chain reaction) using exon flanking intronic primers and Sanger sequenced 
in 19 affected individuals, one or more from each of the seven pedigrees (red stars in 
Figure 3.1, Figure 3.2 and Figure 3.3 indicate individuals in whom the genes were 
sequenced). Sequencing revealed a novel heterozygous single nucleotide insertion in 
PSENEN (c.66_67insG) and a novel single nucleotide substitution in the NCSTN exon 
9/intron9 donor splice site (c.1125+1 G>A) in each of two pedigrees. No other novel or 
rare variants (population frequency of <1%, defined as variants with a frequency < 1% 
in both the 1000 Genomes Project database
260
 and the NHLBI Exome Sequencing 
Project Exome Variant Server (EVS, http://evs.gs.washington.edu/EVS/)) were detected 
in coding regions or within 10 base pairs of splice boundaries in those genes in the 
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3.3 Identification of a novel heterozygous single base insertion in 
PSENEN (c.66_67insG)   
Individuals II:2 and III:1 from pedigree 3 (Figure 3.2) were both heterozygous for a 
novel insertion in PSENEN (c.66_67insG, Figure 3.4). The insertion is predicted to lead 
to a frameshift and an altered protein product (p.Phe23ValfsX98). The mutation co-
segregated with disease status in this kindred (Figure 3.4) and was absent in 200 control 
chromosomes of European ancestry.  
Both affected individuals from pedigree 3 developed painful nodules, pustules, 
abscesses and resultant scars in their axillae, under their breasts and in their groins from 
the age of 15. III:1 was more severely affected, having additional involvement of her 
buttocks and sinus tracts in the axillae and groin. They had a Body Mass Index (BMI) of 
33 (II:2) and 23 (III:1). A BMI of 18 – 25 is considered to be within the normal range, 
25-30 overweight and >30 obese. Therefore individual II:2 would be classed as obese 
but her daughter (III:1) was within the normal range. Neither individual had ever 
smoked. II:2 felt that her symptoms worsened around menstruation, whereas her 
mother, III:2, noticed no cyclical change. On examination III:2 had an atypical speckled 
macular hyperpigmentation in her axillae and groin and II:2 had similar 
hyperpigmentation in the groin. Patient III:2 had failed to respond to multiple antibiotics 
(flucloxicillin, clindamycin and rifampicin), the oral contraceptive, isotretinoin and 
ciclosporin. She did however respond to treatment with the anti-TNF agent Infliximab 
and surgical excision of the affected areas in her axillae and groin was effective. Patient 
II:2 had previously been treated with multiple antibiotics to little effect but no longer 
required treatment as her disease was quiescent. 
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Figure 3.4. The PSENEN c.66_67insG mutation was detected in affected individuals from 
Pedigree 3.  Sequencing of PSENEN exon 3 revealed the c.66_67insG variant (arrow) in 
genomic DNA from III:1 and II:2 and wild type sequence in unaffected individuals II:1 and 
III:2. Individual III:1 had inflamed nodules, abscesses, fistulae and scarring in the axillae. 
Individual II:2 had multiple open comedones and an inflammatory nodule on the background of 
a speckled, macular hyperpigmentation in the axillae (photos courtesy of Guy’s and St. Thomas’ 
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3.4 Identification of a novel heterozygous single nucleotide 
substitution in the NCSTN exon 9/intron9 donor splice site 
(c.1125+1 G>A)  
The proband from Pedigree 4 (Figure 3.2, III:1) was heterozygous for a novel single 
nucleotide substitution in NCSTN (c.1125+1 G>A). The substitution was of the first 
base of intron 9, in the highly conserved donor splice site. The mutation was absent in 
his unaffected mother (Figure 3.4, II:4) but no other members of the kindred were 
available for analysis to confirm co-segregation of the variant with disease status. The 
variant was not observed in 200 control chromosomes of European ancestry. 
Individual III:1 had HS from the age of 16. He reported cysts, painful nodules, pustules, 
abscesses, sinus tracts and scarring over his neck, axillae, suprapubic area, groin, 
buttocks and thighs. He had a body mass index of 30 (overweight) and a 15 pack year 
smoking history. His disease had failed to respond to multiple antibiotics (flucloxicillin, 
erythromycin, oxytetracycline), acitretin and isotretinoin. He had not received 
immunosuppressant medication or anti-TNFα therapy.  
 
Figure 3.5. The NCSTN c.1125+1 G>A mutation was detected in an affected individual 
from pedigree 4.  Sequencing revealed a novel single nucleotide substitution (c.1125+1 G>A, 
see arrow) of the first base of the exon 9/ intron 9 donor splice site (the red dotted line marks the 
end of the exon) in affected individual III:1. No substitution can be seen in the only available 
unaffected individual (II:4).  
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3.5 No large scale deletions or duplications in NCSTN, PSENEN and 
PSEN1 were detected in any of the seven kindreds 
Novel variants were detected in the coding regions of NCSTN and PSENEN in affected 
individuals from two of the seven multiplex kindreds. No variants (<1% population 
frequency) were detected in PSEN1 in these families. The primers used for PCR and the 
standard Sanger sequencing method employed in this study were capable of detecting 
substitutions and small insertion/ deletions in coding regions and flanking splice sites. 
Large deletions and duplications of exons and genes would be missed using this 
screening technique. As a consequence, we hypothesised that whole gene or exon 
deletions and duplications in NCSTN, PSENEN and PSEN1 underlie HS in the five 
kindreds in which no mutations were detected. 
3.5.1 Methodological approaches to detecting copy number variation (CNV) 
There are a number of experimental approaches that can be employed to detect copy 
number variation (CNV). These comprise fluorescence in situ hybridisation (FISH), 
array-comparative genomic hybridisation, single nucleotide polymorphism (SNP) 
arrays, multiplex ligation-dependent probe amplification (MLPA) and, more recently, 
next generation sequencing techniques (such as exome sequencing). The accuracy of 
CNV detection from exome sequencing data is dependent upon the read depth generated 
and the bioinformatic analyses that are employed. At the time of study, there was 
insufficient expertise and experience to consider that a viable option. MLPA was chosen 
as it is a fast, accurate and sensitive technique that can be used to look at multiple exons 
simultaneously
268
. The local clinical diagnostic laboratory routinely perform MLPA and 
consider it to be the most reliable and efficient method for detecting CNV
263
.  
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3.5.2 Multiplex ligation-dependent probe amplification (MLPA)  
MLPA is a multiplex-PCR based method of detecting CNV
268
. Probes are designed 
(forward and reverse) to target specific regions (in this case NCSTN exons 1-17, 
PSENEN exons 1-3 and PSEN1 exons 1-10). These target probes are then run with 
reference probes which bind to known non-variable regions or house-keeping genes. 
Upon binding to their target DNA sequences the forward and reverse probes are ligated. 
As only bound probes can be ligated, the number of ligated products accurately reflects 
the abundance of a specific target in the sample being studied. PCR is performed to 
amplify each product. Each probe pair is designed to be a specific length so that the 
PCR product relating to each individual target can be separated by capillary 
electrophoresis. Probes can be identified on a capillary sequencer because the forward 
primer used for PCR is fluorescently labelled. The amount of probe product detected for 
each target is relative to the amount of target sequence present in the sample. Signals 
relating to the target regions are then normalised against the signals generated from the 
reference probes. Adjusted probe signals are then compared against 3 control DNA 
samples and deletions or duplications of whole exons and/ or genes can be detected.  
3.5.3 No whole exon or gene deletions or duplications were detected in the 
gamma-secretase genes NCSTN, PSEN1 and PSENEN in this HS cohort  
At least one affected individual from each of the five pedigrees in which no mutations 
were detected was assessed for large scale deletions and duplications in NCSTN, 
PSENEN and PSEN1 by MLPA (individuals marked with a green star in Figure 3.1, 
Figure 3.2, Figure 3.3). No whole exon or gene deletions or duplications were detected 
in these individuals. A representative plot of peak ratios can be seen in Figure 3.6. 
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Figure 3.6. A plot of the normalised MLPA peak ratios in one individual with HS (probes 
designed to assess copy number of the exons of PSEN1 and PSENEN).  The green squares 
represent probes designed to bind to exons of interest (relating to PSEN1 and PSENEN). The 
blue squares represent control probes. The green lines represent the upper and lower thresholds 
above and below which results would be interpreted as a duplication or deletion respectively. 
All probes relating to PSEN1 and PSENEN and all control probes fall within the normal limits, 
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3.6 Discussion 
In light of data from China implicating the gamma-secretase genes NCSTN, PSENEN 
and PSEN1 in HS pathogenesis we sought to characterise the involvement of mutations 
in those genes in 7 multigenerational British kindreds demonstrating autosomal 
dominant inheritance. PCR and direct sequencing of those genes in that cohort revealed 
that affected members of two of the seven pedigrees had novel mutations in PSENEN 
(an insertion, c.66_67insG) and NCSTN (a splice site substitution, c.1125+1 G>A). 
None of the remaining five pedigrees harboured rare (<1% population frequency) 
variants in those genes. It was therefore hypothesised that whole exon/ gene deletions or 
duplications may underlie HS in the remaining five cases. MLPA was performed in at 
least one affected individual from each of these pedigrees to interrogate this hypothesis. 
No CNV was detected.   
This was the first report of gamma-secretase mutations in Caucasian individuals and 
these results provided further evidence that mutations in the gamma-secretase genes 
NCSTN and PSENEN underlie some familial cases of HS. It was notable however that 
no rare variation was detected in those genes in the remaining five kindreds. These 
findings were corroborated by a more recent study in which only 3 of 14 French 
pedigrees with HS were found to harbour gamma-secretase mutations in NCSTN, 
PSEN1 or PSENEN
139
. The pedigrees in which no mutations were identified may 
represent alleles comprising undetected coding variants or non-coding variants, 
phenocopies of HS or be explained by further locus heterogeneity in HS. One of the 
limitations of this genetic study was that it only assessed coding regions and associated 
splice site boundaries, thus variants in non-coding regions such as promoter sequences, 
enhancer sequences and silencer sequences would not have been detected.  
The functional characterisation of the two mutations identified in these British pedigrees 
became the focus of further study and this is discussed in Chapter 4. 
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Chapter 4: Results: Functional characterisation of the 
gamma-secretase mutations identified in PSENEN and 
NCSTN in familial HS 
4.1 Introduction 
Familial genetic studies confirmed the presence of heterozygous gamma-secretase gene 
mutations in two Caucasian multiplex kindreds with HS (NCSTN c.1125+1 G>A in 
pedigree 3 and PSENEN c.66_67insG in pedigree 4, Figure 3.2).  
4.1.1 Aims and objectives 
The aim of this study was to functionally characterise those two mutations. Experiments 
were performed to identify the effect of each mutation on their respective transcript, 
protein and on overall gamma-secretase enzyme activity. The location of NCSTN and 
PEN-2 in the skin of individuals harbouring the mutations and healthy volunteers was 
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4.2 Patient cohort and samples 
Samples were obtained from individuals III:1 in pedigree 3, III:2 in pedigree 4 (Figure 
3.2) and 3 age-matched healthy volunteer subjects (demographic and clinical details 
shown in Table 4.1). Each individual provided two 6mm skin biopsies, one from 
axillary skin (affected region) and one from para-axillary skin (unaffected region). 
Primary human fibroblasts were grown in culture and used to harvest RNA, whole cell 
protein and solubilised membrane protein. Whole skin sections were examined by 
immunohistochemistry.  
Table 4.1. Demographics and clinical details of the two mutation-positive patients and 
three healthy volunteer subjects. 






Healthy volunteers (3) 
Age 46 41 37, 39, 35 (average 37) 
Sex M F M, F, F 
Ethnicity White Caucasian White Caucasian White Caucasian  
Smoking status Ex-smoker Non-smoker Ex-smoker, 2 non-smokers 
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4.3 NCSTN transcript and NCSTN protein analysis in an individual 
harbouring the heterozygous NCSTN splice site substitution 
NCSTN c.1125+1 G>A 
4.3.1 NCSTN c. 1125+1 G>A results in the skipping of NCSTN exon 9 
4.3.1.1 PCR and agarose gel electrophoresis of the full length NCSTN transcript 
RNA was extracted from primary human fibroblasts (Figure 4.1) and reverse transcribed 
(RT-PCR) to produce cDNA. cDNA is more stable than RNA and thus facilitates 
experimental analysis of gene transcripts.  
                     
Figure 4.1. Primary human fibroblasts grown in culture. 
 
Primers were designed to amplify the full length NCSTN transcript (full length 2.9Kb, 
amplified segment 2Kb). PCR amplification required optimisation. The efficacy of each 
reaction was assessed via agarose gel electrophoresis of the PCR product. cDNA from 
the mutation-positive patient and a healthy volunteer was amplified. One band was 
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observed at the expected size (2Kb) in the healthy volunteer (control). Two bands were 
observed in the mutation-positive patient, the expected band at 2Kb and an additional 
band at 1.9Kb, suggesting the mutation leads to the generation of a truncated mutant 
transcript (Figure 4.2).  
4.3.1.2 Direct sequencing of the full length NCSTN transcript 
Full length NCSTN cDNA from the mutation-positive patient and the healthy volunteer 
was sequenced to determine the nature of the mutant transcript. Five pairs of 
overlapping primers were designed to sequence the 2Kb transcript. Sequencing revealed 
that NCSTN exon 9 is missing in the mutant allele (Figure 4.2). NCSTN exon 9 is 105 
bases long which approximately corresponds with the distance observed between the 
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Figure 4.2. Agarose electrophoresis and Sanger sequencing of the full length NCSTN 
transcript in the patient harbouring the heterozygous NCSTN 1125+1 G>A mutation.  On 
electrophoresis, two bands were seen in the patient harbouring the mutation versus one band in 
a healthy volunteer. The additional band migrated further and appeared to represent a transcript 
that was around 100 bases lighter. Sequencing corroborated that finding, demonstrating 
skipping of NCSTN exon 9 in the mutant transcript. 
 
4.3.1.3   The NCSTN c.1125+1 G>A mutation is predicted to result in a truncated       
NCSTN protein 
NCSTN exon 9 is 105 bases long (divisible by three), thus any absence of this sequence 
in the mutant transcript would not alter the reading frame but would theoretically result 
in a truncated protein product (amino acids 333-367 predicted to be missing, Figure 
4.3). Exon 9 encodes part of the large nicastrin ectodomain which is known to be 
integral to normal gamma-secretase function. Three domains within the Nicastrin 
protein are highly conserved between animal species, amino acids 306 – 360, 419 – 458 
and 625 – 662. The amino acids affected by this mutation fall within the first of these 
regions within which there is a very highly conserved DYIGS motif (aa 336 – 340)171. 
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Missense mutation of this motif (to AAIGS) has been shown to result in an increase in 
Aβ secretion following APP cleavage whereas homozygous deletion of residues 312-
340 and 312-369 results in a significant reduction in Aβ40 and Aβ42 production. This 
effect was more pronounced with the residue 312-369 deletion, which is most similar to 
the protein predicted to arise as a consequence of this splice site mutation
171
. This data 
strongly supports a pathological role for this mutation and suggests that, if the mutant 




Figure 4.3. The consequences of the NCSTN c.1125+1 G>A mutation on the NCSTN 
transcript and protein.  This mutation results in defective splicing and skipping of NCSTN 
exon 9.  This in turn is predicted to result in a truncated NCSTN ectodomain. The region of the 
ectodomain affected is highly conserved and mutagenesis experiments affecting the highlighted 
amino acid sequences significantly affect gamma-secretase carboxypeptidase activity, reducing 
the overall amount of Aβ40 and Aβ42 produced following APP cleavage.  
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4.3.2 NCSTN transcript abundance is reduced as a consequence of NCSTN 
c.1125+1 G>A 
Transcript abundance in the mutation-positive individual and three healthy volunteers 
(controls) was assessed by real time quantitative PCR. RNA was harvested from 
primary human fibroblasts (grown from skin taken from the affected area in the patient 
harbouring the mutation and matched axillary skin in volunteer subjects) and equal 
concentrations were reverse transcribed to produce cDNA. Real time quantitative PCR 
was performed using Taqman gene expression assays (Life Technologies). The 
principle of these assays is that a fluorescent taqman probe binds to a specific part of the 
transcript. Each time the transcript replicates during the real time PCR fluorescence is 
released and measured. The amount of fluorescence emitted therefore reflects the 
quantity of transcript present in the initial reaction. This result is controlled against a 
gene transcript with reliable and stable expression, otherwise termed a housekeeping 
gene, as it cannot be assumed that equal amounts of cDNA are loaded in every reaction. 
A commercially available NCSTN Taqman probe was chosen for this experiment that 
binds to an exon 2 related portion of the NCSTN transcript. This is well before the site 
of the NCSTN c. 1125+1 G>A mutation, thus the assay results reflect total NCSTN 
transcript abundance (WT and mutant combined) rather than that of the wild type or 
mutant transcript alone. Transcript expression was significantly reduced in mutant 
fibroblasts versus those harvested from healthy controls (Figure 4.4). Experiments were 
initially run with GAPDH as an endogenous control (Figure 4.4a). To confirm the 
validity of the results generated, repeat assays were run with a second endogenous 
control, 18sRNA (Figure 4.4b). Results were consistent with those generated using 
GAPDH. Consequently, GAPDH was used as the endogenous control for all further real 
time PCR reactions reported in this thesis. 
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Figure 4.4. Relative NCSTN transcript abundance in the individual harbouring NCSTN 
c.1125+1 G>A versus healthy volunteers (controls).  All real time PCR reactions were 
performed in triplicate and experiments were repeated three times. The fold changes represent 
the average of the three experiments A) GAPDH was used as an endogenous control. There is a 
significant reduction in transcript abundance in the mutation-positive patient versus control. The 
figure plots mutant expression against one control subject however the result was representative 
of experiments using two further independent controls (p <0.01, p<0.01). B) 18sRNA used as an 
endogenous control. Again, there was a significant reduction in transcript abundance in the 
mutation-positive patient versus control and this result was representative of results obtained 
with two further controls (p<0.001, p<0.001) (error bars = standard deviation (SD), *** denotes 
p < 0.001, unpaired t-test). 
 
4.3.3 The mutant NCSTN transcript is subject to decay 
Real time PCR data suggested that overall NCSTN transcript abundance was reduced in 
mutant fibroblasts versus controls. It was therefore hypothesised that the mutant 
transcript is subject to decay. Numerous mRNA surveillance mechanisms have evolved 
in humans to detect and eliminate aberrant transcripts. These mechanisms are active in 
both the nuclear and extra-nuclear compartment. The nuclear exosome screens pre-
mRNA for splicing defects and appropriate processing prior to release from the 
nucleus
269
.  Within the extra-nuclear compartment, mRNA surveillance appears to be 
most active at the stage of translation. Three specific surveillance mechanisms have 
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been reported, nonsense-mediated decay (NMD, this mechanism recognises premature 
stop codons and induces transcript decay), no-go decay (this mechanism recognises 
when ribosomes get stuck processing transcripts and induces transcript decay) and non-
stop decay (a mechanism that is activated when no stop codon is detected)
270
. 
Methods of investigating nuclear mechanisms of RNA decay (nuclear exosome) are 
limited however extra-nuclear decay can be interrogated by exposing cells to 
cycloheximide. Cycloheximide is a chemical that can block protein translation by 
inhibiting translational elongation. Consequently it has been shown to inhibit the 
translation related RNA surveillance mechanism NMD
267
. Mutant and control 
fibroblasts were exposed to 20µg/ml cycloheximide for up to 24 hours. An incremental 
increase in transcript abundance was observed in cycloheximide treated cells over the 
24 hour period (Figure 4.5). This would suggest that the mutant transcript is subject to 
decay and that the mechanism of RNA decay is arising at the level of translation. As 
previously discussed, the splice site mutation appears to result in the skipping of 
NCSTN exon 9 but is not predicted to alter the reading frame or cause premature 
truncation, thus NMD is an unlikely mechanism of RNA decay. The mutation is not 
predicted to disrupt the native stop codon and would not therefore seem likely to induce 
no-stop decay. It is interesting however that upon running the WT and mutant RNA 
sequences through an RNA secondary structure prediction website 
(http://rna.urmc.rochester.edu/RNAstructureWeb/) that the mutant RNA is predicted to 
adopt an altered secondary structure (Figure 4.6). This may in itself confer instability 
and result in subsequent decay but the association of that hypothetical mechanism with 
translation is unknown. A further explanation is that the altered RNA structure may 
affect ribosomal processing and potentially induce no-go decay
271
. The exact 
mechanism of RNA decay remains to be elicited. 
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Figure 4.5. NCSTN transcript abundance within mutant and control fibroblasts following 
incubation with cycloheximide.  There was a significantly increase in NCSTN transcript 
abundance following a 24 hour incubation with cycloheximide. This was not the case with 
control fibroblasts. All experiments were performed in triplicate and repeated three times. Fold 
changes represent the average fold change achieved over all three experiments (error bars = SD, 
** denotes p < 0.01, unpaired t-test). 
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Figure 4.6. Predicted RNA secondary structure of the WT and mutant (c.1125+1 G>A) 
NCSTN transcript.  These images represent the lowest free energy structure for each respective 
RNA sequence. The NCSTN c.1125+1 G>A mutation results in a truncated RNA transcript, 
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missing the section corresponding to NCSTN exon 9. This is predicted to alter the folding and 
orientation of the secondary RNA structure (lower left portion as represented here, highlighted 
by red box). The images were taken directly from an RNA secondary structure prediction 
website (http://rna.urmc.rochester.edu/RNAstructureWeb/).  
 
4.3.4 Nicastrin protein expression is reduced in mutant fibroblasts versus control 
fibroblasts 
NCSTN transcript expression was reduced in the individual carrying the NCSTN 
c.1125+1 G>A mutation, thus it was hypothesised that there would be a corresponding 
reduction in protein expression. Given that some mutant transcript was present (as seen 
on agarose gel electrophoresis and upon sequencing the full length NCSTN transcript), a 
further hypothesis was that there would be some expression of a mutant form of 
nicastrin. Total cell protein was extracted from primary human fibroblasts in culture 
(chemical lysis with RIPA buffer) and immunoblotting was performed to interrogate 
these hypotheses. 
4.3.4.1 Antibody selection and optimisation 
Four rabbit polyclonal anti-nicastrin antibodies were tested for specificity and 
sensitivity. An anti-nicastrin antibody was chosen that produced few non-specific 
bands, had successfully been used to perform immunoblotting and 
immunohistochemistry in previous publications and because it binds to the N-terminus 
of Nicastrin (immunogen CFTRDLMEKLKGRTSRIAGLAVSL, aa 103 – 124). The 
binding site is well before the segment of nicastrin related to the mutated portion of 
NCSTN (relating to aa 332 – 368), thus the antibody would theoretically detect all 
nicastrin protein variants present (wild type and mutant protein). Conversely, an 
antibody that binds at or after amino acids 332 may only detect the wild type protein. 
The total amount of protein loaded for gel electrophoresis was optimised, 20µg was 
sufficient to produce strong and specific bands with an antibody titre of 1:400.  As 
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discussed in the introduction, nicastrin exists in a mature and immature form in cells. It 
therefore generates two bands on immunoblotting, a light immature band and a heavier 
mature band
198
. Protein electrophoresis on a 10% Tris-HCL gel sufficiently separated 
those two bands. 
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4.3.4.2 SiRNA knockdown of NCSTN in primary human fibroblasts confirmed the  
specificity of the nicastrin bands observed on immunoblotting 
The predicted molecular weight of the nicastrin band, as detailed by the manufacturers 
of the chosen antibody, was 85kDa however the immature and mature bands were 
running at 100kDa and 125kDa on optimisation blots. Despite differing from the 
manufacturers prediction, the appearance and apparent molecular weight of the two 
protein bands was entirely consistent with previous publications
272; 273
. Given the 
discrepancy, SiRNA knockdown experiments were performed to confirm the specificity 
of the bands observed. Primary human fibroblasts derived from a healthy volunteer 
were transfected with commercially available NCSTN SiRNA and cultured for 48 hours. 
Untreated fibroblasts from the same patient were cultured in parallel. RNA and protein 
were extracted from both the transfected and un-transfected cells. RT-PCR of equal 
quantities of RNA produced cDNA. Real-time quantitative PCR of the cDNA products 
confirmed that sufficient knockdown of NCSTN transcript expression had occurred in 
the SiRNA treated cells (Figure 4.7). The total protein concentration harvested from 
treated and un-treated cells was calculated using a BCA assay. 20µg of protein from 
treated and untreated cells was immunoblotted and there was a clear reduction in the 
blot intensity of the nicastrin bands (mature and immature) in SiRNA transfected 
fibroblasts versus un-transfected fibroblasts (Figure 4.7). 
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Figure 4.7. NCSTN transcript abundance and NCSTN protein expression in primary 
human fibroblasts following SiRNA knockdown.  A) The efficacy of knockdown was shown 
by quantitative RT-PCR. There was a significant reduction in transcript abundance in the 
SiRNA treated cells compared to control cells. All quantitative RT-PCR experiments were 
performed in triplicate and repeated three times. The fold change represents the average fold 
change observed over the three experiments (error bar = SD, *** denotes p < 0.001, unpaired t-
test). B) An immunoblot showing a corresponding reduction in NCSTN protein (mature and 
immature) expression in SiRNA treated cells. Immature protein expression was affected to a 
greater extent given the short 48 hour incubation with SiRNA.   
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4.3.4.3   Nicastrin expression was reduced in mutant fibroblasts versus control 
fibroblasts 
Total cell protein was harvested from primary human fibroblasts from the mutation-
positive patient and three healthy volunteers. The total protein concentration in each 
sample was measured by BCA assay. 20µg total cell protein was immunoblotted for 
each sample and β-actin was used as a loading control. Differences in protein 
expression were quantified from each blot using Image J (National Institutes of Health 
(NIH), USA) which assessed the blot density of each sample. All nicastrin band 
densities were controlled against their corresponding β-actin blot density to control for 
loading variation. There was a significant reduction in mature nicastrin expression in 
fibroblasts harvested from the mutation-positive patient versus healthy volunteers (p < 
0.001, Figure 4.8). There was no associated reduction in immature nicastrin expression. 
No additional protein bands were present in the individual harbouring the mutation to 
support the presence of a mutant protein. Increasing blot time and the Tris-HCL gel 
percentage increased the distance between mature and immature bands but did not 
identify a mutant protein. 
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Figure 4.8. Immunoblot of NCSTN in mutant and control primary human fibroblasts.  A) 
Immunoblot of NCSTN in mutant and wild type fibroblasts. There appeared to be a significant 
reduction in mature NCSTN expression in the mutation-positive patient compared to healthy 
volunteers (controls).  β-actin was blotted as an endogenous control and loading appeared equal. 
B, C) Protein band densities were measured and controlled against the blot density of the 
corresponding β-actin band. NCSTN/ B-actin band densities were plotted as a measure of total 
NCSTN expression in each sample. There was a significant reduction in mature protein 
expression in mutant fibroblasts versus control fibroblasts but no significant difference in 
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4.4 PSENEN transcript and PSENEN protein analysis in an 
individual harbouring the heterozygous PSENEN insertion 
PSENEN c.66_67insG  
4.4.1 PSENEN c.66_67insG results in a frameshift and is predicted to result in an 
altered and lengthened protein product 
Primary human fibroblasts were cultured from an individual with the PSENEN 
c.66_67insG mutation. RNA was harvested from these cells and converted to cDNA by 
RT-PCR. PCR primers were designed to bind to regions of cDNA flanking the 
corresponding exonic location of this mutation (mutation within exon 2, primers 
designed to bind to sequences corresponding to exons 1 and 3). Amplification and direct 
sequencing of this segment demonstrated that the insertion is present in the transcript  
(Figure 4.9).  
 
Figure 4.9. PSENEN cDNA sequence in an individual harbouring the heterozygous 
c.66_67insG.  The insertion of a guanine base at position 67 is indicated by the arrow. 
 
This single base insertion is predicted to alter the reading frame and subsequently result 
in an altered protein product (Figure 4.10). PEN-2 has two ectodomains, two 
transmembrane domains and a cytoplasmic domain. This mutation is predicted to alter 
amino acids 23 through to 104 of PEN-2 where there is predicted to be a newly formed 
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stop codon (p.Phe23ValfsX98). The altered protein is predicted to be three bases longer 
than wild type PEN-2 (101aa). This mutation would therefore affect the two trans-
membrane domains, the cytoplasmic domain and one ectodomain, leading one to predict 
that it could have a significant impact on protein function.  The proximal two-thirds of 
the first trans-membrane domain of PEN-2 is known to be critically important for 
facilitating the endoproteolysis of presenilin-1
208
. Furthermore, the carboxy-terminal 
end of PEN-2 is critical in stabilising the presenilin 1 derivatives created by 
endoproteolysis
208
.   
 
Figure 4.10. The predicted PSENEN c.66_67insG mutant transcript and protein.  The 
inserted guanine lies within exon 2 of PSENEN and alters the reading frame. The protein 
product is therefore predicted to be altered from amino acid 23 onwards and 3 amino acids 
longer than the wild-type PEN-2 protein. 
 
- 154 - 
4.4.2 PSENEN transcript abundance is reduced as a consequence of PSENEN 
c.66_67insG 
PSENEN transcript abundance in the mutation-positive patient and three healthy 
volunteers (controls) was assessed by real time quantitative PCR. RNA was harvested 
from primary human fibroblasts cultured from affected skin in the mutation-positive 
patient and a matched axillary site in the three volunteer subjects. cDNA was produced 
from equal concentrations of RNA via RT-PCR. Real time quantitative PCR was 
performed using Taqman gene expression assays (Life Technologies). A specific 
commercially available PSENEN Taqman probe was chosen that binds to an exon 1 
related portion of the PSENEN transcript. This is before the site of the c.66_67insG 
mutation, thus the assay results reflect total PSENEN transcript abundance (WT and 
mutant combined) rather than that of the wild type or mutant transcript alone. Transcript 
expression was significantly reduced in mutant versus control fibroblasts (p<0.001, 
Figure 4.11). 
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Figure 4.11. Relative PSENEN transcript abundance in mutant and control primary 
human fibroblasts.  PSENEN transcript abundance was significantly reduced in mutant 
fibroblasts versus control fibroblasts. The figure plots transcript expression in the mutation-
positive patient versus one healthy volunteer (control) however this result was representative of 
experiments using two further independent controls (p<0.05, p<0.05)). All real time PCR 
reactions were performed in triplicate and experiments were repeated three times. The fold 
changes represent the average of the three experiments (error bars = SD, *** denotes p < 0.001, 
unpaired t-test). 
 
4.4.3 The mechanism underlying the apparent reduction in PSENEN transcript 
abundance is unclear 
PSENEN transcript abundance was reduced in the individual harbouring the mutation 
versus healthy volunteers suggesting that the mutant transcript may be subject to decay. 
WT and mutant PSENEN transcripts were run through an RNA secondary structure 
prediction website (http://rna.urmc.rochester.edu/RNAstructureWeb/). No significant 
alteration in secondary structure was evident as a consequence of the single base 
insertion (Figure 4.12). This would imply that structural instability is an unlikely cause 
of the apparent reduction in transcript abundance in the patient harbouring the mutation. 
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Figure 4.12. Predicted RNA secondary structure of the WT and mutant (c.66_67insG) 
PSENEN transcript.  These images represent the lowest free energy structure for each 
respective RNA sequence. The secondary structure of the mutated RNA is not predicted to 
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significantly differ from that of the wild type transcript. Individual images were taken directly 
from an RNA secondary structure prediction website 
(http://rna.urmc.rochester.edu/RNAstructureWeb/). 
 
To further investigate the mechanism underlying the reduced transcript abundance 
mutant cells were cultured in 20µg/ml cycloheximide for up to 24 hours. A minimal 
increase in transcript abundance was observed in the cycloheximide treated cells over 
the 24 hour period but this was not statistically significant (Figure 4.13). The PSENEN 
mutation was previously shown to result in a frameshift and eliminate the native stop 
codon. This would theoretically result in the ribosomal machinery reading through the 
region relating to the native stop codon and may therefore induce non-stop decay 
(mechanisms of RNA surveillance were discussed in 4.3.3). There would appear to be a 
newly formed stop codon only ten bases after that site however. Furthermore, non-stop 
decay is a translation-associated mechanism and as such, one might have expected 
cycloheximide to increase RNA expression. Whilst this result does not preclude the 
process of non-stop decay it does infer that further investigation is required to clarify 
the exact mechanism by which transcript abundance is reduced as a consequence of the 
PSENEN c.66_67insG mutation.  
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Figure 4.13. PSENEN transcript abundance in mutant fibroblasts following incubation 
with cycloheximide.  There was no significant increase in transcript abundance following a 24 
hour incubation with cycloheximide. All experiments were performed in triplicate and repeated 
three times. Fold changes represent the average fold change achieved over all three experiments 
(error bars = SD). 
 
4.4.4 PEN-2 protein expression was reduced in mutant fibroblasts compared to 
controls 
PSENEN transcript expression was reduced in the individual harbouring the PSENEN 
c.66_67insG mutation. This led to the hypothesis that there would be a corresponding 
reduction in protein expression. Given that some mutant transcript is present (seen when 
sequencing the full length PSENEN transcript) a further hypothesis was that there would 
be some expression of a mutant form of PEN-2. Total cell protein was extracted from 
primary human fibroblasts in culture (chemical lysis with RIPA buffer) and 
immunoblotting was performed to interrogate these hypotheses. 
- 159 - 
4.4.4.1  Antibody selection and optimisation 
Two rabbit polyclonal anti-PEN-2 antibodies were tested for specificity and sensitivity. 
An antibody was chosen on the basis that it produced a specific band corresponding to 
the expected protein weight (12kDa, consistent with previous publications and the use 
of different PEN-2 antibodies
274
) and because it binds to the N-terminus of PEN-2. The 
exact immunogen was commercially sensitive however the binding site was confirmed 
by the manufacturer to be before the segment of PEN-2 corresponding to the insertion 
(relating to aa 23). The antibody would therefore detect all PEN-2 protein variants 
present (wild type and mutant protein). The total amount of protein required for each 
blot was optimised. 25µg was sufficient to produce strong and specific bands with an 
antibody titre of 1:200.  Protein electrophoresis was performed on a 4-20% Tris-HCL 
gel. 
4.4.4.2   PEN-2 expression was reduced in mutant fibroblasts versus control 
fibroblasts 
Total cell protein was extracted from primary human fibroblasts cultured from the 
patient harbouring the mutation and three healthy volunteers (controls). The total 
protein concentration in each sample was measured by BCA assay. 25µg total cell 
protein was immunoblotted for each sample and β-actin was used as a loading control. 
Differences in protein expression were quantified from each blot using Image J (NIH) 
which assessed the blot density of each sample. Whilst the β-actin bands in all samples 
appeared very similar, all PEN-2 band densities were controlled against their 
corresponding β-actin blot density for complete accuracy. There was a significant 
reduction in PEN-2 expression in dermal fibroblasts harvested from the mutation-
positive patient versus those harvested from three control subjects (Figure 4.14). No 
second band was observed in the patient harbouring the mutation to support the 
presence of a mutant protein. This should be interpreted with caution however given 
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that the mutant protein is only predicted to be three amino acids longer in length and 
would therefore be difficult to differentiate from the wild type protein on 
immunoblotting.  
 
Figure 4.14. Immunoblot of PEN-2 in protein samples harvested from mutant and control 
primary human fibroblasts.  A) Immunoblot of PEN-2 in mutant and control primary human 
fibroblasts. PEN-2 expression appears reduced in mutant fibroblasts versus controls. Β-actin 
was blotted as a loading control and loading appeared equal B) Plot of PEN-2 blot density/ β-
actin blot density for each individual. There was a significant reduction in PEN-2 expression in 
mutant fibroblasts versus control fibroblasts (*** denotes p< 0.001, unpaired t-test).  
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4.5 The effect of NCSTN c.1125+1 G>A and PSENEN c.66_67insG 
mutations on gamma-secretase enzyme activity in vitro 
Globally, mutations have now been reported in three of the four components of the 
gamma-secretase complex in HS (PSEN1, NCSTN and PSENEN), firmly implicating 
gamma-secretase in disease pathogenesis. It was therefore hypothesised that the 
identified mutations would affect gamma-secretase enzyme activity.  
4.5.1 Methodological approaches to evaluating gamma-secretase activity in vitro. 
Multiple methods have been devised to assess gamma-secretase enzyme activity in 
vitro. The original and most commonly reported assay uses a Flag-tagged portion of 
APP protein (C100-Flag) as an enzyme substrate
264; 265
. The amount of Flag-tagged 
AICD that is produced reflects endopeptidase enzyme activity and the amount and 
relative ratio of Aβ peptides produced reflects carboxypeptidase enzyme activity. Flag-
tagged Notch is an alternative enzyme substrate with NICD-Flag production acting as a 
measure of endopeptidase activity. Carboxypeptidase activity is not as easy to assess 
with Notch based assays however as whilst Nβ peptide levels can be measured, 
interpretation of the results remains at a premature stage
178; 247
. One commercial in vitro 
gamma-secretase activity assay was produced that utilised APP as the enzyme substrate 
however this lacked formal validation and was withdrawn from the market in 2010
275
. 
The original APP based method was deemed to be the most well-established, reliable, 
interpretable and informative method to determine gamma-secretase enzyme activity in 
vitro in this study. 
4.5.2 Analysis of in vitro gamma-secretase activity using an amyloid precursor 
protein-based assay (C100F substrate) 
Amyloid precursor protein (APP) is a cell-membrane protein. The extra-cellular portion 
of the protein can be cleaved by either α-secretase or β-secretase. β-secretase cleavage 
- 162 - 
leaves a 100 amino acid segment of APP (C100) within the cell membrane which in 
turn is cleaved by gamma-secretase to produce APP intracellular domain (AICD) and 
amyloid β peptides (Aβ) (ε-cleavage, endopeptidase activity). Two different length Aβ 
peptides can be produced following gamma-secretase ε-cleavage, Aβ49 and Aβ48, 
which are progressively processed by gamma-secretase and shortened 
(carboxypeptidase-like activity) as shown in Figure 4.15. It is this processing activity of 
gamma-secretase that is felt to be important in FAD, when the ratio of Aβ42: Aβ40 is 
raised, potentially increasing the likelihood of Aβ deposition in the brain178. 
 
Figure 4.15.  β-secretase and γ-secretase cleavage and processing of amyloid precursor 
protein in the cell membrane.  β-secretase cleaves APP to leave a 100aa C terminal fragment 
(C100) in the cell membrane. Gamma-secretase then cleaves that to form AICD and Aβ48 or 
Aβ49 peptides (ε-cleavage, endopeptidase activity). The Aβ peptides are subsequently 
sequentially cleaved to produce shorter length peptides (carboxypeptidase-like activity). 
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The basis of the gamma-secretase assay employed here is that a Flag-tagged C100 
peptide is produced and used as the enzyme substrate. In the correct environment, 
gamma-secretase (in the form of purified and solubilised membrane protein harvested 
from patient fibroblasts) cleaves this substrate to produce AICD-Flag and Aβ peptides. 
AICD-Flag abundance is measured by immunoblotting (using an anti-Flag antibody) 
and that correlates with overall enzyme activity (ε-cleavage). Aβ40 and Aβ42 are 
quantified by ELISA and the ratio of these two products is an indication of the 
processing (carboxypeptidase-like) activity of gamma-secretase (Figure 4.16). 
 
Figure 4.16. Principle of the C100-Flag APP based gamma-secretase activity assay.  A 
C100-Flag substrate is produced which is cleaved by gamma-secretase to produce AICD-Flag 
(measure of endopeptidase activity) and Aβ peptides (the ratio of Aβ42:Aβ40 is a measure of 
carboxypeptidase activity). AICD-Flag and Aβ peptides can be quantified by immunoblotting 
and ELISA respectively. 
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4.5.3 Production of the C100-Flag enzyme substrate 
A C100-Flag pET-21b (-) plasmid was kindly provided by Dr Oliver Holmes, Centre 
for Neurological Diseases, Harvard Medical School, Boston, USA
264
. C100-Flag protein 
was generated and purified from this plasmid following a protocol developed by the 
Centre for Neurological Diseases, Harvard Medical School. NEB 5-alpha competent e-
coli were transformed with the C100-Flag pET-21b and cultured. The plasmid was 
subsequently purified generating a plasmid concentration of 330ng/µl. BL21 (DE3) 
competent E Coli were then transformed with the purified C100-Flag pET-21b plasmid 
and cultured. C100-Flag protein expression was induced with 1mM IPTG and cells 
were physically lysed in Triton X-100 using a glass homogeniser. The sample was spun 
to create a soluble and insoluble fraction. The insoluble fraction (cell pellet) contained 
cell membranes enriched with C100-Flag, the soluble fraction was discarded. Small 
aliquots of pre-IPTG induced lysed cells, post-IPTG induced lysed cells and the soluble 
and insoluble fraction of that lysate were analysed via electrophoresis to assess whether 
C100-Flag protein expression had indeed been induced. Staining of the protein blot with 
InstantBlue (Expedeon, Harston, UK) confirmed the presence of a protein band at the 
expected weight (15kDa) in samples from post-IPTG induced lysed cells, more 
specifically the insoluble fraction (Figure 4.17). 
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Figure 4.17. Protein electrophoresis of pre- and post-IPTG induced cell lysate samples 
from BL21 (DE3) E.coli cells expressing the C100-Flag pET-21b plasmid.  A protein band 
can be seen at around 15kDa in the IPTG induced cell lysate consistent with C100-Flag 
production. Upon splitting this lysate in to soluble and insoluble fractions the protein can be 
seen in the insoluble fraction, as would be expected given the membranous location of the C100 
protein. 
 
The insoluble fraction (cell pellet) was re-suspended and homogenised with a glass 
homogeniser and C100-Flag protein was selected and purified using anti-flag tagged 
beads. The beads were washed three times and the C100-Flag protein was eluted from 
the beads with five separate aliquots of elution buffer. Aliquots of unbound sample, 
washes 1 – 3 and elutes 1 – 5 were analysed via electrophoresis and InstantBlue 
(Expedeon) staining. C100-Flag was present in elutes 2 and 3 (most abundant in elute 2, 
Figure 4.18). 
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Figure 4.18. Electrophoresis and InstantBlue staining of samples generated during the 
purification of C100-Flag.  A protein band consistent with C100-Flag can be seen at around 
15kDa in elutes 2 and 3. 
 
The five elute samples were assessed by immunoblotting with an anti-Flag primary 
antibody. C100-Flag was present in all five elutes, more so in elutes 2 and 3 (Figure 
4.19). Elute 2 was therefore used as the source of C100-Flag in all gamma-secretase 
assays. 
 
Figure 4.19. Immunoblot of purified C100-Flag samples using a primary anti-Flag 
antibody.  A protein band can be seen at 15kDa in elutes 1 – 5 consistent with C100-Flag.  
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4.5.4 Initiation and maintenance of an S-20 cell line 
S-20 is a Chinese hamster ovary (CHO) cell line that stably expresses Nicastrin-V5/His, 
human PSEN1, N-terminally FLAG-tagged Pen-2 and C-terminally HA-tagged Aph-
1α2266 (Figure 4.20). The relative over-expression of these components means that 
solubilised membrane protein harvested from these cells can be used as a positive 
control in gamma-secretase enzyme activity assays
264; 266
. S-20 cells were kindly 
provided by Dr Oliver Holmes, Centre for Neurological Diseases, Harvard Medical 
School, USA.  
 
Figure 4.20. S20 cells in culture. 
 
4.5.5 Purification and solubilisation of membrane proteins from primary human 
fibroblasts and S20 cells 
Axillary skin was taken from the two patients harbouring mutations (affected skin) and 
three age-matched volunteer subjects (controls) with no history of HS. Primary human 
fibroblasts were isolated and cultured and the total number of cells harvested from each 
individual is shown in Table 4.2. S20 cells were cultured in parallel (Table 4.2). 
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Membrane proteins were purified and solubilised using a protocol devised by our 
collaborators at Harvard Medical School, USA
266
. Cells were physically lysed and cell 
membranes were isolated and washed with sequential ultra-centrifugation and sodium 
bicarbonate. Membranes were solubilised in 1% CHAPSO (amount of 1% CHAPSO 
added shown in Table 4.2) and the sample was further centrifuged. The supernatant was 
defined as solubilised gamma-secretase preparation and was used as crude gamma-
secretase fractions in gamma-secretase assays. The number of fibroblasts used to 




Table 4.2. Number of cells harvested and amount of 1% CHAPSO used to extract 
solubilised membrane proteins 
Sample Number of primary human 
fibroblasts harvested 





















Solubilised gamma-secretase preparations derived from S20 cells and primary human 
fibroblasts (control 1) were subjected to electrophoresis and probed with anti-nicastrin 
and anti-PEN-2 antibodies. Nicastrin and PEN-2 were detected in both samples, thus it 
- 169 - 
was assumed that the gamma-secretase components had been effectively solubilised 
(Figure 4.21). 
  
Figure 4.21. Immunoblotting of NCSTN and PEN-2 in solubilised membrane preparations 
from S20 cells and primary human fibroblasts.  There was good expression of both proteins 
in solubilised membrane preparations harvested from S20 and primary human fibroblasts. 
 
Solubilised gamma-secretase preparation concentrations were measured using a BCA 
protein concentration assay. All assays were performed in triplicate and the standard 
curve for the albumin controls is shown in Figure 4.22. Protein concentrations for all of 
the solubilised membrane protein samples were calculated by plotting light absorbance 
readings against this curve. Protein concentrations are shown in Table 4.3. 
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Figure 4.22. Standard curve plotted using protein concentration and 562nm light 
absorbance readings for protein standards.  The protein concentration of solubilised cell 
membrane preparations were calculated from their 562nm light absorbance readings using this 
standard curve.   
 
Table 4.3. Concentration of the solubilised cell membrane preparations as calculated using 
BCA assays.  
Sample Solubilised membrane protein concentration/ µg/ ml 
S20 1624.3 
PSENEN mutant 565.6 
NCSTN mutant 943.1 
Control 1 737.9 
Control 2 1780.2 
Control 3 409.6 
 
 
y = 1641.4x - 171.6 
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4.5.6 Optimisation of the gamma-secretase activity assay 
Gamma-secretase assays were performed according to a protocol devised by our 
collaborators at Harvard Medical School
264
. 8µg solubilised gamma-secretase 
preparations harvested from S20 cells and primary human fibroblasts were incubated 
with cholesterol, L-α-phosphatidylcholine and L-α-phosphatidylethanolamine. The 
lipids form detergent-lipid mixed micelles which provide a platform upon which 
gamma-secretase can cleave its substrates. C100-Flag substrate was then added and the 
mixture was left to incubate for 4 hours at 37ºC. Runs with no gamma-secretase (ie. no 
solubilised gamma-secretase preparation added) and no substrate were performed as 
negative control experiments. 12µl of the reaction mixtures were subjected to 
electrophoresis and probed with an anti-Flag antibody (Figure 4.23). 
 
Figure 4.23. Immunoblot showing the results of a gamma-secretase activity assay.  The 
C100-Flag substrate runs at 15kDa, the expected enzyme product, AICD, is predicted to run at 
7kDa. The C100-Flag substrate can be seen at 15kDa (the band seen in the no C100F lane 
represents PEN2-Flag expressed by S20 cells). AICD appeared to be visible in reaction mixes 
comprising gamma-secretase harvested from S20 cells and primary human fibroblasts but not 
visible in the no gamma-secretase/ no substrate runs, as would be expected. 
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A 15kDa band could be seen in the no gamma-secretase run, consistent with the C100-
Flag substrate. A 15kDa band could also be seen in the no substrate reaction. As the 
solubilised gamma-secretase preparation used in this reaction was harvested from S20 
cells, this band represents the Flag-tagged PEN-2 protein produced by those cells. A 
very intense signal was observed around 15kDa in the S20 reaction which is likely to 
represent both the Flag-tagged substrate and PEN-2 present in that reaction. Any lighter 
bands (AICD expected at 7kDa) were therefore hard to identify however there did 
appear to be a band visible at 7kDa. The C100-Flag band seen at 15kDa in the primary 
human fibroblast run was smaller and more well-defined than the band seen in the S20 
run. There did appear to be a band visible at 7kDa however this was broken, possibly as 
a consequence of an air bubble affecting protein transfer on to the ECL membrane. 
Overall, there appeared to be some evidence that AICD was being produced in these 
activity assays, however the band expected at 7kDa was not clear and was vastly 
overshadowed by the substrate band seen at 15kDa in the S20 reaction. As a 
consequence, the protein blots were cut at 13kDa prior to exposure in subsequent runs.  
4.5.6.1   Optimisation step 1 – Cutting the ECL membrane at 13kDa prior to 
exposure to separate the substrate and AICD signals 
All optimisation experiments were designed in collaboration with Dr. Oliver Holmes, 
Harvard Medical School, USA. S20 cells were used in all optimisation experiments as 
they are known to over-express the four components of the gamma-secretase complex. 
The experiment was performed exactly as above however the ECL membrane was cut at 
13kDa to form two segments, one theoretically containing C100-Flag (15kDa) and one 
AICD-Flag (7kDa). The immunoblot can be seen in Figure 4.24. Whilst the C100-Flag 
substrate/ Flag-tagged PEN-2 protein was clearly visible at 15kDa there was no signal 
observed at 7kDa suggestive of AICD production.  
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Figure 4.24. Immunoblot of a gamma-secretase activity assay reaction performed using 
enzyme derived from S20 cells.  The C100-Flag substrate was visible at 15kDa but no AICD 
product was detectable. 
 
Films were left for over 60 minutes and no bands were observed. On the assumption 
that there may only be a very small amount of AICD produced, the amount of protein 
blotted was increased from 12µl to 30µl. No band was observed at 7kDa with this 
increased protein load. ECL membranes were cut at 13kDa and 30µl protein was blotted 
in all future optimisation experiments.  
4.5.6.2   Optimisation step 2 – Altering the amount of solubilised gamma-
secretase preparation added to each assay 
To ascertain the impact of altering the amount of solubilised cell membrane protein 
added to each reaction 5µg, 8µg and 12µg protein were added to three different 
reactions. This was done in the knowledge that higher concentrations would increase the 
final CHAPSO concentration in the reaction above the optimal 0.25%. CHAPSO 
concentrations above 0.45% have been shown to reduce enzyme activity, possibly by 
affecting micelle formation (Holmes, unpublished data). 30µl of reaction product was 
subjected to electrophoresis and probed with anti-Flag antibody. The C100-Flag/ PEN-
2-Flag band at 15kDa was visible however no AICD-Flag product was evident on 
prolonged exposure (Figure 4.25).  
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Figure 4.25. Immunoblot of enzyme activity assays using variable concentrations of S20 
solubilised membrane protein.  The C100-Flag substrate is visible however no AICD-Flag 
was produced. 
 
4.5.6.3   Optimisation step 3 – Altering the amount of C100-F substrate added to 
each assay 
The C100-Flag substrate was purified effectively (Figure 4.19) and was visible in 
enzyme activity assays in which no solubilised proteins were added (Figure 4.23). 
Harvard use 1µl of purified substrate and this amount is sufficient to saturate the 
gamma-secretase complexes that are present. This means that the amount of substrate 
available is not a variable in activity assay outcomes. To ensure that assays were not 
failing due to a lack of substrate the amount of C100-Flag added was doubled to 2μg. 
Again the C100-Flag/ PEN-2-Flag band was evident at 15kDa but no AICD product 
was produced (see Figure 4.26). 
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Figure 4.26. Immunoblot of gamma-secretase assays using variable amounts of C100-Flag 
substrate.  No AICD-Flag product can be seen in reactions involving 1 or 2µl C100-Flag. 
 
In summary, immunoblotting of the solubilised gamma-secretase preparations produced 
from S20 cells and human fibroblasts revealed the presence of the gamma-secretase 
components NCSTN and PEN-2 (Figure 4.21), inferring that membrane proteins had 
been isolated and solubilised effectively. The C100-Flag substrate was purified 
effectively (Figure 4.19) and was clearly visible in enzyme activity assays in which no 
solubilised proteins were added (Figure 4.23). The quantity added to each reaction was 
as stated in our collaborators protocol and doubling that amount made no impact on the 
efficacy of the assay. Gamma-secretase complexes and the C100-Flag substrate would 
both therefore appear to be present, thus it was assumed that the enzyme activity assay 
itself was not working effectively. If there was indeed any AICD produced in the very 
first optimisation run, which is unclear from the immunoblot performed, that would 
infer that something had changed in subsequent assays. The method, techniques and 
machinery used did not alter between runs. Reagent batches did not change and storage 
and handling of each reagent was as advised by the supplier. Any degradation or 
conformational/oxidative changes affecting the lipids could have suppressed micelle 
formation. These micelles are integral to the assay as they support the gamma-secretase 
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complexes and facilitate enzyme activity. A further consideration was that there can be 
significant batch to batch variation in cholesterol quality. Our collaborators have 
previously shown that some samples even impair enzyme activity (Holmes, unpublished 
data).  A new batch of cholesterol was therefore used for the next assay and a no 
cholesterol run was performed. 
4.5.6.4   Optimisation step 4 – Cholesterol batch changed and a no-cholesterol 
assay performed 
The assay was repeated three times with 8µg solubilised gamma-secretase preparation. 
Cholesterol from a new batch was used in one run, cholesterol from the previous 
experiments was used in a second run and no cholesterol was added to the final reaction. 
None of these interventions conferred a benefit. No AICD-Flag was detected in any of 
the three runs (Figure 4.27).  
 
Figure 4.27. Immunoblot of gamma-secretase enzyme activity assays using different 
batches of and no cholesterol.  The C100-Flag/ PEN-2-Flag band can be seen at 15kDa but no 
AICD-Flag was evident in any of the three runs. 
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4.5.6.5 Enzyme activity assays were performed at Harvard Medical School 
From the available data, it would appear that both the enzyme and substrate were 
present in these assays but that there was a problem with the enzyme activity assay 
itself. Despite the above optimisation steps the nature of that problem could not be 
identified and therefore corrected. Our collaborators, based at The Centre for 
Neurological Diseases, Harvard Medical School, USA, have optimised and routinely 
perform this assay in their laboratory. It was therefore decided that the solubilised 
gamma-secretase samples and C100-Flag substrate should be sent to their laboratory for 
analysis. All activity assays were performed with the solubilised gamma-secretase 
samples and C100-Flag substrate generated in our laboratory. Experiments detailed 
below were designed in collaboration with Dr Oliver Holmes and performed by Dr 
Oliver Holmes (Harvard Medical School, Centre for Neurological Diseases, USA).   
4.5.7 Gamma-secretase activity assays 
The quantity of solubilised gamma-secretase preparation added to each reaction was 
standardised at 8µg. All activity assays were repeated 7 times for each of the six 
samples (harvested from S20 cells, NCSTN mutant fibroblasts, PSENEN mutant 
fibroblasts and control fibroblasts 1-3) to ensure consistent results. Assay reactions were 
analysed by electrophoresis and immunoblotting with primary antibodies to NCSTN, 
PEN-2, PSEN1, PSEN1-CTF and Flag. A blot from one activity assay is shown in 
Figure 4.28. Bands corresponding to the gamma-secretase components, C100-Flag 
substrate and AICD-Flag product are clearly visible implying that the solubilised 
gamma-secretase preparations and C100-F substrate prepared in-house were of 
sufficient quality and concentration. S20 cells were included as a positive control in this 
study and, as would be expected, there was an over-expression of gamma-secretase 
components and a correspondingly high amount of AICD-Flag produced. This therefore 
acted as a suitable control against which to compare AICD production in the other 
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samples. To confirm that the AICD bands visualised represented products of gamma-
secretase cleavage an assay was run with the gamma-secretase inhibitor L458 (negative 
control). This successfully prevented any AICD-Flag production, confirming the 
specificity of the assay. 
 
Figure 4.28 A representative gamma-secretase activity assay immunoblot.  Bands can be 
seen representing three of the gamma-secretase components NCSTN (mature, mNct, and 
immature, iNct), PSEN1 (PS1, PS1-CTF), PEN-2 (Pen2-Flag, Pen-2), the substrate (C100-Flag) 
and the enzyme product (AICD-Flag). 
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4.5.8 Analysis of gamma-secretase enzyme activity in mutant and control 
primary human fibroblasts 
4.5.8.1 Hypothesis 1: There will be fewer gamma-secretase complexes and a 
consequent reduction in enzyme activity in samples harvested from 
mutant fibroblasts versus control fibroblasts 
One might hypothesise that a reduced expression of any one component of the gamma-
secretase complex (as would appear to be the case with the NCSTN and PSENEN 
mutations reported here) would impact upon the number of mature gamma-secretase 
complexes present at the level of the cell membrane which may consequently alter 
enzyme activity at that site. 
PSEN1-CTF is a stable marker of the number of mature complexes present in any 
sample as it is only produced following successful cleavage of PSEN1 (required for 
complex activity). Whilst PSEN1-CTF levels could be measured and compared across 
individuals in this experiment, there was no reliable ubiquitously expressed endogenous 
control that could be used to confirm equal protein loading on immunoblotting (similar 
to β-actin used in earlier immunoblotting experiments). The original amount of protein 
added to each reaction is however standardised, so excluding any manual handling 
errors (eg. pipetting error) then equal amounts of protein should be added to each 
reaction. The seven experimental repeats would also largely negate any such pipetting 
errors. The average PSEN1_CTF expression for each sample is shown in Figure 4.29. 
Significant variability was observed between the control fibroblast samples but there 
appeared to be no significant difference in PSEN1_CTF expression in mutant 
fibroblasts versus controls.   
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Figure 4.29. PSEN1-CTF expression in solubilised membrane preparations harvested 
from mutant and control fibroblasts.  There was some variability in PSEN1-CTF expression 
observed between controls but there was no significant difference in PSEN1-CTF expression in 
the NCSTN or PSENEN mutant fibroblasts versus controls (error bars = standard error (SE)).  
 
Crude gamma-secretase activity per mg solubilised membrane protein in each sample 
was analysed by comparing AICD-Flag production in every assay against the positive 
control (AICD-Flag production using solubilised membrane samples harvested from 
S20 cells). Average AICD-Flag values were calculated across all seven runs. No 
significant difference was detected between the NCSTN mutant and controls (Figure 
4.30). If anything, a slightly increased enzyme activity was observed in PSENEN 
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Figure 4.30. Crude gamma-secretase activity per mg of total solubilised membrane protein 
expressed as a percentage of the positive control (S20 cells).  There was no significant 
difference in enzyme activity observed between the NCSTN mutant fibroblasts and controls. 
There was a small and significant increase in enzyme activity observed between PSENEN 
mutant fibroblasts and controls (error bars = SE, ** denotes p < 0.01, one-way ANOVA with 
Dunn's correction). 
 
Overall, these data were not consistent with the hypothesis that there would be a 
reduction in complex number or crude gamma-secretase enzyme activity in mutant 
fibroblasts. PSEN-CTF expression was no different in mutant fibroblasts versus controls 
and crude enzyme activity appeared slightly increased, rather than reduced as was 
hypothesised, in PSENEN mutant fibroblasts. Crude gamma-secretase activity may be 
considered an indirect measure of mature gamma-secretase complex number if mature 
complexes are assumed to be of equal activity in all individuals. The indifferent 
PSEN1-CTF expression but apparent increase in enzyme activity observed in PSENEN 
mutant fibroblasts may however infer that enzyme activity per complex may differ 
between individuals.  
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4.5.8.2 Hypothesis 2: Gamma-secretase enzyme activity per complex will be 
reduced in samples harvested form mutant fibroblasts versus control 
fibroblasts  
To measure enzyme activity per gamma-secretase complex AICD-Flag was controlled 
against PSEN1-CTF, a marker of the number of mature complexes present. The AICD-
Flag/ PSEN1-CTF ratio for each individual was expressed as a percentage of the value 
obtained for the positive control S20 sample. Averages were calculated across all seven 
runs and are shown in Figure 4.31.  There was no significant difference in enzyme 
activity per complex in mutant fibroblasts vs. controls. 
 
Figure 4.31. Gamma-secretase enzyme activity per complex expressed as a percentage of 
the positive control (S20 cell line).  There was no significant difference in enzyme activity per 
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4.5.8.3 Hypothesis 3: Gamma-secretase complexes will demonstrate abnormal 
maturation in samples harvested from mutant fibroblasts versus controls 
As discussed in the introduction, the presence of all four gamma-secretase components 
is required for appropriate trafficking, maturation, stability and ultimately activity of the 
complex. It may therefore be hypothesised that a reduction in the available nicastrin or 
PEN-2 in mutation-positive patients, as would be suggested by earlier functional 
studies, may detrimentally affect complex maturity. A measure of complex maturity is 
the PSEN1-CTF/ PEN-2 ratio. One might imagine that this ratio would differ in the 
individual harbouring the PSENEN mutation for example because less PEN-2 may be 
available for uptake. Alternatively the PEN-2 incorporated in to the complexes may not 
facilitate effective proteolysis of PSEN1 which is necessary to produce PSEN1-CTF 
(required for catalytic activity). Ratios were calculated for all seven assays and the 
average result for each sample is presented in Figure 4.32. The ratio did not 
significantly differ in mutant fibroblasts vs. controls. 
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Figure 4.32. PSEN1 CTF/ PEN-2 ratio for each sample expressed as a percentage of the 
ratio observed in the positive control S20 cells.  This ratio is representative of gamma-
secretase complex maturity. There was no discernible difference in complex maturity in mutant 
fibroblasts versus control subjects (error bars = SE). 
 
4.5.8.4    Hypothesis 4: Gamma-secretase carboxypeptidase-like activity 
(processivity) will be altered in samples harvested from mutant fibroblasts 
vs. control fibroblasts. 
The enzyme activity data presented above relates to the Ɛ-cleavage or endopeptidase 
activity (production of AICD) of gamma-secretase which is regarded as a marker of 
overall enzyme activity. However, as stated in the introduction, the presenilin mutations 
reported in FAD unanimously affect carboxypeptidase activity but only rarely the 
endopeptidase activity of gamma-secretase. It is therefore conceivable that the nicastrin 
and presenilin mutations presented here may affect the carboxypeptidase-like 
processing function of gamma-secretase rather than the endopeptidase activity. ELISA’s 
were performed to quantify the amount of Aβ42 and Aβ40 produced in each enzyme 
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fraction of the ratio derived in the positive control S20 reaction. The average ratio was 
calculated across all seven assays and the results are shown in Figure 4.33. There was 
no significant difference in the Aβ42:Aβ40 ratio in assays run with samples harvested 
from NCSTN mutant fibroblasts versus control fibroblasts. A slightly reduced ratio was 
observed in assays run with samples harvested from PSENEN mutant fibroblasts but 
this was not statistically significant.  
 
Figure 4.33. Aβ42: Aβ40 ratios expressed as a percentage of the ratio derived from S20 
cells.  There was no significant difference in the ratio derived in assays run with samples 
harvested from mutant fibroblasts versus control fibroblasts (error bars = SE). 
 
4.5.9 In contrast to total cell fractions, NCSTN and PEN-2 expression in 
solubilised cell membrane fractions is equal in mutant and control 
fibroblasts 
NCSTN and PEN-2 expression was reduced in total cell fractions harvested from 
NCSTN and PSENEN mutant fibroblasts respectively in vitro.(4.3.4, 4.4.4). Their 
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individuals for the purposes of the enzyme activity assays was therefore analysed as a 
comparison. Solubilised cell membrane preparations (also referred to as solubilised 
gamma-secretase preparation) were harvested from mutant and control fibroblasts for 
the purposes of the enzyme activity assays. NCSTN and PEN-2 blot densities were 
calculated from each of the seven independent enzyme activity assays and average 
densities (representing average protein expression) were calculated. It was very 
interesting to note that, in contrast to total cell fractions, there was no significant 
difference in NCSTN and PEN-2 expression in solubilised membrane fractions 
harvested from mutant and control fibroblasts in vitro  (Figure 4.34, Figure 4.35). It 
should be noted however that there was no endogenous solubilised cell membrane 
protein that could be used as a reliable loading control for this analysis (as was the case 
when studying PSEN1-CTF expression in these same samples, section 4.5.8.1). All 
sample concentrations were however measured and equalised using BCA and the seven 
experimental repeats should have minimised any pipetting error. 
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Figure 4.34. NCSTN expression in solubilised cell membrane fractions harvested from 
mutant and control fibroblasts.  Data represents the average protein band density measured 
across seven independent experiments. There was no significant difference in NCSTN 

























- 188 - 
 
Figure 4.35. PEN-2 expression in solubilised cell membrane fractions harvested from 
mutant and control fibroblasts.  Data represents the average protein band density measured 
across seven independent experiments. There was no significant difference in PEN-2 expression 
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4.6 Immunohistochemical analysis of NCSTN and PEN-2 expression 
in the skin 
Gamma-secretase is integral to the cleavage of over 30 trans-membrane proteins and is 
widely expressed throughout the body. The cutaneous location of gamma-secretase 
complexes and their individual constituents has not been studied in detail. We sought to 
investigate this in normal skin, skin from mutation-positive patients and skin from 
mutation-negative HS patients. All immunohistochemistry was performed by Dr. Carl 
Hobbs, The Wolfson Centre for Age Related Diseases, King’s College London.  
4.6.1 Primary antibody optimisation 
The NCSTN and PEN-2 antibodies used for immunoblotting were used to perform 
immunohistochemisry on paraffin-embedded tissue. Antibody concentrations were 
chosen that produced clear and visible staining in skin with no apparent non-specific 
background signal (1:200 and 1:20 for nicastrin and PEN-2 respectively). Nicastrin 
expression is up regulated in tumour cell lines and tissue sections derived from invasive 
ductal breast carcinomas
272
. Tissue from a grade IV invasive and a lobular breast cancer 
(obtained from the Guy’s Hospital Breast Cancer Tissue Bank) was therefore used as a 
positive control to assess antibody specificity. Nicastrin was abundantly expressed in 
both invasive and lobular breast cancer using the chosen nicastrin antibody, supporting 
antibody specificity (Figure 4.36a). As another integral subunit of the gamma-secretase 
complex, one might also expect PEN-2 to be over-expressed in these specimens. This 
was indeed the case, supporting PEN-2 antibody specificity (Figure 4.36a). Co-
localisation of NCSTN and PEN-2 staining in healthy volunteer skin, presumably 
representing the location of gamma-secretase complexes, further supported antibody 
specificity (additionally replicated using a second NCSTN antibody, Figure 4.36b). 
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Figure 4.36. Nicastrin and PEN-2 staining in human breast cancer and healthy skin.  No 
staining was seen in the no primary antibody run in breast cancer or skin. A/ Nicastrin and PEN-
2 were highly expressed in grade 3 invasive ductal and lobular breast cancer (positive control). 
Scale bar = 100µm. B/ NCSTN (two separate primary antibodies) and PEN-2 expression co-
localised in the epidermis, supporting antibody specificity.  Scale bar = 50µm. 
 
4.6.2 Gamma-secretase is concentrated in the epidermis, hair follicle, apocrine 
gland and sebaceous gland in axillary skin harvested from healthy 
volunteers 
Axillary skin was obtained from three healthy volunteer subjects, embedded in paraffin, 
sectioned and probed with the nicastrin and PEN-2 antibodies. Protein expression was 
most abundant in the epidermis, hair follicle, sebaceous gland and apocrine gland 
(Figure 4.37). Whilst Figure 4.37 represents only one of the volunteers, the pattern of 
staining was consistent across all three individuals. The extra-nuclear staining observed 
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in epidermal keratinocytes is consistent with the membrane-bound location of the 
gamma-secretase components (Figure 4.38). 
 
Figure 4.37.NCSTN and PEN-2 expression in healthy volunteer axillary skin.  NCSTN and 
PEN-2 staining co-localised in the epidermis, hair follicle, sebaceous gland and apocrine glands. 
Scale bar = 50µm. 
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Figure 4.38 Close up of NCSTN and PEN-2 staining in the epidermis.  Staining is extra-
nuclear, consistent with the predominantly membrane-bound location of the gamma-secretase 
components in cells. Scale bar = 50µm. 
 
4.6.3 NCSTN and PEN-2 are expressed in the epidermis, hair follicle, apocrine 
gland, sebaceous gland and inflammatory infiltrate in axillary skin 
harvested from patients with NCSTN c.1125+1 G>A and PSENEN 
c.66_67insG mutations 
The expression pattern of nicastrin and PEN-2 in affected, site-matched, axillary skin 
from the two patients harbouring mutations in NCSTN and PSENEN (NCSTN c.1125+1 
G>A, PSENEN c.66_67insG) did not significantly differ from that observed in healthy 
volunteers, however additional staining was evident within the inflammatory infiltrate 
(Figure 4.39, Figure 4.40). Staining with antibodies directed against myeloperoxidase, 
CD3, L26 and CD68 suggested that neutrophils, T cells, B cells and macrophages were 
present within the inflammatory infiltrate.  
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Figure 4.39. Cutaneous NCSTN expression in affected axillary skin from the individual 
harbouring the NCSTN c.1125+1 G>A mutation.  Expression can be seen in the epidermis, 
hair follicle and inflammatory infiltrate. Scale bar = 50µm. 
- 194 - 
 
Figure 4.40. Cutaneous PEN-2 staining in affected axillary skin from the individual 
harbouring the PSENEN c.66_67insG mutation.  Expression can be seen in the epidermis, 
apocrine glands, hair follicle, sebaceous glands and the inflammatory infiltrate. Scale bar = 
50µm. 
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Figure 4.41. Immunohistochemical staining of the inflammatory infiltrate observed in 
axillary skin harvested from the patient harbouring the NCSTN c.1125+1 G>A mutation.  
No staining was observed in the no primary run. Cells within the inflammatory infiltrate 
appeared to express NCSTN and comprised neutrophils, T cells, B cells and macrophages. Scale 
bar = 50µm. 
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Figure 4.42. Immunohistochemical staining of the inflammatory infiltrate observed in 
axillary skin harvested from the patient with the PSENEN 66_67insG mutation.  No 
staining was observed in the no primary run. Cells within the inflammatory infiltrate appeared 
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4.6.4 There was no discernible difference in epidermal Nicastrin and PEN-2 
staining intensity in axillary skin harvested from patients with mutations 
versus healthy volunteers 
NCSTN c.1125+1 G>A and PSENEN c.66_67insG were both associated with a reduced 
expression of their corresponding proteins (NCSTN and PEN-2) in primary human 
fibroblasts in vitro (sections 4.3.4, 4.4.4). It was therefore hypothesised that there would 
be a corresponding detectable reduction in protein expression in paraffin-embedded skin 
harvested from individuals harbouring the mutations. Axillary skin from the two 
mutation-positive patients and three healthy volunteers was analysed in tandem. No 
discernible difference in NCSTN or PEN-2 epidermal staining intensity was detected in 
axillary skin harvested from patients harbouring the mutations versus healthy volunteers 
(Figure 4.43a, Figure 4.44a). HS can dramatically distort the normal histological 
architecture of the skin, thus affected axillary skin from HS patients with wild-type 
NCSTN, PSEN1 and PSENEN was studied as a second comparitor group. Again there 
was no clear difference in NCSTN or PEN-2 expression in the epidermis of mutation-
positive patients versus wild type HS subjects (Figure 4.43b, Figure 4.44b). The effect 
of local inflammation on gamma-secretase expression is unknown. To account for this, 
para-axillary skin (no clinically apparent inflammation) from the patient with the 
PSENEN mutation was compared against matched para-axillary skin from three healthy 
volunteers. No clear difference in PEN-2 expression was observed (Figure 4.45). Para-
axillary skin was not available from the patient harbouring the NCSTN mutation.  
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Figure 4.43. A comparison of NCSTN epidermal staining in axillary skin harvested from 
the patient with an NCSTN c.1125+1 G>A mutation and control subjects.  A) Affected 
axillary skin from the patient harbouring the NCSTN c.1125+1 G>A mutation is compared 
against site-matched axillary skin harvested from healthy volunteer subjects. There was no 
discernible difference in protein expression in the mutation-positive patient versus controls. 
Scale bar = 50µm B) Affected axillary skin from the patient harbouring the NCSTN c.1125+1 
G>A mutation is compared against affected axillary skin harvested from two HS patients wild-
type for the NCSTN, PSENEN and PSEN1 genes. Again, there was no discernible difference in 
NCSTN expression between individuals. Scale bar = 50µm. 
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Figure 4.44. A comparison of PEN-2 epidermal staining in axillary skin harvested from 
the patient harbouring the PSENEN c.66_67insG mutation and healthy volunteers.  A) 
Affected axillary skin from the patient harbouring PSENEN c.66_67insG is compared against 
site-matched axillary skin harvested from healthy volunteer subjects. There was no discernible 
difference in protein expression in the mutation-positive patient and healthy volunteers. Scale 
bar = 50µm. B) Affected axillary skin from the patient harbouring PSENEN c.66_67insG is 
compared against affected axillary skin harvested from two HS patients wild-type for the 
NCSTN, PSENEN and PSEN1 genes. Again, there was no significant difference in PEN-2 
expression between individuals. Scale bar = 50µm. 
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Figure 4.45. A comparison of PEN-2 epidermal staining in para-axillary skin harvested 
from the individual harbouring PSENEN c.66_67insG and healthy volunteers.  There was 
no discernible difference in PEN-2 expression in the epidermis of the individual harbouring the 
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4.7 Discussion 
This aim of this chapter was to functionally characterise the two gamma-secretase 
mutations identified in familial cases of HS in Chapter 3 (NCSTN c.1125+1 G>A, 
PSENEN c.66_67insG). The two mutations confer very different predicted effects on 
their respective transcripts, one causing aberrant splicing, the other resulting in a 
frameshift, however they both appear to share a common downstream pathogenic 
mechanism. Both mutations result in a reduced transcript abundance and a 
corresponding reduction in protein expression, highlighting haploinsufficiency as the 
likely common pathogenic mechanism. This is consistent with functional data generated 
from some other globally reported gamma-secretase mutations. Peripheral lymphocyte 
mRNA expression was assessed in Chinese, Japanese and French individuals with 
gamma-secretase mutations. The following nonsense, frameshift and splice site 
mutations mutations were associated with reduced transcript abundance, NCSTN 
p.R117X, NCSTN c.582+1delG, NCSTN p.Q163SfsX39, PSEN1 p.P242LfsX11
135; 139; 
141
. In contrast, some splice site, frameshift and even nonsense mutations did not affect 
transcript abundance (NCSTN p.R434X, NCSTN p.S590AfsX3, NCSTN p.E584DfsX44 
and NCSTN c.1551+1 G>A). One would hypothesise that NMD underlies the apparent 
transcript reduction in nonsense, frameshift and splice site mutations which result in 
premature stop codons. In the case of the two mutations reported here, and potentially 
NCSTN c.582+1delG reported in a Japanese patient (exact splicing defect not 
characterised), there is no evidence to suggest that premature stop codons are formed, 
thus making NMD an unlikely mechanism of RNA decay. NCSTN c.1125+1 G>A is 
predicted to alter the secondary RNA structure which may render it unstable and subject 
to decay. Alternatively the altered structure may inhibit efficient ribosomal processing 
and potentially induce no-go decay
271
. PSENEN c.66_67insG is not predicted to 
significantly alter the secondary RNA structure but the altered reading frame does 
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eliminate the native stop codon, potentially resulting in non-stop decay. This is however 
a translation-associated mechanism of RNA decay and as such, one might have 
expected cycloheximide to have affected RNA abundance, which was not the case. The 
exact mechanism of RNA decay in these cases requires further investigation
270
. Both 
mutations potentially provide a platform upon which to further our current 
understanding of RNA surveillance and decay mechanisms.   
4.7.1 Both mutations appear to result in haploinsufficiency but the respective 
protein expression at the cell membrane remains unaffected 
Both mutations led to a reduction in respective protein expression in total cell fractions 
but this was not replicated in solubilised cell membrane preparations. This might 
suggest that, despite a reduction in the total amount of protein available, there are 
sufficient levels to support normal protein expression at the cell membrane in the in 
vitro conditions studied. Gamma-secretase gene transcription and protein expression is 
complex and tightly regulated. It has been demonstrated that NCSTN, PSENEN and 
PSEN1 mRNA abundance does not closely correlate with protein expression in the liver 
and heart. High mRNA levels are associated with very limited expression of their 
respective proteins and the authors proposed that this may be due to additional post-
transcriptional mechanisms
160
. Even following effective translation, fewer than 5% of 
gamma-secretase complexes that are assembled in the ER travel to the Golgi and are 
distributed to cell membranes. Proteins that are not incorporated into complexes are 
rapidly degraded
189
. This might suggest that even in a situation of heterozygous 
haploinsufficiency, the 50% wild type protein that is still present may be sufficient to 
support normal enzyme complex formation.  
It should be noted that these conclusions are drawn from immunoblotting experiments 
which are only semi-quantitative. Furthermore, immunoblots of solubilised cell 
membrane protein samples were analysed in the absence of a reliable loading control. 
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This was partially circumnavigated by generating consistent sample concentrations 
using BCA and repeating experiments seven times to reduce any human error (eg. 
pipetting). This does however rely on the accuracy of BCA in measuring solubilised cell 
membrane preparation concentrations in which many proteins, including NCSTN and 
PEN-2, are incorporated in complexes. The efficiency of cell membrane protein 
solubilisation, particularly the solubilisation of gamma-secretase complexes, is another 
important variable in this study. 
4.7.2 These mutations are not associated with a significant difference in gamma-
secretase complex number, structure or activity  
Mutations have now been reported in three of the four gamma-secretase enzyme 
complex components (NCSTN, PSENEN and PSEN1) in HS. This implies that a 
consequential effect on gamma-secretase enzyme function may be the common 
pathogenic mechanism underlying this form of HS. Enzyme activity assays were 
therefore performed to assess gamma-secretase activity in primary dermal fibroblasts in 
vitro. There was no significant difference in PSEN1-CTF expression, representative of 
mature gamma-secretase complex number, in mutant fibroblasts versus controls. 
Complex maturation, as measured by the PSEN1-CTF/ PEN-2 ratio also appeared 
unaffected. It should be noted however that whilst this is a common and accepted way 
to measure complex maturity, one of the patients harbouring a mutation had a mutation 
in PSENEN. Any consequent lack of PEN-2 protein may therefore directly influence the 
PSEN1-CTF/ PEN-2 ratio. This is further confounded by the fact that any reduction in 
PEN-2 may also prevent the cleavage and maturation of PSEN-1 (thus reducing the total 
amount of PSEN1-CTF present) which could also alter, or even revert, the final PSEN1-
CTF/ PEN-2 ratio. This result should therefore be interpreted with caution in the 
individual harbouring a mutation in PSENEN. Contrary to the hypothesis that enzyme 
activity may be reduced in mutant fibroblasts, neat endopeptidase activity per mg of 
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solubilised cell membrane protein was unaltered in NCSTN mutant fibroblasts and 
appeared slightly increased in PSENEN mutant fibroblasts. Endopeptidase activity per 
enzyme complex did not appear to differ in PSENEN mutant fibroblasts versus controls 
however. There was no significant difference in carboxypeptidase activity, as measured 
by Aβ42: Aβ40 ratios, but it was noticeable that the assays run with samples harvested 
from the individual with a PSENEN mutation generated lower ratios than all three 
controls, potentially indicative of marginally increased carboxypeptidase activity.  
Overall, there was no highly significant difference in complex number, maturity or 
activity in mutant fibroblasts versus controls. The slightly increased endopeptidase 
activity per mg solubilised cell membrane protein and the slightly lower Aβ42: Aβ40 
ratios observed in the individual harbouring a PSENEN mutation require further 
investigation and would need to be validated against a larger number of controls. Any 
such effect would provide an intriguing contrast to the enzymatic disruption arising 
from PSEN1 and PSEN2 mutations in FAD.  
These enzyme activity assay results are associated with all of the limitations of in vitro 
cell experimentation. Cells in a tissue culture environment are not truly representative of 
their physiological state. Furthermore, large numbers of cells were required for the 
enzyme activity assays and recurrent cell passaging (up to 10 passages) may have 
significantly affected cell behaviour and function. Despite growing similar numbers of 
cells there was marked variability in the concentration of solubilised cell membrane 
protein generated from each individual. This may be due to variation in the efficiency of 
the protein extraction method or due to subtle differences in general cell culture 
techniques (eg. cell confluency, passaging and general culture conditions). Enzyme 
activity assays are sensitive and results can vary depending upon a multitude of factors 
including the quality of reagents used, pipetting error and variable assay conditions. To 
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reduce this variability, reagents from the same batch were used for all experiments and 
all assays were repeated seven times.   
4.7.3 Cutaneous expression of the gamma-secretase components correlates with 
the histopathological changes observed in HS, supporting a role for gamma-
secretase mutations in disease pathogenesis   
Immunohistochemistry revealed that NCSTN and PEN-2 co-localise in healthy axillary 
skin, as would be expected if the staining is representative of gamma-secretase complex 
location, and are predominantly expressed in the epidermis, hair follicle, sebaceous 
glands and apocrine glands. The widespread expression was not unexpected given the 
integral role of gamma-secretase in maintaining essential cell signalling pathways such 
as Notch signalling. It is noteworthy however that the areas of prominent staining 
correlate with the characteristic histo-pathological changes observed in HS. These 
comprise follicular plugging, follicular dilatation, peri-follicular inflammation, apocrine 
gland stasis and peri-glandular inflammation, inter-follicular epidermal hyperplasia, 
sebaceous gland involution and potentially thinning of the BMZ at the sebo-follicular 
junction
6; 7; 27; 28; 80
.  The distribution of staining therefore potentially supports a role for 
gamma-secretase in disease pathogenesis. The only significant difference observed 
between mutation-positive individuals and healthy volunteers was the additional 
expression of the gamma-secretase components in the mixed inflammatory infiltrate. 
There was no evidence on IHC to support a quantitative difference in NCSTN or PEN-2 
expression in individuals harbouring mutations versus healthy volunteers. This should 
be interpreted with caution however as there is always a degree of variability in 
immunohistochemistry (IHC) results due to the method of staining and the nature of the 
sections studied. For example, in contrast to sections from healthy volunteers, HS 
affected skin may comprise inflammatory infiltrates and will exhibit many of the typical 
histopathologcial changes mentioned above. Furthermore, IHC is not a quantitative 
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technique, thus protein expression cannot be interpreted with any certainty from this 
study. 
The above functional studies used primary dermal fibroblasts as a source of RNA, 
protein and gamma-secretase enzyme because they express the gamma-secretase 
components and are stable and sustainable in cell culture, a factor that was of significant 
importance given the number of cells required to perform the enzyme activity assays. At 
the time of study, it was unclear which cutaneous cell type was most relevant in HS. It 
was subsequently noteworthy that immunohistochemistry revealed significantly 
enhanced expression of gamma-secretase components in keratinocytes compared with 
dermal fibroblasts, potentially highlighting keratinocytes as another cell type worthy of 
future study. 
4.7.4 Conclusions 
The NCSTN and PSENEN mutations studied here appear to result in haploinsufficiency 
and a corresponding reduction in protein expression in total cell fractions. They would 
not however appear to significantly affect protein expression and cause effective 
haploinsufficiency at the level of the cell membrane. There would appear to be no 
detrimental effect on complex maturity, number and activity at membrane level 
however those results only represent the complexes that have reached that site and have 
been effectively solubilised. If haploinsufficiency is indeed the primary pathogenic 
mechanism then attention may need to be focussed on gamma-secretase complex 
formation and trafficking at earlier stages of cell cycling. Any reduction in the levels of 
wild type NCSTN or PEN-2 in the ER may affect the quantity of the other gamma-
secretase constituents. As discussed in the introduction, the gamma-secretase 
components rely on one another for stability. Therefore through an independent or 
compound effect on the other components, a reduction in NCSTN or PEN-2 expression 
may detrimentally affect complex formation. This may result in altered, unstable and 
- 207 - 
dysfunctional complexes. As previously mentioned, only around 5% complexes 
assembled in the ER are transported to the golgi for maturation and are exported to the 
membranes
189
. It is therefore important to ascertain whether there is any alteration in the 
number and nature of complexes exported from the ER. There is no evidence to support 
the presence of altered complexes within the cell membrane however that is not to say 
that they are not present and potentially functional at that site or in sub-membranous 
locations. They may be present within the cell membrane but degraded by the 
solubilisation process employed in this study, thus their enzymatic effects may be 
underestimated. Solubilised cell membrane protein extracted from mouse cells has 
previously been shown to contain bound and unbound gamma-secretase complex 




An intriguing feature of HS is the very characteristic cutaneous distribution of disease. 
Working on the basis that there may be less protein present at the level of the ER one 
might imagine that in certain circumstances or environments there may be a higher 
turnover of complexes required, thus putting more strain on the production and maturity 
of complexes. It is under strained conditions that a 50% reduction in protein would 
become more significant and potentially functionally detrimental. These cases represent 
interesting, and potentially very revealing, models of gamma-secretase function as the 
vast majority of in vitro and in vivo experimentation has involved studying the 
consequences of complete knockout or knockdown of various complex components. 
The subtleties of partial reductions in protein expression need to be investigated. It has 
previously been demonstrated in breast cancer cells that >90% NCSTN knockdown 
only results in a 50% reduction in gamma-secretase activity, demonstrating the resilient 
capability of cells to produce and maintain enzyme function
272
. The anatomical location 
of HS might suggest that intrinsic and extrinsic factors such as temperature, sweat and 
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friction may potentially impact upon complex turnover or function. Temperature, pH 
and salt concentrations have previously been shown to affect endopeptidase and 
carboxypeptidase enzyme activity in vitro
266
. It may therefore be advantageous to 
perform enzyme activity assays on mutant and control cells under different forms of 
stress to look for any subtle alteration in enzyme activity. After all, if mutation-positive 
patients had a significant inherent gamma-secretase dysfunction one might assume that 
it would confer more damaging effects than those observed in HS. 
As mentioned previously, not all globally reported gamma-secretase mutations appear 
to result in haploinsufficiency. That is not to say that protein levels are unaffected 
however, as they were not studied. On the basis of this work, and assuming that there is 
a common pathogenic mechanism underpinning gamma-secretase gene related HS, one 
might imagine that those mutations result in loss of function. It is noteworthy that in the 
cases studied here there was some, however minimal, mutant transcript expressed. 
There was no evidence to support the production of mutant protein on immunoblotting 
but the molecular weight of the predicted mutant proteins would not significantly differ 
from the wild-type proteins and would not be easily visible. One cannot therefore 
exclude the possibility that mutant protein may be conferring some effect in disease 
pathogenesis in these cases and this requires further investigation. 
An important limitation of this study was that the majority of tissue samples were 
harvested from affected axillary skin in mutation-positive patients and site-matched 
unaffected axillary skin in healthy volunteers. As previously discussed, the effect of 
active disease and the associated inflammation (present in affected skin) on RNA, 
protein and enzyme activity is unknown. Whilst in vitro cell culture and the 
accompanying cell passages are likely to negate any such effects this does remain an 
unknown variable. It is clearly important to assess samples taken from affected skin but 
future studies would potentially benefit from analysing additional samples harvested 
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from para-axillary unaffected skin which would provide a more like for like resting state 
comparison. Another limitation of this study was that whilst all healthy volunteer 
subjects (used as controls) reported no personal or family history of HS or associated 
conditions they were not formerly screened for gamma-secretase gene mutations to 
ensure that they were truly wild type controls. In support of this, novel gamma-secretase 
mutations are extremely rare and have not been observed in over 600 in-house controls 
who have been subjected to exome sequencing. It was therefore very unlikely that any 
of these three individuals harboured any such variants. Furthermore, all three behaved in 
a consistent and concordant manner throughout these studies.  
This chapter sought to functionally characterise two gamma-secretase mutations 
identified in multiplex kindreds with HS. These data represent an important step in 
starting to understand the cellular mechanisms underlying disease formation in these 
patients and provide a platform upon which to design further studies. The identification 
and investigation of a more diverse array of mutations may further facilitate that 
process. Ongoing functional work is clearly required to make this genetic discovery 
truly translational. To understand the importance of these functional studies in the 
context of HS as a whole it was important to ascertain the prevalence of gamma-
secretase mutations in the general disease population. This is addressed in Chapter 5. 
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Chapter 5: Results: Mutations in the gamma-secretase 
genes NCSTN, PSENEN and PSEN1 underlie a minority of 
cases of hidradenitis suppurativa 
 
5.1 Introduction 
Gamma-secretase mutations had been reported in 11 multiplex kindreds worldwide 
(Chinese, British and Japanese kindreds)
135-138
 yet, as exemplified by our early familial 
study (Chapter 3), they did not appear to account for all familial cases of HS
139
. 
Ascertaining the prevalence of NCSTN, PSENEN and PSEN1 mutations was therefore 
of paramount importance both in terms of future genetic study and the translational 
relevance of these findings.  
5.1.1 Aims and objectives 
The aim of this work was to determine the prevalence of mutations in each of these 
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5.2 Patient cohort 
Forty eight individuals with HS were sequentially consented and recruited from the 
tertiary referral clinic at St. John’s Institute of Dermatology. The cohort was of mixed 
ethnicity, 65% were female, the average body mass index was 31.1 (clinically obese), 
69% reported a smoking history and the average Sartorius score was 49.9 (see Table 
5.1). 20 (42%) patients reported a family history of HS, 19 consistent with autosomal 
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 5 /  11% 
Body mass index  31.1 (19 – 58) 
Smoking history  33/ 69% (48% started smoking prior to 
disease development) 
Age of onset  21.4 (5 – 48) 
Dermatology life quality index 14.87 (1 – 30) 
Sartorius severity score 49.9 (11-156) 












History of pre-menstrual flares 14 of 31 women (45% women) 
Family history of HS  20/ 42% 
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5.3 Three of forty eight individuals harboured novel variants in the 
gamma-secretase genes NCSTN, PSEN1 and PSENEN 
All coding regions and associated splice sites of NCSTN, PSEN1 and PSENEN were 
amplified by PCR, using exon flanking intronic primers, and Sanger sequenced in all 48 
individuals. The whole cohort was assessed for large scale deletions and duplications in 
NCSTN, PSENEN and PSEN1 by multiplex ligation-dependent probe amplification 
(MLPA). Three subjects harboured novel heterozygous DNA changes in NCSTN 
comprising a missense substitution (NCSTN c.553G>A, p.Asp185Asn) and two single 
base substitutions located within ten base pairs of donor splice junctions (NCSTN 
c.996+7G>A and NCSTN c.1101+10A>G) (Figure 5.1). No novel or rare variants 
(population frequency < 1%, defined as a population frequency of <1% in both the 1000 
Genomes Project database
260
 and NHLBI Exome Sequencing Project EVS 
(http://evs.gs.washington.edu/EVS/)) were detected in coding regions or within 10 base 
pairs of splice boundaries in the remaining 45 individuals. No CNV was detected in 
PSEN1, PSENEN or NCSTN via MLPA. 
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Figure 5.1. Three individuals with novel variants in NCSTN.  A) Patient harbouring NCSTN 
c.553 G>A. Inflammatory nodules, abscesses and scarring in the sub-mammary region. Arrow 
indicating the NCSTN c.553 G>A variant, a novel heterozygous substitution in exon 5 of 
NCSTN. B) Patient harbouring NCSTN c.996+7 G>A. Inflammatory nodules and extensive 
scarring in the axilla. Arrow indicating the NCSTN c.996+7 G>A variant, a heterozygous 
substitution of the seventh base of the donor splice site within intron 8 of NCSTN. C) Patient 
harbouring NCSTN c.1101+10. Inflammatory nodules, sinus tracts and scarring in the groin. 
Arrow indicating the NCSTN c.1101+10 A>G variant, a heterozygous substitution of the tenth 
base of the donor splice site within intron 9 of NCSTN. Photos courtesy of Guy’s and St. 
Thomas’ NHS Foundation Trust, all individuals consented to publication. 
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5.4 Identification of a novel missense variant in exon 5 of NCSTN 
(c.553 G>A, p.Asp185Asn) 
A novel heterozygous missense variant in exon 5 of NCSTN (c.553G>A, p.Asp185Asn) 
was identified in a 45 year old female (Figure 5.1a) with no family history of HS. This 
is predicted to result in the substitution of an acidic, polar and negatively charged 
aspartic acid residue with a polar and neutral asparagine residue. This residue is 
conserved down to rabbit, in which, notably, the aspartic acid residue is substituted with 
an asparagine residue (Figure 5.2). The SIFT and PolyPhen-2 algorithms for predicting 
the functional consequences of non-synonymous variants indicate that this variant is 
unlikely to be of functional significance (SIFT score 0.2, PolyPhen score 0.008)
276; 277
. 
The variant was not observed in 200 control subjects of European origin. 
 
Figure 5.2. Conservation of the aspartic acid residue (D185) affected by the NCSTN c.553 
G>A variant.  The amino acid is not fully conserved in mammals. The aspartic acid residue is 
replaced by an asparagine residue in rabbit and hamster.  
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This lady reported painful nodules, cysts, abscesses and resultant scarring in her axillae, 
sub-mammary region, abdomen, groin and buttocks. She had a BMI of 38 (clinically 
obese) and was an active smoker. Her disease had failed to respond to multiple 
antibiotics including lymecycline, rifampicin and clindamycin, cyproterone acetate, 
acitretin and dapsone. Surgical excision of her axillae was effective.  
Three missense mutations have since been reported in NCSTN in HS (c.223G>A, 
c.632C>G, c.647A>C
138; 140
). One further non-synonymous substitution (c.1768A>G) 
was found to result in aberrant splicing by creating a cryptic splice donor site
139
. Given 
this, we hypothesised that the c.553 G>A substitution reported here may also affect 
splicing. Computational splice site analysis did not predict that this variant would affect 
splicing (all splice site predictions performed using the Automated Splice Site and Exon 
Definition Analysis (ASSEDA) server
278
). RNA was collected from this patient and 
reverse-transcribed to cDNA. The full length NCSTN transcript was amplified by PCR 
and studied alongside that of a control subject by agarose electrophoresis. Only one 
band was visible in both cases (see Figure 5.3). The full length NCSTN transcript was 
Sanger sequenced and the sequence revealed the non-synonymous c.553G>A variant 
but no other abnormalities. These results do not imply that this missense variant affects 
splicing.  
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Figure 5.3. Sequence and agarose electrophoresis of the full length NCSTN transcript in 
the individual with an NCSTN c.553 G>A variant.  The substitution is present in the full 
length NCSTN transcript but the cDNA sequence was otherwise normal. No extra bands were 
detected on agarose electrophoresis of the full length NCSTN transcript to imply that the variant 
affects splicing. 
 
Overall, whilst this substitution is predicted to result in a change in acidity and charge 
of the corresponding amino acid residue it is not evolutionarily conserved, the exact 
same amino acid change is observed in rabbit, it is not predicted to be functionally 
damaging and it does not appear to affect splicing. The variant is therefore unlikely to 
be pathogenic. 
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5.5 Identification of a novel heterozygous substitution in the exon 8/ 
intron 8 splice site of NCSTN (c.996+7G>A) 
A novel heterozygous substitution of the conserved seventh base of intron 8 of NCSTN 
(c.996+7G>A) was identified in a 38 year old female (Figure 5.1b). She did not report a 
family history of the condition however it is noteworthy that both of her parents died 
when she was a child and two of her five siblings have each had one pilonidal abscess. 
The substitution was not observed in 200 controls of European origin. Computational 
splice site analysis predicts that this substitution may confer a detrimental effect on 
splicing (ASSEDA server
278
). RNA was extracted from whole blood lymphoblasts and 
converted to cDNA as previously described. No mutant transcript was evident on 
agarose electrophoresis of the full length NCSTN transcript (single band seen in the 
patient harbouring the mutation and a control subject) or upon sequencing the full 
length transcript (cDNA relating to the exon 8/ exon 9 boundary shown in Figure 5.4). 
There was no significant difference in NCSTN mRNA expression in whole blood 
lymphoblasts taken from the patient harbouring the mutation versus healthy volunteers. 
Whilst computational splice site analysis predicts that this variant may affect splicing, 
there is no experimental evidence to suggest that it is pathogenic. This variant is 
therefore of uncertain pathogenicity.   
This lady had severe HS in the axillae, groin and particularly the buttocks comprising 
painful nodules, cysts, abscesses, sinus tracts and scarring (Figure 5.1b). She was an 
active smoker with a BMI of 37. Her disease failed to respond to treatment with 
clindamycin and ciprofloxacin, however some flares partially responded to treatment 
with Augmentin. Azathiaprine and oral steroids were of some benefit. 
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Figure 5.4. Sequence and agarose electrophoresis of the full length NCSTN transcript in 
the individual harbouring an NCSTN c.996+7 G>A variant.  No abnormality was detected in 
the cDNA transcript, the region relating to the exon 9/ exon 10 border was normal. No extra 
bands were detected on agarose electrophoresis of the full length NCSTN transcript to imply that 
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5.6 Identification of a novel heterozygous substitution in the NCSTN 
exon 9/ intron 9 splice site of NCSTN (c.1101+10 A>G) 
A second novel heterozygous splice site substitution was detected in the donor splice 
site of NCSTN exon 9 (c.1101+10A>G) in a 24 year old male with no family history of 
HS (Figure 5.1c). The variant was absent in 200 European controls but computational 
splice site analysis suggests that this mutation is unlikely to have a significant effect on 
splicing (ASSEDA server
278
). RNA was extracted from whole blood lymphoblasts and 
converted to cDNA as previously described. Agarose electrophoresis and sequencing of 
the full length NCSTN transcript did not support the presence of a mutant transcript 
(Figure 5.5). One band was seen on the agarose gel, as was the case with a healthy 
volunteer control subject, and there were no sequence anomalies detected (cDNA 
sequence related to the exon 9/ exon 10 boundary shown in Figure 5.5).  NCSTN 
transcript abundance within whole blood lymphoblasts was within the range of healthy 
volunteers. This variant is therefore unlikely to be pathogenic. 
This gentleman had painful nodules, cysts, abscesses, sinus tracts and scarring in the 
axillae, groin, buttocks and genital region. He was an active smoker with a BMI of 24. 
His disease failed to respond to numerous antibiotics including oxytetracycline, 
clindamycin and rifampicin but surgical excision of areas over his buttocks was of some 
benefit.  
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Figure 5.5. Sequence and agarose electrophoresis of the full length NCSTN transcript in 
the individual with an NCSTN c.1101+10 A>G variant.  No abnormality was detected in the 
cDNA transcript and the region relating to the exon 8/ exon 9 border was normal. No extra 
bands were detected on agarose electrophoresis of the full length NCSTN transcript to imply that 
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5.7 No large scale deletions or duplications detected in NCSTN, 
PSENEN and PSEN1  
DNA from all 48 subjects was analysed for whole exon or gene deletions or 
duplications in NCSTN, PSENEN and PSEN1 by MLPA. Probes were designed to target 
all exons of NCSTN, PSENEN and PSEN1. No copy number variation was detected in 
this cohort. A representative plot of normalised peak ratios is shown in Figure 5.6. 
 
Figure 5.6. A plot of the normalised MLPA peak ratios derived in one individual with HS 
(probes designed to assess copy number of the exons of NCSTN).  Green squares represent 
probes designed to bind to exons of interest (in this case, relating to NCSTN). The blue squares 
represent control probes. The green lines represent the upper and lower thresholds above and 
below which results would be interpreted as a duplication or deletion respectively. All probes 
relating to NCSTN and all control probes fall within the normal limits, thus no whole exon or 
whole gene duplications or deletions were detected. 
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5.8 A pilot study to investigate the role of NCSTN mutations in 
nodulocystic acne vulgaris revealed a novel missense variant 
(NCSTN c.1315 G>A, p.Val439Ile)  
As discussed in section 3.4, it was noteworthy that the individual found to harbour an 
NCSTN c.1125 G>A mutation reported a past history of severe acne vulgaris and had 
cutaneous features of active nodulocystic acne vulgaris over his neck at the time of 
examination. In total, 7 of the 8 globally reported NCSTN mutations at the time of this 
study appeared to have nodulocystic acne vulgaris/ acne conglobate over their neck, 
chest or back. We therefore hypothesised that mutations in NCSTN underlie 
nodulocystic acne.  
5.8.1 Patient cohort 
Forty eight patients with nodulocystic acne vulgaris were identified, consented and 
recruited from general Dermatology clinics at St. John’s Institute of Dermatology. The 
diagnosis was confirmed by Dermatologists. The coding regions and associated splice 
sites of all of the exons of NCSTN in which mutations had been reported in HS (exons 
3, 4, 5, 8, 9, 11, 13, 15) were amplified by PCR using exon-flanking intronic primers 
and Sanger sequenced.  
5.8.2 A novel missense variant (NCSTN C.1315 G>A, p.Val439Ile) was detected 
in one individual with nodulocystic acne vulgaris 
A novel heterozygous missense variant in NCSTN exon 11 (c.1315 G>A, p.Val439Ile) 
was identified in a 21 year old female (Figure 5.7). She reported no history of HS and 
no family history of HS or nodulocystic acne. The variant was not observed in 200 
control subjects of European origin. The missense variant is predicted to lead to the 
substitution of an evolutionary conserved valine residue with an isoleucine residue 
(Figure 5.8). It is predicted to be tolerated on SIFT (score 0.32) and probably damaging 
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on PolyPhen-2 (score 0.999). This variant is therefore of uncertain pathogenicity. No 
other variants with a population frequency of less than 1% were detected in any other 
individuals within the cohort.  
 
Figure 5.7. A novel heterozygous substitution in NCSTN in a patient with nodulocystic 
acne vulgaris.  The NCSTN c.1315 G>A variant in exon 11 is indicated by an arrow. 
 
 
Figure 5.8. Conservation of the NCSTN Val439 residue.  The amino acid is conserved 
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5.9 Discussion 
At the time of study, gamma-secretase mutations were known to underlie some familial 
forms of HS. The aim of this study was to investigate how prevalent gamma-secretase 
mutations were in the general disease population. This was important both in terms of 
clarifying the genetic architecture of the condition and providing perspective on the 
translational potential of this discovery. The study cohort was recruited from a tertiary 
referral HS clinic and their demographic details closely matched those of previously 
reported HS cohorts. There was a female predominance, average age of onset was 21.4, 
raised average BMI, increased likelihood of smoking and 42% reported a family history 
of the condition. The average Sartorius and DLQI scores were high at 49.9 and 14.87. 
These measures of disease severity highlight one potential limitation of this study which 
was that individuals recruited from a tertiary referral clinic are unlikely to be truly 
representative of the general disease population.  
Three of forty eight individuals harboured novel heterozygous variants in NCSTN. No 
other variants with a population frequency <1% or CNV was detected in NCSTN, 
PSEN1 or PSENEN. The three novel variants comprised a missense change and two 
splice site substitutions. Whilst it is relatively easy to determine the prevalence of rare 
variants in a gene, this study has demonstrated that it is somewhat harder to determine 
their pathogenic potential. The NCSTN c.996+7 G>A splice site substitution was 
predicted to affect splicing using splice site prediction software however there was no 
evidence to support the presence of a mutant transcript and overall transcript abundance 
appeared unaltered. The second splice site substitution (c.1101+10 A>G) was ten bases 
downstream of the NCSTN exon9/ intron 9 donor splice site and did not appear to affect 
splicing or overall transcript abundance. The missense substitution (c.553 G>A) 
affected a poorly conserved amino acid, was not predicted to be damaging on SIFT or 
Polyphen-2 and did not confer any effect on splicing. A maximum of three individuals 
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therefore appear to harbour potentially pathogenic variants in NCSTN, PSENEN or 
PSEN1 in this cohort, representing <7% of the group. This figure is likely to be inflated 
given that there is insufficient evidence to confirm the pathogenicity of any of these 
variants. Two further studies have since screened smaller cohorts of patients for 
mutations in all six of the gamma-secretase genes (NCSTN, PSENEN, PSEN1, PSEN2, 
APH1A, APH1B). No rare variants (population frequency < 1%) were detected in a 
Welsh cohort of 20 individuals
279
. Only one of nine Japanese patients was found to 
harbour rare variation in those genes, a heterozygous missense substitution in PSEN2 
(p.Thr421Met), but that variant was deemed non-pathogenic
141
. Taken together, these 
studies suggest that gamma-secretase mutations in NCSTN, PSENEN and PSEN1 
underlie a minority of HS cases, ranging from 0 - 6.3%. There is no current evidence to 
suggest that variation in PSEN2, APH1A or APH1B underlies HS. Whilst our study 
represents the largest patient cohort to be studied to date, the numbers are still relatively 
small and to gain a more accurate measure of mutation prevalence one would need to 
screen a much larger number of individuals.  
Around 40% of HS patients report a family history of the condition, the majority 
consistent with autosomal dominant inheritance, yet less than 7% of cases appear to 
occur as a consequence of mutations in NCSTN, PSENEN and PSEN1
22
.  The genetic 
basis of the remaining familial cases (representing around 33% of the disease 
population) and apparently sporadic cases therefore remains unclear. Whilst it is 
possible that coding variation may have been missed or that there was pathogenic 
variation in unscreened non-coding regions (promoter regions, enhancer regions and 
intronic variation for example) it would seem unlikely that these explanations account 
for the vast majority of disease cases. An alternative theory is that those genes do not 
underlie the development of HS in the remaining cases and that there is further genetic 
heterogeneity underlying HS.  
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One of the individuals reported in Chapter 3 (section 3.4) who harboured a mutation in 
NCSTN (c.1125+1 G>A) presented with features consistent with nodulocystic acne 
vulgaris over their neck. At least 7 of 8 globally reported NCSTN mutations were also 
associated with a nodulo-cystic acne vulgaris/ acne-conglebate-like presentation over 
the neck, chest and back in addition to the more characteristic features of HS
135-138
. A 
pilot study was therefore performed to examine whether any of 48 individuals with 
nodulocystic acne harboured mutations in any of the exons of NCSTN in which 
mutations had been reported in HS.  Only one variant with a population frequency < 1% 
was detected in this cohort (c.1315 G>A, p.Val439Ile). This variant was of uncertain 
pathogenicity. A role for NCSTN in nodulo-cystic acne cannot therefore be excluded on 
the basis of this work, particularly given that only select exons of NCSTN were 
sequenced. The nature of the identified variant was not sufficient to justify pursuing this 
work further. A larger cohort of individuals would need to be screened for variants in all 
exons of NCSTN to formerly validate or exclude involvement of that gene in the 
pathogenesis of nodulocystic acne vulgaris. 
In summary, the results of this study suggest that gamma-secretase gene mutations 
underlie a minority of HS cases and that there is likely to be further genetic 
heterogeneity underlying HS. This project therefore re-focussed on genetically 
investigating familial cases of HS with no identifiable gamma-secretase mutations with 
a view to discovering further disease-causing genes.  
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Chapter 6: Investigation to determine further disease 
causing genes in HS 
6.1 Introduction 
6.1.1 Hypothesis and objectives 
Gamma-secretase gene mutations appear to underlie a minority of HS cases, implying 
that there is likely further genetic heterogeneity in HS. It was therefore hypothesised 
that further and as yet unidentified genes underlie some cases of HS.  
The aims of this study were two-fold: 
1) Investigate large multiplex kindreds, preferentially those in which gamma-secretase 
gene mutations had been excluded, for novel disease-causing variants.  
2) Investigate meticulously phenotyped subgroups of unrelated individuals with a 
family history of HS (demonstrating autosomal dominant inheritance, preferentially 
those in which gamma-secretase gene mutations had been excluded) for novel disease-
causing variants.  
6.1.2 Methodological considerations 
The methods employed to identify disease-causing variants in Mendelian disorders have 
rapidly evolved over the last 40 years, gathering significant momentum in the last 5 
years with the advent of next generation sequencing. The introduction of DNA 
recombinant technology and polymerase chain reaction (PCR) in the 1980’s enabled the 
identification of an increasing number of disease genes via positional cloning. This 
involved identifying the approximate chromosomal location of a gene via linkage 
analysis, mapping out the genes in the region by DNA cloning and screening the genes 
in affected individuals for mutations. This was a long and technically challenging 
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process. The introduction of genome-wide genotyping technology has facilitated faster 
and more accurate linkage analysis. Large scale genome projects have provided 
increasingly more accurate and comprehensive marker maps, gene identity and location 
data and specific sequence data, negating the need for labour intensive DNA cloning. 
Furthermore, the efficiency of direct sequencing for mutation detection significantly 
improved following the development of Sanger sequencing. All of these technological 
advancements have made positional cloning easier and more efficient, resulting in an 
explosion of papers documenting new disease variants. In 2009, the utilisation of next 
generation sequencing led to a dynamic shift in sequencing capability and has been used 
alone, and in combination with linkage data, to great effect in determining disease-
causing variants in Mendelian disease. 
6.1.2.1 Linkage analysis 
Genetic mapping using linkage analysis is a well established technique for identifying 
the approximate chromosomal location of disease causing variants. The principle of this 
technique is that when maternal and paternal chromosomes pair up in germ cells there is 
a cross-over of genomic material. This process is termed recombination. The further 
apart two genes are on a chromosome, the more likely it is that they will cross-over and 
end up on different chromatids. Conversely, the closer two genes are together, the less 
likely it is that cross-over will occur. As a disease-causing variant is passed down 
through a family, the original flanking haplotype on which the mutation resides will 
steadily become shorter and shorter as recombinations occur. Methodologies to 
ascertain when and where recombinations have occurred in a pedigree are based on 
genotyping respective family members. Numerous techniques have been employed in 
the past to generate this data, including the use of microsatellite markers, but the recent 
development of SNP genotyping microarrays has facilitated rapid analysis of millions of 
SNPs scattered throughout the genome. These SNPs act as genetic markers. Every 
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disease gene will be flanked by two of these markers unless the mutation is located in a 
distal region of a chromosome (the exact distance of the relevant markers from the 
disease gene will vary). Thus by genotyping sites of variation in all family members it is 
possible to determine regions of maternal and paternal DNA in individuals and calculate 
where re-combinations have occurred. Recombinations between the disease gene and its 
flanking markers are highly unlikely because of the shear proximity of theses markers. 
Regions such as this can be mapped, thus highlighting candidate regions within the 
genome. The principle of linkage analysis is that the disease allele, situated within only 
one of those regions, will co-segregate with disease status in any given pedigree. The 
size of the candidate region will vary depending on the size and structure of the 
pedigree studied. 
Genotype data is analysed using linkage analysis software. Information required for 
accurate analysis is the exact pedigree structure, disease status of the individuals 
involved, mode of inheritance (eg. autosomal dominant), estimated population 
frequency of a disease causing variant, the estimated genetic distance between variants 
on the SNP genotyping microarray and the genotype data for the individuals involved. 
Variable analyses can be performed depending upon the nature of the disease in 
question. For example, HS can occur at any age thus it is impossible to conclude that an 
individual is definitely unaffected. This non-penetrance could be modelled or an 
affected-only analysis may be appropriate in that instance. Linkage analysis generates a 
set of data for each pedigree demonstrating the likelihood of linkage at any given point 
in the genome. This data comprises a sequence of logarithm of odds (LOD) scores. 
LOD scores represent the likelihood of generating the observed experimental data if 
markers are indeed linked versus the likelihood of achieving such data if they were not 
linked. It is a logarithmic scale whereby positive scores support the presence of linkage 
and negative scores do not. A LOD score of 3 means that there is only a 1:20 chance 
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that there is no linkage at that site and is therefore taken as good evidence for linkage. 
Another way to interpret such linkage data is that linkage cannot be excluded in any 
regions with a LOD score above -2. 
6.1.2.2 Whole exome sequencing 
Whole exome sequencing (WES) is a next generation sequencing method that involves 
sequencing all of the annotated protein-coding regions of the human genome. It is a fast, 
efficient and, as prices have fallen, increasingly economical way to study the protein 
coding regions of the human genome. Since it was first introduced and successfully 
implemented in 2009
280
 it has revolutionised the genetic investigation of Mendelian 
disorders and exponential numbers of papers utilising this technology have emerged 
over the last three years (>400). The principle method involved is that DNA is 
fragmented, amplified and hybridised to oligonucleotide baits that select out regions of 
the exome (exome capture). The bound DNA is selected out (representing exomic 
regions), eluted from the baits, washed, further amplified and then sequenced using 
massively parallel next generation sequencing.  This generates short sequences which 
are mapped to the reference human genome and aligned. Non-exomic regions are 
filtered out and then variants can be identified and called. Variants are subsequently 
annotated and compiled in a database for bioinformatic analysis.  
6.1.2.2.1 Genetic diseases investigated using WES  
Genetic interrogation of recessive traits has always been relatively successful due to the 
limited number of novel or very rare homozygous variants present in any genome. 
Consequently, when combined with accurate linkage data (or even in the absence of 
such data) and the numerous databases providing the population frequency of any 
genetic variation, WES has proven itself to be a successful tool in determining disease-
causing variants in recessive diseases
281; 282
.  
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Analysing dominant conditions, such as HS, has always been more challenging. Due to 
the comparatively large numbers of novel and rare heterozygous variants present in any 
individual, the isolation of a disease-causing variant from a WES dataset requires as 
much additional support as is available. This may comprise good linkage data from 
large pedigrees with multiple affected members, access to a reliable control cohort 
against which the frequency of variation in any one gene can be assessed and access to 
databases stating the population frequency of rare variants. Familial analysis (assuming 
large and informative pedigrees are available) confers a benefit over analysing unrelated 
subjects. Multiple and far removed individuals from any one family can be subjected to 
exome sequencing. The validity of any shared candidate variants can be confirmed by 
performing linkage analysis and assessing for co-segregation of any identified variants 
with disease status. When studying small numbers of unrelated cases in an apparently 
genetically heterogeneous condition the diagnostic accuracy, and thus the exact 
phenotype being studied, is paramount. There have been recent successes in studies that 
have both used pedigrees and unrelated cases
283; 284
.     
Even non-inheritable diseases (those that affect reproductive capability to the extent that 
they cannot be passed on) have been effectively interrogated using WES. By studying 
apparently sporadic cases and their parents it is possible to determine if variants are 
truly de novo. When there are enough individuals, the number of de novo variants can 
be analysed and mapped to a common disease gene. This principle was effectively 
employed in investigating the genetic predisposition to autism
285
 
The role of WES in determining the genetic architecture of complex diseases is yet to be 
determined. Whilst WES can identify rare coding variants, many thousands of 
individuals would be required to implicate any such variants in disease pathogenesis.   
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6.1.2.3 Potential disadvantages of WES 
Whilst whole exome sequencing provides a very powerful and increasingly utilised 
platform upon which to interrogate genetic disease, there are some disadvantages and 
limitations to this form of sequencing. It can only target known genes, thus any protein-
coding regions of the genome that are not yet known will not be covered using this 
technique. The aim of WES is to target the “functional” regions of the genome, however 
it is becoming increasing evident that non-coding regions play a significant role in 
transcription, splicing, translation and thus protein expression. These comprise gene 
promoters, enhancers, silencers, regions that affect splicing (such as branch sites) and 
non-coding RNAs. Whilst an alternative method, such as whole genome sequencing, 
may circumnavigate this problem, it would not alter the fact that the functional impact 
of many of these non-coding regions is unknown and thus the interpretation of any such 
data is extremely challenging. Furthermore, whole genome sequencing is up to five 
times more expensive and generates at least five-fold more data, posing significant 
problems regarding data storage and analysis. A further limitation of WES is that it is 
not a proven way of detecting structural variation such as copy number variation (CNV) 
or translocations.  
As with any experiment, there will always be intra- and inter-run variability. For 
example the read-depth and sequencing quality will vary across the target exome and 
will not be consistent between individuals. This, compounded by any potential 
variability in the bioinformatic pipeline used to generate the results, may result in false-
positive and false-negative variant calls and significantly affect experimental outcomes. 
In the context of HS, if two individuals from one pedigree are exome sequenced it may 
be that some shared variants are missed because of false-negative calls. A further 
consideration is the heritability of the condition in question. Even with a low read-
depth, genuine homozygous variants are still likely to be identified. With heterozygous 
- 234 - 
conditions, such as HS, the risk of false-positive and false-negative calls is much 
greater. A high coverage depth is therefore an essential requirement when studying 
dominant conditions. Another potential variable in data analysis is the accuracy of read-
alignment. Each of the sequences generated via massively parallel sequencing in WES 
have to be aligned to their corresponding sequence in the genome. The repetitive nature 
of large parts of the human genome make this difficult and thus the filtering strategies 
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6.2 Genetic methods and patient selection 
6.2.1 WES, combined with linkage analysis in familial cases, was deemed an 
appropriate method by which to further interrogate the genetic 
architecture of HS  
Despite the above mentioned disadvantages, WES remains an extremely powerful, fast 
and relatively cost-efficient way to analyse the functional parts of the human genome 
and experimental techniques and bioinformatic analysis methods have significantly 
improved since their introduction in 2009. Our group set up WES at King’s College 
London and has successfully used the technique to identify multiple novel disease 
causing mutations over the last 3 years
281; 283; 284; 286
. The advantages of this cutting edge 
technology, combined with the experience in the group, meant that it was a highly 
appropriate experimental approach to employ in searching for new disease-causing 
mutations and genes in HS. Linkage analysis was performed as an adjunct to WES in 
multiplex kindreds to facilitate more effective WES data filtering. 
6.2.2 Whole exome sequencing 
6.2.2.1 Selection of individuals for exome sequencing 
As layed out in the Chapter aims, there were two broad groups of patients analysed as 
part of this study: 
1/ Related individuals: Pedigree-centred analysis of individuals from six large multiplex 
kindreds 
2/ Unrelated individuals: Phenotype-centred analysis of phenotypically grouped 
unrelated individuals  
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6.2.2.1.1 Related individuals 
Six pedigrees were identified that demonstrated autosomal dominant inheritance and 
from whom at least one individual had been screened to exclude novel or rare 
(population frequency <1% in both the 1000 Genomes Project database and the NHLBI 
Exome Sequencing Project EVS) variation in the gamma-secretase genes NCSTN, 
PSENEN and PSEN1. Five of these pedigrees had been studied in Chapter 3, all six are 
shown in Figure 6.1. The number of individuals subjected to WES in each pedigree was 
decided by analysing pedigree structures to determine which individuals would provide 
the most contrasting and therefore revealing genetic information (dependent upon 
availability of relevant clinical samples). For example, the two individuals sequenced in 
pedigree 3 represent the two most genetically distant (2 meioses) subjects that were 
available within that pedigree. One would therefore expect fewer shared variants upon 
comparing results generated from both individuals than if father and daughter (1 
meiosis) were compared for example, thus aiding analysis. A total of 13 individuals 
from the six pedigrees were subjected to exome sequencing.  
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Figure 6.1. Multiplex kindreds studied using WES.  All individuals circled were subjected to 
WES. 
 
6.2.2.1.2 Unrelated individuals 
A further 53 unrelated probands, all but three with a family history of HS, were chosen 
based upon their clinical phenotype. When this study was designed there was no 
phenotypic classification scheme for HS. By taking detailed clinical histories and 
performing meticulous clinical examinations patients were categorised into 4 broad 
groups. The first comprised a small group of individuals with severe cutaneous disease 
(nodules, multiple sinus tracts and significant genital oedema) and an associated 
inflammatory arthritis (exacerbations corresponded with cutaneous flares, variable sites 
including spondyloarthropathy, sacro-ileitis and large joint oligoarthritis). Four of these 
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seven individuals reported a family history of HS and three were apparently sporadic 
cases. Due to the rare but entirely consistent signs and symptoms observed in these 
individuals all seven were taken forward for exome sequencing. The second group had 
predominantly sinus tract disease in all affected areas (comedones and nodules also 
often present). The third group comprised females with inflammatory nodules, no sinus 
tracts and a history suggesting hormonal involvement (disease associated with pre-
menstrual flares, many individuals formally diagnosed with poly-cystic ovarian 
syndrome). The final group comprised individuals with comedonal and cystic disease 
and no sinus tracts. These patients were predominantly male and almost exclusively 
smokers.  
The sinus tract disease and nodular disease groups were the most phenotypically distinct 
and were thus considered for exome sequencing. Individuals with sinus tract disease 
were chosen ahead of those with nodular disease based on the severity and consistency 
of that presentation (30 individuals). A further 16 candidates were selected from the 
nodular disease group based on the algorithm shown in Figure 6.2. This was designed to 
identify people who were more likely to have a genetic basis for their disease.  
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Figure 6.2. The algorithm used to select individuals within the sinus tract and nodular 
disease cohorts for WES. 
 
17 of these individuals had previously been screened and not found to harbour any 
mutations in NCSTN, PSEN1 or PSENEN as part of the study described in Chapter 5. 
The remaining 36 individuals had not however been sequenced, thus raising the 
question as to whether they should be screened prior to inclusion in the study. Upon 
considering the time required to complete such sequencing, the projected sequencing 
costs in relation to the falling cost of WES and the low prevalence of gamma-secretase 
mutations in the general disease population, it was decided that pre-screening was not 
essential. 
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6.2.2.1.3 A summary of individuals taken forward for exome sequencing 
In total, 66 individuals were subjected to WES. These comprised 13 individuals from 
multiplex kindreds (to be used in pedigree-centred analyses) and 53 unrelated and 
phenotypically grouped cases (to be used for phenotype-centred analyses). Individuals 
from two of the multiplex kindreds had sinus tract disease and thus one individual from 
each pedigree was included in the sinus tract disease cohort as part of the phenotype 
centred analysis. In total there were 7 individuals with HS/ arthritis, 32 with sinus tract 
disease and 16 with nodular disease (Table 6.1).   
Table 6.1. A table showing the phenotypic subgroups analysed via WES and the number 
of individuals within each group. 
Clinical subgroup  No. Individuals for analysis  
Familial analysis  13  
HS and arthritis   7   
Sinus tract disease  32  
Nodular hormonal disease  16  
 
6.2.3 Genotyping of individuals from the multiplex kindreds and linkage analysis  
In addition to exome sequencing individuals from each of the six pedigrees studied as 
part of the pedigree-centred analysis (detailed in section 6.2.2.1.1, Figure 6.1), all 
affected and any important unaffected individuals from those kindreds were also 
genotyped using the Illumina Infinium HumanExome 12v1.1 chip to generate linkage 
data (genotyped individuals shown in Figure 6.3). An affected only analysis was 
performed that assumed an autosomal dominant inheritance model. 
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Figure 6.3. A figure showing the individuals within each pedigree that were genotyped 
using the Illumina Infinium HumanExome 12v1.1 chip to generate linkage data. 
 
6.2.4 Data analysis strategy 
All coding variants and variants within 10bp of splice sites were included in the analysis 
along with any copy number variation affecting coding regions.  
6.2.4.1   Exclusion of individuals harbouring likely pathogenic variants in the 
gamma-secretase genes 
All exomes were initially screened for variants with a population frequency of <5% and 
CNV in or affecting the gamma-secretase genes NCSTN, PSEN1, PSEN2, PSENEN, 
APH1A and APH1B. Variants with a population frequency of <5% were defined as 
having a population frequency <5% in the 1000 Genomes Project database
260
, the 
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NHLBI Exome Sequencing Project Exome Variant Server (EVS, 
http://evs.gs.washington.edu/EVS/) and in 600 in-house control subjects. All population 
frequencies stated throughout the remainder of this chapter are based on these criteria. 
The potential pathogenicity of each variant was predicted by considering the population 
frequency, conservation, nature of the variant, predicted functional consequences and 
where relevant running the variants through pathogenicity prediction software. 
Missense variants were run through SIFT
276
 and/ or Polyphen-2
277
 and splice site 
variants through the Automated Splice Site and Exon Definition Analysis (ASSEDA) 
server
278
. Any variants that were predicted to be pathogenic were confirmed with 
Sanger sequencing and the relevant individuals were excluded from further exome 
sequencing analysis. 
6.2.4.2   Analysis of substitutions and small insertions and deletions in individual 
exomes in which pathogenic gamma-secretase gene mutations had been 
excluded  
The remaining exome variant profiles were analysed under an autosomal dominant 
inheritance model. Substitutions and small insertion/ deletions were filtered according 
to Figure 6.4. Only heterozygous and protein altering (nonsynonymous, splice site 
substitutions or small coding deletions/ insertions) variants were considered to be 
pathogenic. As there is no evidence to suggest X or Y linked inheritance in HS, variants 
on those chromosomes were excluded. Common variation was then excluded by 
performing two separate analyses (analyses 1 and 2). Only novel variants (variants not 
reported in 1000 genomes, EVS or >600 in-house controls) were included in the first 
analysis (analysis 1) and only variants with a population frequency of < 1% were 
included in the second analysis (analysis 2).  
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Figure 6.4. Algorithm for filtering coding variants or variants detected within 10bp of 
splice site boundaries identified through WES. 
 
6.2.4.3   Analysis of CNV in individual exomes in which pathogenic gamma-
secretase gene variants had been excluded  
Copy number variants were filtered as shown in Figure 6.5. CNV affecting the X or Y 
chromosomes was excluded. Only CNV’s that did not overlap by more than 50% with 
known regions of common CNV and that did not affect regions known to be duplicated 
elsewhere in the genome were included for further analysis. 
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Figure 6.5. Algorithm for filtering CNV identified by WES. 
 
6.2.4.4   Combinational analysis of individuals within their respective 
experimental subgroups 
Filtered coding variants (+ those within 10bp splice sites) and CNV’s were then 
combined for each individual. Novel filtered variants described in Figure 6.4 were 
combined with the filtered CNV’s described in Figure 6.5 for analysis 1. Rare filtered 
variants (< 1% population frequency) documented in Figure 6.4 were combined with the 
filtered CNV’s described in Figure 6.5 for analysis 2.  
Data from the separate individuals was then collated. Regarding the familial group, data 
from individuals within the same pedigree was pooled. Regarding unrelated individuals, 
data from individuals within each specific phenotypic group was pooled (Figure 6.6). 
For familial analysis, any variants shared between all exome sequenced relatives were 
identified. Only those that fell within defined regions of linkage in the family were 
taken forward for further study. For the analysis of unrelated individuals, all genes were 
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identified in which multiple individuals within any one clinical subgroup shared 
variation. Individuals did not need to share the same variants in these genes.  
 
Figure 6.6. Algorithm detailing how data from individuals within the familial and 
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6.3 Results 
6.3.1 Exome sequencing coverage 
Across all exomes, 82.84% of reads mapped to target regions (+/- 150 base pairs), 
89.25% of the exomes had a read-depth >20. An average of 22657 coding variants were 
called per individual of which 170 were novel (defined as not present on the EVS, 1000 
genomes server or in > 600 in-house control exomes). Detailed coverage statistics and 
variant profiles are shown in Table 6.2 and Figure 6.7 respectively. 
Table 6.2. Coverage statistics for all individuals subjected to WES 
 Average Range 
Total reads 84655696 40954786 – 136309125 
Mapped to target/ % 73.87 69.1 – 83.55 
Mapped to target + 150bp/ % 82.84 77.83 – 92.86 
Mean coverage 111.97 56.73 – 183.64 
≥ 20 x read-depth/ % 89.25 67.9 – 93.98 
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Figure 6.7. Variant statistics for all individuals subjected to WES.  The figures represent the 
averages across all sequenced individuals. Novel variants represent a minority of the total 
number of variants detected in any individual. 
 
6.3.2 Analysis of the gamma-secretase genes in all individuals subjected to exome 
sequencing 
Mutations in NCSTN, PSEN1 and PSENEN are known to underlie some cases of HS and 
on a candidate basis, mutations in the other gamma-secretase genes, PSEN2, APH1A, 
APH1B may also underlie HS. As a consequence, all exome-sequenced individuals were 
assessed for variants (synonymous, non-synonymous, splice site, small 
insertion/deletion variants and copy number variation) in the gamma-secretase genes 
NCSTN, PSEN1, PSEN2, PSENEN, APH1A and APH1B with a population frequency of 


















Average variant statistics for all individuals subjected to WES 
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Table 6.3. All variants with a population frequency < 5% detected in the gamma-secretase 
genes in the cohort of individuals subjected to WES. 
Gene Variant Variant type Population 
frequency/ % 
APH1A c.C735G, p.C245W Nonsynonymous SNV 0.33 - 0.62 
APH1B c.285-7 A>T Splicing 0 - 2.5 
APH1B c.G642A, p.A214A Synonymous SNV 0.038 – 0.15 
APH1B c.G472T, p.V158L Nonsynonymous SNV 0.97 - 2.67 
NCSTN c.T201C, p.S67S Synonymous SNV 0.33 – 1.61 
NCSTN c.G231C, p.E77D Nonsynonymous SNV 0.16 - 1.57 
NCSTN c.G237A, p.E79E Synonymous SNV 0 – 2.33 
NCSTN c.A1083G, p.S361S Synonymous SNV 0.66 – 1.86 
NCSTN c.C1314T, P.G438G Synonymous SNV 0.33 - 0.89 
NCSTN c.1352+1 G>C Splicing Novel 
NCSTN c.1010delA, p.Y337fs Frameshift deletion Novel 
NCSTN c.C349T, p.R117X Nonsense substitution Novel 
PSEN1 c.1236+8 T>C Splicing 0.33 – 1.76 
PSEN1 c.A941G, p.E314G Nonsynonymous SNV 0.91 – 2.5 
PSEN2 c.A520G, p.M174V Nonsynonymous SNV 0 – 0.02 
PSEN2 c.T132A, p.T44T Synonymous SNV 0.14 - 0.99 
PSEN2 c.G185A, p.R62H Nonsynonymous SNV 1.44 – 2.5 
PSEN2 c.C423T, p.N141N Synonymous SNV 0.41 – 0.66 
PSEN2 c.C441T, p.S147S Synonymous SNV 0.66 – 1.74 
PSEN2 c.T708C, p.S236S Synonymous SNV 1.83 – 3.39 
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PSEN2 c.G756C, p.A252A Synonymous SNV 0.31 – 0.66 
PSEN2 c.C771T, p.G257G Synonymous SNV 0 
PSEN2 C.G903T, p.T301T Synonymous SNV 1 – 3.85 
 
Only three individuals were found to harbour novel variants (not reported in 1000 
genomes, EVS server or in >600 in-house control exomes) in these genes, all in NCSTN. 
These comprised one splice site substitution (NCSTN c.1352+1G>C), a frameshift 
deletion (NCSTN c.1010delA, p.Y337fs) and a nonsense mutation (NCSTN c.C349T, 
p.R117X). All three variants were confirmed by amplifying the relevant segments of 
DNA via PCR and performing standard Sanger sequencing (Figure 6.8). 
 
Figure 6.8. Sanger sequencing validated the WES results and confirmed the presence of 
novel heterozygous variants in NCSTN in three individuals. NCSTN c.C349T, c.1010delA 
and c.1352+1 G>C (each mutation shown by an arrow in the respective figures) were verified 
by Sanger sequencing NCSTN exons 4, 9 and 11 respectively. 
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 The NCSTN c.1352+1G>C splice site substitution is of the highly conserved first base 
of the NCSTN exon 10 donor splice site. This is predicted to be damaging (splice site 
abolished). The pathogenicity of this variant is further supported by a previous report of 
a different substitution at the same site (c.1352+1G>A) in a Chinese family with HS 
(full co-segregation demonstrated)
137
. The frameshift deletion and nonsense variants are 
both predicted to result in premature truncation (p.Y337fsX19, p.R117X) and are 
therefore likely to be pathogenic. The pathogenicity of the p.R117X variant is supported 
by the same mutation being reported in a Chinese HS kindred
135
. On the basis that these 
three variants are likely to be pathogenic, the relevant individuals were excluded from 
further exome sequencing analysis.  
Of the remaining rare variants (<5% population frequency), none would be predicted to 
result in premature truncation. Two splice site variants were detected (PSEN1 
c.1236+8T>C, APH1B c.285-7A>T) with a population frequency of 0.3-1.8% and 0-
0.3% respectively, neither of which were predicted to affect splicing. Ten 
nonsynonymous variants were detected, one of which (APH1A c.C735G (p.C245W)) 
was predicted to be potentially damaging (SIFT score 0, Polyphen not scored). APH1A 
c.C735G has a frequency of 0.37-0.61% in 1000 genomes, EVS and in house controls 
and it is hard to predict the pathogenic potential of this variant. On the basis of this, this 
individual was taken forward for further exome sequencing analysis. None of the 12 
synonymous variants identified within the gamma-secretase genes fell within 10 bases 
of a splice site or were predicted to alter splicing. All individuals with synonymous 
variants were therefore taken forward for further exome sequencing analysis. 
Exome sequencing only provides data relating to the coding regions of the genome and 
associated splice site boundaries. Sequences relating to regions such as promoters, 
enhancers, silencers and branch sites are not specifically targeted. Potentially 
pathogenic variants in those regions could not therefore be excluded in this cohort. All 
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easily identifiable variation in the gamma-secretase genes was however examined prior 
to interrogating the data to find novel disease-causing genes. 
6.3.3 Familial analysis 
6.3.3.1 Linkage analysis 
Selected affected and unaffected individuals from the six pedigrees were genotyped 
using the Illumina Infinium HumanExome 12v1.1 chip to generate linkage data 
(individuals shown in Figure 6.3). All regions of linkage are shown in Appendix 5. 
These areas represent regions in which the data is consistent with linkage (LOD score > 
-2). In contrast, linkage is excluded in the regions that are not listed. This data was 
generated to facilitate more efficient filtering of exome sequencing results by reducing 
the respective search space. 
6.3.3.2 Combined WES and linkage analysis of pedigrees 1-6  
Analyses were performed as stated in Figure 6.6. The results of analyses 1 and 2 are 
presented for each of the kindreds studied. 
6.3.3.2.1  Pedigree 1 
6.3.3.2.1.1 Analysis 1 
No novel variants were shared between all four individuals subjected to exome 
sequencing. No filtered CNV was shared between all four individuals. 
6.3.3.2.1.2 Analysis 2 
Three variants with a population frequency of less than 1% were shared between all four 
individuals, two of which fell within identified regions of linkage (see Table 6.4).  
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6.3.3.2.2 Pedigree 2 
6.3.3.2.2.1 Analysis 1 
Fifteen novel protein-altering or splice site variants were shared between the three 
members of this kindred who were exome sequenced, two falling within regions of 
linkage defined by genotyping (Table 6.4). No filtered CNV was shared between all 
three individuals. 
6.3.3.2.2.2 Analysis 2 
Five additional variants with a population frequency of < 1% were shared between those 
three individuals that fell within regions of linkage (Table 6.4).   
6.3.3.2.3 Families 3-6 
The structure of the remaining pedigrees, combined with the available patient resources, 
meant that variants could not be filtered down to the minimal numbers seen in families 
1 and 2 using the analysis 1 and 2 algorithms described in Figure 6.6. Only one 
individual was exome sequenced from Families 5 and 6 but all available family 
members were genotyped to determine regions of linkage within those families. The 
number of variants remaining following analyses 1 and 2 in pedigrees 3-6 is shown in 
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Table 6.4. A table showing the number of potentially disease-causing variants identified by 
analyses 1 and 2 in pedigrees 1-6. 
 Number of variants 
detected via analysis 1 
Number of additional 
variants detected via 
analysis 2 
Family 1 0 2 
Family 2 2 5 
Family 3 35 239 
Family 4 12  29 
Family 5 17  43 
Family 6 34  119 
 
6.3.3.3 Combinational analysis of data generated from all six pedigrees 
Upon analysing all of the novel variants and CNV that were identified within defined 
regions of linkage within each of the six kindreds there were no genes harbouring novel 
variants or affected by CNV that were shared between families. Upon performing the 
same analysis, but studying variants with a population frequency of < 1% there were 
three genes containing variants that were each shared between two kindreds.  
6.3.3.4 Summary 
These familial analyses have highlighted a number of candidate variants and genes that 
may underlie the development of HS in these pedigrees. Bioinformatic interrogation of 
these data is ongoing. It was notable that there was no one gene in which all 6 pedigrees 
shared novel or rare variation, implying further genetic heterogeneity in HS.  
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6.3.4 Analysis of phenotypically grouped, unrelated individuals with HS  
Analyses 1 and 2 were performed on data generated from individuals within the 
respective phenotypic sub-groups detailed in section 6.2.2. The hypotheses being tested 
were that a) all individuals will share novel protein altering variantion, splice site 
variation or CNV affecting the disease-causing gene (analysis 1), b) all individuals will 
share rare (<1% population frequency) protein altering variation, splice site variation or 
CNV affecting the disease-causing gene (analysis 2). Neither hypothesis was proven in 
any of the sub-groups analysed. Within each group, the maximum number of 
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6.3.4.1 HS/arthritis cohort 
6.3.4.1.1 Analysis 1 
Table 6.5. A table showing the distribution in the number of genes in which novel genetic 
variation was common to X number of individuals within the HS/ arthritis cohort 
(variation did not have to be exactly the same, it included any protein-altering, splice site 
or CNV affecting the relevant gene). 
No. Individuals with novel variation in 
gene: 
(Total no. in group = 7) 
4 3 2 1 
No. genes 4 5 78 1065 
 
6.3.4.1.2 Analysis 2 
Table 6.6. A table showing the distribution in the number of genes in which rare (<1% 
population frequency) genetic variation was common to X number of individuals within 
the HS/ arthritis cohort (variation did not have to be exactly the same, it included any 
protein-altering, splice site or CNV affecting the relevant gene). 
No. individuals with rare 
variation in gene 
(Total no. in group = 7) 
6 5 4 3 2 1 
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6.3.4.2 Sinus tract disease cohort 
6.3.4.2.1 Analysis 1 
Table 6.7. A table showing the distribution in the number of genes in which novel genetic 
variation was common to X number of individuals within the sinus tract disease cohort 
(variation did not have to be exactly the same, it included any protein-altering, splice site 
or CNV affecting the relevant gene). 
No. individuals 
with rare 
variation in gene 
(Total no. 
individuals = 30) 
17 11 10 8 7 6 5 4 3 
No. genes 1 2 1 2 3 6 11 41 150 
 
6.3.4.2.2 Analysis 2 
Table 6.8. A table showing the distribution in the number of genes in which rare genetic 
variation (<1% population frequency) was common to X number of individuals within the 
HS/ arthritis cohort (variation did not have to be exactly the same, it included any protein-








23 19 17 16 15 14 13 12 11 10 9 8 7 
No. genes 1 1 3 1 3 6 5 6 13 19 32 41 90 
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6.3.4.3 Nodular disease (hormonal) cohort 
6.3.4.3.1 Analysis 1 
Table 6.9. A table showing the distribution in the number of genes in which novel 
variation was common to X number of individuals within the nodular disease cohort 
(variation did not have to be exactly the same, it included any protein-altering, splice site 
or CNV affecting the relevant gene). 
No. individuals with novel 
variation in gene: 
(Total no. in group = 15) 
6 5 4 3 2 1 
No. genes 1 1 2 26 201 1960 
 
6.3.4.3.2 Analysis 2 
Table 6.10. A table showing the distribution in the number of genes in which rare genetic 
variation (<1% population frequency) was common to X number of individuals within the 
nodular disease cohort (variation did not have to be exactly the same, it included any 
protein-altering, splice site or CNV affecting the relevant gene). 
No. individuals 
with rare 
variation in gene 
(Total no. 
individuals = 15) 
11 10 9 8 7 6 5 4 3 
No. genes 1 1 1 3 9 24 30 111 339 
 
6.3.4.4 Summary 
There was no subgroup in which all individuals shared novel or rare variation in any 
one gene however genes in which variation was identified in multiple individual 
patients could be considered as potential disease-causing candidates. Bioinformatic 
analysis of these data is ongoing.  
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6.4 Discussion 
Work in chapters 3 and 5 implied that, in addition to the involvement of NCSTN, 
PSENEN and PSEN1, there may be further genetic heterogeneity underlying HS. 
Consequently, the aim of this study was to identify further disease-causing genes using 
a combination of positional cloning and next generation sequencing technologies. The 
patient cohorts being studied were integral to the potential success of this work, thus 
great care was taken in phenotyping both familial and unrelated cases. Two broad 
groups of individuals were recruited to the study, related individuals from multiplex 
kindreds with HS and unrelated individuals carefully grouped by phenotype. 
6.4.1 Three novel mutations in NCSTN were identified through WES  
Of the 66 individuals studied, 30 had partaken in prior studies (Chapters 3 and 5) and 
had subsequently been screened for mutations in NCSTN, PSENEN and PSEN1. Of the 
remaining 36 individuals (all unrelated cases), three were found to harbour likely 
pathogenic variants in NCSTN by WES (no likely pathogenic variants were detected in 
PSEN1 or PSENEN). One could therefore conclude, bearing in mind that 33 of those 36 
cases reported a family history of HS (including all three individuals with NCSTN 
mutations), that around 9% (3/33) of British familial cases of HS arise as a consequence 
of mutations in NCSTN, PSENEN or PSEN1. This figure is slightly higher than that 
relating to the general disease population (<7%, presented in Chapter 5) which is 
perhaps not surprising given the familial nature of the group.  These data require 
validation in a larger patient cohort.  
6.4.2 Familial studies identify potential candidate variants 
This study demonstrates the enormous amount of data that is generated through WES 
and highlights the challenges faced in analysing and interpreting such information in the 
context of autosomal dominant inheritance and apparent genetic heterogeneity. Familial 
studies provide one way of circumnavigating genetic heterogeneity, as one would 
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expect only one disease gene in any single kindred. The success of such studies 
however depends upon the size, nature and availability of samples from individuals 
within the relevant pedigree. The structure of pedigrees 1 and 2 suggested that WES of 
multiple genetically distant individuals could significantly reduce the number of 
candidate disease-causing, shared variants. Data filtering (using the documented 
algorithms) further reduced the number of candidate variants to the extent that in 
pedigree 1 only three rare variants were shared between all four individuals subjected to 
WES (two within regions of linkage). The size and architecture of pedigree 2 meant 
that, despite multiple family members being sequenced, the list of potentially 
pathogenic variants could not be filtered down to the extent seen with pedigree 1. There 
were however only two novel variants and five rare variants shared between individuals. 
The nature and number of individuals sequenced from pedigrees 3-6 meant that variants 
could not be filtered down to the small numbers seen with pedigrees 1 and 2.  
6.4.3 Exclusion of genetic homogeneity outside of the gamma-secretase genes 
A combinational analysis of data generated from all six pedigrees revealed that there 
was no single gene in which all six pedigrees shared novel or rare variation. Different 
pairs of pedigrees shared rare variation in a total of three genes. These data suggest that 
there is no genetic homogeneity outside of the gamma-secretase genes (assuming 
pathogenic variants would be novel or rare), implying significant further genetic 
heterogeneity in familial HS.  
6.4.4 Analysis strategies employed to interpret WES data  
WES has revolutionised gene sequencing capabilities, yet the success of implementing 
this technique in the discovery of new disease genes is dependent upon the efficiency 
and accuracy of the bioinformatic analysis techniques that are available to analyse the 
vast amounts of data produced.  At present, and dependent upon the nature, inheritance 
and genetic heterogeneity of the condition in question, bioinformatic approaches are 
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frequently insufficient to discern disease-causing mutations. This is partly because the 
efficiency of any such analyses depends upon the accuracy and completeness of genome 
databases, the resource against which all newly identified variants are compared to 
generate a measure of novelty. These databases are becoming increasingly 
comprehensive yet, at present, they largely comprise data derived from European 
Caucasian individuals, posing a significant challenge when analysing variation in 
individuals of other ethnicities (individuals of Afro-Carribean and Asian ethnicity were 
included in this study). The completeness of data on these servers will improve with 
time and it is interesting to consider that the term “novel”, whilst useful in facilitating 
data filtering in this study, is likely to become increasingly redundant as even the rarest 
variants become documented in these servers.   
Given the enormous quantity of data generated from the individuals studied in this 
project, analysis algorithms had to be designed with the primary aim of filtering out 
variants of unlikely pathogenicity. Those algorithms however were created in the 
knowledge that it would be possible to unintentionally filter out disease-causing 
variation in the process. For example, it was assumed that all cases were single gene 
disorders inherited in an autosomal dominant manner (thus homozygous variants were 
excluded), but that may not be the case. Furthermore, synonymous variants were 
excluded in the analysis 1 and 2 algorithms documented above. That was done in the 
knowledge that they are less likely to be pathogenic, not that they can never be 
pathogenic. Whilst generally considered as non-protein altering, it is well known that 
these variants can disrupt existing splice sites and create new splice sites, potentially 
conferring significant functional consequences
287
. Even accounting for the potential 
errors in this process, it is still critical to devise filtering algorithms that reduce the 
number of variants to a number that can practically be analysed in a more 
comprehensive manner. As pedigrees 3-6 and the large phenotypically defined, but 
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unrelated, cohorts demonstrated, even with the present algorithms in place there are still 
an enormous number of variants left to analyse.  
6.4.5 Potential analysis strategies that could be employed in the future 
interrogation of these data 
After data filtering (using algorithms stated in this chapter), the main mechanism by 
which candidate genes were identified in this study was by considering sharing of 
variation across either a pedigree or across a phenotypic subgroup of unrelated 
individuals. This has created variant lists which can now be further refined by adopting 
a more in-depth analytical approach. This may include assessing the nature of the 
variants (ie. nonsense variants are more likely to be more significant than missense 
variants etc.), conservation, predicted functional outcomes and known function of the 
relevant gene (potential algorithm of assessment shown in Figure 6.9). Whilst this kind 
of approach may be beneficial there are a few caveats. Firstly, using the above filtering 
criteria would further increase the risk of filtering out pathogenic variants. This is not 
just because yet more filtering steps are being added, but also because of the nature of 
those steps. Predictions regarding the functional consequences of mutations are only 
predictions, based on often limited knowledge about any given base and corresponding 
amino acid. Furthermore, whilst considering the function of the relevant genes may be 
helpful, it is important to remember that gamma-secretase gene variants would likely 
have been ruled out on that basis as the only known disease association at the time was 
FAD. The second problem with this overall kind of analytical approach is that, in the 
context of the groups studied here, it would still leave a large number of potentially 
pathogenic variants in the majority of analyses.  
- 262 - 
 
Figure 6.9. A proposed detailed variant analysis algorithm.  This is a potential algorithm by 
which variants identified by WES and filtered using the algorithms described above could be 
further interrogated. 
 
Another angle from which to approach data analysis is to acknowledge that some genes 
are more polymorphic than others. An analysis based purely on the sharing of different 
variants between individuals does not account for that variability. Some genes, whether 
because they are just larger or perhaps less functionally important, are more 
polymorphic. A more accurate approach would therefore be to acknowledge the general 
frequency of genetic variation in individual genes when prioritising candidate variants. 
One mechanism by which this analytical challenge can be addressed is currently being 
developed within the department.  This in-house filtering programme will be able to 
compare variation in any given gene against variation in that gene in a control cohort (a 
gene-centric case control analysis). For example, if 50% of any given disease cohort 
(eg. sinus tract HS) had rare variation in gene X and this was unrelated to the clinical 
phenotype, then one would expect a similar frequency of variation in control cases. If 
PSENEN were the disease-causing gene in that group however, due to the conserved 
nature of that gene, the likelihood of individuals within the disease group sharing 
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variation in the gene versus the control group is much higher, thus identifying it as a 
candidate. Statistical probabilities can therefore be calculated on this basis, creating a 
new mechanism by which candidate genes can be analysed. The data generated in this 
study is currently being analysed in this way.  
Another complexity in data analysis is highlighted by the identification of gamma-
secretase mutations in HS. The above mechanisms of data analysis all assume that one 
gene is responsible for the disease in any given cohort. That was of course not the case 
with the gamma-secretase mutant group where three entirely independent genes were 
identified yet they were all functionally linked by their integration and function in the 
gamma-secretase complex. Thus, in future data analyses of apparently genetically 
heterogenous conditions it is important to identify whether variants are arising in groups 
of functionally related genes. One mechanism of integrating this into any analysis is by 
using protein-protein interaction software. This is capable of functionally grouping 
variants based on known protein functions, however much of the existing software is in 
its infancy and requires further development. One significant limitation with such 
programmes is that they are entirely dependent upon whether any research has been 
performed to link any two or more given proteins. It should never the less be 
considered, as without employing such a method, one would potentially need enormous 
numbers of unrelated individuals to detect three independent but functionally related 
genes. This problem was only circumnavigated in the initial identification of gamma-
secretase genes in Chinese populations due to the number of pedigrees available for 
study and the structure and number of affected members within each kindred
135
. 
When studying large groups of unrelated individuals, very accurate phenotyping is one 
further way to try and minimise genetic heterogeneity in any given study cohort. 
Assuring phenotypic homogeneity is difficult in the absence of a validated phenotypic 
classification however and, as was the case in this study, any attempt to clinically group 
- 264 - 
individuals cannot be evidence based. Furthermore, in a condition with such subtle 
phenotypic variation, segregating individuals on a purely clinical basis may be very 
difficult. One such example is that whilst the HS/ inflammatory arthritis cohort was 
interesting and consistent, there is nothing to say that the arthritis was not purely 
reactive and in no way related to the genetic basis of their HS. A further obstacle to 
accurate phenotyping is that, as again demonstrated by the gamma-secretase mutations, 
multiple functionally related genes can underlie the same phenotype (the phenotype of 
individuals harbouring gamma-secretase gene mutations is reviewed in Chapter 7 and 
put in to the context of ongoing clinical efforts to refine disease classification). Thus, 
even when studying a truly distinct clinical phenotype, there may still be a degree of 
genetic heterogeneity confounding the analysis. Ultimately, the number of unrelated 
individuals that are required to facilitate the identification of a disease-causing gene is 
partly dependent upon the amount of genetic heterogeneity within the cohort.   
6.4.6 Conclusion 
In summary, these data demonstrate that there is no single disease gene that is shared 
between pedigrees or shared between individuals within any of the distinct phenotypic 
subgroups. This implies that there is significant further genetic heterogeneity underlying 
HS. The data generated in this study is a valuable resource worthy of further 
bioinformatic interrogation and the algorithms devised in this project represent an 
important first step in data analysis. Ongoing statistical, network and pathway based 
analyses have the potential to further facilitate data filtering and combined with the 
mechanisms of in-depth analysis proposed in Figure 6.9 harbour the potential to identify 
new disease-causing genes in HS. 
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Chapter 7:  Phenotypic analysis of individuals 
harbouring mutations in the gamma-secretase genes 
NCSTN and PSENEN   
7.1 Introduction and aims 
Inter-individual variability in cutaneous features, disease distribution and associated 
systemic symptoms implies phenotypic heterogeneity in HS (discussed in section 1.1.4). 
Clinical efforts to categorise the disease remain at a premature stage but a recent study 
proposed three phenotypic sub-groups, “axillary-mammary”, “follicular” and 
“gluteal”30. Individuals with gamma-secretase mutations represent the first genetically 
defined subgroup of HS.  
7.1.1 Aims and objectives 
The aim of this study was to present a case series of all mutation-positive individuals 
identified as part of this programme of research and to review the clinical phenotype of 
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7.2 Patient cohort 
A total of ten novel or rare (<1% population frequency) sequence altering gamma-
secretase variants have been reported in this thesis, seven in NCSTN, one in PSENEN, 
one in PSEN2 and one in APH1A. These comprise three missense, four splice site, two 
frameshift and one nonsense mutation. The missense changes in NCSTN, PSEN2 and 
APH1A and two of the splice site substitutions in NCSTN are of uncertain pathogenicity 
(discussed in sections 5.5, 5.6 and 6.3.2). Individuals harbouring those variants were 
therefore excluded from this study on the basis that their clinical phenotype may not be 
related to the gamma-secretase genes. Two affected individuals within the same family 
were found to harbour the PSENEN mutation, both were taken forward for phenotypic 
analysis. A total of six individuals were therefore analysed, representing all of the likely 
pathogenic gamma-secretase variants that have been identified as part of this 
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Table 7.1. All of the likely pathogenic gamma-secretase gene variants identified in this 
study.  
Patient ID Gene Mutation Nature of mutation Predicted protein 
HS-01 NCSTN c.C349T Nonsense p.Arg117X 
HS-02 NCSTN c.1010delA Frameshift deletion p.Tyr337Serfs*20 










*HS-05a PSENEN c.66_67insG Frameshift insertion p.Phe23ValfsX98 
*HS-05b PSENEN c.66_67insG Frameshift insertion p.Phe23ValfsX98 
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7.3 Clinical phenotype of patients harbouring gamma-secretase gene 
mutations 
HS-01: An Afro-Caribbean male who developed paired comedones, painful 
erythematous nodules, cysts, abscesses and sinus tracts in the post-auricular area, 
axillae, groin, buttocks and genitalia from the age of 32 (Figure 7.1, HS-01). He 
presented with features consistent with nodulocystic acne over his face, neck and trunk, 
had a BMI 27 and was an active smoker. 
HS-02: A Caucasian male developed paired comedones, painful erythematous nodules, 
cysts, abscesses and scarring over the neck, post-auricular region, axillae, back, groin 
and buttocks from the age of 17. He also presented with an atypical, speckled, macular 
hyperpigmentation in axillae and groin (Figure 7.1, HS-02). He reported a history of 
acne vulgaris, had a BMI of 34 and was an active smoker.   
HS-03: A Caucasian male developed paired comedones, pustules, cysts, erythematous 
nodules and abscesses over the neck, axillae, suprapubic area, groin, buttocks and 
medial thighs from the age of 16. He had features consistent with nodulocystic acne 
over his neck and back, his BMI was 30 and he was active smoker (no clinical photos 
available).   
HS-04: A Caucasian female developed paired comedones, painful erythematous 
nodules and abscesses in the post-auricular region, groin and buttocks from the age of 
20. She reported a history of acne vulgaris, had a BMI of 27 and was a non-smoker (no 
clinical photos available).  
HS-05a/05b: HS05a is the daughter of HS05b. These Caucasian females developed 
paired comedones, pustules, painful erythematous nodules and abscesses in the axillae, 
groin and buttocks from the age of 15. HS-05a had additional sinus tract formation and 
medial thigh involvement and HS-05b had additional sub-mammary involvement. Both 
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also presented with an atypical, speckled, macular hyperpigmentation in the axillae and 
groin (Figure 7.1, HS05a, HS05b). HS-05a reported a history of acne vulgaris. They had 
BMI’s of 23 and 33 and had never smoked.  
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Figure 7.1. Clinical images of individuals with likely pathogenic gamma-secretase 
mutations.  HS-01 had inflammatory nodules, sinus tracts and hypertrophic scars in the axillae 
and groin. HS-02 had atypical, speckled, macular hyperpigmentation in the axillae. 
Histopathological analysis of an axillary skin biopsy revealed hyperkeratosis, horn cysts and 
elongated thin filiform interconnecting epidermal strands extending into the superficial dermis. 
HS-05a has multiple suppurative sinus tracts and scars in both axillae. There was a faint 
speckled hyperpigmentation in both axillae which was more evident in the groin (no photo 
available). Her mother, HS-05b, had speckled hyperpigmentation, multiple comedones and one 
nodule in the left axilla. Photos courtesy of Guy’s and St. Thomas’ NHS Foundation Trust, all 
individuals consented to publication. 
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7.4 Discussion 
This represents a small case series however a number of phenotypic features appeared 
common to the group. All six individuals presented with severe, persistent, widespread 
(involving “atypical” areas) and treatment resistant disease from a young age (average 
age 19, the average age of onset in the general disease population in 22.2
9
) and reported 
a family history of the condition. Common cutaneous features comprised paired 
comedones, painful erythematous nodules, abscesses and scars. Two of the more unique 
phenotypic features, and ones that may help in differentiating these individuals from the 
general disease population, included cystic acne-like changes in “atypical” areas (post-
auricular area, neck and trunk) and an atypical speckled hyperpigmentation in the 
flexures. It should however be noted that those features were not universally present. A 
further noteworthy observation was that some individuals were non-smokers of normal 
BMI, which is unusual in the context of HS. Genetic and clinical details are summarised 
in Table 7.2. 
“Typical” HS has been proposed to involve the axillae, sub-mammary region and groin 
whereas “atypical HS” comprises additional involvement of other sites30. All of these 
individuals would therefore be classified as having “atypical” disease. This terminology 
should be applied with caution however given that, as reported in Chapter 5, the gluteal 
region (an “atypical” site) was involved in up to 79% of cases studied 22.  
Flexural speckled hyperpigmentation was observed in three of the six individuals and 
arose prior to HS in all cases (distinguishing it from post-inflammatory pigmentation) 
and fully co-segregated with HS in the respective pedigrees.  A fourth individual (HS-
01) also had hyperpigmentation in the axillae and groin however the pigmentation was 
poorly defined and hard to characterise given the skin type.  Cutaneous appearances 
clinically resembled those of Dowling-Degos Disease (DDD) which has been associated 
with mutations in KRT5 and POFUT1
71; 288
.  None of the three individuals with 
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pigmentary changes (HS02/05a/05b) harboured novel or rare (<1% population 
frequency) variants in KRT5 or POFUT1 on exome sequencing. DDD has frequently 
been reported to arise in association with HS yet, to our knowledge, no KRT5 or 
POFUT1 mutations have been reported in those cases
70
 thus it is plausible that those 
individuals never had DDD but in fact harboured gamma-secretase gene mutations. 
Indeed, the clinical phenotype of those individuals very closely mirrors that of the 
mutation-positive subset reported here
70; 289
.  
Analysis of all globally reported individuals with gamma-secretase mutations supports 
many of the phenotypic features observed in this group. All had severe and widespread 
disease. The majority had cystic involvement in the atypical sites mentioned above
22; 109-
113; 115; 116; 290
. In total, including the mutations reported here, twelve of eighteen 
mutations reported in NCSTN, two of three mutations in PSENEN and the only PSEN1 
mutation appear to be associated with significant involvement of the neck and trunk
22; 
135-139; 141; 142
. This would appear to be a prominent feature of the gamma-secretase 
phenotype. That said, there was no such involvement in three of the six patients studied 
here, thus it should not preclude one from considering more “typical” HS patients as 
harbouring gamma-secretase mutations. At least two of the globally reported individuals 
with NCSTN mutations appeared to have atypical pigmentary changes in the flexures, 
similar to that seen in some of our patients
139; 142
. It is notable that three individuals 
from globally reported mutation-positive multiplex kindreds have been reported to 
develop SCC in regions of HS
135; 141
. Furthermore, the father of HS03 developed SCC in 
a perianal region of HS and died from metastatic disease. This may be significant given 
that SCC is comparatively rare in the general disease population (5 of 2119 HS cases 
retrospectively analysed in one study)
25
 and that heterozygous NCSTN knockout in 
mouse skin can induce the development of SCC
291
. It is not inconceivable therefore that 
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mutation-positive individuals may be at higher risk of developing SCC and this is a 
hypothesis worthy of future investigation.  
A clinical approach to classification was recently adopted in France whereby they 
examined over 600 patients with HS and retrospectively grouped them according to 
defined clinical parameters. Latent class analysis identified three phenotypes; “axillary-
mammary”, “follicular” and “gluteal”30. It is interesting that the individuals reported 
here appear to fall within the “follicular” group (an observation also reported by Ingram 
and Piguet
292
), partially validating that disease classification. Minor discrepencies in 
clinical characteristics (such as the percentage of patients with gluteal involvement and 
disease severity) and the proportion of total HS cases that fall within the gamma-
secretase mutation and “follicular” groups (<7% vs. 26%) would however imply that 
there are likely to be multiple sub-phenotypes within the “follicular” cohort (Figure 
7.2).  
This represents a small case series and ongoing genotype-phenotype correlations are 
now required to refine the clinical characteristics associated with gamma-secretase gene 
mutations. We have now recruited over 300 cases for genetic analysis which will 
facilitate this process and potentially enable the future recognition and genetic testing of 
these individuals in the clinical setting. This may impact upon the stratification of 
patients for clinical studies, trials and hopefully, in the not too distant future, novel and 
more personalised treatments. 
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Early age of 
onset (≤ 20) 
   Family   




“Atypical” sites affected  
(areas outside of axillae, sub-
mammary region  and groins) 
 





abscesses and scars 
present 
 





HS-01 c.C349T   
(p.Arg117X) 
- ● ● ● ● ● ● ● 
HS-02 c.1010delA 
(p.Tyr337Serfs*20) 
● ● ● ● ● ● ● ● 
HS-03 C.1125+1 G>A 
(p.Glu333_Gln367del) 
● ● ● ● ● ● - ● 





● ● ● ● ● ● ● - 
HS-05b c.66_67insG 
(p.Phe23ValfsX98) 
● ● ● ● ● ● ● - 
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Figure 7.2 A diagram representing the different sub-types of HS that have now been 
described.  Gamma-secretase mutation-positive patients appear to fall within the “follicular” 
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Chapter 8: Conclusions and future work 
8.1 Introduction 
HS is a debilitating and therapeutically challenging chronic inflammatory skin 
condition. The current paucity of effective treatment options partly reflects a poor 
understanding of disease pathogenesis. It can follow autosomal dominant inheritance in 
some familes
22; 39
, thus genetic investigation represents one method by which to identify 
the molecular mechanisms driving disease development and propogation. The aim of 
this project was to investigate the genetic architecture of HS. In 2010, shortly after 
commencing this research, mutations were reported in the gamma-secretase genes 
NCSTN, PSENEN and PSEN1 in six Chinese multiplex kindreds with HS
135
. This 
revelatory finding redefined the initial focus of this programme of research to 
investigating the potential role of gamma-secretase mutations in British pedigrees with 
HS and subsequently functionally characterising any mutations that were identified. The 
findings presented in this thesis confirm the involvement of gamma-secretase gene 
mutations in British familial cases of HS (Chapter 3), provide a novel insight in to the 
genetic mechanisms by which gamma-secretase mutations result in disease (Chapter 4), 
approximate the prevalence of gamma-secretase mutations in the general disease 
population (Chapter 5), contribute towards clarifying the gamma-secretase-associated 
HS phenotype (Chapter 7) and provide insight in to the complex and heterogenous 
genetic architecture underlying the condition (Chapter 6). Taken together, these findings 
have contributed towards characterising the first genetically defined sub-group of HS, 
conferring significant translational potential in individuals harbouring gamma-secretase 
mutations and potentially the wider disease cohort. 
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8.2 Gamma-secretase gene mutations in HS 
Following the initial report of heterozygous gamma-secretase gene mutations in 
Chinese pedigrees with HS
135
 these studies were the first to replicate those findings and 
to identify mutations in individuals of European descent (Chapter 3). A total of ten 
novel or rare (<1% population frequency) gamma-secretase gene variants have been 
identified as part of this project, 7 in NCSTN, 1 in PSENEN, 1 in PSEN2 and 1 in 
APH1A. Five of these were predicted to be pathogenic (4 in NCSTN, 1 in PSENEN). 
Globally, gamma-secretase gene mutations have now been reported in six Chinese, five 
British, one Japanese and three French multiplex kindreds as well as two apparently 
sporadic Chinese cases
135-142
. These comprise 18 mutations in NCSTN, three in 
PSENEN and one in PSEN1
135-141
 of which five are nonsense mutations, nine result in 
frameshifts, five in altered splicing and three are missense mutations (Table 8.1). All 
but two of these mutations were reported in familial cases of HS and demonstrated 
complete penetrance in the pedigrees studied (two mutation positive cases without HS 
have been reported yet both were under the age of 12 and are thus too young to be 
confirmed as unaffected)
135
. No mutations have thus far been identified in PSEN2, 
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Table 8.1. All gamma-secretase mutations now reported in HS. 



































































1.Wang et al., 2010 2. Miskinyte el al., 2012 3. Li et al., 2011 4.Lui et al., 2011 5. Zhang et al., 2012 6. 
Nomura et al., 2012 7. Jiao et al. 2013 8. Identified as part of this project 
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8.2.1 A loss of function of the gamma-secretase genes appears to underlie HS 
Functional analysis of the first two mutations reported in this thesis (NCSTN c.1125+1 
G>C and PSENEN c.66_67insG) revealed that they conferred very different effects on 
the nature of their respective mutant transcripts yet shared a downstream reduction in 
transcript abundance and corresponding protein expression. These data imply that 
haploinsufficiency is the common pathogenic mechanism by which both mutations are 
likely to result in HS. The nature of the globally reported mutations partially supports 
that mechanism as the majority are predicted to result in premature truncation which, in 
many cases, would be expected to induce NMD and thus reduce overall transcript 
abundance. Indeed, of those mutations in which RNA expression has been studied, 
many, but not all, were associated with a reduced transcript abundance
135; 139
. It should 
however be noted that the spectrum of global mutations and the associated functional 
data does not support a mechanism of haploinsufficiency in all cases, but it does 
potentially infer that loss of function of the gamma-secretase components is likely to be 
the unifying mechanism underlying disease development
135-141
. 
It is noteworthy that the three missense mutations so far reported in HS (p.Val75Ile, 
p.Pro211Arg, p.Gln216Pro, ) 
22; 138; 140
 are located within the NCSTN ectodomain. The 
site of these missense changes does not correspond with the highly conserved regions of 
the NCSTN ectodomain discussed in the introduction (amino acids 306-360, 419-458, 
625-662) however mutagenesis of nearby amino acids (C213S and C230S) significantly 
affects gamma-secretase-induced APP cleavage and those amino acids are thought to 
play a key role in substrate specificity
198
. The exact mechanism by which these 
mutations result in disease is worthy of further exploration but the genetic location of 
the mutations supports a key functional role for the NCSTN ectodomain in the gamma-
secretase complex and in HS pathogenesis. 
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Figure 8.1. The location of all gamma-secretase gene mutations now reported in HS.  The 
majority of mutations have been reported in NCSTN. The three missense mutations correspond 
with amino acids within the ectodomain of NCSTN. 
 
8.2.2 Cell membrane expression of the gamma-secretase components appears 
tightly regulated and gamma-secretase enzyme activity was not significantly 
impaired in mutant fibroblasts in vitro 
The identification of mutations in genes encoding three of the four gamma-secretase 
complex components implicates complex function, rather than complex-independent 
roles of the individual components, in disease pathogenesis. To our knowledge, these 
are the first studies to investigate gamma-secretase protein expression and enzymatic 
function in HS and whilst this is preliminary data that needs to be replicated in a larger 
cohort of mutation-positive individuals, it provides a unique insight in to protein 
regulation and enzyme function in these individuals.  
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Immunoblotting data revealed that total cell protein levels of NCSTN and PEN-2 
respectively appeared reduced in the two individuals harbouring mutations, yet that 
reduction was not replicated at the level of the cell membrane.  These findings appear 
consistent with previous studies demonstrating that the production, maturation and 
export of the gamma-secretase components to the cell membrane is very tightly 
regulated
189
. There was subsequently no evidence to indicate a reduction in number or 
an impairment in maturity or activity of the gamma-secretase complexes present at the 
level of the cell membrane in mutant dermal fibroblasts. Indeed, if anything, raw 
endopeptidase enzyme activity per mg of solubilised membrane protein and 
carboxypeptidase processing of Aβ peptides seemed very slightly increased in the 
individual harbouring the PSENEN mutation. Whilst this is an interesting observation, 
differences were slight and would require replication in that individual and other 
mutation-positive individuals for verification. 
8.2.3 Immunohistochemical studies of human skin and in vivo gamma-secretase 
gene mutagenesis animal models support a role for gamma-secretase 
mutations in HS 
The anatomical distribution of NCSTN and PEN-2 in axillary skin mirrored sites of 
common histopathological changes in HS, thus supporting the involvement of gamma-
secretase mutations in disease development. The widespread expression of gamma-
secretase components however meant that few further conclusions could be drawn 
regarding the origins of HS development in the skin. Widespread expression was not 
unexpected given that the gamma-secretase complex is integral to such a wide range of 
essential cell processes. 
The side effects experienced by individuals recently trialled on the gamma-secretase 
inhibitor Semagacestat (for Alzheimer’s disease) also partially support gamma-secretase 
involvement in HS. Cutaneous side effects included non-specific skin rashes, hair 
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colour changes and an increased risk of skin cancer
293; 294
. It is unclear whether the skin 
changes resembled HS, however the alterations in hair colour would potentially support 
a biological role for gamma-secretase in the hair follicle.  
In vivo animal models provide further evidence that the gamma-secretase components 
are involved in HS. Disrupture of presenilin and nicastrin (PSEN1 -/ PSEN2 -, PSEN1 - 
and NCSTN +/-) in the skin of mice results in follicular keratinisation, follicular atrophy, 
the formation of epidermal cysts, absent sebaceous glands and epidermal hyperplasia, 
all histological features of HS in humans
291; 295; 296
. Interestingly, these cutaneous 
manifestations initially appeared around the ears, eyelids, nose, mouth, inguinal and 
perineal areas. These, in part, correspond with cutaneous regions commonly affected in 
HS, namely the post-auricular, inguinal and perineal regions. Some nodules on the 
PSEN1 – and NCSTN +/- mice underwent malignant transformation (developed in to 
SCC), which may correlate with the observation that multiple individuals with gamma-
secretase gene mutations have developed SCC’s in regions of affected skin. The 
apparent tumour-suppressor function of gamma-secretase in the skin is potentially 
mediated by its effects on Notch signalling (a known tumour suppressor) and the 
endocrine growth factor receptor (gamma-secretase inhibition results in an up regulation 
of EGFR which is up regulated in over 90% of head and neck SCC’s)291.  
A further interesting observation in these studies was that mice treated with a gamma-
secretase enzyme inhibitor (LY-411,575), which leaves the gamma-secretase complex 
intact and at normal levels, develop similar lesions to NCT +/- mice
291
. This potentially 
implicates reduced enzyme activity, rather than a deficiency of any individual complex 
component, as a cause of the cutaneous manifestations observed in HS. This emphasises 
the need to further explore enzymatic function in mutation positive patients 
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8.2.4 Gamma-secretase mutations may result in HS by affecting Notch signalling  
Taken together, the genetic evidence, the anatomical distribution of the gamma-
secretase components in the skin and the phenotypic and histopathological similarities 
observed in mutagenised in vivo animal models firmly imply a role for the gamma-
secretase components in disease pathogenesis. As well as further characterising the 
exact biological effects of gamma-secretase mutations on enzyme function it is also 
translationally important to investigate the downstream pathways through which these 
mutations result in HS. In vivo work in mice suggests that the skin changes observed in 
gamma-secretase deficient mice may be due to altered Notch signalling.  The hair 
follicle and sebaceous glands of mice deficient in gamma-secretase are phenotypically 
identical to those of mice deficient in Notch 1 and 2 and the additional epidermal 
changes are present in mice deficient in Notch 1, 2 and 3
295
. Furthermore, and as eluded 
to above, gamma-secretase and Notch 1 deficiency have both been shown to induce 
SCC formation in mouse skin. 
As discussed in the introduction, Notch is a trans-membrane receptor protein involved 
in cell to cell signalling. Gamma-secretase is integral to effective Notch signalling as, 
upon ligands binding to the extra-cellular domain of the Notch receptor, gamma-
secretase cleaves the intracellular domain (NICD) which, in turn, re-locates to the 
nucleus and affects gene expression (Figure 1.9)
297
. Within the epidermis, Notch 
signalling is involved in stem cell clustering, epidermal cell differentiation (via the 
ligand delta-like 1), hair follicle differentiation (via jagged1) and epidermal 
proliferation
298-300
. It plays an integral role in maintaining hair follicles and sebaceous 
glands and acts as a tumour suppressor in the skin via its ability to control epidermal 
proliferation
301
. Notch signalling also appears to regulate inflammation via at least three 
mechanisms, 1) suppressing-TLR-4 induced cytokine expression in macrophages, 2) 
promoting IL-22 expression by CD4+ T cells and 3) inducing the production of NK 
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cells
302-304
. Consequently, any suppression of Notch signalling could induce or 
propagate the development of HS in two ways; 1) affect the structure and maintenance 
of the pilo-sebaceous unit and 2) alter cytokine profiles and contrinute towards the 
inflammatory response observed in HS skin (IL-22 expression and NK production is 
reduced in HS
90; 91
). Notch signalling may therefore represent one downstream pathway 
through which gamma-secretase mutations, and any subsequent alteration in gamma-
secretase function, could result in HS. It is potentially noteworthy that smoking has 
been shown to suppress Notch signalling in lung epithelium and if this were to confer 
any form of systemic effect then it may provide a hypothetical link between smoking 
and HS
305; 306
. It should, however, be noted that many of the individuals harbouring 
gamma-secretase mutations were non-smokers.  
8.2.5 Gamma-secretase mutations provide an insight in to the pathogenic 
mechanisms underlying HS 
In addition to implicating the gamma-secretase genes in disease development the 
discovery of gamma-secretase gene mutations may also inform matters of historical 
pathogenic importance such as the histological basis of the disease. As discussed in the 
introduction, HS was originally considered a disease of the apocrine gland yet recent 
histopathological studies have consistently highlighted follicular occlusion as the 
primary pathological phenomenon. The involvement of non-apocrine gland-bearing 
sites in HS, such as the sub-mammary folds, abdominal fold and medial thighs also 
partially supports those findings. The fact that gamma-secretase deficiency in mice, 
animals that do not have apocrine glands, results in follicular hyperkeratosis and cyst 
formation similar to that seen in human HS further implicates primary follicular 
involvement in HS, at least in the subset of patients harbouring mutations.  
Primary immune dysregulation has recently been proposed to underlie HS
82
. There is 
little doubt, both clinically and histologically, that a significant inflammatory response 
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accompanies the disease yet it remains unclear whether that is a primary event, 
somehow resulting in the characteristic follicular occlusion noted on histology, or 
secondary to the build up of bacteria and keratin caused by initial follicular plugging. 
The identification of gamma-secretase mutations may inform this debate given that the 
follicular keratinisation and epidermal cyst formation observed in gamma-secretase 
deficient (PSEN1 -/ PSEN2 -) mice was rarely accompanied by an inflammatory 
response (<20% cases 
295
). This suggests that follicular occlusion is likely to occur prior 
to any inflammatory response in individuals harbouring pathogenic gamma-secretase 
mutations. 
8.2.6 Gamma-secretase mutations underlie a minority of HS cases in the UK 
It is notable that the majority of familial and apparently sporadic cases of HS had no 
identifiable mutations or CNV in NCSTN, PSENEN or PSEN1. Only 2 of 7 multiplex 
kindreds, 3 of 32 familial cases and 3 of 48 cases sequentially recruited from a tertiary 
referral clinic harboured novel variants in these genes. Whilst this latter study may not 
be truly reflective of the general disease population, potentially over-representing severe 
disease, it is the largest study performed to date and provides an important estimate of 
mutational prevalence in HS. From these data we estimate that less than seven percent 
of British cases of HS are due to mutations in the gamma-secretase genes NCSTN, 
PSENEN and PSEN1. Given that there remains no evidence to implicate involvement of 
the other gamma-secretase genes, APH1A, APH1B or PSEN2 in HS development, this 
figure probably reflects the prevalence of mutations in any of the gamma-secretase 
genes in HS. 
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8.2.7 A gamma-secretase mutation-related clinical phenotype is emerging which 
represents the first genetically defined phenotypic sub-group of HS 
In the knowledge that only a small proportion of HS cases appear to arise as a 
consequence of gamma-secretase gene mutations it was hypothesised that the mutation-
positive group may harbour a specific and distinguishable clinical phenotype. 
Meticulous clinical examination of all individuals harbouring likely pathogenic gamma-
secretase mutations combined with a review of the clinical data presented on all 
mutation-positive individuals in the literature, identified numerous phenotypic features 
common to the gamma-secretase mutant cohort. Some of these features, such as the 
atypical speckled flexural macular hyperpigmentation and superimposed cystic acne-
like appearances in atypical areas, are relatively unique and have the potential to 
differentiate patients harbouring mutations in the clinical setting. It should be noted 
however that these phenotypic observations were limited by the small clinical sample 
size and that very few clinical features were consistent throughout the group. Indeed, 
even within the same pedigrees there was a degree of variation in phenotypic severity 
and cutaneous features. This phenotypic variation may, in part, be due to the many 
environmental and intrinsic factors that can impact on the condition, such as infection, 
smoking, obesity and hormonal factors. It is important that the clinical phenotype is 
continually refined as more mutation-positive cases emerge. This may ultimately 
improve the ability of clinicians to detect and genetically test these individuals in the 
clinical setting. 
This work has contributed to initiating the long required process of classifying HS in to 
phenotypic sub-groups. In time, this may stimulate an alteration of the existing 
nomenclature to account for the variable pathogenic mechanisms underlying HS. This 
would raise clinical awareness that different sub-types exist, stimulate more disease-
specific clinical studies and trials and ultimately potentially result in the application of 
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more effective differential treatments. That said, an over-arching terminology such as 
HS remains an important mechanism for grouping and recognising individuals such as 
this in the primary care setting, especially considering the already limited recognition of 
this disease in that environment.  
8.2.8 There is no evidence to support an association between HS and FAD 
As discussed in the introduction (section 1.3.7), gamma-secretase mutations (PSEN1 
and PSEN2) were first identified in familial Alzheimer’s disease (FAD). The vast 
majority of mutations in FAD are heterozygous missense changes but the exact 
mechanism by which they result in disease remains unclear.  Both diseases appear to 
share a common genetic basis in as much as they affect genes involved in the gamma-
secretase complex but it should be noted that only one mutation has been identified in 
HS in either of the presenilin genes implicated in FAD
135
. This mutation was in PSEN1, 
but mutations in this gene have not been replicated in this thesis or any other 
international study. No PSEN2 mutations have been reported in HS to date. In contrast 
to the missense changes observed in FAD, the vast majority of mutations identified in 
HS are nonsense, frameshift and splice site mutations. The nature of the mutations 
identified in FAD (missense) might suggest that the mutant protein needs to be 
expressed in order to affect presenilin/ gamma-secretase activity
294
 whereas, as we have 
demonstrated in this thesis, some of the mutations in HS appear to result in 
haploinsufficiency of the relevant genes. At an enzyme level, the unifying mechanism 
underlying FAD appears to be an alteration in carboxypepidase-like gamma-secretase 
activity
178
. FAD mutations confer variable and often no effect on endopeptidase 
activity
178
. In HS, neither mutation studied in this thesis appeared to significantly affect 
endopeptidase activity and, in contrast to FAD, there was no statistically significant 
alteration in carboxypeptidase activity. Intriguingly, and in direct contrast with FAD, 
enzyme generated from PSENEN mutant fibroblasts appeared to generate reduced 
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Aβ42:Aβ40 ratios. This clearly requires replication in a larger cohort of mutation-
positive individuals. A further consideration is that the FAD mutations appear to result 
in disease by affecting downstream APP processing, whereas in HS, the Notch 
signalling pathway potentially appears more relevant.   
Aside from gamma-secretase enzymatic function, reports of mutations in only one 
complex component in FAD have lead some to propose that presenilin may act 
independently of the gamma-secretase complex to cause FAD.  For example, PSEN1 
and PSEN2 mutations can affect the expression and activity of β-secretase, another 
enzyme which is capable of converting amyloid precursor protein to β-amyloid307; 308, 
and can affect intracellular calcium levels
191; 309
 (alterations in calcium fluctuations have 
been shown to occur prior to the development of amyloid plaques in AD)
310
. Mutations 
in multiple complex components would suggest that this is unlikely to be the case in 
HS.  
The differing mechanisms that would appear to underlie these two disparate diseases go 
part way to explaining why there is no known clinical association between the two, or 
reports of FAD in the mutation positive multiplex kindreds with HS. The presence of 
HS and FAD in an individual or family should be interpreted with caution given the 
prevalence of both conditions in the population (prevalence of HS estimated to be up to 
1%
4
). Even the detection of a mutation in PSEN1 in such individuals would be 
inconclusive given the apparent heterogeneity in HS and one would need to establish 
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8.3 The future of gamma-secretase related research in HS 
The discovery of gamma-secretase gene mutations in HS suggests that the respective 
gamma-secretase complex components are involved in the pathogenesis of at least some 
cases of HS. Further functional characterisation of these mutations is now required to 
determine the specific genetic and molecular mechanisms underlying disease 
development and to realise the translational potential of these findings. 
8.3.1 Future functional characterisation of the gamma-secretase mutations 
identified in HS 
Two of the mutations characterised as part of this thesis appeared to result in 
haploinsufficiency, however, as previously mentioned, that would not appear to be the 
pathogenic mechanism underlying all globally reported mutation-positive cases. Whilst 
the spectrum of mutations might imply that loss of function is the common pathogenic 
mechanism, that remains to be proven. Careful elicitation of the exact mechanisms 
underlying all identified mutations, including the splice and missense variants, is 
required to verify this hypothesis.  
A further hypothesis is that these mutations result in HS by affecting gamma-secretase 
complex function rather than through independent, and as yet potentially unidentified, 
mechanisms associated with the individual components. Whilst the endopeptidase and 
carboxypeptidase-like activites of the gamma-secretase complex represent two of the 
better understood and most extensively studied facets of the enzyme, it should not be 
forgotten that these represent but two of an increasing number of functions attributed to 
the complex. Gamma-secretase also appears to play a role in endocytosis, protein 
trafficking and phagocytosis and complex dysfunction may affect any of those 
processes. The in vivo data potentially implicating Notch signalling in HS would 
however imply that the endopeptidase or carboxypeptidase properties of gamma-
secretase are indeed relevant in disease pathogenesis. 
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It is now important to assess the impact of a larger number and wider spectrum of 
gamma-secretase mutations on endopeptidase and carboxypeptidase enzyme activity. 
Many factors need to be considered in designing such experiments given the cost, 
potential time input, technical difficulty and sheer number of cells required for such 
work. Primarily one would need to decide upon the substrate or substrates to be studied. 
If it is hypothesised that Notch signalling is the relevant downstream pathway in HS 
then Notch, rather than APP, may be the optimal substrate to study, particularly given 
that some FAD mutations have been reported to affect substrate specificity
311
. Whilst 
Notch has been used in gamma-secretase activity assays, the relative inexperience with 
that substrate combined with a poor understanding of Nβ processing (reflecting 
carboxypeptidase activity), means that data interpretation could be a significant 
challenge.   
The in vitro APP based gamma-secretase activity assay described in this study is a 
standard, accepted and commonly used method of analysing enzymatic function but it 
represents just one of many potential methods to explore complex activity. A faster but 
slightly more indirect method of examining enzymatic function is to assess the 
expression of genes involved in signalling cascades downstream of gamma-secretase. 
One could look at the expression of single gene transcripts, eg. HES1 (expression driven 
specifically by Notch signalling)
272
 or the expression of multiple genes from a variety of 
signalling pathways, eg. via microarrays. This type of work would not only provide an 
insight in to enzymatic function but also contribute towards confirming the specific 
downstream pathways relevant in HS.  
A further consideration when performing any of the above experiments is the cell type 
to be studied. Primary dermal fibroblasts were the source of gamma-secretase 
complexes in all enzyme activity assays reported as part of this thesis but 
immunohistochemical analysis of axillary skin revealed keratinocytes to be another cell 
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type worthy of future study (strong expression of NCTSN and PEN-2). The relative 
instability of primary keratinocytes in culture would however require careful 
consideration in this context. It may be beneficial to perform the above suggested 
experiments in a range of different cell types to establish any cell-type specific 
variation. In considering the source of these respective cells, whilst primary mutant cells  
represent a very valuable resource, preliminary experiments could initially focus on the 
effects of knocking down NCSTN or PSENEN (using SiRNA technology) in control 
cells (either primary or immortalised) on gamma-secretase enzyme activity and 
downstream signalling. 
One of the intriguing and potentially revealing features of HS is the unusual cutaneous 
distribution. Gamma-secretase is widely expressed in the skin and internal organs and is 
integral to multiple essential cellular signalling pathways yet the heterozygous 
mutations reported in HS are only associated with a cutaneous disease with a very 
specific anatomical distribution. If these mutations significantly impaired or inhibited 
enzyme function then one would perhaps expect more severe and widespread 
consequences, corroborated by PSEN1 knockout in mice resulting in mortality in 
embryo. The heterozygous nature of the mutations in HS may be a key factor in the 
disease distribution. Heterozygous knockout of PSEN1 (PSEN1 -/+) in mouse skin 
confers no apparent effect
296
, yet full knockout (PSEN1 -/-) results in the 
aforementioned skin changes
285; 289; 290
. This in vivo data implies that a heterozygous 
mutation alone, at least in that gene, animal model and particular environment, is not 
sufficient to induce disease. These data may relate to the results documented in this 
thesis stating that an apparent total cellular reduction in NCSTN or PEN-2 expression 
was not sufficient to affect corresponding protein expression or enzyme function at the 
level of the cell membrane. One might therefore hypothesise that other exogenous or 
endogenous factors are required to induce disease. The full penetrance observed in all 
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globally reported kindreds implies that any such triggering factors are likely to be 
universal to everyone (eg. hormonal influences, apocrine secretions) rather than specific 
to individuals (eg. smoking). This is perhaps consistent with some of the mutation-
positive patients described in this study being non-smokers of normal BMI, which is 
unusual in the context of HS. Accounting for the anatomical sites of HS these triggering 
factors may include heat, sweat, friction, apocrine gland or eccrine gland secretions and 
the local microbiome for example. Assuming that an alteration in enzyme function 
underlies disease development then one might imagine that one or a combination of 
these factors is sufficient to alter complex formation, maturation, turnover and 
ultimately function beyond a critical threshold required for normal follicular function. 
This would potentially explain why the entire skin surface is not affected in these 
individuals. It is noteworthy that pH, temperature and salinity have all been 
demonstrated to confer a significant impact on gamma-secretase enzyme function in 
vitro
266
. The flexural areas associated with HS are sites of skin occlusion (previously 
shown to significantly increase pH), sweat (potentially tying in the effect of salinity on 
enzyme function) and warmth
122
. It would therefore seem highly pertinent to investigate 
for any differential effects of temperature, pH and salinity on enzyme function in mutant 
versus wild type cells.  
It may also be interesting to explore the extent and distribution of follicular occlusion in 
patients harbouring mutations. One might hypothesise that there is generalised follicular 
occlusion which only generates an inflammatory response in the presence of one or 
more of the factors mentioned above (eg. a specific microbiome in flexural areas). A 
further hypothesis worthy of exploration is that gamma-secretase complex composition 
may play a role in the unusual disease distribution. As discussed in the introduction, 
there are at least 6 different possible complexes and their differential location and 
distribution within the skin is as yet unknown. As the molecular mechanisms driving 
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disease development emerge in these cases it will be important to consider how gamma-
secretase mutations and any potential subsequent alteration in gamma-secretase 
complex function relate to the immunological and inflammatory responses described in 
HS. Methods to explore this may include studying the effects of gamma-secretase 
mutations, or at least knockdown of the relevant constituents, on cytokine expression 
and dendritic cell differentiation, migration and function (given the emerging role of the 
hair follicle in facilitating the migration of Langerhan cell precursors in to the 
epidermis, discussed in section 1.2.1).  
This recent genetic breakthrough and the contributory data presented as part of this 
thesis clearly generate many new and interesting hypotheses worthy of further 
investigation. Future studies need to harness these findings and make them 
translationally relevant by identifying new therapeutic targets. It should be born in mind 
when interpreting future functional studies that numerous therapies have already been 
developed to target the gamma-secretase/ Notch signalling axis including gamma-
secretase inhibitors and modifiers.  
8.3.2 The translational relevance of the above functional studies is partially 
dependent upon the prevalence of gamma-secretase gene mutations in the 
general disease population  
The relevance and impact of the above proposed studies depends somewhat on the 
proportion of total HS cases that are in any way related to the gamma-secretase 
components. Data generated as part of this thesis implies that gamma-secretase gene 
mutations are only present in a minority of HS cases, including cases from kindreds 
exhibiting autosomal dominant inheritance suggestive of single gene inheritance. That 
does not exclude the involvement of gamma-secretase, or at least gamma-secretase 
related pathways, in the remaining cases however. Some individuals may harbour as yet 
unidentified variation in the gamma-secretase genes or mutations in other genes that are 
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associated with the complex or encode proteins involved in up or down-stream 
signalling pathways. Two broad mechanisms by which this could be addressed would 
be to 1/ identify further disease causing genes and further clarify the genetic architecture 
of the condition, 2/ perform functional assays to assess downstream products produced 
as a consequence of gamma-secretase related pathways, as briefly mentioned above. 
Not only would such work provide a perspective on the relevance of ongoing 
translational work related to the gamma-secretase gene mutations but it could identify 
the specific molecular pathway or pathways through which the gamma-secretase 
mutations result in HS (potentially the Notch signalling pathway, as discussed above). 
Further genetic studies may alternatively reveal genes that are functionally independent 
of gamma-secretase. The first of those methods (attempting to identify new disease 
genes) was employed as part of this thesis. Next generation sequencing identified a 
number of candidate genes worthy of further exploration (described in Chapter 6). 
These results and the experimental methods that could be employed to further 
interrogate this genetically heterogeneous condition are discussed in Section 8.4.  
8.3.3 Functional characterisation of the gamma-secretase gene mutations 
identified in HS may provide a novel insight into general gamma-secretase 
enzyme complex function   
As well as providing a basis upon which to further our understanding of HS disease 
pathogenesis, the gamma-secretase mutations identified in HS now represent a novel 
model through which to gain a better understanding of general gamma-secretase 
function. This knowledge could be of significant relevance in far wider reaches of 
medicine, including Alzheimer’s disease. Deciphering the subtle mechanistic 
differences associated with HS and FAD mutations may provide a unique insight in to 
gamma-secretase complex formation, maturation, function and the mechanisms 
involved in processing substrates such as Notch and APP. Furthermore, affected regions 
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of skin are easily accessible in comparison with brain tissue in the context of FAD. A 
better understanding of complex biology is of broad physiological relevance. In the skin 
alone it may provide insight into basic hair follicle biology and the pathophysiology of 
related cutaneous conditions such as acne conglobate, acne vulgaris, dissecting cellulitis 
and pilonidal abscesses. 
8.3.4 Further investigations are required to determine if there is any association 
between HS and FAD 
As previously discussed, there is no clear association between the gamma-secretase 
gene mutations identified in HS and the development of FAD. That does not however 
exclude a functional relationship between the two conditions. If the mutations identified 
in HS are found to impair enzymatic endopeptidase activity or indeed alter 
carboxpeptidase activity such that the Aβ42:Aβ40 ratio is decreased then it could be 
hypothesised that they may in fact confer a protective affect against developing 
Alzheimers disease. Prospective clinical studies to address such a hypothesis would 
require very large numbers of patients. A pilot neuro-imaging study however, in which 
elderly mutation-positive individuals from affected HS kindreds and age matched 
healthy volunteers could be scanned for cranial amyloid deposition, would be one way 
to gather some preliminary data.  
8.3.5 Refinement of the gamma-secretase related clinical phenotype 
The phenotypic observations documented in Chapter 7 are based on a small cohort of 
individuals. The phenotypic characteristics need to be verified and statistically 
differentiated from the remaining HS population by studying a much larger group of 
patients. We have now recruited over 300 individuals with HS for ongoing genetic 
analysis and are collecting detailed phenotypic information on all patients attending our 
tertiary referral clinic. This should provide a firm basis from which to perform such 
work as well as facilitating ongoing phenotypic dissection of the remaining HS cohort. 
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As mentioned in chapter 7, it is notable that multiple individuals reported to harbour 
gamma-secretase mutations have developed SCC in regions affected by HS
128; 134
. SCC 
is comparatively rare in the general disease population
25
, although it should be noted 
that few HS patients have been retrospectively analysed and reported in the detail that 
these mutation-positive individuals have over the last three years. In vivo data implying 
that heterozygous NCSTN knockout in mouse skin can induce the development of 
SCC
291
 would however potentially support a hypothesis that individuals harbouring 
gamma-secretase gene mutations are more prone to developing SCC in regions affected 
by HS than mutation-negative affected individuals. A prospective analysis of a large 
number of closely matched mutation-postive patients, mutation-negative patients and 
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8.4 Ongoing genetic investigation of HS  
8.4.1 Further genetic heterogeneity in HS 
As discussed in Chapters 3 and 5, only a small proportion of HS patients appear to 
harbour mutations in the gamma-secretase genes. There are a number of potential 
explanations for these results. It may be that mutation-negative individuals harbour non-
coding variants (for example in promoter, enhancer or silencer regions), undetected 
coding variants or undetected CNV affecting the gamma-secretase genes. This would 
seem unlikely to explain over 93% of disease cases however. An alternative explanation 
is that there is further genetic heterogeneity underlying HS. This hypothesis is supported 
by co-segregation data in two of the largest mutation-negative kindreds being 
inconsistent with involvement of NCSTN, PSENEN or PSEN1 and also by the 
observation that there appear to be subtle phenotypic differences in the gamma-
secretase mutation-positive cohort. Consequently, mutation-negative families and 
meticulously phenotyped clinical subgroups were studied using a combination of 
traditional and next generation gene mapping techniques with the aim of identifying 
further disease causing mutations and genes (Chapter 6).  
8.4.2 A combination of traditional and next generation methods of genetic 
interrogation identified further potential candidate genes in HS and 
excluded genetic homogeneity outside of the gamma-secretase genes  
This study exemplified the quantity of data generated by exome sequencing and the 
challenges faced in analysing such data. Genetic interrogation of the two larger 
pedigrees highlighted a handful of potentially causative variants, which are a focus of 
ongoing study. The employed filtering strategies were unable to filter variants down to 
such small numbers in the remaining pedigrees and the phenotypically defined groups 
of unrelated individuals, emphasising the bioinformic challenges faced in analysing a 
genetically heterogeneous condition such as HS. It was noteworthy that there was no 
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single gene in which variation was shared between all familial cases, excluding genetic 
homogeneity outside of the gamma-secretase genes. 
8.4.3 The future of genetic studies in HS   
Given the likelihood of further genetic heterogeneity in HS, genetic studies remain an 
important method by which to investigate disease pathogenesis. The genetic basis of a 
minority of cases is now known, yet the genetic architecture of the remaining HS 
population is undetermined. Up to 42% of HS cases report a family history of the 
condition but the influence of genetic susceptibility in the remaining cohort is unclear. 
The validity of clinically determined measures of heritability in HS, such as people 
reporting a family history of the condition, should be interpreted with caution. Factors 
such as under-reporting within families (potentially as a consequence of embarrassment 
or lack of family communication) and variability in disease inheritance or penetrance 
are potential confounders. From the data presented in Chapter 5 it may therefore be 
more appropriate to conclude that at least 42% of HS cases are familial. The proportion 
of HS cases that follow single gene mendelian inheritance, more complex polygenic 
inheritance and no genetic predisposition remains to be elicited. 
The ever increasing armoury of genetic methodologies and bioinformatic approaches to 
data analysis will help to identify new disease genes in HS and facilitate a better 
understanding of the genetic architecture of the condition. Efforts to analyse the 
valuable exome sequencing data generated as part of this research are ongoing, 
comprising a more statistical (gene-centric case-control analysis) and network/ pathway 
(using protein-protein interaction software) based approach (discussed in Chapter 6).  
The knowledge that gamma-secretase mutations are involved in HS highlights a range 
of functionally related candidate genes to look out for in all ongoing analyses. That does 
of course assume that any further disease-causing genes encode proteins that are in 
some way related to that enzyme complex. Proteins integral to gamma-secretase 
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structure, assembly and activity are discussed in the introduction along with all 
currently known interactors and substrates. Genes encoding proteins integral to the 
complex such as APH1A, APH1B and PSEN2 are clear candidates, however no 
mutations have been identified in those genes to date. This is partly consistent with 
functional work in mice demonstrating that PSEN2 deficiency does not alter the ability 
of the gamma-secretase complex to cleave Notch and APP (in contrast to PSEN1 
deficiency)
312
 and PSEN2 and APH1B knockout mice have a normal phenotype but for 
the development of lung haemorrhages and fibrosis with age in PSEN2 knockouts
160; 212
. 
APH1A appears more important given that APH1A knockout is lethal
213
 and that recent 
functional work has demonstrated that PSEN1, PEN-2 and APH-1A are vital for normal 
enzyme function
273
. APH1A would therefore seem the most likely of these genes to be 
involved in HS. Further genes to consider would be those involved in the Notch 
signalling pathway. Proteins involved in the core Notch signalling cascade are 
documented in the introduction. Protein interaction analyses mentioned above and in 
Chapter 6 provide a key mechanism by which exome data can be assessed in relation to 
genes within known candidate pathways such as the gamma-secretase/ Notch signalling 
axis.  
Despite implementing comprehensive analysis algorithms and devising new data 
analysis strategies (statistical and protein/ pathway analyses) the degree of locus 
heterogeneity apparent in HS poses a significant challenge when attempting to identify 
new disease genes. A more familial approach, restricting the amount of genetic 
heterogeneity in any given sample, probably represents the most efficient method by 
which to identify new disease genes. A multidisciplinary approach to refining the 
phenotypic classification in HS would aid that process by facilitating the study and joint 
analysis of multiple but phenotypically similar pedigrees. This would also be integral to 
efficiently analysing any large unrelated patient cohorts. Clinical observations, 
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statistical group analyses, histo-pathological discriminators or immunological signatures 
have the potential to contribute towards defining these particular phenotypic sub-
groups. As described in Chapter 7, a recent clinical study proposed a preliminary 
phenotypic classification in HS, dividing the disease in to three phenotypic groups. The 
gamma-secretase mutation-associated phenotype described here appeared to fall within 
the ”follicular” group but indicated that there are likely to be further sub-phenotypes 
within that “follicular” cohort. Given the higher proportion of familial cases reported in 
that group, prioritising genetic investigation of the gamma-secretase mutation negative 
individuals harbouring the “follicular” phenotype may prove worthwhile.  Upon 
deciding which phenotypic groups should be studied, patients could be further filtered 
based on factors implicating a firm genetic basis to their disease. These may comprise a 
clear autosomal dominant family history, early age of onset, non-smokers and 
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8.5 Concluding remarks 
This thesis supports the involvement of gamma-secretase gene mutations in familial HS 
and verifies that some familial cases of HS are single gene disorders demonstrating 
autosomal dominant Mendelian inheritance. It has demonstrated that haploinsufficiency 
is at least one pathogenic mechanism by which these mutations are likely to result in 
disease. The involvement of genes encoding three of the four gamma-secretase 
components implicates complex function in disease pathogenesis yet these studies 
revealed no significant alteration in gamma-secretase complex maturity or activity at the 
level of the cell membrane in mutation-positive individuals. The cohort of individuals 
with gamma-secretase mutations is the first genetically and increasingly phenotypically 
defined subgroup of HS but only appears to represent a minority of overall HS cases. 
There would appear to be significant further genetic heterogeneity underlying the 
condition and investigations are ongoing to identify more disease-causing genes. The 
nature of any such genes may highlight the up or downstream pathways through which 
the gamma-secretase complex is involved in HS, or may highlight entirely novel and 
independent molecular pathways. Whilst continuing phenotypic dissection of this 
clinically heterogenous condition will potentially aid such studies it may be that subtly 
different clinical phenotypes will only be characterised as our genetic knowledge 
evolves. The data presented in this thesis provides a firm basis for ongoing functional 
investigation and highlights the gamma-secretase complex and potentially the gamma-
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Appendix 1 – All known gamma-secretase substrates 
 
All reported gamma-secretase substrates 
 
Substrate Function 
Alcadeins Cadherin-related membrane protein 
APLP1-2 Synaptogenesis/ neurite outgrowth 
ApoER2 Signalling receptor 
APP Unknown role, Alzheimers disease 
Bri2 Unknown role 
CD43 Cell adhesion 
CD44 Cell adhesion 
CSF-1 Protein-tyrosine kinase 
CXCL16, CX3CL1 Chemokine ligands 
DCC Netrin-1 receptor 
Delta Notch receptor ligand 
DNER Notch receptor ligand 
DSG2 Desmosomes 
Dystroglycan Dystrophin-glycoprotein complex 
E-Cadherin Cell adhesion 
EphB2 Receptor tyrosine kinase 
Ephrin-B1 Eph receptor ligand 
Ephrin-B2 Receptor tyrosine kinase 
Erb4 Receptor tyrosine kinase 
Gamma-protocadherins Cell adhesion 
GHR Growth hormone receptor 
GluR subunit 3 Glutamate receptor 
HLA-A2 MHC Class I protein 
IFNaR2 IFN-α receptor 
Insulin receptor Receptor tyrosine kinase 
IGFI-R Receptor tyrosine kinase 
Ire1α/ Ire1β ER TM protein 
IL-1R II Cytokine receptor 
IL-1R I Cytokine receptor 
Jagged Notch receptor ligand 
LAR Receptor tyrosine phosphatise 
LDLR Lipoprotein receptor 
LRP Signalling receptor 
Megalin Signalling receptor 
N-Cadherin Cell adhesion 
NCAM-L1 Cell adhesion 
Nectin-1α Adherens junction protein 
Notch 1-4 Signalling receptor 
NPR-C Natriuretic peptide receptor 
NRADD Death-receptor-like protein 
NRG-1 Growth factor 
P75 Neurotrophin receptor 
PLXDC2 Nervous system protein 
Polyductin Cell receptor 
RPTP Cell adhesion receptor 
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SorLA Sorting receptor 
SorCS1-3 Sorting receptor 
Sortilin Sorting receptor 
Syndecan1-3 Heparan sulphate proteoglycan co-receptor 
Tie1 Receptor tyrosine kinase 
Tyrosinase/ tyrosinase related proteins 1-2 Pigment synthesis 
VGSC β1-4 subunits Sodium channel 
Vasorin TGF-β inhibitor 
VE-Cadherin Cell adhesion 
VLDL receptor Signalling receptor 
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1. BACKGROUND AND RATIONALE 
 
Hidradenitis suppurativa (HS), otherwise known as acne inversa, is a common cause of 
chronic inflammatory skin disease with a prevalence as high as 1 per 100 in European 
populations. It is characterised by painful cutaneous nodules, cysts and abscesses in 
flexural sites resulting in sinus formation, fibrosis, and scarring with the potential for 
malignant transformation (squamous cell carcinoma) [1]. It commonly results in 
significant physical, psychological and social morbidity. 
 
The pathogenesis of this disease is poorly understood, such that studies to date have 
been unable to distinguish whether HS represents a primary disorder of the hair follicle, 
the apocrine gland or an intrinsic defect of the host response. The efficacy of anti-
tumour necrosis factor- therapy indicates that the condition is maintained by an 
intense inflammatory response [2]. Importantly, environmental factors including obesity 
and in particular smoking have been strongly implicated in disease development (up to 
90% of sufferers smoke [3]). 
 
There is substantial evidence for an inherited component in the aetiology of HS. 
Fitzsimmons et al [4] demonstrated that 34% of first degree relatives of probands were 
affected and reassessment of the same families 15 years later supported an autosomal 
dominant inheritance pattern. Until recently, three putative genetic loci had been 
proposed including a very large (80cM) region at chromosome 1p21.1-1q25.3 [5], a 
0.53cM region at chromosome 6q25 and a 16.8cM region spanning the centromere of 
chromosome 19 (McLean, unpublished data), but no causative genes had been 
identified. Mutations have recently been reported in the gamma-secretase genes 
(PSENEN, PSEN1 and NCSTN) [5], which we have replicated and reported in two of 
seven families that we had recruited with Hidradenitis Suppurativa [6]. How mutations 
in those genes result in disease are unclear however it has been proposed that it 
maybe via the gamma-secretase-NOTCH signaling pathway [5]. It is interesting to note 
that of the seven families that we had recruited with hidradenitis suppurativa, only two 
had mutations in these genes, indicating likely genetic heterogeneity [6]. The relevance 
of mutations in the gamma-secretase genes in sporadic cases of hidradenitis 
suppurativa is as yet unknown. 
 
In our own tertiary referral clinic at St John’s Institute of Dermatology, London, we have 
observed that up to 40% of patients with HS describe a family history of the condition, 
whereas 60% appear to be sporadic cases. Via the recruitment of familial and sporadic 
cases of HS we intend to identify the other genes underlying this condition and 
determine the relevance of all known mutations in sporadic cases. We intend to use 
Sangar sequencing, genome-wide linkage analysis, exome sequencing and bio-
informatics to identify new disease genes. The second aim of our study is to initiate 
functional studies in order to understand how mutations in the gamma-secretase 
genes, and any further genes identified, result in the HS phenotype. This work will 
require tissue from affected individuals, such as hair plucks and skin, in order to set up 
cell cultures to perform in-vitro cell work.. 
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2. STUDY OBJECTIVES, DESIGN AND STATISTICS: 
 




1. To identify the genes underlying HS 
2. To determine the relevance of those genes in sporadic cases 
3. To understand how mutations in those genes result in the disease phenotype. 
 
 
2.2 Study Design: 
  
There are five main components of the study design:  
1. Clinical questioning and examination to identify patients with HS (familial and 
sporadic cases) and collection of a blood or saliva sample for DNA extraction. 
2. Clinical questioning +/-  examination of relatives of patients with HS (only those with 
a family history) and collection of a blood or saliva sample for DNA extraction. 
3. Genetic analysis of extracted DNA to identify candidate genes within families and to 
determine the relevance of those genes in sporadic cases. 
4. In those patients in which mutations are identified, hair plucks and/or skin biopsies 
(or tissue from planned surgical interventions) will be performed to gain tissue for 
functional analysis. 
5. Healthy volunteers will be recruited to provide blood, hair plucks and skin to act as 
normal controls. 
2.3 Study Duration: 
 
Data and sample collection will take place over a maximum period of 5 years. 
 
2.4 Study Flowchart: 
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2.5 Study Statistics: 
 
 
2.5.1 Sample size 
 
A maximum of 50 families, 300 sporadic cases and 10 healthy control subjects will be 
recruited. These figures are based on the estimated number of recruitable patients 
seen in the primary centre (Guy’s and St Thomas’ Hospitals) in a 3 year period and on 
pilot data generated from sequencing the first 24 sporadic cases for mutations in the 
gamma-secretase genes. This sequencing revealed that 3 of 24 (12.5%) sporadic 
cases had mutations in the gamma-secretase genes (NCSTN, PSEN1 and PSENEN). 
Patient presents with hidradenitis suppurativa and 
following written informed consent agrees to give a 
blood or saliva sample record: 
 Patient demographic details 
 
 History of HS 
 
 Clinical and family history 
 
 Details of affected family members 
 
 Details of patient records enabling return 
to source records for further phenotypic 
data should it be required 
   Conduct 10mins. Telephone 
interview to confirm clinical 
diagnosis 
 
   Post saliva collection pack for 
DNA collection  
 Confirm clinical diagnosis 
of HS 
 
 Obtain blood or saliva 
sample  
If family history, contact affected family member 
Is family member able to attend clinic? 
YES NO 
   If mutation identified, 
contact patient. Is 





 Following written 
informed consent hair 
plucks and/or skin biopsy 
taken (or if surgical 
intervention planned, 
excised tissue may be 
used) 
 
 Obtain further blood or 
saliva sample if 
necessary 
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The involvement of 300 sporadic cases will enable us to achieve a more accurate 
estimation of population frequency and would provide us with an estimated 37 patients 
with mutations for functional analysis. By recruiting 50 families we will have enough 
large pedigrees to successfully perform genome-wide linkage analysis and perform 
exome sequencing. Statistical analysis of genetic data will be performed using non-
parametric or parametric statistical methods as appropriate in the Department of 
Genetics and Molecular Medicine, King’s College London.  
 
 
3. SELECTION AND WITHDRAWAL OF SUBJECTS: 
 
Target population:  
 
Our target population will consist of patients attending our tertiary centre Hidradenitis 
Suppurativa clinic at St. John’s Institute of Dermatology, Guy’s and St. Thomas’ 




1. Patient given written informed consent. 
2. Patient 16 years or older 
3. Patient with an established diagnosis of hidradenitis suppurativa (based on typical       
history and clinical examination) 
 
 Exclusion criteria 
 
1. Patients who are unable to give written informed consent. 
2. Patients aged under 16 years  
3. Patients who have received a blood transfusion in the last 4 weeks 
4. Patients in whom a diagnosis of hidradenitis suppurativa is not established. 
 
 
Withdrawal of Subjects  
 
Patients can withdraw from the study at any time. This will not affect his/her current or 
future treatment. The principal investigator/co-investigators can decide to withdraw a 
patient from the study at any time if they feel their participation is inappropriate. 
 
4. INVESTIGATIONAL PLAN 
 
4.1  Clinical Studies:  
 
There are four main components of the study design:  
1. Clinical questioning and examination to identify patients with HS (familial and 
sporadic cases) and collection of a blood or saliva sample for DNA extraction. 
2. Clinical questioning +/-  examination of relatives of patients with HS (only those with 
a family history) and collection of a blood or saliva sample for DNA extraction. 
3. Genetic analysis of extracted DNA to identify candidate genes within families and to 
determine the relevance of those genes in sporadic cases. 
4. In those patients in which mutations are identified, hair plucks and/or skin biopsies 
will be performed to gain tissue for functional analysis. Alternatively, if a surgical 
procedure is planned, excised tissue may be used. 
5. Healthy controls will be recruited so as to supply genetic material and tissue to act 
as a normal control. 
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1. Patients.  
 
i. Patients attending dermatology clinic (referred by their GP, other dermatologists or 
hospital practitioners) for clinical assessment and treatment of their disease will be 
invited to participate in the study. Patients who agree to participate in the study will 
undertake detailed clinical genetic questioning as described below: 
 







Smoking status (current, past and pack-year history) 
Ethnicity 
History of 5 or more boils in flexural sites 
Sites affected with HS 
Age when first affected 
Relation of symptoms to menstrual cycle 
Past medical history 
Family history (+ draw pedigree if relevant) 
 
These include questions to establish affected and unaffected members of their family. 
A family tree will be constructed, focussing on relatives with HS. Patients will also be 
asked to complete a Dermatology Life Quality Index score. 
 
ii. Patients will be asked to provide a small sample of blood (17ml EDTA vacutainer) . 
This will be performed by a trained phlebotomist, a dermatologist or a dermatology 
nurse (who has been trained in phlebotomy during the course of their career). Patients 
who are needle phobic or unable to give blood will be asked to provide a 2ml sample of 
saliva using collection pots. Blood and saliva samples will be taken as described in 
Appendix 1. 
 
iii. Blood and/ or saliva will be transported to St John's Institute of Dermatology (King's 
College London), Guys Hospital, London by courier or by post where it will be stored in 
the laboratory of the division of genetics and molecular medicine (storage of biological 
material will be in accordance with section 4.3; inter-site transport of samples will be in 
accordance with Appendix 1). 
 
iv. Genetic studies on blood and or saliva samples will be carried out at St John's 
Institute of Dermatology (King's College), Guys Hospital, London.  
 
v. Patients with affected family members will be asked to deliver study invitations and 
patient information leaflets to unaffected and affected family members or to provide 
contact details for family members. 
 
 
2. Family members 
 
i. Affected and unaffected family members will be invited to attend the department of 
dermatology for a short clinical interview to establish patient demographics and medical 
history (questions as above).  
 
ii. Family members will be invited to have a brief clinical examination of the skin to 
confirm if they have a diagnosis of HS or a related disease.  
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iii. Family members who are unwilling/ unable to attend the department of dermatology 
will be invited to participate in a 10 minute telephone interview about skin symptoms to 
try and accurately establish if they are suffering with HS or related diseases. 
 
iv.a. Family members able to attend the department will be asked to provide a small 
sample of blood (17ml EDTA vacutainer). This will be performed by a trained 
phlebotomist, a dermatologist or a dermatology nurse (who has been trained in 
phlebotomy during the course of their career). 
 
iv.b.Family members unable to attend the department or those who are unable to 
donate blood (e.g. needle phobia) will be asked to donate a sample of saliva.  
 
v. Blood or saliva will be transported to St John's Institute of Dermatology (King's 
College), Guys Hospital, London by courier or post where it will be stored in the 
laboratory of the Division of Genetics and Molecular Medicine. 
 
vi. Blood or saliva will be stored at St John's Institute of Dermatology (King's College 
London), Guys Hospital, London, in the laboratory of the division of genetics and 
molecular medicine. 
 
vii. Genetic studies on DNA extracted from the blood or saliva sample will be carried 
out at St John's Institute of Dermatology (King's College), Guys Hospital, London. 
 
The inconvenience of hospital attendance for family members and minimal risk and 
discomfort of having a blood test and/ or providing a sample of saliva for patients and 
their families will be outweighed by the anticipated benefit for the community of HS 
patients. Although the research will not directly benefit participants during the course of 
the study, it may lead to the development of novel therapies in the future. The results of 
the research will be presented to peers at scientific meetings and in peer−reviewed 
journals 
 
3. Affected individuals in whom mutations are identified. 
 
 i. Affected individuals in whom mutations are identified will be asked to re-attend the 
department for 6 hair plucks and/ or a skin biopsy. Alternatively, if surgical intervention 
is planned as a treatment for their disease then excised tissue may be used. 
 
ii. 6 hairs will be plucked from the scalp as described in appendix 2. Two 6mm skin 
biopsies will be obtained from a lesional site and a non-lesional site in affected 
individuals. The skin biopsies will be performed using standard NHS protocols for 
biopsy sampling. 
 
iii. Hair plucks and skin biopsies will be stored in accordance with section 4.3  
 
4. Healthy control subjects 
 
 i. Healthy volunteers will be asked to attend the department and undertake questioning 





Any history of hidradenitis suppurativa 
Any history of related conditions such as acne, pilonidal abscesses, dissecting cellulitis 
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ii. If they report no history of those conditions they will be asked to provide a small 
blood sample (17ml, as detailed for patients above), 6 hairs will be plucked from the 
scalp as described in appendix 2 and two 6mm skin biopsies will be obtained from a 
flexural site (eg. Axilla) and a non-flexural site (eg. Back), performed using standard 
NHS protocols for biopsy sampling. 
 
iii. Hair plucks and skin biopsies will be stored in accordance with section 4.3  
 
4.2 Sample DNA - Insufficient DNA concentration 
 
In the event of there being too low a concentration of DNA in the sample the patient 
would be contacted by letter and asked to provide a further sample in the form of saliva 
(if the patient is not returning for a Dermatology clinic appointment in the near future 
(within 4 weeks)). The patient would initially be contacted by letter and asked to 
complete and return a reply slip.  If the patient agrees they will be sent a saliva 
collection kit, asked to donate a sample and told to return it to the Skin Therapy 
Research Unit for further analysis. 
 
4.3 Laboratory studies: 
 
DNA from affected and unaffected family members will be extracted from blood 
samples using standard methodologies. In participants unable to provide blood, DNA 
will be extracted from saliva samples.  
 
Affected individuals will be screened for mutations in the gamma-secretase genes via 
standard Sangar sequencing methods. As well as determining which familial forms of 
the disease are due to mutations in these genes, this work will help to determine the 
genetic epidemiology of the disease by identifying how many sporadic cases are due to 
mutations in these genes.  
 
The next part of the project will explore the hypothesis that there are more, as yet 
unidentified, genes of large effect size underlying familial forms of HS. This genetic 
heterogeneity is supported by our recent work demonstrating that only 2 of 7 pedigrees 
with HS had mutations in the gamma-secretase genes. We propose to use genome-
wide linkage analysis in large families with no mutations in the gamma-secretase to 
identify further candidate genes underlying HS. Genetic loci giving strong statistical 
support for linked genes will then be submitted to positional cloning and candidate 
genes will be sequenced. One or more affected individuals from some of these, and 
smaller, families may be exome sequenced [7] (a technique that scans the whole 
exome of patients, capable of identifying novel mutations). By combining the results of 
these investigations along with bioinformatic analysis we aim to identify further genes 
underlying this debilitating condition. Validity of positive findings will be sought in further 
families and sporadic cases and also in patients with severe acne vulgaris. The latter 
are being collected on a large scale at St John’s Institute of Dermatology (>2000 
patients).  
 
The final component of the project will explore the hypothesis that the pathogenic 
mechanisms of HS can be elucidated through the exploration of the biological role of 
the causative gene and its protein product. This work will involve the use of tissue 
harvested via skin biopsies and/ or hair plucks [8]. Experimentally, we will establish 
whether the restriction of the clinical phenotype to flexural sites is a consequence of a 
tissue specific expression pattern by generating gene and protein expression profiles 
across a range of tissues. These experiments will be extended with in situ hybridisation 
and immunohistological investigation to ascertain the cellular expression patterns in the 
hair follicle and the apocrine sweat glands. We will also undertake a series of 
experiments to delineate the cellular role of the protein product. We aim to define 
cellular phenotypes associated with over expression and gene silencing of the HS 
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gene. We will undertake these studies through the generation of gene expression and 
siRNA constructs and transfection into primary keratinocytes and HACAT cell lines. We 
will also explore the hypothesis that the mutation(s) identified disrupt the cellular 
phenotype associated with over expression by undertaking site-directed mutagenesis 
to incorporate the mutation into the expression construct. Model based systems are 
essential tools for establishing the biological mechanisms of a genetic disease. We aim 
to initiate the generation of a cellular model of HS through induced pluripotent stem cell 
techniques. 
 
The potential benefits of this research are enormous with the possibility of diagnostic, 
prognostic and therapeutic advance led by the identification of underlying genes and a 
better understanding of their function.  
 
Storage of Biological Specimens 
 
Blood, saliva, skin and hair plucks will be stored in a secure facility at St John’s Institute 
of Dermatology, Division of Genetics and Molecular Medicine, King’s College London, 
9th Floor, Guy’s Tower, Guy’s Hospital, London, SE1 9RT.  
 
Whole blood for DNA will be stored at -20C until extraction. Saliva will be stored at 
ambient temperature until DNA extraction.  Skin samples and hair plucks will be 
processed shortly after harvesting. 
 
 
5. IMPLICATION OF RESULTS: 
 
Isolation of candidate genes for HS and a better understanding of their function will 
contribute towards an improved understanding of the pathogenesis and molecular 





Procedures for recording and Adverse Events 
 
Although the occurrence of an adverse event is unlikely, the Principal Investigator is 
ultimately responsible for any adverse events that occur. Co-investigators, 
dermatologists and dermatology nurses will be available to assess and appropriately 




7. PARTICIPANT RE-IMBURSEMENT 
 
Volunteers will be re-imbursed £150 to cover the inconvenience and the time they 
spend participating in the study.  This is in respect of patient time and inconvenience 
regarding donation of blood samples, hair plucks, two skin biopsies and return to clinic 
for biopsy stitch removal 10 days later.  Their initial visit will last approx 60 minutes and 
the follow-up appointment will last 10 minutes. 
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8. ADMINISTRATIVE ASPECTS 
 
8.1 Good Clinical practice 
 
The planning, conduct and reporting of this study will be in the spirit of the International 
conference on Harmonisation in Good Clinical Practice (ICH-GCP) 1996. 
 
8.2 Declaration of Helsinki and Ethical Review 
 
The study will be performed in accordance with the principles stated in the Declaration 
of Helsinki, 2008. 
 
Any protocol amendments will be submitted to the London Stanmore REC for approval 
(Research Ethics Committee Office, level 7, maternity block, Northwick Park Hospital, 
Watford Road, Harrow, HA1 3UJ).These will comply with ICH-GCP guidelines over the 
reporting of adverse events (AE’s), serious adverse events (SAE’s) & suspected, 
unexpected serious adverse reactions (SUSAR’s) as well as providing the REC with 
progress reports, and a copy of the Final Study Report 
 
8.3 Subject information and consent 
 
The investigator will ensure that the subject is given full and adequate verbal and 
written information about the nature, purpose, possible risk and benefit of the study. 
Dubjects must also be notified that they are free to discontinue their participation in the 
study at any time. The subject will be given appropriate time to consider their 
participation in the study and have the opportunity to ask questions. Patient and family 
informations leaflets are attached. The informed consent forms are also 
attachedWritten informed consent will be obtained from all subjects before enrolment 
into the study. The subject    
 
8.4 Subject protection 
 
Subjects will be assigned an anonymised study number to ensure subject 
confidentiality throughout the duration of the study. Only the subject number will be 
referenced in data summaries and study publications and presentations. The principal 
investigators will be responsible for keeping a Subject Identification Log of all subjects 
enrolled into the study and their corresponding study number. This information will be 
kept on a secure NHS server in a password protected file and will only be available to 
study personnel. 
  
8.5 Direct access to source data and documents 
 
Key investigators of the project will be the only personnel with access to patient and 
study data and all data will be stored in accordance with the Data Protection Act, 1998.  
The chief investigator (Professor J Barker) will have overall control of and act as the 
custodian for all data for the full duration of time. 
 
8.6 Peer review 
 
The study plan has been reviewed externally and approved to ensure the study is   
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9. OTHER STUDY ISSUES 
 
9.1 Study timetable 
 
Estimated start date: August 2011 
Estimated end date:  August 2016 
 
9.2 Changes to the present protocol 
 
The study must be conducted as defined by the present protocol. All changes must be 
documented by signed protocol amendments or a revised protocol, which will be 
submitted to the appropriate REC for approval. The investigator is responsible for 
notifying and obtaining approval from the Ethics Committee and the Regulatroy 
Authorities for any changes to the protocol before implementation. National     
requirements will be followed. 
 
9.3 Retention of study records 
 
Copies of protocols, results, correspondence, informed consents and other documents 
relevant to the study will be kept on file by the Principal Investigator and retained for at 




The results of the study will be reported and disseminated in peer reviewed scientific 
journal and/ or conference presentations. 
 
9.5 Study termination 
 
The study may be terminated at any time for reasons of safety and tolerability as 
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Protocol Appendix 1 
 
 
Sample collection and transport: 
 
The patient can give either a saliva sample or a blood sample for collection of their 
DNA sample. Please note that a blood sample is preferable.  
 
Collection and transport of Saliva Samples: 
 
The saliva sample (2ml.) should be collected as per the manufacturer’s instructions 
which can be found in the packaging of the pot. The patient must not have had 
anything to eat or drink for 30mins prior to giving the sample.  
 
The pot must be labeled with the participant’s site-specific study number using a 
cryopen and placed in a clear plastic specimen bag.  A sample request form should 
accompany the saliva sample with details of the participant study number, date of birth, 
gender, ethnicity, date of sample collection, site name and name of dermatologist.  
 
Saliva samples are stable at room temperature for up to 12 months and as such 
samples may be posted in batches of 6-10.  Prior to postage please ensure the pot is 
sealed securely.  Place the pot, specimen bag and form inside a Freepost padded 
envelope and post to the Skin Therapy Research Unit* using normal post.   
 
Collection and transport of Blood Sample: 
 
Blood should be collected in accordance with site-specific local guidelines.  Where 
appropriate the patient should be given a completed sample request form and 
collection tubes and be seen by the phlebotomist or if not available then by the 
research study nurse if appropriately trained. 
 
Two pink 6ml. EDTA vaccutainer tubes should be used for blood collection.  Once 
collected blood tubes should be inverted 3x to ensure thorough mixing of blood and 
EDTA.  These should be labeled using a cryo-pen with the participants surname and 
the date of sample collection and placed in a clear plastic specimen bag with a sample 
request form as detailed above.  
 
Depending upon local site arrangements blood may be dispatched soon after collection 
or stored at -20C 
 
If facilities are available blood should be stored at either -20C or at -80C (depending 
upon equipment available to the Department) prior to collection by courier and 
transported on dry-ice to the Skin Therapy Research Unit.  Collections can be arranged 
once there are a sufficient number of blood tubes to optimize the collection process. If 
freezer storage space is not available blood tubes should be placed in a pre-paid Royal 
Mail blood transport box and posted to the Skin Therapy Research Unit* using normal 
post as soon as possible.  Blood samples may be retained for up to 3 days at 4C if 
available prior to postage if necessary to avoid posting on a Friday, or to maximize the 
number of tubes that are dispatched at any one time. 
 
*Please dispatch to the following address until further notice: 
 
Skin Therapy Research Unit 
St. John's Institute of Dermatology 
St.Thomas's Hospital 
Westminster Bridge Road 
London SE1 7RT 
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Protocol Appendix 2 
 
 
Protocol for the derivation of keratinocytes from plucked hair ● TIMING 2-3 weeks 
 
1| Prepare a non-coated 100-mm dish containing HBSS and Gentamycin 50g/ml  
 
2| Use tweezers to gently pull the hair out and place in HBSS medium. It is possible to 
use hair from any part of the body, although the occipital part of the head is particularly 
suitable and accessible, giving many hairs in anagen growth phase with a large amount 
of ORS cells on the hair shaft 
 
CRITICAL STEP Although a noninvasive procedure, the donor should agree and sign 
consent forms as with normal biopsies.  
 
CRITICAL STEP Hair should be in anagen growth phase with a clearly visible ORS (as 
shown below) and should be immediately transferred to some medium to avoid the 




3| While submerged in the medium, cut off the external part of the hair leaving the bulb 
and ORS (one may also remove the bulb of the hair). 
 
4| At this stage (according to the Belmonte lab), two optional procedures for growing 
keratinocytes from the plucked hair are described, direct outgrowth and enzymatic 
digestion.  
 
5| Coat the required number of 6-well plates with Matrigel by adding sufficient Matrigel 
to cover the plate and incubate overnight at 4 °C.  
 
6| Place the hair obtained from Step 2 in the coated culture plates. 
 
  
CRITICAL STEP During the first 24 h, it is absolute essential to ensure that the hair 
sticks to the culture dish and does not float.  
 
Important. In the Belmonte protocol they say to use MEF-coditioned hES media at this 
stage 
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7| Media change daily with MEF conditioned DMEM advanced (+10%serum, +bFGF, 
w/o antibiotics) and outgrowth is usually visible after 3-4 days.  
 
8| After around 7 days switch to Epilife based media (no adaptation necessary). The 
keratinocytes will then proliferate more rapidly and migrate.  
 
9| After a further 7 days in Epilife media they are then usually ready to passage. The 
cells are very strongly adherent at this stage, especially around the hair shaft.  It is 
therefore necessary to use 2.5% trypsin (rather than the usual 0.25%) to lift them off.  I 
would also recommend not having serum in the trypsin neutralising solution as I find 
even a brief exposure to serum results in differentiation once the keratinocytes are 
adapted to low calcium Epilife. 
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We would like to invite you to take part in our research study of the skin disease 
hidradenitis suppurativa. Please find enclosed a patient information leaflet detailing 













Dr Andrew Pink   Professor Jonathan Barker 
Dermatology Registrar  Professor of Dermatological Medicine 
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I am writing to you because your relative, ……………………………………… has a 
confirmed diagnosis of hidradenitis suppurativa and has attended the specialist 
Hidradenitis Suppurativa clinic at Guy’s Hospital, London.  He/She has given your 
name as a relative who may or may not be diagnosed with hidradenitis suppurativa and 
I am writing to ask if you would consider participating in a research study looking at the 
genetics of this condition.  I have included a patient information leaflet for your 
consideration. We are interested in all family members, including anyone with ‘normal’ 
skin. 
 
We are carrying out a research project at St.Thomas’ Hospital to look at the genes that 
may cause hidradentitis suppurativa and to identify a target for novel therapies in the 
future.  If at all possible we would like to see you in clinic to confirm if you have this 
diagnosis. This would be done by a trained dermatologist who would check your skin. 
We would then ask you if you would kindly donate a sample of blood or saliva. 
 
If you are unable to attend the clinic could we conduct a short interview over the 
telephone, which would not last longer than 10mins.  We can send you a saliva 
collection pack for a sample of your DNA so you would not have to attend for a blood 
sample. 
 
If you are interested in participating I would ask that you return the reply slip so we may 
contact you at a time that is convenient for you. 
 
You are under no obligation to take part in this study, and if you decline to take part, 
this will not affect any medical care you might be receiving at the moment or need in 
the future.  If you do not wish to take part I would ask you to return the reply slip ticking 
the box that you are not interested, that way you will not be approached further.  
 
Please see the attached supplementary information leaflet for some more information 
about this research. 
 
Best wishes and many thanks 
 
 




Dr Andrew Pink       Prof. Jonathan Barker 
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Patient name:  …………………………………… 
 
Date of birth:  …………………………………… 
 
I do not wish to take part in this research, please do not contact me further –  
 
I am interested in taking part in the study 
 
Please indicate if you are able to attend at clinic. 
 
Able/not able* to attend  -  *delete as applicable 
 
Please indicate a time that would be suitable to you for us to conduct a short 
telephone interview if you are un-able to attend at clinic. 
 
Date:    Time: 
 
Current Address:………………………………….. 
    …………………………………... 
    …………………………………... 
    …………………………………... 
    …………………………………... 
    …………………………………... 
 
Tel Number:     ………………………………….. 
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               Information Leaflet: Patient 
 
           Genetics Studies of Hidradenitis Suppurativa 
 
Our invitation 
You are being invited to take part in a research study. Before you decide it is 
important to understand why the research is being done and what it will involve. 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
Hidradenitis Suppurativa (HS) is a chronic skin disease in which patients suffer 
with recurrent abscesses and boils in the armpits and groin. As the disease 
progresses it has a disabling affect on patients lives, causing severe pain and 
scarring, interfering with day to day activities such as sitting, walking and arm 
movements. We know that a number of patients with HS have family members who 
also suffer with HS or related conditions (e.g. acne). In these patients the 
condition is likely to be inherited and caused by a single gene. Some genes for HS 
have now been identified, however there would appear to be more to find, and it is 
important to understand how changes in these genes result in HS.  
The purpose of this study is to try and identify further genes that cause HS in 
patients and their families and try to understand how changes in known and any 
newly identified genes result in the disease . We hope that this work will help us 
to understand the cause of HS and help scientists develop new treatments for HS 
and related conditions. 
 
Why have I been chosen? 
You have been diagnosed with HS.  Comparing genetic material from people who 
are affected with HS to unaffected individuals and the genetic material of their 
relatives (who may not necessarily be affected) may help researchers. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. You are 
still free to withdraw at any time and without explaining why. A decision to 
withdraw at any time or a decision not to take part, will not affect the standard 
of care you receive.  
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What do I have to do? 
In order to participate in the study we will ask you to sign a consent form.  You 
will be asked to attend the hospital for one appointment, which should take 
approximately 10 minutes.  You may wish to be seen now, if you have the time, or 
make an appointment for a later date.   
 
What will happen to me if I take part? 
On attending your appointment, a study doctor will discuss the purpose of the 
study and will go through the consent procedure with you. You will be able to ask 
any questions about your participation.  
 You will be asked to complete a short questionnaire about your family in 
particular details of any relatives you know who also suffer with HS or 
related skin conditions (e.g. acne). This should take approximately 10 
minutes.  
 
 You will then be asked to donate a blood sample or saliva sample for 
analysis of your genetic material (DNA).  A blood sample will involve taking 
a small amount of blood (approximately 17mls) from your arm. A saliva 
sample involves spitting 2.5mls (approximately 1 teaspoon) into a plastic pot.  
 
 If we do identify a possible causative gene in you then you may, at a later 
stage, be asked to attend one further appointment to obtain a hair sample 
(6 hairs only) and/ or a small skin biopsy. Alternatively, if at any stage you 
are scheduled to have surgical treatment we may be able to use some 
excised skin.   
 
What are the possible disadvantages of joining this study? 
There are no perceived risks of giving a sputum sample. Blood tests can sometimes 
be a little uncomfortable and can cause minor bruising or irritation at the site.  In 
rare cases there may be local infection. There are no perceived risks of giving hair 
plucks. Small skin biopsies may result in bleeding, a 4mm scar and there is a very 
small risk of infection. There are no other perceived risks. 
Our research team is comprised of doctors who are highly trained to carry out 
these procedures. You must contact us if you experience any problems. 
 
What are the benefits of taking part? 
The information obtained from this study will help future treatment of patients 
with HS and related conditions, but is unlikely to benefit you personally. You may 
help future generations by advancing what is known about HS, in particular what 
causes the disease, which will help scientists develop new treatments. 
 
What happens if there is a problem? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed by negligence, then you may have 
grounds for legal action but you may have to pay your legal costs.  Regardless of 
this, if you wish to complain, or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
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National Health Service complaints mechanism will be available to you. In the 
event of this, please contact the Patient Advisory Liaison Service (PALS) via 
telephone 02071888803 or visit in person by asking at the hospital reception. You 
can also contact Dr Andrew Pink on 020 71886277 and he will try his best to 
resolve the matter for you. His address is: St John’s Institute of Dermatology, 
St. Thomas’ Hospital, London, SE1 7EH.  
 
Will I receive any money for taking part in this study? 
You will not receive any financial benefits from this study.  
  
Will my taking part in the study be kept confidential? 
All information that is collected about you during the course of the research will 
be kept strictly confidential. Only the research staff and approved regulatory 
personnel will have access to any information about you. Any information about you 
that is seen by other people will have your name and address removed so that you 
cannot be recognised.  
 
What will happen to the results at the end of the study 
Your samples will be stored for an indefinite period of time and will be potentially 
used for further research in HS and related diseases (acne). The samples will be 
stored anonymously. If you do not wish us at any time to continue to store your 
sample, then please contact the unit and we will provide you with a form to 
complete and return to us asking us to destroy your sample.   
When the study has been completed we will aim to publish the results in a medical 
journal.  Please let us know if you wish to be informed of the publication of the 
study and we will aim to keep you fully informed.  You will not be identified in any 
publication. 
 
Who is organizing and funding the research? 
This study is being funded, organised and conducted by the Skin Therapy 
Research Unit (King’s College London), Guy’s and St Thomas’ Hospitals London and 
by the Medical Research Council.  As we recruit more participants and the project 
expands, we will apply to external funding sources.  
 
Who has reviewed the study? 
This study has been reviewed by independent clinicians and scientists and has 
been approved by the London Stanmore Research Ethics Committee. 
 
Who can I contact for further information on the study? 
Please contact Dr. Andrew Pink on 02071886277 any time if you have questions 
about the study.  
 
What will happen if I wish to withdraw from the study? 
Your participation is voluntary. You may refuse to be in this study, or withdraw 
from the study at any time without giving a reason. We would like to keep any 
samples you have already given us and continue to use them in our study. 
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None of these actions will affect your future treatment. If you decide to 
participate, your doctor can decide to withdraw you from the study at any time.  
 
If you have understood all the information above and wish to participate in 
the study you will be asked to sign an Informed Consent Form. You should 
keep a copy of this Information Sheet for yourself.  
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           Information Leaflet: Family member 
 
          Genetics Studies of Hidradenitis Suppurativa 
 
Our invitation 
You are being invited to take part in a research study. Before you decide it is 
important to understand why the research is being done and what it will involve. 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
Hidradenitis Suppurativa (HS) is a chronic skin disease in which patients suffer 
with recurrent abscesses and boils in the armpits and groin. As the disease 
progresses it has a disabling affect on patients lives, causing severe pain and 
scarring, interfering with day to day activities such as sitting, walking and arm 
movements. We know that a number of patients with HS have family members who 
also suffer with HS or related conditions (e.g. acne). In these patients the 
condition is likely to be inherited and caused by a single gene. Some genes for HS 
have now been identified, however there would appear to be more to find, and it is 
important to understand how changes in these genes result in HS.  
The purpose of this study is to try and identify further genes that cause HS in 
patients and their families and try to understand how changes in known and any 
newly identified genes result in the disease . We hope that this work will help us 
to understand the cause of HS and help scientists develop new treatments for HS 
and related conditions. 
 
Why have I been chosen? 
Your relative has been diagnosed with HS.  Comparing genetic material from 
people who are affected with HS to that of their relatives (who may not 
necessarily be affected) will help researchers. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. You are 
still free to withdraw at any time and without explaining why. A decision to 
withdraw at any time or a decision not to take part, will not affect the standard 
of care you receive.  
 
What do I have to do? 
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In order to participate in the study we will ask you to sign a consent form.  You 
will be asked to attend the hospital for one appointment (approximately 15-20 
minutes). In you are unable to attend our hospital we will try and arrange a 
telephone discussion instead (approximately 10 minutes). 
 
What will happen to me if I take part? 
On attending your appointment, a study doctor will discuss the purpose of the 
study and will go through the consent procedure with you. You will be able to ask 
any questions about your participation.  
 You will be asked to complete a short questionnaire about your medical 
history, your family’s medical history, in particular whether you suffer with 
symptoms of HS or related skin conditions (e.g. acne). Your skin will be 
briefly checked to confirm if you have HS or a related condition. This 
should take approximately 10-15 minutes.  
 
 You will then be asked to donate a blood sample or saliva sample for 
analysis of your genetic material (DNA).  A blood sample will involve taking 
a small amount of blood (approximately 17mls) from your arm. A saliva 
sample involves spitting 2.5mls (approximately 1 teaspoon) into a plastic pot.  
 
 If we do identify a possible causative gene in you then you may, at a later 
stage, be asked to attend one further appointment to obtain a hair sample 
(6 hairs only) and/ or a small skin biopsy.  
 
If you are unable to attend Guy’s hospital for the questionnaire and skin check, we 
will arrange a telephone interview (approximately 10 minutes). If you unable to 
attend Guy’s hospital for a blood/ saliva sample, we will post a simple saliva 
collection pot with instructions to your home.  
 
What are the possible disadvantages of joining this study? 
There are no perceived risks of giving a sputum sample. Blood tests can sometimes 
be a little uncomfortable and can cause minor bruising or irritation at the site.  In 
rare cases there may be local infection. There are no perceived risks of giving hair 
plucks. Small skin biopsies may result in bleeding, a 4mm scar and there is a very 
small risk of infection. There are no other perceived risks. 
Our research team is comprised of doctors who are highly trained to carry out 
these procedures. You must contact us if you experience any problems. 
 
What are the benefits of taking part? 
The information obtained from this study will help future treatment of patients 
with HS and related conditions, but is unlikely to benefit you personally. You may 
help future generations by advancing what is known about HS, in particular what 
causes the disease, which will help scientists develop new treatments. 
 
What happens if there is a problem? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed by negligence, then you may have 
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grounds for legal action but you may have to pay your legal costs.  Regardless of 
this, if you wish to complain, or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanism will be available to you. In the 
event of this, please contact the Patient Advisory Liaison Service (PALS) via 
telephone 02071888803 or visit in person by asking at the hospital reception. You 
can also contact Dr Andrew Pink on 020 71886277 and he will try his best to 
resolve the matter for you. His address is: St John’s Institute of Dermatology, 
St. Thomas’ Hospital, London, SE1 7EH.  
 
Will I receive any money for taking part in this study? 
You will not receive any financial benefits from this study.  
  
Will my taking part in the study be kept confidential? 
All information that is collected about you during the course of the research will 
be kept strictly confidential. Only the research staff and approved regulatory 
personnel will have access to any information about you. Any information about you 
that is seen by other people will have your name and address removed so that you 
cannot be recognised.  
 
What will happen to the results at the end of the study 
Your samples will be stored for an indefinite period of time and will be potentially 
used for further research in HS and related diseases (acne). The samples will be 
stored anonymously. If you do not wish us at any time to continue to store your 
sample, then please contact the unit and we will provide you with a form to 
complete and return to us asking us to destroy your sample.   
When the study has been completed we will aim to publish the results in a medical 
journal.  Please let us know if you wish to be informed of the publication of the 
study and we will aim to keep you fully informed.  You will not be identified in any 
publication. 
 
Who is organizing and funding the research? 
This study is being funded, organised and conducted by the Skin Therapy 
Research Unit (King’s College London), Guy’s and St Thomas’ Hospitals London and 
by the Medical Research Council.  As we recruit more participants and the project 
expands, we will apply to external funding sources.  
 
Who has reviewed the study? 
This study has been reviewed by independent clinicians and scientists and has 
been approved by the London Stanmore Research Ethics Committee. 
 
Who can I contact for further information on the study? 
Please contact Dr. Andrew Pink on 02071886277 any time if you have questions 
about the study.  
 
What will happen if I wish to withdraw from the study? 
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Your participation is voluntary. You may refuse to be in this study, or withdraw 
from the study at any time without giving a reason. We would like to keep any 
samples you have already given us and continue to use them in our study. 
None of these actions will affect your future treatment. If you decide to 
participate, your doctor can decide to withdraw you from the study at any time.  
 
If you have understood all the information above and wish to participate in 
the study you will be asked to sign an Informed Consent Form. You should 
keep a copy of this Information Sheet for yourself.  
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                 Genetic Studies of  Hidradenitis Suppurativa 
                 CONSENT FORM: Patient 
     LREC Study Number: 
 
 
                                   - 
Name of participant              Identification Number  
              
Name of Investigators: Professor J Barker, Dr A Pink                                     Please initial box 
 
1. I confirm that I have read and understand the information sheet (Version dated 3/6/2011) for 
the above study for hidradenitis patients and their family members and have had the 
opportunity to consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by  hospital staff 
and regulatory authorities where it is relevant to my taking part in research.  I give 
permission for these individuals to have access to my records. 
 
4.    I agree that my family members can be contacted to participate in this study once I have 
       discussed it with them. 
 
5.    I agree to take part in the above study. 
    
 
 
                            
Signature
*
         Name of participant
*




                            




Relationship to participant (if participant unable to sign)  
  
 
Statement of Interpreter (where appropriate) 
I have interpreted the information above to the best of my ability and in a way which I believe 
he/she can understand. 
 
                            
Signature
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                 Genetic Studies of  Hidradenitis Suppurativa 
                 CONSENT FORM: Family member 
     LREC Study Number: 
 
 
                                     
Name of participant              Identification Number  
              
Name of Investigators: Professor J Barker, Dr Andrew Pink                      Please initial box 
 
1. I confirm that I have read and understand the information sheet (Version dated 3/6/2011) for 
the  above study for hidradenitis patients and their family members and have had the 
opportunity to consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
3.    I understand that sections of any of my medical notes may be looked at by  hospital staff   
       and regulatory authorities where it is relevant to my taking part in research.  I give  
       permission for these individuals to have access to my records. 
 
4. I agree to take part in the above study.    
 
 
                            
Signature
*
         Name of participant
*




                            




Relationship to participant (if participant unable to sign)  
  
 
Statement of Interpreter (where appropriate) 
I have interpreted the information above to the best of my ability and in a way which I believe 
he/she can understand. 
 
                            
Signature
 
         Name (PRINT)   Date 
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CONSENT TO DONATION AND STORAGE OF BLOOD OR SALIVA 
SAMPLES FOR FUTURE MEDICAL RESEARCH IN HIDRADENITIS 
SUPPURATIVA AND RELATED DISEASES 
 
    
Name of investigators and department: Professor J Barker, Dr Andrew Pink, 
Guys and St. Thomas’ Hospital London 
Research Ethics Committee Reference:  
Sample to be taken: BLOOD and/or SALIVA +/- HAIR PLUCKS 
and/or SKIN BIOPSY 
 
Blood, saliva, hair or skin collected as part of the research project may be stored and used by 
St. John’s Institute of Dermatology (Guys & St. Thomas’ Hospital London) for future medical 
research. All personal data collected for the research project will be anonymised. You will 
receive the outcome of future research projects if requested. All staff undertaking future studies 
will abide by the Data Protection Act 1998 with any medical information relating to you being 
kept confidential. All samples will be disposed of lawfully when no longer required. 
 
I understand that the blood/ saliva/ hair or skin samples taken for this study will not be used for 
diagnostic purposes. 
  
I accept that I have given my consent voluntarily for the storage of blood/ saliva/ hair or skin 
samples and that I am free to withdraw my consent at any time. 
 
I agree that the blood/ saliva/ hair/ skin may be used for future genetic research but not for 
research that involves reproductive cloning without my express consent. 
 
I agree that following completion of this study my personal data and materials may be stored for 
future studies in hidradenitis suppurativa in a Research Tissue Bank. This will only take place 
following the necessary ethical approval required to establish a Research Tissue Bank.  
 
If during the course of the study, I lose the capacity to consent, any data or samples previously 
obtained with my consent will be retained and used in the study. 
 





                             - 
Signature of participant            Name (PRINT)      Date 
 
                            
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DoB ………………………………………...                




St George’s clinic 
St John’s clinic 




Weight                           .           Kg      Height        .         cm         BMI 
 
 










Mixed race, please state …………………….. 




Current smoker                                                              Yes                No                       
Ex-smoker (smoked at any stage in the past)                Yes                No 
Start smoking prior to disease development?                Yes                No 
(If so, how long before?                       Years  ) 
 









         
History of 5 or more boils/abscesses in flexural sites                        YES               NO                                                                                                                                                                               
                                        
Which sites have been affected (include present or past): 
      
Posterior ears 
Neck 
Axilla                                                  
Arms 
Submammary                 
Chest wall 
Back                               
Suprapubic                                                
Groin                  
Genital 
Buttocks                               
Thighs                       
Legs 
Other   ………….. 
  
Age when first affected              
 
Frequency of flares                                 ≥12/year          6-11/year           1-5/year            ≤1/year 
                       
Related to menstrual cycle                                                                           YES                NO 
 
(If so, how long before menstruation on average?                                                      days 
 
Systemic upset associated with flares                                                          YES                NO  
(fever/malaise/fatigue)  
 
Requiring hospital admission at any stage                                                   YES                NO 
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Acne vulgaris                                 
Nodulocystic acne                          
Scalp folliculitis                             
Dissecting cellulitis                       
Pilonidal sinus   





History of any other skin disorder    YES   NO  
If so, please detail   ………………………        
Keratitis                                                  
Crohn’s disease 
Ulcerative colitis 
Arthritis                                                                       Diagnosis .................................                                                                                    
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OTHER PAST MEDICAL HISTORY 
Please fill in only one diagnosis per line. 
 
                                                                                                      
                                                                                                    Onset Date          
SD No.                                  Diagnosis             Date Resolved  Tick if 
         
                                                                                                     M          Yr                     Ongoing 
  
   1 
 
    
    
   2 
 
    
    
   3 
 
  




   5 
    






CURRENT THERAPY FOR HIDRADENITIS SUPPURATIVA 
Treatment Name       Start Date          Responder Status             Ongoing  
                       (Responder, indeterminate    (tick)                          











* Responder = Patient felt there was a definite clinical improvement on this medication 
   Indeterminate = Patient unsure whether the medicine resulted in any clinical improvement 
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OTHER CONCOMMITANT MEDICATION (on today’s visit) 
Treatment Name        Start Date           Indication                           Ongoing          
                                                                                 (Should relate to a medical   (tick) 
                                       Month    Year                     diagnosis stated above) 






























PREVIOUS THERAPY FOR HIDRADENITIS SUPPURATIVA 
(topical/ oral antibiotics/ acitretin/ isotretinoin / ciclosporin/ dapsone/ anti-TNF / surgery / other) 
 
Treatment Name                          Start Date           Responder Status                               
                          Stop Date                        (responder, indeterminate 
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FAMILY SKIN DISEASE HISTORY 
This would include hidradenitis suppurativa or other related diseases i.e. acne vulgaris, conglobate acne, 
dissecting folliculitis of the scalp, pilonidal sinus, folliculitis, atopic dermatitis, psoriasis or any other skin 
disease. 
 
Anyone else in the family affected with HS                           Yes                         No 
 
(Tick box if family history UNKNOWN        ) 
 
















ANY FAMILY HISTORY OF   
Acne vulgaris                                 
Scalp folliculitis/ Dissecting cellulitis                         
Pilonidal sinus                                
Squamous cell carcinoma  
Alzheimers                                                   
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EXAMINATION/ CLINICAL MEASURES 
 
 LESION TYPE                Comedones    Nodules    Sinus tracts     Scarring             Disease active        
                                                                                                                      YES            NO 
 
Axilla                                                      
Submammary                  
Suprapubic                              
Groin                                                           
Genital              
Buttocks                               
Other   ..................                     
Other   ………….. 
 
Acanthosis nigricans                                 Where?.................................... 
 
Keratosis pilaris                                         Where?...................................... 
 








Scalp folliculitis/ dissecting cellulitis 
 
   
GRADING SCORES 
HURLEY STAGE (Please ring as appropriate) 
     I           ≥ 1inflammatory nodule with NO sinuses or scarring 
     II         ≥ 1 widely separated inflammatory nodules + scarring + sinuses 
     III         Multiple interconnected nodules + sinuses throughout entire affected area 
 
Sartorius score  
 
 
QUALITY OF LIFE 
 
Dermatology Life Quality Index (DLQI) Score                     (patient should be given sheet to complete) 
 
Time from first symptoms to presentation to a Dermatologist                     years                      months 
 











































MRI performed      
 














     
Date Collected      
 
Blood                             Yes                No 
 
Saliva                             Yes                No 
 




THERAPIES TO BE COMMENCED TODAY 
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Treatment Name              Start Date                         
                                                                                                 















OVERALL FEELING re: PHENOTPYE................................................................................................ 
 
Form completed by …………………………………. 
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Advertisement for recruitment of volunteers for the Molecular Genetic 
Analysis of Hidradenitis Suppurativa study. Ref: 11/LO/0966 approved by 
the NRES Committee London-Stanmore on 26th August 2011.   
 
You are under no obligation to take part in this study however if you choose to, 
participation in this research is voluntary and you may withdraw at any time. 
 
We would like to invite you to participate in a study in which we are investigating 
the genetic basis of a skin condition called Hidradenitis Suppurativa. We hope 
that the information obtained from analysis of these samples will help us better 
understand the processes involved in this chronic inflammatory skin condition 
and in the future therapies.   
  
You will be asked to provide 3 types of samples:  
- 17 mls (approximately four level teaspoons) of your blood for DNA 
analysis and for the study your blood cells.  
- Six hair plucks from your scalp for the study of your skin.  
- Two 6mm punch biopsy samples, one from a flexural area (eg. arm pit) 
and one from a non-flexural area (eg. back).  
- In addition you will be asked some questions about yourself – gender; 
age; ethnicity; medical history (regarding skin disease) 
 
The 2 punch biopsy sites will each have 2 stitches in place for 10 days. You will 
need to return to the clinic to have these stitches removed. 
 
You can take part if:  
 
- You are over 18 
- You have no medical history of hidradenitis suppurativa, pilonidal abscesses 
or acne 
  
You will receive compensation for your time of £150. Any risks involved will be 
detailed in the information sheet. This is not a treatment study.  All participant 
information will be anonymised and kept confidential. 
  
If you are interested in participating please contact one of the study team for 
















- 371 - 
    
 
 
              Information Leaflet: Volunteer 
 
         Genetics Studies of Hidradenitis Suppurativa 
 
Our invitation 
You are being invited to take part in a research study. Before you decide it is 
important to understand why the research is being done and what it will involve. 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
Hidradenitis Suppurativa (HS) is a chronic skin disease in which patients suffer 
with recurrent abscesses and boils in the armpits and groin. As the disease 
progresses it has a disabling affect on patients lives, causing severe pain and 
scarring, interfering with day to day activities such as sitting, walking and arm 
movements. We know that a number of patients with HS have family members who 
also suffer with HS or related conditions (e.g. acne). In these patients the 
condition is likely to be inherited and caused by a single gene. Some genes for HS 
have now been identified, however there would appear to be more to find, and it is 
important to understand how changes in these genes result in HS.  
The purpose of this study is to try and identify further genes that cause HS in 
patients and their families and try to understand how changes in known and any 
newly identified genes result in the disease . We hope that this work will help us 
to understand the cause of HS and help scientists develop new treatments for HS 
and related conditions. 
 
Why is it important for unaffected volunteers to take part in this study? 
Comparing genetic material, cells and skin from people who are affected with HS 
with that of unaffected healthy volunteers will help researchers to understand 
the key differences that result in disease. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. You are 
still free to withdraw at any time and without explaining why. A decision to 
withdraw at any time or a decision not to take part will not affect the standard of 
medical care that you receive now or in the future.  
 
What do I have to do? 
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In order to participate in the study we will ask you to sign a consent form.  You 
will be asked to attend the hospital for an initial appointment lasting 
approximately 60 minutes and then for a follow-up appointment 10 days later 
lasting approximately 10 minutes.  
 
What will happen to me if I take part? 
On attending your appointment, a study doctor will discuss the purpose of the 
study and will go through the consent procedure with you. You will be able to ask 
any questions about your participation.  
 You will be asked to complete a short questionnaire about your medical 
history, in particular whether you suffer with symptoms of HS or related 
skin conditions (e.g. acne).   
 
 You will then be asked to donate a blood sample. This will involve taking a 
small amount of blood (approximately 17mls) from your arm.  
 
 You will then be asked to donate a hair sample (6 hairs, plucked from your 
scalp) and two small skin biopsies (one from your armpit, groin or buttock 
and one from nearby skin). The skin biopsies will be performed under local 
anaesthetic. You will be asked to return 10 days later for the removal of 
stitches. 
 
What are the possible disadvantages of joining this study? 
Blood tests can sometimes be a little uncomfortable and can cause minor bruising 
or irritation at the site.  In rare cases there may be local infection. There are no 
perceived risks of giving hair plucks. Small skin biopsies may result in bleeding, a 
6mm scar and there is a very small risk of infection. There are no other perceived 
risks. Our research team is comprised of doctors who are highly trained to carry 
out these procedures. You must contact us if you experience any problems. 
 
What are the benefits of taking part? 
The information obtained from this study will help future treatment of patients 
with HS and related conditions but is unlikely to benefit you personally. You may 
help future generations by advancing what is known about HS, in particular what 
causes the disease, which will help scientists develop new treatments. 
 
What happens if there is a problem? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed by negligence, then you may have 
grounds for legal action but you may have to pay your legal costs.  Regardless of 
this, if you wish to complain, or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanism will be available to you. In the 
event of this, please contact the Patient Advisory Liaison Service (PALS) via 
telephone 02071888803 or visit in person by asking at the hospital reception. You 
can also contact Dr Andrew Pink on 020 71886277 and he will try his best to 
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resolve the matter for you. His address is: Floor 9, Guy’s Tower, Guy’s Hospital, 
London, SE1 7EH.  
 
Will I receive any money for taking part in this study? 
You will receive £150 for taking part in this study.  
  
Will my taking part in the study be kept confidential? 
All information that is collected about you during the course of the research will 
be kept strictly confidential. Only the research staff and approved regulatory 
personnel will have access to any information about you. Any information about you 
that is seen by other people will have your name and address removed so that you 
cannot be recognised.  
 
What will happen to the results at the end of the study 
Your samples will be stored for an indefinite period of time and will potentially be 
used for further research in HS and related diseases (acne). The samples will be 
stored anonymously. If you do not wish us at any time to continue to store your 
sample, then please contact the unit and we will provide you with a form to 
complete and return to us asking us to destroy your sample.   
When the study has been completed we will aim to publish the results in a medical 
journal.  Please let us know if you wish to be informed of the publication of the 
study and we will aim to keep you fully informed.  You will not be identified in any 
publication. 
 
Who is organizing and funding the research? 
This study is being funded, organised and conducted by the Skin Therapy 
Research Unit (King’s College London), Guy’s and St Thomas’ Hospitals London and 
by the Medical Research Council.   
 
Who has reviewed the study? 
This study has been reviewed by independent clinicians and scientists and has 
been approved by the London Stanmore Research Ethics Committee. 
 
Who can I contact for further information on the study? 
Please contact Dr. Andrew Pink on 02071886277 any time if you have questions 
about the study.  
 
What will happen if I wish to withdraw from the study? 
Your participation is voluntary. You may refuse to be in this study, or withdraw 
from the study at any time without giving a reason. We would like to keep any 
samples you have already given us and continue to use them in our study. 
None of these actions will affect your future treatment. If you decide to 
participate, your doctor can decide to withdraw you from the study at any time.  
 
If you have understood all the information above and wish to participate in 
the study you will be asked to sign an Informed Consent Form. You should 
keep a copy of this Information Sheet for yourself.  
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                 Genetic Studies of  Hidradenitis Suppurativa 
                 CONSENT FORM: Volunteer 
     LREC Study Number: 
 
 
                                    
Name of participant              Identification Number  
              
Name of Investigators: Professor J Barker, Dr Andrew Pink                Please initial box 
 
1. I confirm that I have read and understand the volunteer information sheet (Version dated 
16/5/2012) for the  above study and have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
3.    I understand that sections of any of my medical notes may be looked at by  hospital staff   
       and regulatory authorities where it is relevant to my taking part in research.  I give   
       permission for these individuals to have access to my records. 
 
4. I agree to take part in the above study. 
    
 
 
                            
Signature
*
         Name of participant
*




                            




Relationship to participant (if participant unable to sign)  
  
 
Statement of Interpreter (where appropriate) 
I have interpreted the information above to the best of my ability and in a way which I believe 
he/she can understand. 
 
                            
Signature
 







- 376 - 
 
Volunteer Clinical Research Form                                                              
 
 
Please tick YES or NO (if the answer is NO to any of these questions then the patient is to be excluded from the study) 
INCLUSION CRITERIA YES NO 
Written informed consent   
≥ 16 years    
 
Please tick YES or NO (if the answer is YES to any of these questions then the patient is to be excluded from the study) 
EXCLUSION CRITERIA YES NO 
Unable to give written informed consent   
< 16 years old   
Blood transfusion received within last 4 weeks   
History of HS    
Family history of HS   
History of related disorder of follicular occlusion (acne, pilonidal abscess, dissecting cellulitis)   
 
Consent obtained (forms 1 and 2)                                    Yes            No 
 
  




Weight                                                 .             Kg 
 





Current smoker                                                               Yes                 No                                      
Ex-smoker (smoked at any stage in the past)                  Yes                No 
                                              
Pack/year history   (1 pack year history = 20 cigarettes smoked for 1 year)                                   
 
White                                                                                                                                                                                                                                       
White Irish 
Asian 
Black                                                                                                                                                                         
Chinese 
Mixed race, please state …………………….. 
Other, please state          …………………….. 
 
 
Previous history of:  Acne vulgaris 
                                 Scalp folliculitis/ dissecting cellulitis 
                                 Pilonidal sinus 
                                 Crohn’s disease               
                                  
 
 
Is any one else in the family affected       Yes             No                           If so, please draw family pedigree 
 
 
Sample collection     
 
Date Collected                  /            /                                       
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Appendix 3 – Primers used to amplify exons of NCSTN, 
PSENEN and PSEN1  
 
Primers used to amplify all exons of NCSTN, PSENEN and PSEN1: 
Gene Exon Forward primer Reverse primer 
NCSTN 1 CGAACTTCCGGTCTCTTAGG CAGGAACCAGAAGGGAGACA 
NCSTN 2 CCCAAGCCATACTTCAGGTT TCTCCTAAGCAGGACATGGA 
NCSTN 3 GGGCAACAGCTTTTCAGTTC CAGCCAAGGGAAGTTTTCAC 
NCSTN 4 CCCCTAGTTCCCCATTTGTT CATCCCTCACAAAGACGTAAG 
NCSTN 5 AAGATTCTTCTGCCGTCACC TGCCATCTCAGCTCACTGAA 
NCSTN 6 ATGTCTCCGAAAAGGGTGTG ATGCAGAGCTCCTTCATGGT 
NCSTN 7 GGCACTGGTCAGAGATTTCC GGCTTCCCAATTTAGCAACT 
NCSTN 8 CCTCAAATGGGGAGGAATCT GCTGAGGTCTTCTCCAACCA 
NCSTN 9 CCTACAGCTTTGATGATCTG GAAGAGCGGCTGCTTCCT 
NCSTN 10 CGCCTCTTCCCTTGACTTCT CTGGGGCTTGGTGGAAAC 
NCSTN 11 ATAGGGTAGCTCCCCAAGCA GTTCTGGAGGGGGTAGTGTG 
NCSTN 12 TCCCTGCATAAGGAGCATTT AATGGCCCACCTCTCCTATC 
NCSTN 13 CACTGCCAAGGTAGCACTGA GTTTGGGACACTAGGGCAAG 
NCSTN 14 TATCTGGCCAGTCTGGTTCC GAAGGGCAATGGAAAAGGAT 
NCSTN 15 TTCCATTGCCCTTCTTTCTG AACACCCAATTGCTGAGGAC 
NCSTN 16 TTGGTTAGAGCATGGCACTG ATGGGAGATGGAAAGGGCTA 
NCSTN 17 GGAGAGATGTTGCCCATGAT AGGGAGGTTCCAGTGACAAA 
    
PSEN1 1 TGCACAAAGTTCTGTTTTTCTTC CTAGCCCCCTCAGCATTTCT 
PSEN1 2 TGACGGGTCTGTTGTTAATCC CTGCTCCTGACCATCACAGA 
PSEN1 3 AAAATTCTGTGTTGGAGGTGGT TTACACATGCACCTGGCTTC 
PSEN1 4 GCGACAAAGTGAGACCCTGT CAACAAAGTACATGGCTTTAAATGA 
PSEN1 5 TGTTTGGGAGCCATCACAT CCAGCCGAAATCTTCAAATG 
PSEN1 6 TCGTTAATTCCTCCCTACCA CAGGAATGCTGTGCATTTAAGA 
PSEN1 7 GGAAGACTGGCGATTTGTGT GGAGTCTATGACCAAAGAAAGACG 
PSEN1 8 ACTGCTACAGCCCATGCTTT CACTCTCAATTCATTTTATTCTCAAA 
PSEN1 9 GGGTTGAGTAGGGCAGTGATA CTGGGGTTAAAACAGAACTGC 
PSEN1 10 TTCCAGATTGAATGAACGTCTG TGGACACAGGAAAATCACCTT 
    
PSENEN 1 TTCTAATAGGGGCGTGGTTG TCGCAGGTCCTTCATCTCTT 
PSENEN 2 ATCCCAAAGAGGAGCCAGAT CCTAGACCAGCCTTCCCTTC 
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Appendix 4 – Left and right hybridisation sequences used for 
MLPA  
 
Left hybridisation sequences for MLPA 
PSENEN 1 GGGTTCCCTAAGGGTTGGAGACGACCCGGCCCCAGCGCAGCTATGAACCTGGAGCGAGTGT 
PSENEN 2 GGGTTCCCTAAGGGTTGGATTCCTGCCTTTTCTCTGGTTGGTCAACATCTTCT 
PSENEN 3 GGGTTCCCTAAGGGTTGGATGTCCTGGGAGCCCCTTCTCAAACTCCTAAGACTTGT 
  
NCSTN 1 GGGTTCCCTAAGGGTTGGAGAAACACGAACTTCCGGTCTCTTAGGCTCCGGGCCACAGAGACGGTGTCAGTGGTA 
NCSTN 2 GGGTTCCCTAAGGGTTGGATGCAGGGGAAACTCAGTGGAGAGGAAGATATATATCCCCTTA 
NCSTN 3 GGGTTCCCTAAGGGTTGGATTGACTGATGGCCCCAACCCCCCTTA 
NCSTN 4 GGGTTCCCTAAGGGTTGGATTAATGGAGAAGCTGAAAGGGAGAACCAGCCGAAT 
NCSTN 5 GGGTTCCCTAAGGGTTGGATTCCTATGGGCCAGAGTTTGCTCACTGCAGAGAAATACAGTGGAAT 
NCSTN 6 GGGTTCCCTAAGGGTTGGATGCCATGCAGCTCTTTTCACACATGCATGCTGTCAT 
NCSTN 7 GGGTTCCCTAAGGGTTGGATGTCTGATTACAATGTGTGGAGCATGCTAAAG 
NCSTN 8 GGGTTCCCTAAGGGTTGGATTTTTCTGGAATGTGGCCCCAGGGGCTGAAAGCGCAGTGGCTTCCTTT 
NCSTN 9 GGGTTCCCTAAGGGTTGGACATTGGCAGCTCGAGGATGGTCTA 
NCSTN 10 GGGTTCCCTAAGGGTTGGAGAGCTTTGGATGCACACAGATCCTGTTT 
NCSTN 11 GGGTTCCCTAAGGGTTGGAGAGTGGTGCTGGTGTCCCTGCTGTCATCCTCAGGAGGCCAAATC 
NCSTN 12 GGGTTCCCTAAGGGTTGGATTACCAGAGTATTTACGACACTGCTGAGAACATTAATGTG 
NCSTN 13 GGGTTCCCTAAGGGTTGGAGATGTGGCCACGGTGCTGGGACGTGCTCTGTATG 
NCSTN 14 GGGTTCCCTAAGGGTTGGATATGGGTTCCTGATTAAAGCCAACAACTCA 
NCSTN 15 GGGTTCCCTAAGGGTTGGATCAACATTACATCGCTGTCTCCAGCCCCACCAACACCACTTATGTTGTAC 
NCSTN 16 GGGTTCCCTAAGGGTTGGAGTCCAGGGCCCTTTGCATTCTAATGAGACGGACCGACTCCCCCGGTGTGT 
NCSTN 17 GGGTTCCCTAAGGGTTGGATTCACTTCCTAGAGCATCTGTCCCACTGGGACACAACCACTAATTTGTCACTGG 
 
 Right hybridisation sequences for MLPA 
PSENEN 1 CCAATGAGGAGAAATTGAACCTGTGCCGGAAGTACTACTCTAGATTGGATCTTGCTGGCAC 
PSENEN 2 GGTTCTTCCGAGAGGCCTTCCTTGTCCCAGCCTATCTAGATTGGATCTTGCTGGCAC 
PSENEN 3 TTTCATGTCCCACGTTCTCTGCTGACATCCCCCAATATCTAGATTGGATCTTGCTGGCAC 
  
NCSTN 1 GCCTAGAGAGGCCGCTAACAGACAGGAGCCGAACGGGGGCTTCCGCTCAGCAGAGATCTAGATTGGATCTTGCTGGCAC 
NCSTN 2 AATAAAACAGCTCCCTGTGTTCGCCTGCTCAACGCCACTCATTCTAGATTGGATCTTGCTGGCAC 
NCSTN 3 CATGGTTCTGCTGGAGAGCAAGCATTTCTAGATTGGATCTTGCTGGCAC 
NCSTN 4 TGCTGGTCTTGCAGTGTCCTTGACCAAGCCCAGTCCTGCCTTCTAGATTGGATCTTGCTGGCAC 
NCSTN 5 TCGCTGGGCAATGGTTTGGCTTATGAAGACTTTAGTTTCCCCATCTTCTAGATTGGATCTTGCTGGCAC 
NCSTN 6 CAGCACTGCCACCTGCATGCGGCGCAGCTCCATCCATCTAGATTGGATCTTGCTGGCAC 
NCSTN 7 CCTATAAATACAACTGGGACATTAAAGCCTGATCTAGATTGGATCTTGCTGGCAC 
NCSTN 8 GTCACCCAGCTGGCTGCTGCTGAAGCTTTGCAAAAGGCACCTGATGTGTCTAGATTGGATCTTGCTGGCAC 
NCSTN 9 CGATATGGAGAAGGGCAAGTTTCCTCTAGATTGGATCTTGCTGGCAC 
NCSTN 10 CTCAGAAAAATGAGTCTGTACGGAACCATCTAGATTGGATCTTGCTGGCAC 
NCSTN 11 AGTCCCAGCCTCTCCCACCATCTTCCCTGCAGCGATTTCTTCGATCTAGATTGGATCTTGCTGGCAC 
NCSTN 12 AGCTATCCCGAATGGCTGAGCCCTGAAGAGGACCTGAACTTCTAGATTGGATCTTGCTGGCAC 
NCSTN 13 AGCTTGCAGGAGGAACCAACTTCAGCGACACAGTTCTAGATTGGATCTTGCTGGCAC 
NCSTN 14 TGGTTCCAGTCTATCCTCAGGCAGGACCTATCTAGATTGGATCTTGCTGGCAC 
NCSTN 15 AGTATGCCTTGGCAAATTTGACTGGCACAGTGGTCAACCTCACCCGAGAGTCTAGATTGGATCTTGCTGGCAC 
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NCSTN 16 GCGTTCTACTGCACGATTAGCCAGGGCCTTGTCTCCTGCCTTTGAACTGATCTAGATTGGATCTTGCTGGCAC 
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Appendix 5 – Regions of linkage in pedigrees 1 – 6 (reported 






Chromosome From (bp) To (bp) 
1 229355000 232007196 
3 36214197 45296740 
3 51568137 58036651 
3 59475736 68812466 
3 70274229 74112675 
3 76992952 85683470 
3 107805334 115340900 
4 35653192 37996334 
6 122945140 127208390 
6 129980436 130936249 
6 134248060 137941227 
6 159944996 166570346 
7 44808091 49435299 
7 52544356 53662097 
9 1 1519043 
9 2951475 6722212 
10 130665155 132992902 
11 18001888 20301930 
12 5603632 6905181 
13 79801863 105328137 
16 605481 2982708 
16 3747204 7442293 
18 66881895 70501767 
19 56372705 57182204 






Chromosome From (bp) To (bp) 
1 40049184 48048060 
1 197482265 227418130 
2 125061838 154452223 
3 7142227 36979042 
4 145658429 147246721 
4 176721793 188905061 
5 14989346 26809915 
5 73986648 87513775 
7 146226582 153970767 
8 27405809 105805344 
8 138467144 End 
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9 1 2196734 
10 28294586 89912106 
10 132992902 End 
11 1 4639292 
11 103506972 118755738 
12 131225471 End 
14 100087364 104155317 
18 33674808 72022671 
19 14450812 17927041 
19 56822413 End 






Chromosome From (bp) To (bp) 
1 1 5347155 
1 100376448 200107578 
1 234524045 End 
2 1 4050728 
2 42012857 224713026 
4 140888081 End 
6 1 End 
7 1 152402621 
8 11728994 73379450 
8 122805639 132007359 
10 51503335 End 
11 16007446 75390240 
12 20605116 79391433 
13 31587270 67798928 
15 76402624 End 
16 Start 8088550 
19 3030118 End 






Chromosome From (bp) To (bp) 
1 57760458 95276691 
1 115427218 222093006 
2 173686798 206830563 
3 44141157 73336315 
3 97741821 150609866 
4 66773365 121429891 
5 141573265 172737199 
6 1 13097658 
6 14492000 42658752 
7 109297612 135354582 
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8 1 18207413 
9 9501741 37020622 
9 109312922 1315276676 
10 1 7722848 
10 125665080 End 
11 5491183 12083579 
11 107874113 113477081 
12 78636050 117082846 
13 106632499 End 
14 94954368 End 
15 58177757 92604461 
16 80071458 End 
17 6285864 12171195 
17 35010976 End 
18 23413944 46976586 
20 43970377 50466232 






Chromosome From (bp) To (bp) 
2 15807637 27384579 
2 181314519 192458747 
5 174897200 End 
6 1 1295151 
6 40921160 43396325 
6 109049607 136227558 
6 148995849 163697439 
7 33926351 37951726 
7 38741626 45522229 
9 1519043 4895391 
9 78724005 81125839 
10 49201964 60548276 
10 82454295 132139508 
11 18001888 66079786 
11 74401763 85766185 
12 10848803 13870080 
12 122318985 126171662 
13 1 30670985 
14 99157430 105154105 
15 86278479 95378243 
15 96856201 End 
16 1 3747204 
16 83727833 89587871 
17 75038439 End 
18 8439366 10597874 
19 52712828 End 
 
 




Chromosome From (bp) To (bp) 
1 1 106774642 
1 154688197 End 
2 66665146 80698371 
2 141096291 165647332 
3 1 3767186 
3 30690424 64171993 
3 116269592 169801658 
3 183995341 End 
4 1 56977309 
4 71439354 112591777 
4 152900692 End 
5 1 14989346 
5 30881510 71674855 
5 74302658 116319808 
5 162626996 End 
6 137076010 End 
7 139185449 End 
8 19076995 48089751 
9 1 74186310 
9 111945992 End 
10 15613080 90759724 
10 132992902 End 
11 1 3743046 
11 89892250 128379964 
12 1 12578786 
12 89653020 97416064 
12 127284785 End 
13 37877935 74474851 
14 1 26840301 
15 1 60145962 
15 96856201 End 
16 1 8305679 
16 13489119 75483806 
17 1 3569913 
18 60568428 End 
19 36904463 End 
20 2488753 End 
21 1 27168049 
21 42293410 End 
22 45251423 48526700 
 
 
 
 
 
